US20020198198A1 - Spirotricyclic derivatives and their use as phosphodiesterase-7 inhibitors - Google Patents

Spirotricyclic derivatives and their use as phosphodiesterase-7 inhibitors Download PDF

Info

Publication number
US20020198198A1
US20020198198A1 US10/101,996 US10199602A US2002198198A1 US 20020198198 A1 US20020198198 A1 US 20020198198A1 US 10199602 A US10199602 A US 10199602A US 2002198198 A1 US2002198198 A1 US 2002198198A1
Authority
US
United States
Prior art keywords
selected
dihydro
cyclohexane
quinazolin
lower alkyl
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
US10/101,996
Inventor
Patrick Bernardelli
Pierre Ducrot
Edwige Lorthiois
Fabrice Vergne
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Warner Lambert Co LLC
Original Assignee
Patrick Bernardelli
Pierre Ducrot
Edwige Lorthiois
Fabrice Vergne
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
Priority to PCT/EP2001/003355 priority Critical patent/WO2002076953A1/en
Priority to EPPCT/EP01/03355 priority
Application filed by Patrick Bernardelli, Pierre Ducrot, Edwige Lorthiois, Fabrice Vergne filed Critical Patrick Bernardelli
Publication of US20020198198A1 publication Critical patent/US20020198198A1/en
Assigned to WARNER-LAMBERT COMPANY LLC reassignment WARNER-LAMBERT COMPANY LLC ASSIGNMENT OF ASSIGNORS INTEREST (SEE DOCUMENT FOR DETAILS). Assignors: BERNARDELLI, PATRICK, DUCROT, PIERRE, LORTHIOIS, EDWIGE, VERGNE, FABRICE
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=8164349&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=US20020198198(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application status is Abandoned legal-status Critical

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D239/00Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/70Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings condensed with carbocyclic rings or ring systems
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D401/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/04Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D401/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D403/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/04Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D405/00Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/12Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D413/00Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/12Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links

Abstract

The invention provides compounds which are PDE7inhibitors, having the following formula (I), (II) and (III)
Figure US20020198198A1-20021226-C00001
in which X1, X2, X3, X4, X, Y, Z, A and Z1 are as defined in the description, methods for preparing them and their use for the treatment of disorders for which therapy by a PDE7 inhibitor is relevant.

Description

    FIELD OF THE INVENTION
  • The invention relates to spirotricyclic derivatives, the process for their preparation, and their use as phosphodiesterase 7 (PDE7) inhibitors. [0001]
  • BACKGROUND OF THE INVENTION
  • Phosphodiesterases (PDE) play an important role in various biological processes by hydrolysing the key second messengers adenosine and guanosine 3′,5′-cyclic monophosphates (cAMP and cGMP respectively) into their corresponding 5′-monophosphate nucleotides. Therefore, inhibition of PDE activity produces an increase of cAMP and cGMP intracellular levels that activate specific protein phosphorylation pathways involved in a variety of functional responses. [0002]
  • At least eleven isoenzymes of mammalian cyclic nucleotide phosphodiesterases, numbered PDE 1 through PDE 11, have been identified on the basis of primary structure, substrate specificity or sensitivity to cofactors or inhibitory drugs. [0003]
  • Among these phosphodiesterases, PDE7 is a cAMP-specific PDE. The biochemical and pharmacological characterization showed a high-affinity cAMP-specific PDE (Km=0.2 μM), that was not affected by cGMP potent selective PDE isoenzyme inhibitors. [0004]
  • PDE7 activity or protein has been detected in T-cell lines, B-cell lines, airway epithelial (AE) cell lines and several foetal tissues. [0005]
  • Increasing cAMP levels by selective PDE7 inhibition appears to be a potentially promising approach to specifically block T-cell mediated immune responses. Further studies have demonstrated that elevation of intracellular cAMP levels can modulate inflammatory and immunological processes. This selective approach could presumably be devoid of the side effects associated with known selective PDE inhibitors (e.g. PDE3 or PDE4 selective inhibitors) and which limit their use. [0006]
  • A functional role of PDE7 in T-cell activation has also been disclosed; therefore selective PDE7 inhibitors would be candidates for the treatment of T-cell-related diseases. [0007]
  • AE cells actively participate in inflammatory airway diseases by liberating mediators such as arachidonate metabolites and cytokines. Selective inhibition of PDE7 may be a useful anti-inflammatory approach for treating AE cells related diseases. [0008]
  • Thus, there is a need for selective PDE7 inhibitors, which are active at very low concentrations, i.e. preferably nanomolar inhibitors. [0009]
  • WO 88/01508 discloses compounds of formula [0010]
    Figure US20020198198A1-20021226-C00002
  • where R is hydrogen, alkyl, alkoxyalkyl, hydroxyalkyl, halo, cyano, carbamoyl, alkyl carbamoyl, formyl, alkylamino or amino; [0011]
  • X is —(CR4R5)a-NR6-(CR4R5)b-; [0012]
  • R1, R2, R3, and R5 are hydrogen or alkyl; [0013]
  • R4 and R6 are hydrogen, alkyl or aralkyl; a and b are 0, 1 or 2 and a+b=0, 1 or 2; [0014]
  • R4 and R5 groups on vicinal carbon atoms may together form a carbon-carbon double bond; and geminal R4 and R5 groups may together form a spiro substitutent, —(CH2)d-, where d is 2 to 5; or a pharmaceutically acceptable salt thereof. These compounds are described as cardiotonics. [0015]
  • WO 00/66560 discloses compounds of formula [0016]
    Figure US20020198198A1-20021226-C00003
  • These compounds are described as progesterone receptor modulators [0017]
  • SUMMARY OF THE INVENTION
  • The invention provides the use of spirotricyclic derivatives, which are PDE inhibitors and more particularly PDE7 inhibitors, having the following formula (I), (II) or (III): [0018]
    Figure US20020198198A1-20021226-C00004
  • in which, [0019]
  • a) X[0020] 1, X2, X3 and X4 are the same or different and are selected from:
  • N, provided that not more than two of the groups X[0021] 1, X2, X3 and X4 simultaneously represent a nitrogen atom, or,
  • C—R[0022] 1, in which R1 is selected from:
  • Q1, or [0023]
  • lower alkyl, lower alkenyl or lower alkynyl, these groups being unsubstituted or substituted with one or several groups Q2; [0024]
  • the group X[0025] 5—R5 in which,
  • X[0026] 5 is selected from:
  • a single bond, [0027]
  • lower alkylene, lower alkenylene or lower alkynylene, optionally interrupted with 1 or 2 heteroatoms chosen from O, S, S(═O), SO[0028] 2 or N, the carbon atoms of these groups being unsubstituted or substituted with one or several groups, identical or different, selected from SR6, OR6, NR6R7, ═O, ═S or ═N—R6 in which R6 and R7 are the same or different and are selected from hydrogen or lower alkyl, and,
  • R[0029] 5 is selected from aryl, heteroaryl, cycloalkyl optionally interrupted
  • with C(═O) or with 1, 2, or 3 heteroatoms chosen from O, S, S(═O), [0030]
  • SO[0031] 2 or N, cycloalkenyl optionally interrupted with C(═O) or with 1, 2, or
  • 3 heteroatoms chosen from O, S, S(═O), SO[0032] 2 or N, or a bicyclic group, these groups being unsubstituted or substituted with one or several groups selected from Q3, heteroaryl or lower alkyl optionally substituted with Q3;
  • in which Q1, Q2, Q3 are the same or different and are selected from [0033]
  • hydrogen, halogen, CN, NO[0034] 2, SO3H, P(═O)(OH)2
  • OR[0035] 2, OC(═O)R2, C(═O)OR2, SR2, S(═O)R2, C(═O)—NH—SO2—CH3, NR3R4, Q-R2, Q-NR3R4, NR2-Q-NR3R4 or NR3-Q-R2 in which Q is selected from C(═NR), C(═O), C(═S) or SO2, R is selected from hydrogen, CN, SO2NH2 or lower alkyl and R2, R3 and R4 are the same or different and are selected from:
  • hydrogen, [0036]
  • lower alkyl optionally interrupted with C(═O), Q4-aryl, Q4-heteroaryl, Q4-cycloalkyl optionally interrupted with C(═O) or with 1 or 2 heteroatoms chosen from O, S, S(═O), SO[0037] 2 or N, or Q4-cycloalkenyl optionally interrupted with C(═O) or with 1 or 2 heteroatoms chosen from O, S, S(═O), SO2 or N, in which
  • Q4 is selected from (CH[0038] 2)n, lower alkyl interrupted with one heteroatom selected from O, S or N, lower alkenyl or lower alkynyl, these groups being optionally substituted with lower alkyl, OR′ or NR′R″ in which R′ and R″ are the same or different and are selected from hydrogen or lower alkyl;
  • n is an integer selected from 0, 1, 2, 3 or 4; [0039]
  • these groups being unsubstituted or substituted with one or several groups selected from lower alkyl, halogen, CN, CH[0040] 3, SO3H, SO2CH3, C(═O)—NH—SO2—CH3, CF3, OR6, COOR6, C(═O)R6, NR6R7, NR6C(═O)R7, C(═O)NR6R7 or SO2NR6R7, in which R6 and R7 are the same or different and are selected from hydrogen or lower alkyl optionally substituted with one or two groups selected from OR, COOR or NRR8 in which R and R8 are hydrogen or lower alkyl, and,
  • R[0041] 6 and R7, and/or, R3 and R4, together with the nitrogen atom to which they are linked, can form a 4- to 8-membered heterocyclic ring, which may contain one or two heteroatoms selected from O, S, S(═O), SO2 or N, and which may be substituted with,
  • (CH[0042] 2)n-Q5, in which n is an integer selected from 0, 1, 2 and 3, and Q5 is a 4- to 8-membered heterocyclic ring which may contain one or two heteroatoms selected from O, S or N and which may be substituted with a lower alkyl, or,
  • a lower alkyl optionally substituted with OR′, NR′R″, C(═O)NR′R″ or COOR′ in which R′ and R″ are the same or different and are selected from, [0043]
  • H, or, [0044]
  • lower alkyl optionally substituted with OR or COOR in which R is hydrogen or lower alkyl and, [0045]
  • R′ and R″ together with the nitrogen atom to which they are linked, can form a 4- to 8-membered heterocyclic ring, which may contain one or two heteroatoms selected from O, S or N; or, [0046]
  • when X[0047] 1 and X2 both represent C—R1, the 2 substituents R1 may form together with the carbon atoms to which they are attached, a 5-membered heterocyclic ring comprising a nitrogen atom and optionally a second heteroatom selected from O, S or N;
  • b) X is O, S or NR[0048] 9, in which R9 is selected from,
  • hydrogen, CN, OH, NH[0049] 2,
  • lower alkyl, lower alkenyl or lower alkynyl, these groups being unsubstituted or substituted with cycloalkyl optionally interrupted with 1 or 2 heteroatoms chosen from O, S, S(═O), SO[0050] 2 or N, cycloalkenyl optionally interrupted with 1 or 2 heteroatoms chosen from O, S, S(═O), SO2 or N, aryl, heteroaryl, OR10, COOR10 or NR10R11 in which R10 and R11 are the same or different and are selected from hydrogen or lower alkyl;
  • c) Y is selected from O, S or N—R[0051] 12, in which R12 is selected from:
  • hydrogen, CN, OH, NH[0052] 2,
  • lower alkyl, lower alkenyl or lower alkynyl, these groups being unsubstituted or substituted with cycloalkyl optionally interrupted with 1 or 2 heteroatoms chosen from O, S, S(═O), SO[0053] 2 or N, cycloalkenyl optionally interrupted with 1 or 2 heteroatoms chosen from O, S, S(═O), SO2 or N, aryl, heteroaryl, R10, COOR10 or NR10R11 in which R10 and R11 are the same or different and are selected from hydrogen or lower alkyl;
  • d) Z is chosen from CH—NO[0054] 2, O, S or NR13 in which R13 is selected from:
  • hydrogen, CN, OH, NH[0055] 2, aryl, heteroaryl, cycloalkyl optionally interrupted with one or several heteroatoms chosen from O, S, S(═O), SO2 or N, cycloalkenyl optionally interrupted with one or several heteroatoms chosen from O, S, S(═O), SO2 or N, C(═O)R14, C(═O)NR14R15, OR14, or,
  • lower alkyl, unsubstituted or substituted with one or several groups which are the same or different and which are selected OR[0056] 14, COOR14 or NR14R15;
  • R[0057] 14 and R15 being independently selected from hydrogen or lower alkyl, or, R14 and R15, together with the nitrogen atom to which they are linked, can form a 4- to 8-membered heterocyclic ring which may contain one or two heteroatoms chosen from O, S or N, and which may be substituted with a lower alkyl, or,
  • when Y is N—R[0058] 12 and Z is N—R13, R12 and R13 may form together a —CH═N— group or a —C═C— group,
  • when X is N—R[0059] 9 and Z is N—R13, R9 and R13 may form together a —CH═N— group or a —C═C— group;
  • e) Z[0060] 1 is chosen from H, CH3 or NR16R17 in which R16 and R17 are the same or different and are selected from:
  • hydrogen, CN, aryl, heteroaryl, cycloalkyl optionally interrupted with one or several heteroatoms chosen from O, S, S(═O), SO[0061] 2 or N, cycloalkenyl optionally interrupted with one or several heteroatoms chosen from O, S, S(═O), SO2 or N, C(═O)R14, C(═O)NR14R15, OR14, or,
  • lower alkyl unsubstituted or substituted with one or several groups selected from OR[0062] 14, COOR14 or NR14R15,
  • R[0063] 14 and R15 being chosen from hydrogen or lower alkyl, and,
  • R[0064] 14 and R15, and/or, R16 and R17, together with the nitrogen atom to which they are linked, can form a 4- to 8-membered heterocyclic ring which may contain one or two heteroatoms chosen from O, S or N, and which may be substituted with a lower alkyl;
  • f) A is a cycle chosen from: [0065]
    Figure US20020198198A1-20021226-C00005
  •  in which, [0066]
  • A[0067] 1, A2, A3, A4, A5 and A6 are the same or different and are selected from O, S, C, C(═O), SO, SO2 or N—R18 in which R18 is selected from:
  • hydrogen, aryl, heteroaryl, cycloalkyl optionally interrupted with one or several heteroatoms chosen from O, S, S(═O), SO[0068] 2 or N, cycloalkenyl optionally interrupted with one or several heteroatoms chosen from O, S, S(═O), SO2 or N,
  • lower alkyl unsubstituted or substituted with aryl, heteroaryl, cycloalkyl optionally interrupted with one or several heteroatoms chosen from O, S, S(═O), SO[0069] 2 or N, cycloalkenyl optionally interrupted with one or several heteroatoms chosen from O, S, S(═O), SO2 or N, CN, NR19R20, C(═O)NR19R20, OR19, C(═O)R19 or C(═O)OR19 in which R19 and R20 are identical or different and are selected from hydrogen or lower alkyl;
  • * represents the carbon atom which is shared between the cycle A and the backbone cycle containing X and/or Y; [0070]
  • each carbon atom of the cycle A is unsubstituted or substituted with 1 or 2 groups, identical or different, selected from lower alkyl optionally substituted with OR[0071] 21, NR21R22, COOR21 or CONR21R22, lower haloalkyl, CN, F, ═O, SO2NR19R20, OR19, SR19, C(═O)OR19, C(═O)NR19R20 or NR19R20 in which R19 and R20 are identical or different and are selected from hydrogen or lower alkyl optionally substituted with OR21, NR21R22, COOR21 or CONR21R22 in which R21 and R22 are identical or different and are selected from hydrogen or lower alkyl, and,
  • R[0072] 19 and R20, and/or, R21 and R22, together with the nitrogen atom to which they are linked, can form a 4- to 8-membered heterocyclic ring;
  • 2 atoms of the cycle A, which are not adjacent, may be linked by a 2, 3 or 4 carbon atom chain which may be interrupted with 1 heteroatom chosen from O, S or N; [0073]
  • provided that not more than two of the groups A[0074] 1, A2, A3, A4, A5 and A6 simultaneously represent a heteroatom;
  • of their tautomeric forms, their racemic forms or their isomers and of their pharmaceutically acceptable derivatives, [0075]
  • for the prevention or the treatment of disorders for which therapy by a PDE7 inhibitor is relevant. [0076]
  • The invention also relates to compounds, which are PDE7 inhibitors, having the following formula (I), (II) or (III) [0077]
    Figure US20020198198A1-20021226-C00006
  • in which, [0078]
  • a) X[0079] 1, X2, X3 and X4 are the same or different and are selected from:
  • N, provided that not more than two of the groups X[0080] 1, X2, X3 and X4 simultaneously represent a nitrogen atom, or,
  • C—R[0081] 1, in which R1 is selected from:
  • Q1, or [0082]
  • lower alkyl, lower alkenyl or lower alkynyl, these groups being unsubstituted or substituted with one or several groups Q2; [0083]
  • the group X[0084] 5—R5 in which,
  • X[0085] 5 is selected from:
  • a single bond, [0086]
  • lower alkylene, lower alkenylene or lower alkynylene; optionally interrupted with 1 or 2 heteroatoms chosen from O, S, S(═O), SO[0087] 2 or N, ,the carbon atoms of these groups being unsubstituted or substituted with one or several groups, identical or different, selected from SR6, OR6, NR6R7, ═O, ═S or ═N—R6 in which R6 and R7 are the same or different and are selected from hydrogen or lower alkyl, and,
  • R[0088] 5 is selected from aryl, heteroaryl, cycloalkyl optionally interrupted with C(═O) or with 1, 2, or 3 heteroatoms chosen from O, S, S(═O), SO2 or N, cycloalkenyl optionally interrupted with C(═O) or with 1, 2, or 3 heteroatoms chosen from O, S, S(═O), SO2 or N, or a bicyclic group, these groups being unsubstituted or substituted with one or several groups selected from Q3, heteroaryl or lower alkyl optionally substituted with Q3;
  • in which Q1, Q2, Q3 are the same or different and are selected from [0089]
  • hydrogen, halogen, CN, NO[0090] 2, SO3H, P(═O)(OH)2
  • OR[0091] 2, OC(═O)R2, C(═O)OR2, SR2, S(═O)R2, C(═O)—NH—SO2—CH3, NR3R4, Q-R2, Q-NR3R4, NR2-Q-NR3R4 or NR3-Q-R2 in which Q is selected from C(═NR), C(═O), C(═S) or SO2, R is selected from hydrogen, CN, SO2NH2 or lower alkyl and R2, R3 and R4 are the same or different and are selected from:
  • hydrogen, [0092]
  • lower alkyl optionally interrupted with C(═O), Q4-aryl, Q4-heteroaryl, Q4-cycloalkyl optionally interrupted with C(═O) or with 1 or 2 heteroatoms chosen from O, S, S(═O), SO[0093] 2 or N, or Q4-cycloalkenyl optionally interrupted with C(═O) or with 1 or 2 heteroatoms chosen from O, S, S(═O), SO2 or N, in which
  • Q4 is selected from (CH[0094] 2)n, lower alkyl interrupted with one heteroatom selected from O, S or N, lower alkenyl or lower alkynyl, these groups being optionally substituted with lower alkyl, OR′ or NR′R″ in which R′ and R″ are the same or different and are selected from hydrogen or lower lower alkyl;
  • n is an integer selected from 0, 1, 2, 3 or 4; [0095]
  • these groups being unsubstituted or substituted with one or several groups selected from lower alkyl, halogen, CN, CH[0096] 3, SO3H, SO2CH3, C(═O)—NH—SO2—CH3, CF3, OR6, COOR6, C(═O)R6, NR6R7, NR6C(═O)R7, C(═O)NR6R7 or SO2NR6R7, in which R6 and R7 are the same or different and are selected from hydrogen or lower alkyl optionally substituted with one or two groups selected from OR, COOR or NRR8 in which R and R8 are hydrogen or lower alkyl, and,
  • R[0097] 6 and R7, and/or, R3 and R4, together with the nitrogen atom to which they are linked, can form a 4- to 8-membered heterocyclic ring, which may contain one or two heteroatoms selected from O, S, S(═O), SO2, or N, and which may be substituted with,
  • (CH[0098] 2)n-Q5, in which n is an integer selected from 0, 1, 2 and 3, and Q5 is a 4- to 8-membered heterocyclic ring which may contain one or two heteroatoms selected from O, S or N and which may be substituted with a lower alkyl, or,
  • a lower alkyl optionally substituted with OR′, NR′R″, C(═O)NR′R″ or COOR′ in which R′ and R″ are the same or different and are selected from, [0099]
  • H,or, [0100]
  • lower alkyl optionally substituted with OR or COOR in which R is hydrogen or lower alkyl and, [0101]
  • R′ and R″ together with the nitrogen atom to which they are linked, can form a 4- to 8-membered heterocyclic ring, which may contain one or two heteroatoms selected from O, S or N; or, [0102]
  • when X[0103] 1 and X2 both represent C—R1, the 2 substituents R1 may form together with the carbon atoms to which they are attached, a 5-membered heterocyclic ring comprising a nitrogen atom and optionally a second heteroatom selected from O, S or N;
  • b) X is O or NR[0104] 9, in which R9 is selected from,
  • hydrogen, CN, OH, NH[0105] 2,
  • lower alkyl, lower alkenyl or lower alkynyl, these groups being unsubstituted or substituted with cycloalkyl optionally interrupted with 1 or 2 heteroatoms chosen from O, S, S(═O), SO[0106] 2 or N, cycloalkenyl optionally interrupted with 1 or 2 heteroatoms chosen from O, S, S(═O), SO2 or N, aryl, heteroaryl, OR10, COOR10 or NR10R11 in which R10 and R11 are the same or different and are selected from hydrogen or lower alkyl;
  • c) Y is selected from O, S or N—R[0107] 12, in which R12 is selected from:
  • hydrogen, CN, OH, NH[0108] 2,
  • lower alkyl, lower alkenyl or lower alkynyl, these groups being unsubstituted or substituted with, cycloalkyl optionally interrupted with 1 or 2 heteroatoms chosen from O, S, S(═O), SO[0109] 2 or N, cycloalkenyl optionally interrupted with 1 or 2 heteroatoms chosen from O, S, S(═O), SO2 or N, aryl, heteroaryl, OR10, COOR10 or NR10R11 in which R10 and R11 are the same or different and are selected from hydrogen or lower alkyl;
  • d) Z is chosen from CH—NO[0110] 2, O, S or NR13 in which R13 is selected from:
  • hydrogen, CN, OH, NH[0111] 2, aryl, heteroaryl, cycloalkyl optionally interrupted with one or several heteroatoms chosen from O, S, S(═O), SO2 or N, cycloalkenyl optionally interrupted with one or several heteroatoms chosen from O, S, S(═O), SO2 or N, C(═O)R14, C(═O)NR14R15, OR14, or,
  • lower alkyl, unsubstituted or substituted with one or several groups which are the same or different and which are selected OR[0112] 14, COOR10 or NR14R15;
  • R[0113] 14 and R15 being independently selected from hydrogen or lower alkyl, or, R14 and R15, together with the nitrogen atom to which they are linked, can form a 4- to 8-membered heterocyclic ring which may contain one or two heteroatoms chosen from O, S or N, and which may be substituted with a lower alkyl, or,
  • when Y is N—R[0114] 12 and Z is N—R13, may form together a —CH═N— group or a —C═C— group,
  • when X is N—R[0115] 9 and Z is N—R13, R9 and R13 may form together a —CH═N— group or a —C═C— group;
  • e) Z[0116] 1 is chosen from H, CH3 or NR16R17 in which R16 and R17 are the same or different and are selected from:
  • hydrogen, CN, aryl, heteroaryl, cycloalkyl optionally interrupted with one or several heteroatoms chosen from O, S, S(═O), SO[0117] 2 or N, cycloalkenyl optionally interrupted with one or several heteroatoms chosen from O, S, S(═O), SO2 or N, C(═O)R14, C(═O)NR14R15 OR14, or,
  • lower alkyl unsubstituted or substituted with one or several groups selected from OR[0118] 14, COOR14 or NR14R15,
  •  R[0119] 14 and R15 being chosen from hydrogen or lower alkyl, and,
  •  R[0120] 14 and R15, and/or, R16 and R17, together with the nitrogen atom to which they are linked, can form a 4- to 8-membered heterocyclic ring which may contain one or two heteroatoms chosen from O, S or N, and which may be substituted with a lower alkyl;
  • f) A is a cycle chosen from: [0121]
    Figure US20020198198A1-20021226-C00007
  •  in which, [0122]
  • A[0123] 1, A2, A4, A5 and A6 are the same or different and are selected from O, S, C, C(═O), SO, SO2 or N—R18 in which R18 is selected from:
  • hydrogen, aryl, heteroaryl, cycloalkyl optionally interrupted with one or several heteroatoms chosen from O, S, S(═O), SO[0124] 2 or N, cycloalkenyl optionally interrupted with one or several heteroatoms chosen from O, S, S(═O), SO2 or N,
  • lower alkyl unsubstituted or substituted with aryl, heteroaryl, cycloalkyl optionally interrupted with one or several heteroatoms chosen from O, S, S(═O), SO[0125] 2 or N, cycloalkenyl optionally interrupted with one or several heteroatoms chosen from O, S, S(═O), SO2 or N, CN, NR19R20, C(═O)NR19R20, OR19, C(═O)R19 or C(═O)OR19 in which R19 and R20 are identical or different and are selected from hydrogen or lower alkyl;
  • A[0126] 3 is selected from O, S, C, C(═O), SO or SO2, or N—R18 when A1 and/or A2 are C(═O) or when Y is O or S, wherein R18 is as defined above;
  • *represents the carbon atom which is shared between the cycle A and the backbone cycle containing X and/or Y; [0127]
  • each carbon atom of the cycle A is unsubstituted or substituted. with 1 or 2 groups, identical or different, selected from lower alkyl optionally substituted with OR[0128] 21, NR21R22, COOR21 or CONR21R22, lower haloalkyl, CN, F, ═O, SO2NR19R20, OR19, SR19, C(═O)OR19, C(═O)NR19R20 or NR19R20 in which R19 and R20 are identical or different and are selected from hydrogen or lower alkyl optionally substituted with OR21, NR21R22, COOR21 or CONR21R22 in which R21 and R22 are identical or different and are selected from hydrogen or lower alkyl, and,
  • R[0129] 19 and R20, and/or, R21 and R22, together with the nitrogen atom to which they are linked, can form a 4- to 8-membered heterocyclic ring;
  • 2 atoms of the cycle A, which are not adjacent, may be linked by a 2, 3 or 4 carbon atom chain which may be interrupted with 1 heteroatom chosen from O, S or N; [0130]
  • provided that: [0131]
  • not more than two of the groups A[0132] 1, A2, A3, A4, A5 and A6 simultaneously represent a heteroatom;
  • the cycle A does not contain more than 2 carbon atoms in an sp[0133] 2 hybridization state;
  • when X is O, X[0134] 2 is not C—R1 in which R1 is
  • a thienyl substituted with CN or with CN and CH[0135] 3,
  • a phenyl substituted with CN, Cl, NO[0136] 2 or CN and F,
  • Br [0137]
  • F; [0138]
  • or their tautomeric forms, their racemic forms or their isomers and their pharmaceutically acceptable derivatives. [0139]
  • These compounds are selective PDE7 inhibitors. They can be used in the treatment of various diseases, such as T-cell-related diseases, autoimmune diseases, osteoarthritis, rheumatoid arthritis, multiple sclerosis, osteoporosis, chronic obstructive pulmonary disease (COPD), asthma, cancer, acquired immune deficiency syndrome (AIDS), allergy or inflammatory bowel disease (IBD). [0140]
  • The invention also relates to a process for preparing the above compounds. [0141]
  • The invention further concerns the use of a compound of formula (I), (II) or (III) for the preparation of a medicament for the prevention or the treatment of disorders for which therapy by a PDE7 inhibitor is relevant. [0142]
  • The invention also provides a method for the treatment of a disorder for which therapy by a PDE7 inhibitor is relevant, comprising administering to a mammal in need thereof an effective amount of compound of formula (I), (II) or (III). [0143]
  • The invention also provides a method for the treatment of T-cell-related diseases, autoimmune diseases, osteoarthritis, rheumatoid arthritis, multiple sclerosis, osteoporosis, chronic obstructive pulmonary disease (COPD), asthma, cancer, acquired immune deficiency syndrome (AIDS), allergy or inflammatory bowel disease (IBD), comprising administering to a mammal in need thereof an effective amount of compound of formula (I), (II) or (III). [0144]
  • The invention also concerns a pharmaceutical composition comprising a compound of formula (I), (II) or (III) together with a pharmaceutically acceptable carrier, excipient, diluent or delivery system. [0145]
  • DETAILED DESCRIPTION OF THE INVENTION
  • The present invention provides the use of compounds, which are PDE7 inhibitors, having formula (I), (II) or (III), [0146]
    Figure US20020198198A1-20021226-C00008
  • in which [0147]
  • a) X[0148] 1, X2, X3 and X4 are the same or different and are selected from:
  • N, provided that not more than two of the groups X[0149] 1, X2, X3 and X4 simultaneously represent a nitrogen atom, or,
  • C—R[0150] 1, in which R1 is selected from:
  • Q1, or [0151]
  • lower alkyl, lower alkenyl or lower alkynyl, these groups being unsubstituted or substituted with one or several groups Q2; [0152]
  • the group X[0153] 5—R5 in which,
  • X[0154] 5 is selected from:
  • a single bond, [0155]
  • lower alkyl, lower alkenylene or lower alkynylene, optionally interrupted with 1 or 2 heteroatoms chosen from O, S, S(═O), SO[0156] 2 or N, ,the carbon atoms of these groups being unsubstituted or substituted with one or several groups, identical or different, selected from SR6, OR6, NR6R7, ═O, ═S or═N—R6 in which R6 and R7 are the same or different and are selected from hydrogen or lower alkyl, and,
  • R[0157] 5 is selected from aryl, heteroaryl, cycloalkyl optionally interrupted with C(═O) or with 1, 2, or 3 heteroatoms chosen from O, S, S(═O), SO2 or N, cycloalkenyl optionally interrupted with C(═O) or with 1, 2, or 3 heteroatoms chosen from O, S, S(═O), SO2 or N, or a bicyclic group, these groups being unsubstituted or substituted with one or several groups selected from Q3, heteroaryl or lower alkyl optionally substituted with Q3;
  • in which Q1, Q2, Q3 are the same or different and are selected from [0158]
  • hydrogen, halogen, CN, NO[0159] 2, SO3H, P(═O)(OH)2
  • OR[0160] 2, OC(═O)R2, C(═O)OR2, SR2, S(═O)R2, NR3R4, Q-R2, Q-NR3R4, NR2-Q-NR3R4 or NR3-Q-R2 in which Q is selected from C(═NR), C(═O), C(═S) or SO2, R is selected from hydrogen or lower alkyl and R2, R3 and R4 are the same or different and are selected from:
  • hydrogen, [0161]
  • lower alkyl optionally interrupted with C(═O), (CH[0162] 2)n-aryl, (CH2)n-heteroaryl, (CH2)n-cycloalkyl optionally interrupted with C(═O) or with 1 or 2 heteroatoms chosen from O, S, S(═O), SO2 or N or (CH2)n-cycloalkenyl optionally interrupted with C(═O) or with 1 or 2 heteroatoms chosen from O, S, S(═O), SO2 or N, in which n is an integer selected from 0, 1, 2, 3 or 4;
  • these groups being unsubstituted or substituted with one or several groups selected from lower alkyl, halogen, CN, SO[0163] 3H, CH3, SO2CH3, CF3, C(═O)—NH—SO2—CH3, OR6, COOR6, NR6R7, C(═O)NR6R7 or SO2NR6R7, in which R6 and R7 are the same or different and are selected from hydrogen or lower alkyl optionally substituted with one or two groups selected from OR, COOR or NRR8 in which R and R8 are hydrogen or lower alkyl, and,
  • R[0164] 6 and R7, and/or, R3 and R4, together with the nitrogen atom to which they are linked, can form a 4- to 8-membered heterocyclic ring, which may contain one or two heteroatoms selected from O, S, S(═O), SO2 or N, and which may be substituted with,
  • a 4- to 8-membered heterocyclic ring, which may contain one or two heteroatoms selected from O, S or N and which may be substituted with a lower alkyl, or, [0165]
  • a lower alkyl optionally substituted with OR′, NR′R″, C(═O)NR′R″ or COOR′ in which R′ and R″ are the same or different and are selected from, [0166]
  • H,or, [0167]
  • lower alkyl optionally substituted with OR or COOR in which R is hydrogen or lower alkyl and, [0168]
  • R′ and R″ together with the nitrogen atom to which they are linked, can form a 4- to 8-membered heterocyclic ring, which may contain one or two heteroatoms selected from O, S or N; [0169]
  • b) X is O, S or NR[0170] 9, in which R9 is selected from,
  • hydrogen, CN, OH, NH[0171] 2,
  • lower alkyl, lower alkenyl or lower alkynyl, these groups being unsubstituted or substituted with cycloalkyl optionally interrupted with 1 or 2 heteroatoms chosen from O, S, S(═O), SO[0172] 2 or N, cycloalkenyl optionally interrupted with 1 or 2 heteroatoms chosen from O, S, S(═O), SO2 or N, aryl, heteroaryl, OR10 or NR10R11 in which R10 and R11 are the same or different and are selected from hydrogen or lower alkyl;
  • c) Y is selected from O, S or N—R[0173] 12, in which R12 is selected from:
  • hydrogen, CN, OH, NH[0174] 2,
  • lower alkyl, lower alkenyl or lower alkynyl, these groups being unsubstituted or substituted with, cycloalkyl optionally interrupted with 1 or 2 heteroatoms chosen from O, S, S(═O), SO[0175] 2 or N, cycloalkenyl optionally interrupted with 1 or 2 heteroatoms chosen from O, S, S(═O), SO2 or N, aryl, heteroaryl, OR10 or NR10R11 in which R10 and R11 are the same or different and are selected from hydrogen or lower alkyl; d) Z is chosen from CH—NO2, O, S or NR13 in which R13 is selected from:
  • hydrogen, CN, OH, NH[0176] 2, aryl, heteroaryl, cycloalkyl optionally interrupted with one or several heteroatoms chosen from O, S, S(═O), SO2 or N, cycloalkenyl optionally interrupted with one or several heteroatoms chosen from O, S, S(═O), SO2 or N, C(═O)R14, C(═O)NR14R15, OR14, or,
  • lower alkyl, unsubstituted or substituted with one or several groups which are the same or different and which are selected OR[0177] 14 or NR14R15;
  • R[0178] 14 and R15 being independently selected from hydrogen or lower alkyl, or, R14 and R15, together with the nitrogen atom to which they are linked, can form a 4- to 8-membered heterocyclic ring which may contain one or two heteroatoms chosen from O, S or N, and which may be substituted with a lower alkyl;
  • e) Z[0179] 1 is chosen from H, CH3 or NR16R17 in which R16 and R17 are the same or different and are selected from:
  • hydrogen, CN, aryl, heteroaryl, cycloalkyl optionally interrupted with one or several heteroatoms chosen from O, S, S(═O), SO[0180] 2 or N, cycloalkenyl optionally interrupted with one or several heteroatoms chosen from O, S, S(═O), SO2 or N, C(═O)R14, C(═O)NR14R15, OR14, or,
  • lower alkyl unsubstituted or substituted with one or several groups selected from OR[0181] 14 or NR14R15,
  • R[0182] 14 and R15 being chosen from hydrogen or lower alkyl, and,
  • R[0183] 14 and R15, and/or, R16 and R17, together with the nitrogen atom to which they are linked, can form a 4- to 8-membered heterocyclic ring which may contain one or two heteroatoms chosen from O, S or N, and which may be substituted with a lower alkyl;
  • f) A is a cycle chosen from: [0184]
    Figure US20020198198A1-20021226-C00009
  •  in which, [0185]
  • A[0186] 1, A2, A3, A4, A5 and A6 are the same or different and are selected from O, S, C, C(═O), SO, SO2 or N—R18 in which R18 is selected from:
  • hydrogen, aryl, heteroaryl, cycloalkyl optionally interrupted with one or several heteroatoms chosen from O, S, S(═O), SO[0187] 2 or N, cycloalkenyl optionally interrupted with one or several heteroatoms chosen from O, S, S(═O), SO2 or N,
  • lower alkyl unsubstituted or substituted with aryl, heteroaryl, cycloalkyl optionally interrupted with one or several heteroatoms chosen from O, S, S(═O), SO[0188] 2 or N, cycloalkenyl optionally interrupted with one or several heteroatoms chosen from O, S, S(═O), SO2 or N, CN, NR19R20, C(═O)NR19R20, OR19, C(═O)R19 or C(═O)OR19 in which R19 and R20 are identical or different and are selected from hydrogen or lower alkyl;
  • represents the carbon atom which is shared between the cycle A and the backbone cycle containing X and/or Y; [0189]
  • each carbon atom of the cycle A is unsubstituted or substituted with 1 or 2 groups, identical or different, selected from lower alkyl optionally substituted with OR[0190] 21, NR21R22, COOR21or R21 or CONR21R22, lower haloalkyl, CN, F, ═O, SO2NR19R20, OR19, SR19, C(═O)OR19, C(═O)NR19R20 or NR19R20 in which R19 and R20 are identical or different and are selected from hydrogen or lower alkyl optionally substituted with OR21, NR21R22, COOR21 or CONR21R22 in which R21 and R22 are identical or different and are selected from hydrogen or lower alkyl, and,
  • R[0191] 19 and R20, and/or, R21 and R22, together with the nitrogen atom to which they are linked, can form a 4- to 8-membered heterocyclic ring;
  • 2 atoms of the cycle A, which are not adjacent, may be linked by a 2, 3 or 4 carbon atom chain which may be interrupted with 1 heteroatom chosen from O, S or N; [0192]
  • provided that not more than two of the groups A[0193] 1, A2, A3, A4, A5 and A6 simultaneously represent a heteroatom;
  • of their tautomeric forms, their racemic forms or their isomers and of their pharmaceutically acceptable derivatives, [0194]
  • for the prevention or the treatment of disorders for which therapy by a PDE7 inhibitor is relevant. [0195]
  • A preferred use concerns the PDE7 inhibitors of formula (I), [0196]
    Figure US20020198198A1-20021226-C00010
  • in which X[0197] 1, X2, X3, X4, X, Y, Z and A are as defined above, for the prevention or the treatment of disorders for which therapy by a PDE7 inhibitor is relevant.
  • A more preferred use concerns the PDE7 inhibitors of formula (II) or (III) in which, [0198]
  • a) X[0199] 1, X2 and X3 are the same or different and are C—R1, in which R1 is selected from:
  • hydrogen, halogen, CN, SO[0200] 3H, NO2, CF3, OR2, SR2, NR2R3, COR2, COOR2, CONR2R3, SO2CH3, SO2NR2R3 in which R2 and R3 are the same or different and are selected from hydrogen or lower alkyl optionally substituted with halogen, CN, SO3H, OR6, COOR6, NR6R7, SO2NR6R7 or C(═O)NR6R7 in which R6 and R7 are the same or different and are selected from hydrogen or lower alkyl, and,
  • R[0201] 6 and R7, together with the nitrogen atom to which they are linked, can form a 4- to 8-membered heterocyclic ring
  • lower alkyl, lower alkenyl or lower alkynyl, these groups being unsubstituted or substituted with 1, 2 or 3 groups selected from halogen, CN, OR[0202] 2, COOR2, NR3R4, SO2NR3R4 or C(═O)NR3R4 in which R2, R3 and R4 are the same or different and are selected from hydrogen or lower alkyl, and,
  • R[0203] 3 and R4, together with the nitrogen atom to which they are linked, can form a 4- to 8-membered heterocyclic ring;
  • the group X[0204] 5—R5 in which,
  • X[0205] 5 is selected from a lower alkylene or a single bond, and,
  • R[0206] 5 is selected from phenyl, pyridyl or indolyl, these groups being unsubstituted or substituted with one or several groups selected from Q3, heteroaryl or lower alkyl optionally substituted with Q3 in which Q3 is selected from:
  • halogen, CN, SO[0207] 3H, NO2, CF3, OR2, OC(═O)R2, C(═O)R2, C(═O)OR2, NH—C(═O)R2, NR3R4, SO2NR3R4 or C(═O)NR3R4 in which R2, R3 and R4 are the same or different and are selected from:
  • hydrogen, lower alkyl unsubstituted or substituted with one or several groups selected from halogen, OR[0208] 6, COOR6 or NR6R7 in which R6 and R7 are the same or different and are selected from hydrogen or lower alkyl and,
  • R[0209] 6 and R7, and/or, R3 and R4, together with the nitrogen atom to which they are linked, can form a 4- to 8-membered heterocyclic ring, which may contain one or two heteroatoms selected from O, S or N, and which may be substituted with
  • a 4- to 8-membered heterocyclic ring, which may contain one or two heteroatoms selected from O, S or N and which may be substituted with a lower alkyl, or, [0210]
  • a lower alkyl optionally substituted with OR′, NR′R″, C(═O)NR′R″ or COOR′ in which R′ and R″ are the same or different and are selected from [0211]
  • H,or, [0212]
  • lower alkyl optionally substituted with OR or COOR in which R is hydrogen or lower alkyl and, [0213]
  • R′ and R″ together with the nitrogen atom to which they are linked, can form a 4- to 8-membered heterocyclic ring, which may contain one or two heteroatoms selected from O, S or N; [0214]
  • b) X[0215] 4 is C—R1 in which R1 is selected from hydrogen, halogen, CN, NO2, SO2CH3, SO3H, CH3, CF3, OR2, SR2, NR2R3, COOR2, CONR2R3, SO2NR2R3in which R2 and R3 are the same or different and are selected from hydrogen or lower alkyl;
  • c) X is NH; [0216]
  • d) Y is NH; [0217]
  • e) Z[0218] 1 is chosen from NR16R17 in which R16 and R17 are the same or different and are selected from:
  • hydrogen, CN, C(═O)R[0219] 14, (C═O)NR14R15, OR14, or,
  • lower alkyl unsubstituted or substituted with one or several groups selected from OR[0220] 14 or NR14R15,
  • R[0221] 14 and R15 being chosen from hydrogen or lower alkyl, and,
  • R[0222] 14 and R15, and/or, R16 and R17, together with the nitrogen atom to which they are linked, can form a 4- to 8-membered heterocyclic ring which may contain one or two heteroatoms selected from O, S or N, and which may be substituted with a lower alkyl;
  • f) A is a cycle chosen from: [0223]
    Figure US20020198198A1-20021226-C00011
  •  in which, [0224]
  • A[0225] 1, A2, A3, A4 and A5 are the same or different and are selected from:
  • a carbon atom, unsubstituted or substituted with 1 or 2 groups, identical or different selected from lower alkyl, OH or F, or, [0226]
  • an oxygen atom; [0227]
  • *represents the carbon atom which is shared between the cycle A and the backbone cycle containing X and/or Y; [0228]
  • 2 atoms of the cycle A, which are not adjacent, may be linked by a 2, 3 or 4 carbon atom chain, [0229]
  • provided that: [0230]
  • not more than one of the groups A[0231] 1, A2, A3, A4 and A5 simultaneously represent an oxygen atom;
  • for the prevention or the treatment of disorders for which therapy by a PDE7 inhibitor is relevant. [0232]
  • A particularly preferred use concerns the PDE7 inhibitors of formula (I), in which, [0233]
  • a) X[0234] 1, X2 and X3 are the same or different and are C—R1, in which R1 is selected from:
  • hydrogen, halogen, CN, SO[0235] 3H, NO2, CF3, OR2, SR2, NR2R3, COR2, COOR2, CONR2R3, SO2CH3, SO2NR2R3 in which R2 and R3 are the same or different and are selected from hydrogen or lower alkyl optionally substituted with halogen, CN, OR6, COOR6, NR6R7, SO2NR6R7 or C(═O)NR6R7 in which R6 and R7 are the same or different and are selected from hydrogen or lower alkyl, and,
  • R[0236] 6 and R7, together with the nitrogen atom to which they are linked, can form a 4- to 8-membered heterocyclic ring;
  • lower alkyl, lower alkenyl or lower alkynyl, these groups being unsubstituted or substituted with 1, 2 or 3 groups selected from halogen, CN, SO[0237] 3H, OR2, COOR2, NR3R4, SO2NR3R4 or C(═O)NR3R4 in which R2, R3 and R4 are the same or different and are selected from hydrogen or lower alkyl, and,
  • R[0238] 3 and R4, together with the nitrogen atom to which they are linked, can form a 4- to 8-membered heterocyclic ring;
  • the group X[0239] 5—R5 in which,
  • X[0240] 5 is selected from a lower alkylene or a single bond, and,
  • R[0241] 5 is selected from phenyl, pyridyl or indolyl,
  • these groups being unsubstituted or substituted with 1, 2 or 3 groups selected from Q3, heteroaryl or lower alkyl optionally substituted with Q3 in which Q3 is selected from: [0242]
  • halogen, CN, SO[0243] 3H, NO2, CF3, OR2, OC(═O)R2, C(═O)R2, C(═O)OR2, NH—C(═O)R2, NR3R4, SO2NR3R4, C(═O)NR3R4 in which R2, R3 and R4 are the same or different and are selected from:
  • hydrogen, lower alkyl unsubstituted or substituted with one or several groups selected from halogen, OR[0244] 6, COOR6 or NR6R7 in which R6 and R7 are the same or different and are selected from hydrogen or lower alkyl and,
  • R[0245] 6 and R7, and/or, R3 and R4, together with the nitrogen atom to which they are linked, can form a 4- to 8-membered heterocyclic ring, which may contain one or two heteroatoms selected from O, S or N, and which may be substituted with,
  • a 4- to 8-membered heterocyclic ring, which may contain one or two heteroatoms selected from O, S or N and which may be substituted with a lower alkyl, or, [0246]
  • a lower alkyl optionally substituted with OR′, NR′R″, C(═O)NR′R″ or COOR′ in which R′ and R″ are the same or different and are selected from, [0247]
  • H,or, [0248]
  • lower alkyl optionally substituted with OR or COOR in which R is hydrogen or lower alkyl and, [0249]
  • R′ and R″ together with the nitrogen atom to which they are linked, can form a 4- to 8-membered heterocyclic ring, which may contain one or two heteroatoms selected from O, S or N; [0250]
  • b) X[0251] 4 is C—R1 in which R1 is selected from hydrogen, halogen, CN, NO2, SO2CH3, SO3H, CH3, CF3, OR2, SR2, NR2R3, COOR2, CONR2R3, SO2NR2R3 in which R2 and R3 are the same or different and are selected from hydrogen or lower alkyl;
  • c) X is NH; [0252]
  • d) Y is NH; [0253]
  • e) Z is chosen from O, S or NR[0254] 13 in which R13 is hydrogen or CN;
  • f) A is a cycle chosen from: [0255]
    Figure US20020198198A1-20021226-C00012
  •  in which, [0256]
  • A[0257] 1, A2, A3, A4 and A5 are the same or different and are selected from:
  • a carbon atom, unsubstituted or substituted with 1 or 2 groups, identical or different ,selected from lower alkyl, OH or F, or, [0258]
  • an oxygen atom; [0259]
  • *represents the carbon atom which is shared between the cycle A and the backbone cycle containing X and/or Y; [0260]
  • 2 atoms of the cycle A, which are not adjacent, may be linked by a 2, 3 or 4 carbon atom chain, [0261]
  • provided that: [0262]
  • not more than one of the groups A[0263] 1, A2, A3, A4 and A5 simultaneously represent an oxygen atom;
  • for the prevention or the treatment of disorders for which therapy by a PDE7 inhibitor is relevant. [0264]
  • A preferred group of compounds of formula (II) or (III) are those in which, [0265]
  • a) X[0266] 1, X2 and X3 are the same or different and are C—R1, in which R1 is selected from:
  • hydrogen, halogen, CN, SO[0267] 3H, NO2, CF3, OR2, SR2, NR2R3, COR2, COOR2, CONR2R3, SO2CH3, SO2NR2R3 in which R2 and R3 are the same or different and are selected from hydrogen or lower alkyl optionally substituted with halogen, CN, SO3H, OR6, COOR6, NR6R7, SO2NR6R7 or C(═O)NR6R7 in which R6 and R7 are the same or different and are selected from hydrogen or lower alkyl, and,
  • R[0268] 6 and R7, together with the nitrogen atom to which they are linked, can form a 4- to 8-membered heterocyclic ring;
  • lower alkyl, lower alkenyl or lower alkynyl, these groups being unsubstituted or substituted with 1, 2 or 3 groups selected from halogen, CN, OR[0269] 2, COOR2, NR3R4, SO2NR3R4 or C(═O)NR3R4 in which R2, R3 and R4 are the same or different and are selected from hydrogen or lower alkyl, and,
  • R[0270] 3 and R4, together with the nitrogen atom to which they are linked, can form a 4- to 8-membered heterocyclic ring;
  • the group X[0271] 5—R5 in which,
  • X[0272] 5 is selected from a lower alkylene or a single bond, and,
  • R[0273] 5 is selected from phenyl, pyridyl or indolyl,
  • these groups being unsubstituted or substituted with one or several groups selected from Q3, heteroaryl or lower alkyl optionally substituted with Q3 in which Q3 is selected from: [0274]
  • halogen, CN, SO[0275] 3H, NO2, CF3, OR2, OC(═O)R2, C(═O)R2, C(═O)OR2, NH—C(═O)R2, NR3R4, SO2NR3R4 or C(═O)NR3R4 in which R2, R3 and R4 are the same or different and are selected from:
  • hydrogen, lower alkyl unsubstituted or substituted with one or several groups selected from halogen, OR[0276] 6, COOR6 or NR6R7 in which R6 and R7 are the same or different and are selected from hydrogen or lower alkyl and,
  • R[0277] 6 and R7, and/or, R3 and R4, together with the nitrogen atom to which they are linked, can form a 4- to 8-membered heterocyclic ring, which may contain one or two heteroatoms selected from O, S or N, and which may be substituted with
  • a 4- to 8-membered heterocyclic ring, which may contain one or two heteroatoms selected from O, S or N and which may be substituted with a lower alkyl, or, [0278]
  • a lower alkyl optionally substituted with OR′, NR′R″, C(═O)NR′R″ or COOR′ in which R′ and R″ are the same or different and are selected from [0279]
  • H, or, [0280]
  • lower alkyl optionally substituted with OR or COOR in which R is hydrogen or lower alkyl and, [0281]
  • R′ and R″ together with the nitrogen atom to which they are linked, can form a 4- to 8-membered heterocyclic ring, which may contain one or two heteroatoms selected from O, S or N; [0282]
  • b) X[0283] 4 is C—R1 in which R1 is selected from hydrogen, halogen, CN, NO2, SO2CH3, SO3H, CH3, CF3, OR2, SR2, NR2R3, COOR2, CONR2R3 or SO2NR2R3 in which R2 and R3 are the same or different and are selected from hydrogen or lower alkyl;
  • c) X is NH; [0284]
  • d) Y is NH; [0285]
  • e) Z[0286] 1 is chosen from NR16R17 in which R16 and R17 are the same or different and are selected from:
  • hydrogen, CN, C(═O)R [0287] 4, (C═O)NR 14R 15, OR14,
  • lower alkyl unsubstituted or substituted with one or several groups selected from OR[0288] 14 or NR14R15,
  • R[0289] 14 and R15 being chosen from hydrogen or lower alkyl, and,
  • R[0290] 14 and R15, and/or, R16 and R17, together with the nitrogen atom to which they are linked, can form a 4- to 8-membered heterocyclic ring which may contain one or two heteroatoms selected from O, S or N, and which may be substituted with a lower alkyl;
  • f) A is a cycle chosen from: [0291]
    Figure US20020198198A1-20021226-C00013
  •  in which, [0292]
  • A[0293] 1, A2, A3, A4 and A5 are the same or different and are selected from:
  • a carbon atom, unsubstituted or substituted with 1 or 2 groups, identical or different ,selected from lower alkyl, OH or F, or, [0294]
  • an oxygen atom; [0295]
  • *represents the carbon atom which is shared between the cycle A and the backbone cycle containing X and/or Y; [0296]
  • 2 atoms of the cycle A, which are not adjacent, may be linked by a 2, 3 or 4 carbon atom chain; [0297]
  • provided that: [0298]
  • not more than one of the groups A[0299] 1, A2, A3, A4 and A5 simultaneously represent an oxygen atom.
  • A preferred group of compounds of formula (II) or (III) are the one in which X[0300] 1, X2, X3, X4, X, Y, Z1 and A are as disclosed hereabove wherein when X2 is C—R1 and R1 is X5—R5, then X5 is not a single bond;
  • Another preferred group of compounds are compounds of formula (I) in which, [0301]
  • a) X[0302] 1, X2, X3 and X4 are the same or different and are selected from:
  • N, provided that not more than two of the groups X[0303] 1, X2, X3 and X4 simultaneously represent a nitrogen atom, or,
  • C—R[0304] 1, in which R1 is selected from:
  • Q1,or [0305]
  • lower alkyl, lower alkenyl or lower alkynyl, these groups being unsubstituted or substituted with one or several groups Q2; [0306]
  • the group X[0307] 5—R5 in which,
  • X[0308] 5 is selected from:
  • a single bond, [0309]
  • lower alkylene, lower alkenylene or lower alkynylene, optionally interrupted with 1 or 2 heteroatoms chosen from O, S, S(═O), SO[0310] 2 or N, , the carbon atoms of these groups being unsubstituted or substituted with one or several groups, identical or different, selected from SR6, OR6, NR6R7, ═O, ═S or═N—R6 in which R6 and R7 are the same or different and are selected from hydrogen or lower alkyl, and,
  • R[0311] 5 is selected from aryl, heteroaryl, cycloalkyl optionally interrupted with C(═O) or with 1, 2, or 3 heteroatoms chosen from O, S, S(═O), SO2 or N, cycloalkenyl optionally interrupted with C(═O) or with 1, 2, or 3 heteroatoms chosen from O, S, S(═O), SO2 or N, or a bicyclic group, these groups being unsubstituted or substituted with one or several groups selected from Q3, heteroaryl or lower alkyl optionally substituted with Q3;
  • in which Q1, Q2, Q3 are the same or different and are selected from [0312]
  • hydrogen, halogen, CN, NO[0313] 2, SO3H,
  • OR[0314] 2, OC(═O)R2, C(═O)OR2, SR2, S(═O)R2, NR3R4, Q-R2, Q-NR3R4, NR2-Q-NR3R4 or NR3-Q-R2 in which Q is selected from C(═NR), C(═O), C(═S) or SO2, R is selected from hydrogen or lower alkyl and R2, R3 and R4 are the same or different and are selected from:
  • hydrogen, [0315]
  • lower alkyl optionally interrupted with C(═O), (CH[0316] 2)n-aryl, (CH2)n-heteroaryl, (CH2)n-cycloalkyl optionally interrupted with C(═O) or with 1 or 2 heteroatoms chosen from O, S, S(═O), SO2 or N or (CH2)n-cycloalkenyl optionally interrupted with C(═O) or with 1 or 2 heteroatoms chosen from O, S, S(═O), SO2 or N, in which n is an integer selected from 0, 1, 2 or 3;
  • these groups being unsubstituted or substituted with one or several groups selected from lower alkyl, halogen, CN, SO[0317] 3H, CH3, SO2CH3, CF3, C(═O)—NH—SO2—CH3, OR6, COOR6, NR6R7, C(═O)NR6R7 or SO2NR6R7, in which R6 and R7 are the same or different and are selected from hydrogen or lower alkyl optionally substituted with one or two groups selected from OR, COOR or NRR8 in which R and R8 are hydrogen or lower alkyl, and,
  • R[0318] 6 and R7, and/or, R3 and R4, together with the nitrogen atom to which they are linked, can form a 4- to 8-membered heterocyclic ring, which may contain one or two heteroatoms selected from O, S, S(═O), SO2 or N, and which may be substituted with
  • a 4- to 8-membered heterocyclic ring, which may contain one or two heteroatoms selected from O, S or N and which may be substituted with a lower alkyl, or, [0319]
  • a lower alkyl optionally substituted with OR′, NR′R″, C(═O)NR′R″ or COOR′ in which R′ and R″ are the same or different and are selected from [0320]
  • H, or, [0321]
  • lower alkyl optionally substituted with OR or COOR in which R is hydrogen or lower alkyl and, [0322]
  • R′ and R″ together with the nitrogen atom to which they are linked, can form a 4- to 8-membered heterocyclic ring, which may contain one or two heteroatoms selected from O, S or N; [0323]
  • b) X is NR[0324] 9, in which R9 is selected from,
  • hydrogen, CN, OH, NH[0325] 2,
  • lower alkyl, lower alkenyl or lower alkynyl, these groups being unsubstituted or substituted with cycloalkyl optionally interrupted with 1 or 2 heteroatoms chosen from O, S, S(═O), SO[0326] 2 or N, cycloalkenyl optionally interrupted with 1 or 2 heteroatoms chosen from O, S, S(═O), SO2 or N, aryl, heteroaryl, OR10 or NR10R11 in which R10 and R11 are the same or different and are selected from hydrogen or lower alkyl;
  • c) Y is selected from O, S or N—R[0327] 12, in which R12 is selected from:
  • hydrogen, CN, OH, NH[0328] 2,
  • lower alkyl, lower alkenyl or lower alkynyl, these groups being unsubstituted or substituted with, cycloalkyl optionally interrupted with 1 or 2 heteroatoms chosen from O, S, S(═O), SO[0329] 2 or N, cycloalkenyl optionally interrupted with 1 or 2 heteroatoms chosen from O, S, S(═O), SO2 or N, aryl, heteroaryl, OR10 or NR10R11 in which R10 and R11 are the same or different and are selected from hydrogen or lower alkyl;
  • d) Z is chosen from CH—NO[0330] 2, O, S or NR13 in which R13 is selected from:
  • hydrogen, CN, OH, NH[0331] 2, aryl, heteroaryl, cycloalkyl optionally interrupted with one or several heteroatoms chosen from O, S, S(═O), SO2 or N, cycloalkenyl optionally interrupted with one or several heteroatoms chosen from O, S, S(═O), SO2 or N, C(═O)R14, C(═O)NR14R15, OR14, or,
  • lower alkyl, unsubstituted or substituted with one or several groups which are the same or different and which are selected OR[0332] 14 or NR14R15;
  • R[0333] 14 and R15 being independently selected from hydrogen or lower alkyl, or, R14 and R15, together with the nitrogen atom to which they are linked, can form a 4- to 8-membered heterocyclic ring which may contain one or two heteroatoms chosen from O, S or N, and which may be substituted with a lower alkyl;
  • e) A is a cycle chosen from: [0334]
    Figure US20020198198A1-20021226-C00014
  •  in which, [0335]
  • A[0336] 1, A2, A4, A5 and A6 are the same or different and are selected from O, S, C, C(═O), SO, SO2 or N—R18 in which R18 is selected from:
  • hydrogen, aryl, heteroaryl, cycloalkyl optionally interrupted with one or several heteroatoms chosen from O, S, S(═O), SO[0337] 2 or N, cycloalkenyl optionally interrupted with one or several heteroatoms chosen from O, S, S(═O), SO2 or N,
  • lower alkyl unsubstituted or substituted with aryl, heteroaryl, cycloalkyl optionally interrupted with one or several heteroatoms chosen from O, S, S(═O), SO[0338] 2 or N, cycloalkenyl optionally interrupted with one or several heteroatoms chosen from O, S, S(═O), SO2 or N, CN, NR19R20, C(═O)NR19R20, OR19, C(═O)R19 or C(═O)OR19 in which R19 and R20 are identical or different and are selected from hydrogen or lower alkyl;
  • A[0339] 3 is selected from O, S, C, C(═O), SO or SO2, or N—R18 when A1 and/or A2 are C(═O) or when Y is O or S, wherein R18 is as defined above;
  • *represents the carbon atom which is shared between the cycle A and the backbone cycle containing X and/or Y; [0340]
  • each carbon atom of the cycle A is unsubstituted or substituted with 1 or 2 groups, identical or different, selected from lower alkyl optionally substituted with OR[0341] 21, NR21R22, COOR21 or CONR21R22, lower haloalkyl, CN, F, ═O, SO2NR19R20, OR19, SR19, C(═O)OR19, C(═O)NR19R20 or NR19R20 in which R19 and R20 are identical or different and are selected from hydrogen or lower alkyl optionally substituted with OR21, NR21R22, COOR21 or CONR21R22 in which R21 and R22 are identical or different and are selected from hydrogen or lower alkyl, and,
  • R[0342] 19 and R20, and/or, R21 and R22, together with the nitrogen atom to which they are linked, can form a 4- to 8-membered heterocyclic ring;
  • 2 atoms of the cycle A, which are not adjacent, may be linked by a 2, 3 or 4 carbon atom chain which may be interrupted with 1 heteroatom chosen from O, S or N; [0343]
  • provided that: [0344]
  • not more than two of the groups A[0345] 1, A2, A3, A4, A5 and A6 simultaneously represent a heteroatom;
  • the cycle A does not contain more than 2 carbon atoms in an Sp2 hybridization state. [0346]
  • A preferred group of compounds of formula (I) is a group in which X[0347] 1, X2, X3, X4, X, Y, Z and A are as disclosed hereabove wherein when X2 is C—R1 and R1 is X5—R5, then X5 is not a single bond;
  • Preferred compounds of formula (I) are those in which, [0348]
  • a) X[0349] 1, X2, X3 and X4 are the same or different and are selected from:
  • N, provided that not more than two of the groups X[0350] 1, X2, X3 and X4 simultaneously represent a nitrogen atom, or,
  • C—R[0351] 1, in which R1 is selected from:
  • Q1, or [0352]
  • lower alkyl, lower alkenyl or lower alkynyl, these groups being unsubstituted or substituted with 1, 2 or 3 groups Q2; [0353]
  • the group X[0354] 5—R5 in which,
  • X[0355] 5 is selected from:
  • a single bond, [0356]
  • lower alkylene, lower alkenylene or lower alkynylene, optionally interrupted with 1 or 2 heteroatoms chosen from O, S or N, ,the carbon atoms of these groups being unsubstituted or substituted with 1 or 2 groups, identical or different, selected from SR[0357] 6, OR6, NR6R7, ═O, ═S or ═N—R6 in which R6 and R7 are the same or different and are selected from hydrogen or lower alkyl, and,
  • R[0358] 5 is selected from aryl, heteroaryl, cycloalkyl optionally interrupted with C(═O) or with 1, 2, or 3 heteroatoms chosen from O, S or N, cycloalkenyl optionally interrupted with C(═O) or with 1, 2, or 3 heteroatoms chosen from O, S or N, or a bicyclic group,
  • these groups being unsubstituted or substituted with 1, 2 or 3 groups selected from Q3, heteroaryl or lower alkyl optionally substituted with Q3; [0359]
  • in which Q1, Q2, Q3 are the same or different and are selected from: [0360]
  • hydrogen, halogen, CN, NO[0361] 2, SO3H,
  • OR[0362] 2, OC(═O)R2, C(═O)OR2, SR2, S(═O)R2, NR3R4, Q-R2, Q-NR3R4, NR2-Q-NR3R4 or NR3-Q-R2 in which Q is selected from C(═NR), C(═O), C(═S) or SO2, R is selected from hydrogen or lower alkyl and R2, R3 and R4 are the same or different and are selected from:
  • hydrogen, [0363]
  • lower alkyl optionally interrupted with C(═O), (CH[0364] 2)n-aryl, (CH2)n-heteroaryl, (CH2)n-cycloalkyl optionally interrupted with C(═O) or with 1 or 2 heteroatoms chosen from O, S or N or (CH2)n-cycloalkenyl optionally interrupted with C(═O) or with 1 or 2 heteroatoms chosen from O, S or N, in which n is an integer selected from 0, 1, 2 or 3;
  • these groups being unsubstituted or substituted with 1, 2 or 3 groups selected from halogen, CN, SO[0365] 3H, CH3, SO2CH3, CF3, OR6, COOR6, NR6R7, C(═O)NR6R7 or SO2NR6R7, in which R6 and R7 are the same or different and are selected from hydrogen or lower alkyl optionally substituted with one or two groups selected from OR, COOR or NRR8 in which R and R8 are hydrogen or lower alkyl, and,
  • R[0366] 6 and R7, and/or, R3 and R4, together with the nitrogen atom to which they are linked, can form a 4- to 8-membered heterocyclic ring, which may contain one or two heteroatoms selected from O, S, S(═O), SO2 or N, and which may be substituted with
  • a 4- to 8-membered heterocyclic ring, which may contain one or two heteroatoms selected from O, S or N and which may be substituted with a lower alkyl, or, [0367]
  • a lower alkyl optionally substituted with OR′, NR′R″, C(═O)NR′R″ or COOR′ in which R′ and R″ are the same or different and are selected from [0368]
  • H, or, [0369]
  • lower alkyl optionally substituted with OR or COOR in which R is hydrogen or lower alkyl and, [0370]
  • R′ and R″ together with the nitrogen atom to which they are linked, can form a 4- to 8-membered heterocyclic ring, which may contain one or two heteroatoms selected from O, S or N; [0371]
  • b) X is NH; [0372]
  • c) Y is NH; [0373]
  • d) Z is chosen from O, S or NR[0374] 13 in which R13 is hydrogen or CN;
  • f) A is a cycle chosen from: [0375]
    Figure US20020198198A1-20021226-C00015
  •  in which, [0376]
  • A[0377] 1, A2, A4 and A5 are the same or different and are selected from O, S, C, C(═O), SO, SO2 or N—R18 in which R18 is selected from:
  • hydrogen, aryl, heteroaryl, cycloalkyl optionally interrupted with 1 or 2 heteroatoms chosen from O, S, S(═O), SO[0378] 2 or N, cycloalkenyl optionally interrupted with 1 or 2 heteroatoms chosen from O, S, S(═O), SO2 or N,
  • lower alkyl unsubstituted or substituted with aryl, heteroaryl, cycloalkyl optionally interrupted with 1 or 2 heteroatoms chosen from O, S, S(═O), SO[0379] 2 or N, cycloalkenyl optionally interrupted with 1 or 2 heteroatoms chosen from O, S, S(═O), SO2 or N, CN, NR19R20, C(═O)NR19R20, OR19, C(═O)R19 or C(═O)OR19 in which R19 and R20 are identical or different and are selected from hydrogen or lower alkyl;
  • A[0380] 3 is selected from O, S, C, C(═O), SO or SO2, or N—R18 when A1 and/or A2 are C(═O) or when Y is 0 or S, wherein R18 is as defined above;
  • represents the carbon atom which is shared between the cycle A and the backbone cycle containing X and/or Y; [0381]
  • each carbon atom of the cycle A is unsubstituted or substituted with 1 or 2 groups, identical or different, selected from lower alkyl optionally substituted with OR[0382] 21, NR21R22, COOR21 or CONR21R22, lower haloalkyl, CN, F, ═O, SO2NR19R20, OR19, SR19, C(═O)OR19 or C(═O)NR19R20 or NR19R20 in which R19 and R20 are identical or different and are selected from hydrogen or lower alkyl optionally substituted with OR21, NR21R22, COOR21 or CONR21R22 in which R21 and R22 are identical or different and are selected from hydrogen or lower alkyl, and,
  • R[0383] 19 and R20, and/or, R21 and R22, together with the nitrogen atom to which they are linked, can form a 4- to 8-membered heterocyclic ring;
  • 2 atoms of the cycle A, which are not adjacent, may be linked by a 2, 3 or 4 carbon atom chain which may be interrupted with 1 heteroatom chosen from O, S or N; [0384]
  • provided that: [0385]
  • not more than one of the groups A[0386] 1, A2, A3, A4 and A5 simultaneously represent a heteroatom;
  • the cycle A does not contain more than 2 carbon atoms in an Sp[0387] 2 hybridization state.
  • A preferred group of compounds of formula (I) is a group in which X[0388] 1, X2, X3, X4, X, Y, Z and A are as disclosed hereabove wherein when X2 is C—R1 and R1 is X5—R5, then X5 is not a single bond;
  • More preferred compounds of formula (I) are those in which, [0389]
  • a) X[0390] 1, X2 and X3 are the same or different and are C—R1, in which R1 is selected from:
  • hydrogen, halogen, CN, SO[0391] 3H, NO2, CF3, OR2, SR2, NR2R3, COR2, COOR2, CONR2R3, SO2CH3, SO2NR2R3 in which R2 and R3 are the same or different and are selected from hydrogen or lower alkyl optionally substituted with halogen, CN, OR6, COOR6, NR6R7, SO2NR6R7 or C(═O)NR6R7 in which R6 and R7 are the same or different and are selected from hydrogen or lower alkyl, and,
  • R[0392] 6 and R7, together with the nitrogen atom to which they are linked, can form a 4- to 8-membered heterocyclic ring;
  • lower alkyl, lower alkenyl or lower alkynyl, these groups being unsubstituted or substituted with 1, 2 or 3 groups selected from halogen, CN, SO[0393] 3H, OR2, COOR2, NR3R4, SO2NR3R4 or C(═O)NR3R4 in which R2, R3 and R4 are the same or different and are selected from hydrogen or lower alkyl, and,
  • R[0394] 3 and R4, together with the nitrogen atom to which they are linked, can form a 4- to 8-membered heterocyclic ring;
  • the group X[0395] 5—R5 in which,
  • X[0396] 5 is selected from a lower alkylene or a single bond, and,
  • R[0397] 5 is selected from phenyl, pyridyl or indolyl, these groups being unsubstituted or substituted with 1, 2 or 3 groups 30 selected from Q3, heteroaryl or lower alkyl optionally substituted with Q3 in which Q3 is selected from:
  • halogen, CN, SO[0398] 3H, NO2, CF3, OR2, OC(═O)R2, C(═O)R2, C(═O)OR2, NH—C(═O)R2, NR3R4, SO2NR3R4 or C(═O)NR3R4 in which R2, R3 and R4 are the same or different and are selected from: hydrogen, lower alkyl unsubstituted or substituted with one or several groups selected from halogen, OR6, COOR6 or NR6R7 in which R6 and R7 are the same or different and are selected from hydrogen or lower alkyl and,
  • R[0399] 6 and R7, and/or, R3 and R4, together with the nitrogen atom to which they are linked, can form a 4- to 8-membered heterocyclic ring, which may contain one or two heteroatoms selected from O, S or N, and which may be substituted with,
  • a 4- to 8-membered heterocyclic ring, which may contain one or two heteroatoms selected from O, S or N and which may be substituted with a lower alkyl, or, [0400]
  • a lower alkyl optionally substituted with OR′, NR′R″, C(═O)NR′R″ or COOR′ in which R′ and R″ are the same or different and are selected from, [0401]
  • H, or, [0402]
  • lower alkyl optionally substituted with OR or COOR in which R is hydrogen or lower alkyl and, [0403]
  • R′ and R″ together with the nitrogen atom to which they are linked, can form a 4- to 8-membered heterocyclic ring, which may contain one or two heteroatoms selected from O, S or N; [0404]
  • b) X[0405] 4 is C—R1 in which R1 is selected from hydrogen, halogen, CN, NO2, SO2CH3, SO3H, CH3, CF3, OR2, SR2, NR2R3, COOR2, CONR2R3 or SO2NR2R3 in which R2 and R3 are the same or different and are selected from hydrogen or lower alkyl;
  • c) X is NH; [0406]
  • d) Y is NH; [0407]
  • e) Z is chosen from O, S or NR[0408] 13 in which R13 is hydrogen or CN;
  • f) A is a cycle chosen from: [0409]
    Figure US20020198198A1-20021226-C00016
  •  in which, [0410]
  • A[0411] 1, A2, A3, A4 and A5 are the same or different and are selected from:
  • a carbon atom, unsubstituted or substituted with 1 or 2 groups, identical or different selected from lower alkyl, OH or F, or, [0412]
  • an oxygen atom; [0413]
  • represents the carbon atom which is shared between the cycle A and the backbone cycle containing X and/or Y; [0414]
  • 2 atoms of the cycle A, which are not adjacent, may be linked by a 2, 3 or 4 carbon atom chain; [0415]
  • provided that: [0416]
  • not more than one of the groups A[0417] 1, A2, A3, A4 and A5 simultaneously represent an oxygen atom.
  • A preferred group of compounds of formula (I) is a group in which X[0418] 1, X2, X3, X4, X, Y, Z and A are as disclosed hereabove wherein when X2 is C—R1 and R1 is X5—R5, then X5 is not a single bond;
  • Most preferred compounds of formula (I) are those in which, [0419]
  • a) X[0420] 1, X2 and X3 are the same or different and are C—R1, in which R1 is selected from:
  • hydrogen, halogen, CN, OR[0421] 2, in which R2 is selected from hydrogen or lower alkyl;
  • lower alkyl, lower alkenyl or lower alkynyl, these groups being unsubstituted or substituted with 1, 2 or 3 groups selected from halogen, CN, SO[0422] 3H, OR2, COOR2, NR3R4, SO2NR3R4 or C(═O)NR3R4 in which R2,
  • R[0423] 3 and R4 are the same or different and are selected from hydrogen or lower alkyl, and,
  • R[0424] 3 and R4, together with the nitrogen atom to which they are linked, can form a 4- to 8-membered heterocyclic ring;
  • b) X[0425] 4 is C—R1 in which R1 is selected hydrogen, halogen, CH3, CN, OR2, in which
  • R[0426] 2 is selected from hydrogen or lower alkyl;
  • c) X is NH; [0427]
  • d) Y is NH; [0428]
  • e) Z is chosen from O, S or NR[0429] 13 in which R13 is hydrogen or CN; f) A is a cycle chosen from:
    Figure US20020198198A1-20021226-C00017
  •  in which, [0430]
  • A[0431] 1, A2 A3, A4 and A5 are the same or different and are selected from carbon atoms, unsubstituted or substituted with CH3;
  • represents the carbon atom which is shared between the cycle A and the backbone cycle containing X and/or Y; [0432]
  • 2 atoms of the cycle A, which are not adjacent, may be linked by a 2, 3 or 4 carbon atom chain. [0433]
  • Preferably, X[0434] 1, X2, X3 and X4 are the same or different and are C—R1, in which R1 is selected from:
  • Q1, or [0435]
  • lower alkyl, lower alkenyl or lower alkynyl, these groups being unsubstituted or substituted with 1, 2 or 3 groups Q2; [0436]
  • the group X[0437] 5—R5 in which,
  • X[0438] 5 is selected from
  • a single bond, [0439]
  • a lower alkylene, optionally interrupted with 1 heteroatoms chosen from O, S and N [0440]
  • R[0441] 5 is selected from aryl, heteroaryl, cycloalkyl optionally interrupted with C(═O) or with 1, 2, or 3 heteroatoms chosen from O, S, S(═O), SO2 or N, cycloalkenyl optionally interrupted with C(═O) or with 1, 2, or 3 heteroatoms chosen from O, S, S(═O), SO2 or N, or a bicyclic group,
  • these groups being unsubstituted or substituted with 1, 2 or 3 groups selected from Q3, heteroaryl or lower alkyl optionally substituted with Q3; [0442]
  • in which Q1, Q2, Q3 are the same or different and are selected from [0443]
  • hydrogen, halogen, CN, NO[0444] 2, SO3H,
  • OR[0445] 2, OC(═O)R2, C(═O)OR2, SR2, S(═O)R2, C(═O)—NH—SO2—CH3, NR3R4, Q-R2, Q-NR3R4, NR2-Q-NR3R4 or NR3-Q-R2 in which Q is selected from C(═NR), C(═O), C(═S) or SO2, R is selected from hydrogen or lower alkyl and R2, R3 and R4 are the same or different and are selected from:
  • hydrogen, [0446]
  • lower alkyl optionally interrupted with C(═O), Q4-aryl, Q4-heteroaryl, Q4-cycloalkyl optionally interrupted with C(═O) or with 1 or 2 heteroatoms chosen from O, S, S(═O), SO[0447] 2 or N, or Q4-cycloalkenyl optionally interrupted with C(═O) or with 1 or 2 heteroatoms chosen from O, S, S(═O), SO2 or N, in which
  • Q4 is selected from (CH[0448] 2)n, lower alkyl interrupted with one heteroatom selected from O, S or N, lower alkenyl or lower alkynyl, these groups being optionally substituted with lower alkyl, OR′ or NR′R″ in which R′ and R″ are the same or different and are selected from hydrogen or lower alkyl;
  • n is an integer selected from 0, 1, 2, 3 or 4; [0449]
  • these groups being unsubstituted or substituted with 1 or 2 groups selected from lower alkyl, halogen, CN, CH[0450] 3, SO3H, SO2CH3, CF3, C(═O)NH—SO2CH3, OR6, COOR6, C(═O)R6, NR6R7, C(═O)NR6R7 or SO2NR6R7, in which R6 and R7 are the same or different and are selected from hydrogen or lower alkyl optionally substituted with one or two groups selected from OR, COOR or NRR8 in which R and R8 are hydrogen or lower alkyl, and,
  • R[0451] 6 and R7, and/or, R3 and R4, together with the nitrogen atom to which they are linked, can form a 4- to 8-membered heterocyclic ring, which may contain one or two heteroatoms selected from O, S, S(═O), SO2 or N, and which may be substituted with,
  • (CH[0452] 2)n-Q5, in which n is an integer selected from 0, 1, 2 and 3, and Q5 is a 4- to 8-membered heterocyclic ring which may contain one or two heteroatoms selected from O, S or N and which may be substituted with a lower alkyl, or,
  • a lower alkyl optionally substituted with OR′, NR′R″, C(═O)NR′R″ or COOR′ in which R′ and R″ are the same or different and are selected from, [0453]
  • H, or, [0454]
  • lower alkyl optionally substituted with OR or COOR in which R is hydrogen or lower alkyl and, [0455]
  • R′ and R″ together with the nitrogen atom to which they are linked, can form a 4- to 8-membered heterocyclic ring, which may contain one or two heteroatoms selected from O, S or N. [0456]
  • A preferred group of compounds of formula (I) is a group in which X[0457] 1, X2, X3 and X4, are as disclosed hereabove wherein when X2 is C—R1 and R1 is X5—R5, then X5is not a single bond;
  • Preferably, X[0458] 1, X2, X3 and X4 are the same or different and are C—R1, in which R1 is selected from:
  • Q1, or [0459]
  • lower alkyl or lower alkynyl, these groups being unsubstituted or substituted with 1, 2 or 3 fluor atoms, OR[0460] 3, COOR3 or NR3R4 in which R3 and R4 are the same or different and are selected from hydrogen or lower alkyl;
  • R[0461] 3 and R4 together with the nitrogen atom to which they are linked, may also form a 6-membered heterocyclic ring, which may contain one or two heteroatoms selected from O or N;
  • the group X[0462] 5—R5 in which X5 is a single bond and R5 is selected from aryl, preferably phenyl, heteroaryl, preferably pyridyl, or a bicyclic group, preferably indolyl, these groups being unsubstituted or substituted with 1, 2 or 3 groups selected from Q3,
  • in which Q1 and Q3 are the same or different and are selected from [0463]
  • hydrogen, halogen, CN, lower alkyl, [0464]
  • OR[0465] 2, C(═O)OR2, NR3R4, C(═O)NR3R4 or SO2NR3R4 in which R2, R3 l and R 4 are the same or different and are selected from:
  • hydrogen, [0466]
  • lower alkyl, Q4-heteroaryl in which Q4 is selected from lower alkyl interrupted with one heteroatom selected from O, S or N and (CH[0467] 2)n in which n is an integer selected from 0, 1, 2 or 3;
  • these groups being unsubstituted or substituted with 1 or 2 groups selected from lower alkyl, CN, SO[0468] 3H, C(═O)—NH—SO2—CH3, OR6, COOR6 or NR6R7, in which R6 and R7 are the same or different and are selected from hydrogen or lower alkyl optionally substituted with one or two groups selected from OR, COOR or NRR8 in which R and R8 are hydrogen or lower alkyl, and,
  • R[0469] 6 and R7, and/or, R3 and R4, together with the nitrogen atom to which they are linked, can form a 4- to 6-membered heterocyclic ring, which may contain one or two heteroatoms selected from O or N, and which may be substituted with,
  • a 6-membered heterocyclic ring, which may contain one or two heteroatoms selected from O or N and which may be substituted with a lower alkyl, or, [0470]
  • a lower alkyl optionally substituted with OR′, NR′R″, C(═O)NR′R″ or COOR′ in which R′ and R″ are the same or different and are selected from, [0471]
  • H, or, [0472]
  • lower alkyl optionally substituted with OR or COOR in which R is hydrogen or lower alkyl and, [0473]
  • R′ and R″ together with the nitrogen atom to which they are linked, can form a 6-membered heterocyclic ring, which may contain one or two heteroatoms selected from O or N. [0474]
  • A preferred group of compounds of formula (I) is a group in which X[0475] 1, X2 X3 and X4, are as disclosed hereabove wherein when X2 is C—R1 and R1 is X5—R5, then X5 is not a single bond;
  • A preferred group of compounds is the group in which one of X[0476] 1, X2, X3 and X4 is C—R1 in which R1 is hydrogen while the others are identical or different and are C—R1 in which R1 is selected from:
  • Q1, or [0477]
  • lower alkyl, lower alkenyl or lower alkynyl, these groups being unsubstituted or substituted with 1, 2 or 3 groups Q2; [0478]
  • the group X[0479] 5—R5 in which,
  • X[0480] 5 is selected from:
  • a single bond, [0481]
  • a lower alkylene, optionally interrupted with 1 heteroatoms chosen from O, S and N [0482]
  • R[0483] 5 is selected from aryl, heteroaryl, cycloalkyl optionally interrupted with C(═O) or with 1, 2, or 3 heteroatoms chosen from O, S, S(═O), SO2 or N, cycloalkenyl optionally interrupted with C(═O) or with 1, 2, or 3 heteroatoms chosen from O, S, S(═O), SO2 or N, or a bicyclic group, these groups being unsubstituted or substituted with 1, 2 or 3 groups selected from Q3, heteroaryl or lower alkyl optionally substituted with Q3;
  • in which Q1, Q2, Q3 are the same or different and are selected from [0484]
  • hydrogen, halogen, CN, NO[0485] 2, SO3H,
  • OR[0486] 2, OC(═O)R2, C(═O)OR2, SR2, S(═O)R2, C(═O)—NH—SO2—CH3, NR3R4, Q-R2, Q-NR3R4, NR2-Q-NR3R4 or NR3-Q-R2 in which Q is selected from C(═NR), C(═O), C(═S) or SO2, R is selected from hydrogen or lower alkyl and R2, R3 and R4 are the same or different and are selected from:
  • hydrogen, [0487]
  • lower alkyl optionally interrupted with C(═O), Q4-aryl, Q4-heteroaryl, Q4-cycloalkyl optionally interrupted with C(═O) or with 1 or 2 heteroatoms chosen from O, S, S(═O), SO[0488] 2 or N, or Q4-cycloalkenyl optionally interrupted with C(═O) or with 1 or 2 heteroatoms chosen from O, S, S(═O), SO2 or N, in which
  • Q4 is selected from (CH[0489] 2)n, lower alkyl interrupted with one heteroatom selected from O, S or N, lower alkenyl or lower alkynyl, these groups being optionally substituted with lower alkyl, OR′ or NR′R″ in which R′ and R″ are the same or
  • different and are selected from hydrogen or lower alkyl; n is an integer selected from 0, 1, 2, 3 or 4; [0490]
  • these groups being unsubstituted or substituted with 1 or 2 groups selected from lower alkyl, halogen, CN, CH[0491] 3, SO3H, SO2CH3, CF3, C(═O)—NH—SO2—CH3, OR6, COOR6, C(═O)R6, NR6R7, C(═O)NR6R7 or SO2NR6R7, in which R6 and R7 are the same or different and are selected from hydrogen or lower alkyl optionally substituted with one or two groups selected from OR, COOR or NRR8 in which R and R8 are hydrogen or lower alkyl, and,
  • R[0492] 6 and R7, and/or, R3 and R4, together with the nitrogen atom to which they are linked, can form a 4- to 8-membered heterocyclic ring, which may contain one or two heteroatoms selected from O, S, S(═O), SO2 or N, and which may be substituted with,
  • (CH[0493] 2)n-Q5, in which n is an integer selected from 0, 1, 2 and 3, and Q5 is a 4- to 8-membered heterocyclic ring which may contain one or two heteroatoms selected from O, S or N and which may be substituted with a lower alkyl, or,
  • a lower alkyl optionally substituted with OR′, NR′R″, C(═O)NR′R″ or COOR′ in which R′ and R″ are the same or different and are selected from, [0494]
  • H, or, [0495]
  • lower alkyl optionally substituted with OR or COOR in which R is hydrogen or lower alkyl and, [0496]
  • R′ and R″ together with the nitrogen atom to which they are linked, can form a 4- to 8-membered heterocyclic ring, which may contain one or two heteroatoms selected from O, S or N. [0497]
  • A preferred group of compounds of formula (I) is a group in which X[0498] 1, X2, X3 and X4, are as disclosed hereabove wherein when X2 is C—R1 and R1 is X5—R5, then X5 is not a single bond;
  • A preferred group of compounds is the group in which one of X[0499] 1, X2, X3 and X4 is C—R1 in which R1 is hydrogen while the others are identical or different and are C—R1 in which R1 is selected from:
  • Q1,or [0500]
  • lower alkyl or lower alkynyl, these groups being unsubstituted or substituted with 1, 2 or 3 groups halogen or with OR[0501] 3, COOR3 or NR3R4 in which R3 and R4 are the same or different and are selected from hydrogen or lower alkyl;
  • R[0502] 3 and R4 together with the nitrogen atom to which they are linked, may also form a 6-membered heterocyclic ring, which may contain one or two heteroatoms selected from O or N;
  • the group X[0503] 5—R5 in which X5 is a single bond and R5 is selected from aryl, preferably phenyl, heteroaryl, preferably pyridyl, or a bicyclic group, preferably indolyl, these groups being unsubstituted or substituted with 1, 2 or 3 groups selected from Q3,
  • in which Q1 and Q3 are the same or different and are selected from [0504]
  • halogen, CN, lower alkyl [0505]
  • OR[0506] 2, C(═O)OR2, NR3R4, C(═O)NR3R4 or SO2NR3R4 in which R2, R3 and R4 are the same or different and are selected from:
  • hydrogen, [0507]
  • lower alkyl, Q4-heteroaryl in which Q4 is selected from lower alkyl interrupted with one heteroatom selected from O, S or N and (CH[0508] 2)n in which n is an integer selected from 0, 1, 2 or 3;
  • these groups being unsubstituted or substituted with 1 or 2 groups selected from lower alkyl, CN, SO[0509] 3H, C(═O)—NH—SO2—CH3, OR6, COOR6 or NR6R7, in which R6 and R7 are the same or different and are selected from hydrogen or lower alkyl optionally substituted with one or two groups selected from OR, COOR or NRR8 in which R and R8 are hydrogen or lower alkyl, and,
  • R[0510] 6 and R7, and/or, R3 and R4, together with the nitrogen atom to which they are linked, can form a 4- to 6-membered heterocyclic ring, which may contain one or two heteroatoms selected from O or N, and which may be substituted with,
  • a 6-membered heterocyclic ring, which may contain one or two heteroatoms selected from O or N and which may be substituted with a lower alkyl, or, [0511]
  • a lower alkyl optionally substituted with OR′, NR′R″, C(═O)NR′R″ or COOR′ in which R′ and R″ are the same or different and are selected from, [0512]
  • H, or, [0513]
  • lower alkyl optionally substituted with OR or COOR in which R is hydrogen or lower alkyl and, [0514]
  • R′ and R″ together with the nitrogen atom to which they are linked, can form a 6-membered heterocyclic ring, which may contain one or two heteroatoms selected from O or N. [0515]
  • A preferred group of compound is the group disclosed hereabove in which X[0516] 3is C—R1 in which R1 is hydrogen.
  • Preferably, X[0517] 3 is C—R1, in which R1 is selected from:
  • hydrogen or halogen, preferably Cl, or, [0518]
  • X[0519] 5—R5 in which R5is a single bond and R5 is aryl, preferably phenyl or heteroaryl, preferably pyridyl, optionally substituted with one, two or three groups which are the same or different and which are selected from halogen, CN, CF3, SO2Me, OR2, COOR2, NR2R3, SO2NR2R3 and CONR2R3 in which R2 and R3 are the same or different and are selected from hydrogen and lower alkyl.
  • Preferably, X[0520] 3 is C—R1, in which R1 is selected from hydrogen or halogen, preferably Cl.
  • Preferably, X[0521] 3 is C—R1 in which R1 is hydrogen.
  • Preferably, X[0522] 4 is C—R1, in which R1 is selected from
  • hydrogen, halogen, CF[0523] 3, O-lower alkyl, COOR2 or,
  • lower alkyl optionally substituted with OR[0524] 2, COOR2 or SO2NR2R3 in which R2 and R3 are the same or different and are selected from hydrogen and lower alkyl.
  • Preferably, X[0525] 4 is C—R1, in which R1 is selected from hydrogen, halogen, CF3, methyl and methoxy.
  • Preferably, X[0526] 1 is C—R1, in which R1 is selected from
  • hydrogen, halogen, preferably Cl or Br, OR[0527] 2, COR2, COOR2,CONR2R3 in which R2 and R3 are the same or different and are selected from
  • hydrogen, [0528]
  • lower alkyl, Q4-aryl, Q4-heteroaryl, Q4-cycloalkyl optionally interrupted with C(═O) or with 1 or 2 heteroatoms chosen from O, S, or N, or Q4-cycloalkenyl optionally interrupted with C(═O) or with 1 or 2 heteroatoms chosen from O, S, or N, in which [0529]
  • Q4 is selected from (CH[0530] 2)n, lower alkyl interrupted with one heteroatom selected from O, S or N, lower alkenyl or lower alkynyl;
  • n is an integer selected from 0,1, 2 or 3; [0531]
  • these groups being unsubstituted or substituted with lower alkyl, CN, C(═O)—NH—SO[0532] 2—CH3, OR6, SO3H, CONR6R7, COOR6, COR6 or NR6R7,
  • in which and R[0533] 6 and R7 are the same or different and are selected from hydrogen or lower alkyl, optionally substituted with NH2, COOH, OH;
  • R[0534] 6 and R7 together with the nitrogen atom to which they are linked, can form a 4- to 8-membered heterocyclic ring, which may contain one or two heteroatoms selected from O, S or N and which may be substituted with,
  • (CH[0535] 2)n-Q5, in which n is an integer selected from 0, 1, 2 and 3, and Q5 is a 4- to 8-membered heterocyclic ring which may contain one or two heteroatoms selected from O, S or N and which may be substituted with a lower alkyl, or,
  • COR′ or lower alkyl optionally substituted with OR′, NR′R″, C(═O)NR′R″ or COOR′ in which R′ and R″ are the same or different and are selected from hydrogen or lower alkyl; [0536]
  • lower alkyl optionally substituted with CN, SO[0537] 3H, OR3, NR3R4, COOR3 or CONR3R4 in which R3 and R4 are the same or different and are selected from
  • hydrogen and, [0538]
  • lower alkyl optionally substituted with OH, COOH or NH[0539] 2
  • the group X[0540] 5—R5 in which X5 is a lower alkylene optionally interrupted with a heteroatom selected O and N and R5 is selected from aryl, heteroaryl, cycloalkyl optionally interrupted with C(═O) or with 1, 2, or 3 heteroatoms chosen from O, S or N and cycloalkenyl optionally interrupted with C(═O) or with 1, 2, or 3 heteroatoms chosen from O, S or N,
  • these groups being unsubstituted or substituted OR3 or COOR[0541] 3 in which R3 is selected from hydrogen and lower alkyl;
  • R[0542] 3 and R4, together with the nitrogen atom to which they are linked, can form a 4- to 6-membered heterocyclic ring, which may contain one or two heteroatoms selected from O or N, and which may be substituted with,
  • (CH[0543] 2)n-Q5, in which n is an integer selected from 0, 1, 2 and 3, and Q5 is a 4- to 8-membered heterocyclic ring which may contain one or two heteroatoms selected from O, S or N and which may be substituted with a lower alkyl, or,
  • C(═O)—R′ or a lower alkyl optionally substituted with OR′, NR′R″, C(═O)NR′R″ or COOR′ in which R′ and R″ are the same or different and are selected from hydrogen or lower alkyl. [0544]
  • Preferably, X[0545] 1 is C—R1, in which R1 is selected from hydrogen, halogen, preferably Cl or Br, or OR2 in which R2 is selected from
  • hydrogen, [0546]
  • lower alkyl, unsubstituted or substituted with CN, C(═O)—NH—SO[0547] 2—CH3, OR6, SO3H, COOR6 or NR6R7,
  • Q4-oxadiazole, Q4-tetrazole, Q4-morpholine, Q4-furan, Q4-isoxazole, in which Q4 is selected from lower alkyl interrupted with one heteroatom selected from O, S or N and (CH[0548] 2)nin which n is an integer selected from 1 and 2;
  • these groups being unsubstituted or substituted with CH[0549] 3, OR6 or COOR6, in which R6 and R7 are the same or different and are selected from hydrogen or lower alkyl, optionally substituted with NH2 or COOH.
  • Preferably, X[0550] 2 is C—R1, in which R1 is X5—R5, in which
  • X[0551] 5 is a single bond,
  • R[0552] 5 is phenyl or pyridyl,
  • optionally substituted with a lower alkyl, and, [0553]
  • substituted with C(═O)NR[0554] 3R4 in which R3 and R4 together with the nitrogen atom to which they are linked, form a 4- to 8-membered heterocyclic ring, which may contain one or two heteroatoms selected from O, S, S(═O), SO2 or N, and which may be substituted with,
  • a 4- to 8-membered heterocyclic ring, which may contain one or two heteroatoms selected from O, S or N and which may be substituted with a lower alkyl, or, [0555]
  • a lower alkyl optionally substituted with OR′, NR′R″, C(═O)NR′R″ or COOR′ in which R′ and R″ are the same or different and are selected from, [0556]
  • H, or, [0557]
  • lower alkyl optionally substituted with OR or COOR in which R is hydrogen or lower alkyl and, [0558]
  • R′ and R″ together with the nitrogen atom to which they are linked, can form a 4- to 8-membered heterocyclic ring, which may contain one or two heteroatoms selected from O, S or N. [0559]
  • Preferably, X[0560] 2 is C—R1, in which R1 is X5—R5, in which
  • X[0561] 5 is a single bond,
  • R[0562] 5 is phenyl,
  • optionally substituted with a methyl, and [0563]
  • substituted with C(═O)NR[0564] 3R4 in which R3 and R4 together with the nitrogen atom to which they are linked, form a 6-membered heterocyclic ring, which may contain one or two nitrogen atoms, and which may be substituted with,
  • a 6-membered heterocyclic ring, which may contain one or two nitrogen atoms and which may be substituted with a lower alkyl, or, [0565]
  • a lower alkyl optionally substituted with OR′, NR′R″, C(═O)NR′R″ or COOR′ in which R′ and R″ are the same or different and are selected from, [0566]
  • H, or, [0567]
  • lower alkyl optionally substituted with OR or COOR in which R is hydrogen or lower alkyl and, [0568]
  • R′ and R″ together with the nitrogen atom to which they are linked, can form a 6-membered heterocyclic ring, which may contain one or two heteroatoms selected from O or N; [0569]
  • In each of all the group of compounds defined above, the following substitutions are further preferred: [0570]
  • Preferably, compounds of the invention are compounds of formula (I). [0571]
  • Preferably, X is NH. [0572]
  • Preferably, Y is NH. [0573]
  • Preferably, Z is O. [0574]
  • Preferably, X is NH, Y is NH, and Z is O. [0575]
  • Preferably, A is selected from cyclohexyl or cycloheptyl, optionally interrupted with C(═O) or 0, and unsubstituted or substituted with CH[0576] 3, OH or OCH3.
  • Preferably, A is selected from unsubstituted cyclohexyl or cycloheptyl. [0577]
  • Preferably, A is unsubstituted cyclohexyl. [0578]
  • Preferably X is NH, Y is NH, Z is O and A is unsubstituted cyclohexyl. [0579]
  • Preferably X is NH, Y is NH, Z is O, A is unsubstituted cyclohexyl, X[0580] 3 is C—R1 in which R1 is hydrogen and X4 is C—R1, in which R1 is selected from hydrogen, halogen, CF3, methyl or methoxy.
  • In the following and in the foregoing text: [0581]
  • Halogen includes fluoro, chloro, bromo, and iodo. Preferred halogens are F and Cl. [0582]
  • Lower alkyl includes straight and branched carbon chains having from 1 to 6 carbon atoms. Examples of such alkyl groups include methyl, ethyl, isopropyl, tert-butyl and the like. [0583]
  • Lower alkenyl includes straight and branched hydrocarbon radicals having from 2 to 6 carbon atoms and at least one double bond. Examples of such alkenyl groups are ethenyl, 3-buten-1-yl, 2-ethenylbutyl, 3-hexen-1-yl, and the like. [0584]
  • Lower alkynyl includes straight and branched hydrocarbon radicals having from 2 to 6 carbon atoms and at least one triple bond. Examples of such alkynyl groups are ethynyl, 3-butyn-1-yl, propynyl, 2-butyn-1-yl, 3-pentyn-1-yl, and the like. [0585]
  • Lower haloalkyl includes a lower alkyl as defined above, substituted with one or several halogens. A preferred haloalkyl is trifluoromethyl. [0586]
  • Aryl is understood to refer to an aromatic carbocycle containing between 6 and 10, preferably 6, carbon atoms. A preferred aryl group is phenyl. [0587]
  • Heteroaryl includes aromatic cycles which have from 5 to 10 ring atoms, from 1 to 4 of which are independently selected from the group consisting of O, S, and N. [0588]
  • Preferred heteroaryl groups have 1, 2, 3 or 4 heteroatoms in a 5- or 6-membered aromatic ring. Examples of such groups are tetrazole, pyridyl, thienyl and the like. [0589]
  • Preferred cycloalkyl contain from 3 to 8 carbon atoms. Examples of such groups are cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, cycloheptyl and cyclooctyl. [0590]
  • The term “interrupted” means that in a backbone chain, a carbon atom is replaced by an heteroatom or a group as defined herein. For example, in “cycloalkyl or cycloalkenyl optionally interrupted with C(═O) or with 1 heteroatom chosen from O, S, S(═O), SO[0591] 2 or N”, the term “interrupted” means that C(═O) or a heteroatom can replace a carbon atom of the ring. Example of such groups are morpholine or piperazine.
  • Cycloalkenyl includes 3- to 10- membered cycloalkyl containing at least one double bond. [0592]
  • Heterocyclic ring include heteroaryl as defined above and cycloalkyl or cycloalkenyl, as defined above, interrupted with 1, 2 or 3 heteroatoms chosen from O, S, S(═O), SO[0593] 2, or N.
  • Bicyclic substituents refer to two cycles, which are the same or different and which are chosen from aryl, heterocyclic ring, cycloalkyl or cycloalkenyl, fused together to form said bicyclic substituents. A preferred bicyclic substituent is indolyl. [0594]
  • Sp[0595] 2 hybridization state: carbon atoms in an Sp2 hybridization state are trigonal instead of tetraedric. It means that the carbon atoms in a SP2 hybridization state are linked to three atoms and form a double bond with one of these three atoms.
  • Preferred compounds are: [0596]
  • Spiro[cyclohexane-1-4′-(3′,4′-dihydro)quinazolin]-2′(1′H)-one, [0597]
  • 6′-Methoxyspiro[cyclohexane-1-4′-(3′,4′-dihydro)quinazolin]-2′(1′H)-one, [0598]
  • Spiro[cycloheptane-1-4′-(3′,4′-dihydro)quinazolin]-2′(1′H)-one, [0599]
  • 7′-Methoxyspiro[cyclohexane-1-4′-(3′,4′-dihydro)quinazolin]-2′(1′H)-one, [0600]
  • 6′-Phenylspiro[cycloheptane-1-4′-(3′,4′-dihydro)quinazolin]-2′(1′H)-one, [0601]
  • 8′-Methoxyspiro[cyclohexane-1-4′-(3′,4′-dihydro)quinazolin]-2′(1′H)-one, [0602]
  • 8′-Chlorospiro[cyclohexane-1-4′-(3′,4′-dihydro)quinazolin]-2′(1′H)-one, [0603]
  • 7′-chlorospiro[cyclohexane-1-4′-(3′,4′-dihydro)quinazolin]-2′(1′H)-one, [0604]
  • 5′-chlorospiro[cyclohexane-1-4′-(3′,4′-dihydro)quinazolin]-2′(1′H)-one, [0605]
  • 8′-methylspiro[cyclohexane-1-4′-(3′,4′-dihydro)quinazolin]-2′(1′H)-one, [0606]
  • 6′-chlorospiro[cyclohexane-1-4′-(3′,4′-dihydro)quinazolin]-2′(1′H)-one, [0607]
  • 8′-bromospiro[cyclohexane-1-4′-(3′,4′-dihydro)quinazolin]-2′(1′H)-one, [0608]
  • 8′-fluorospiro[cyclohexane-1-4′-(3′,4′-dihydro)quinazolin]-2′(1′H)-one, [0609]
  • 6′-methylspiro[cyclohexane-1-4′-(3′,4′-dihydro)quinazolin]-2′(1′H)-one, [0610]
  • 5′,8′-dichlorospiro[cyclohexane-1-4′-(3′,4′-dihydro)quinazolin]-2′(1′H)-one, [0611]
  • 6′,7′-dichlorospiro[cyclohexane-1-4′-(3′,4′-dihydro)quinazolin]-2′(1′H)-one, [0612]
  • 5′,6′-dichlorospiro[cyclohexane-1-4′-(3′,4′-dihydro)quinazolin]-2′(1′H)-one, [0613]
  • 6′-phenylspiro[cyclohexane-1-4′-(3′,4′-dihydro)quinazolin]-2′(1′H)-one, [0614]
  • 8′-iodospiro[cyclohexane-1-4-(3′,4′-dihydro)quinazolin]-2′(1′H)-one, [0615]
  • 8′-Bromospiro[cyclobutane-1-4′-(3′,4′-dihydro)quinazolin]-2′(1′H)-one, [0616]
  • 8′-Bromospiro[cycloheptane-1-4′-(3′,4′-dihydro)quinazolin]-2′(1′H)-one, [0617]
  • 8′-Bromo-4-methylspiro[cyclohexane-1-4′-(3′,4′-dihydro)quinazolin]-2′(1′H)-one, [0618]
  • 8′-Bromospiro[bicyclo[3,2,1]octane-2-4′-(3′,4′-dihydro)quinazolin]-2′(1′H)-one, [0619]
  • 6′,8′-dichlorospiro[cyclohexane-1-4′-(3′,4′-dihydro)quinazolin]-2′(1′H)-one [0620]
  • 8′-chloro-6′-iodospiro[cyclohexane-1-4′-(3′,4′-dihydro)quinazolin]-2′(1′H)-one, [0621]
  • 8′-chloro-6′-methoxyspiro[cyclohexane-1-4′-(3′,4′-dihydro)quinazolin]-2′(1′H)-one, [0622]
  • 8′-chloro-6′-phenylspiro[cycloheptane-1-4′-(3′,4′-dihydro)quinazolin]-2′(1′H)-one, [0623]
  • 8′-chloro-6′-phenylspiro[cyclohexane-1-4′-(3′,4′-dihydro)quinazolin]-2′(1′H)-one, [0624]
  • 8′-chloro-6′-methylspiro[cyclohexane-1-4′-(3′,4′-dihydro)quinazolin]-2′(1′H)-one, [0625]
  • 8′-chloro-6′-(3-pyridyl)spiro[cyclohexane-1-4′-(3′,4′-dihydro)quinazolin]-2′(1′H)-one, [0626]
  • 8′-chloro-6′-(4-pyridyl)spiro[cyclohexane-1-4′-(3′,4′-dihydro)quinazolin]-2′(1′H)-one, [0627]
  • 6′-(4-carboxyphenyl)-8′-chlorospiro[cyclohexane-1-4′-(3′,4′-dihydro)-quinazolin]-2′(1′H)-one, [0628]
  • 6′-(3-carboxyphenyl)-8′-chlorospiro[cyclohexane-1-4′-(3′,4′-dihydro)-quinazolin]-2′(1′H)-one, [0629]
  • 8′-chloro-6′-(1H-indol-5yl)spiro[cyclohexane-1-4′-(3′,4′-dihydro)-quinazolin]-2′(1′H)-one, [0630]
  • 8′-chloro-6′-(2-pyridyl)spiro[cyclohexane-1-4′-(3′,4′-dihydro)quinazolin]-2′(1′H)-one, [0631]
  • 8′-chloro-6′-(3-dimethylamino-prop-1-ynyl)spiro[cyclohexane-1-4′-(3′,4′-dihydro)-quinazolin]-2′(1′H)-one, [0632]
  • 8′-chloro-6′-(3-methylamino-prop-1-ynyl)spiro[cyclohexane-1-4′-(3′,4′-dihydro)quinazolin]-2′(1′H)-one, [0633]
  • 8′-chloro-6′-[4-(4-methyl-piperazine-1-carbonyl)phenyl]spiro[cyclohexane-1-4′-(3′,4′-dihydro)quinazolin]-2′(1′H)-one, [0634]
  • 8′-chloro-6′-[4-(3-N-dimethylamino-propylcarboxamide)phenyl]-spiro-[cyclohexane-1-4′-(3′,4′-dihydro)quinazolin]-2′(1′H)-one, [0635]
  • 8′-chloro-6′-[4-(2-N-dimethylamino-ethylcarboxamide)phenyl]-spiro-[cyclohexane-1-4′-(3′,4′-dihydro)quinazolin]-2′(1′H)-one, [0636]
  • 8′-chloro-6′-[3-(3-N-dimethylamino-propylcarboxamide)phenyl]-spiro-[cyclohexane-1-4′-(3′,4′-dihydro)quinazolin]-2′(1′H)-one, [0637]
  • 8′-chloro -6′-[3-(4-methyl-piperazine-1-carbonyl)-phenyl]spiro-[cyclohexane-1-4′-(3′,4′-dihydro)quinazolin]-2′(1′H)-one, [0638]
  • 8′-chloro-6′-[3-(2-N-dimethylamino-ethylcarboxamide)phenyl]spiro-[cyclohexane-1-4′-(3′,4′-dihydro)quinazolin]-2′(1′H)-one, [0639]
  • 8′-Chlorospiro[cyclohexane-1-4′-(3′,4′-dihydro)quinazolin]-2′( 1′H)-thione [0640]
  • 8′-Chloro-2′-cyanoiminospiro[cyclohexane-1-4′-(3′,4′-dihydro)quinazoline [0641]
  • 8′-Chloro-2′-methoxyiminospiro[cyclohexane-1-4′-(3′,4′-dihydro)quinazoline, [0642]
  • 8′-Chloro-2′-dimethylaminospiro[cyclohexane-1-4′-(3′,4′-dihydro)quinazoline], [0643]
  • 8′-Chloro-1′-methylspiro[cyclohexane-1-4′-(3′,4′-dihydro)quinazolin]-2′(1′H)-one, [0644]
  • 8′-Chloro-1′-(ethoxycarbonylmethyl)spiro[cyclohexane-1-4′-(3′,4′-dihydro)-quinazolin]-2′(1′H)-one, [0645]
  • 8′-Chloro-3′-methylspiro[cyclohexane-1-4′-(3′,4′-dihydro)quinazolin]-2′(1′H)-one, [0646]
  • 8′-chloro-6′-[4-(4-pyrimidin-2-yl-piperazine-1-carbonyl)phenyl]spiro[-cyclohexane-1-4′-(3′,4′-dihydro)quinazolin]-2′(1′H)-one, [0647]
  • 8′-chloro-6′-[4-(4-(2-morpholin-4-yl-ethyl)-piperazine-1-carbonyl)-phenyl]spiro[-cyclohexane-1-4′-(3′,4′-dihydro)quinazolin]-2′( 1′H)-one, [0648]
  • 8′-chloro-6′-[4-(4-(2-morpholin-4-yl-2-oxo-ethyl)-piperazine-1-carbonyl)-phenyl]spiro[-cyclohexane-1-4′-(3′,4′-dihydro)quinazolin]-2′(1′H)-one, [0649]
  • 8′-chloro-6′-[4-(4-(2-hydroxy-ethoxy)-ethyl)-piperazine-1-carbonyl)-phenyl]spiro[-cyclohexane-1-4′-(3′,4′-dihydro)quinazolin]-2′(1′H)-one, [0650]
  • 9′-Chlorospiro[cyclohexane-1-5′-(5′,10′-dihydro)]-imidazo[2,1-b]quinazoline [0651]
  • 9′-Chlorospiro[cyclohexane-1-5′-(5′,10′-dihydro)]-[1,2,4]triazolo[3,4-b]quinazoline, [0652]
  • 9′-Chlorospiro[cyclohexane-1-5′-(4′,5′-dihydro)]-[1,2,4]triazolo[4,3-a]quinazoline, Spiro[cyclohexane-1-9′-(8′,9′-dihydro)-pyrazolo[4′,3′-f]quinazolin]-7′(6′H)-one, [0653]
  • 8′-Chloro-5′-methoxyspiro[cyclohexane-1-4′-(3′,4′-dihydro)quinazolin]-2′(1′H)-one, [0654]
  • 5′,8′-difluorospiro[cyclohexane-1-4′-(3′,4′-dihydro)quinazolin]-2′(1′H)-one, [0655]
  • 8′-Chloro-5′-methylspiro[cyclohexane-1-4′-(3′,4′-dihydro)quinazolin]-2′(1′H)-one, [0656]
  • 8′-Chloro-6′-(morpholin-4-yl)methylspiro[cyclohexane-1-4′-(3′,4′-dihydro)quinazolin]-2′(1′H)-one, [0657]
  • 8′-Chloro-5′-hydroxyspiro[cyclohexane-1-4′-(3′,4′-dihydro)quinazolin]-2′(1′H)-one, [0658]
  • 8′-Chloro-5′-hydroxy-6′-iodo-spiro[cyclohexane-1-4′-(3′,4′-dihydro)quinazolin]-2′(1′H)-one, [0659]
  • 8′-Chloro-6′-iodo-5′-methoxy-spiro[cyclohexane-1-4′-(3′,4′-dihydro)quinazolin]-2′(1′H)-one, [0660]
  • 8′-Chloro-6′-cyano-5′-methoxy-spiro[cyclohexane-1-4′-(3′,4′-dihydro)quinazolin]-2′(1′H)-one, [0661]
  • 8′-Chloro-5′-[2-(4-morpholino)ethoxy]spiro[cyclohexane-1-4′-(3′,4′-dihydro)quinazolin]-2′(1′H)-one, [0662]
  • 8′-Chloro-5′-[2-dimethylaminoethoxy]spiro[cyclohexane-1-4′-(3′,4′-dihydro)quinazolin]-2′(1′H)-one, [0663]
  • 8′-Chloro-5′-(2-aminoethoxy)-spiro[cyclohexane-1-4′-(3′,4′-dihydro)quinazolin]-2′(1′H)-one, [0664]
  • 8′-Chloro-5′-[2-(methylamino)ethoxy]-spiro[cyclohexane-1-4′-(3′,4′-dihydro)quinazolin]-2′(1′H)-one, [0665]
  • 8′-Chloro-5′-[2-(2-aminoethoxy)ethoxy]spiro[cyclohexane-1-4′-(3′,4′-dihydro)quinazolin]-2′(1′H)-one, [0666]
  • 8′-Chloro-5′-[3-dimethylaminopropoxy]spiro[cyclohexane-1-4′-(3′,4′-dihydro)quinazolin]-2′(1′H)-one, [0667]
  • 8′-Chloro-5′-ethoxycarbonylmethoxyspiro[cyclohexane-1-4′-(3′,4′-dihydro)quinazolin]-2′(1′H)-one, [0668]
  • 5′-carboxymethoxy-8′-chloro-spiro[cyclohexane-1-4′-(3′,4′-dihydro)quinazolin]-2′(1′H)-one, [0669]
  • 5′-carboxypropoxy-8′-chloro-spiro[cyclohexane-1-4′-(3′,4′-dihydro)quinazolin]-2′(1′H)-one, [0670]
  • 8′-chloro-5′-(3-sulphopropoxy)-spiro[cyclohexane-1-4′-(3′,4′-dihydro)quinazolin]-2′(1′H)-one, [0671]
  • 8′-Chloro-5′-[2-(tetrahydro-pyran-2-yloxy)-ethoxy]-spiro[cyclohexane-1-4′-(3′,4′-dihydro)quinazolin]-2′(1′H)-one, [0672]
  • 8′-Chloro-5′-(2-hydroxy-ethoxy)-spiro[cyclohexane-1-4′-(3′,4′-dihydro)quinazolin]-2′(1′H)-one, [0673]
  • 8′-Chloro-5′-(5-ethoxycarbonyl-furan-2-ylmethoxy)-spiro[cyclohexane-1-4′-(3′,4′-dihydro)quinazolin]-2′(1′H)-one, [0674]
  • 8′-Chloro-5′-(5-carboxy-furan-2-ylmethoxy)-spiro[cyclohexane-1-4′-(3′,4′-dihydro)quinazolin]-2′(1′H)-one, [0675]
  • 8′-Chloro-5′-cyanomethoxyspiro[cyclohexane-1-4′-(3′,4′-dihydro)quinazolin]-2′(1′H)-one, [0676]
  • 8′-Chloro-5′-(1H-tetrazol-5-ylmethoxy)-spiro[cyclohexane-1-4′-(3′,4′-dihydro)quinazolin]-2′(1′H)-one, [0677]
  • 8′-Chloro-5′-(5-hydroxy-[1,2,4]oxadiazol-3-ylmethoxy)-spiro[cyclohexane-1-4′-(3′,4′-dihydro) quinazolin]-2′(1′H)-one, [0678]
  • 8′-Chloro-6′-iodo-5′-[2-dimethylamino-ethoxy]spiro[cyclohexane-1-4′-(3′,4′-dihydro)quinazolin]-2′(1′H)-one, [0679]
  • 6′-(4-carboxyphenyl)-8′-chloro-5′-methoxyspiro[cyclohexane-1-4′-(3′,4′-dihydro)quinazolin]-2′( 1′H)-one, [0680]
  • 6′-(3-carboxyphenyl)-8′-chloro-5′-methoxyspiro[cyclohexane-1-4′-(3′,4′-dihydro)quinazolin]-2′(1′H)-one, [0681]
  • 8′-chloro-6′-[2-(4-methyl-piperazine-1-carbonyl)phenyl]spiro[cyclohexane-1-4′-(3′,4′-dihydro)quinazolin]-2′(1′H)-one, [0682]
  • 8′-chloro-6′-[2-methyl-4-(4-methyl-piperazine-1-carbonyl)phenyl]spiro[cyclohexane-1-4′-(3′,4′-dihydro)quinazolin]-2′(1′H)-one, [0683]
  • 8′-chloro-6′-[4-(piperazine-1-carbonyl)phenyl]spiro[cyclohexane-1-4′-(3′,4′-dihydro)quinazolin]-2′(1′H)-one, [0684]
  • 8′-chloro-6′-[4-carbamoyl-phenyl]spiro[cyclohexane-1-4′-(3′,4′-dihydro)quinazolin]-2′(1′H)-one, [0685]
  • 8′-chloro-6′-[4-((1-methyl-piperidin-4-yl)-piperazine-1-carbonyl)phenyl]spiro[cyclohexane-1-4′-(3′,4′-dihydro)quinazolin]-2′(1′H)-one, [0686]
  • 8′-chloro-5′-methoxy-6′-[4-(4-methyl-piperazine-1-carbonyl)phenyl]spiro[cyclohexane-1-4′-(3′,4′-dihydro)quinazolin]-2′(1′H)-one, [0687]
  • 8-Chloro-5-methoxyspiro[4H-benzo[d][1,3]oxazin-2-ylamine-4-4′-(tetrahydro-pyran-4′-yl)], [0688]
  • 8′-Trifluoromethylspiro[cyclohexane-1-4′-(3′,4′-dihydro)quinazolin]-2′(1′H)-one, [0689]
  • 8′-Chloro-6′-cyanomethylspiro[cyclohexane-1-4′-(3′,4′-dihydro)quinazolin]-2′(1′H)-one, [0690]
  • 8′-Chloro-5′-(3-dimethylamino-2-hydroxy-propoxy)-spiro[cyclohexane-1-4′-(3′,4′-dihydro)quinazolin]-2′(1′H)-one, [0691]
  • 8′-Chloro-5′-(3-methylamino-2-hydroxy-propoxy)-spiro[cyclohexane-1-4′-(3′,4′-dihydro)quinazolin]-2′(1′H)-one, [0692]
  • 8′-Chloro-5′-[2-(ethoxycarbonylmethyl-amino)-ethoxy]-spiro[cyclohexane-1-4′-(3′,4′-dihydro)quinazolin]-2′(1′H)-one, [0693]
  • 8′-Chloro-5′-[2-(carboxymethyl-amino)-ethoxy]-spiro[cyclohexane-1-4′-(3′,4′-dihydro)quinazolin]-2′(1′H)-one hydrochloride, [0694]
  • 8′-Chloro-5′-(2-methanesulfonylamino-2-oxo-ethoxy)-spiro[cyclohexane-1-4′-(3′,4′-dihydro)quinazolin]-2′(1′H)-one, [0695]
  • 8′-Chloro-5′-(2-[(5-methyl-isoxazol-3-ylmethyl)-amino]ethoxy)-spiro[cyclohexane-1-4′-(3′,4′-dihydro)quinazolin]-2′(1′H)-one. [0696]
  • Among the compounds mentioned above, the following compounds are more preferred: [0697]
  • 6′-Phenylspiro[cycloheptane-1-4′-(3′,4′-dihydro)quinazolin]-2′(1′H)-one, [0698]
  • 8′-Chlorospiro[cyclohexane-1-4′-(3′,4′-dihydro)quinazolin]-2′(1′H)-one, [0699]
  • 5′-chlorospiro[cyclohexane-1-4′-(3′,4′-dihydro)quinazolin]-2′(1′H)-one, [0700]
  • 8′-methylspiro[cyclohexane-1-4′-(3′,4′-dihydro)quinazolin]-2′(1′H)-one, [0701]
  • 8′-bromospiro[cyclohexane-1-4′-(3′,4′-dihydro)quinazolin]-2′(1′H)-one, [0702]
  • 8′-fluorospiro[cyclohexane-1-4′-(3′,4′-dihydro)quinazolin]-2′(1′H)-one, [0703]
  • 5′,8′-dichlorospiro[cyclohexane-1-4′-(3′,4′-dihydro)quinazolin]-2′(1′H)-one, [0704]
  • 5′,6′-dichlorospiro[cyclohexane-1-4′-(3′,4′-dihydro)quinazolin]-2′(1′H)-one, [0705]
  • 6′-phenylspiro[cyclohexane-1-4′-(3′,4′-dihydro)quinazolin]-2′(1′H)-one, [0706]
  • 8′-Bromospiro[cycloheptane-1-4′-(3′,4′-dihydro)quinazolin]-2′(1′H)-one, [0707]
  • 8′-Bromo-4-methylspiro[cyclohexane-1-4′-(3′,4′-dihydro)quinazolin]-2′(1′H)-one, [0708]
  • 8′-Bromospiro[bicyclo[3,2,1]octane-2-4′-(3′,4′-dihydro)quinazolin]-2′(1′H)-one, [0709]
  • 6′,8′-dichlorospiro[cyclohexane-1-4′-(3′,4′-dihydro)quinazolin]-2′(1′H)-one [0710]
  • 8′-chloro-6′-iodospiro[cyclohexane-1-4′-(3′,4′-dihydro)quinazolin]-2′(1′H)-one, [0711]
  • 8′-chloro-6′-methoxyspiro[cyclohexane-1-4′-(3′,4′-dihydro)quinazolin]-2′(1′H)-one, [0712]
  • 8′-chloro-6′-phenylspiro[cycloheptane-1-4′-(3′,4′-dihydro)quinazolin]-2′(1′H)-one, [0713]
  • 8′-chloro-6′-phenylspiro[cyclohexane-1-4′-(3′,4′-dihydro)quinazolin]-2′(1′H)-one, [0714]
  • 8′-chloro-6′-methylspiro[cyclohexane-1-4′-(3′,4′-dihydro)quinazolin]-2′(1′H)-one, [0715]
  • 8′-chloro-6′-(3-pyridyl)spiro[cyclohexane-1-4′-(3′,4′-dihydro)quinazolin]-2′(1′H)-one, [0716]
  • 8′-chloro-6′-(4-pyridyl)spiro[cyclohexane-1-4′-(3′,4′-dihydro)quinazolin]-2′(1′H)-one, [0717]
  • 6′-(4-carboxyphenyl)-8′-chlorospiro[cyclohexane-1-4′-(3′,4′-dihydro)-quinazolin]-2′(1′H)-one, [0718]
  • 6′-(3-carboxyphenyl)-8′-chlorospiro[cyclohexane-1-4′-(3′,4′-dihydro )-quinazolin]-2′(1′H)-one, [0719]
  • 8′-chloro-6′-(1H-indol-5yl)spiro[cyclohexane-1-4′-(3′,4′-dihydro)-quinazolin]-2′(1′H)-one, [0720]
  • 8′-chloro-6′-(2-pyridyl)spiro[cyclohexane-1-4′-(3′,4′-dihydro)quinazolin]-2′(1′H)-one, [0721]
  • 8′-chloro-6′-(3-dimethylamino-prop-1-ynyl)spiro[cyclohexane-1-4′-(3′,4′-dihydro)-quinazolin]-2′(1′H)-one, [0722]
  • 8′-chloro-6′-(3-methylamino-prop-1-ynyl)spiro[cyclohexane-1-4′-(3′,4′-dihydro)quinazolin]-2′(1′H)-one, [0723]
  • 8′-chloro-6′-[4-(4-methyl-piperazine-1-carbonyl)phenyl]spiro[cyclohexane-1-4′-(3′,4′-dihydro)quinazolin]-2′(1′H)-one, [0724]
  • 8′-chloro-6′-[4-(3-N-dimethylamino-propylcarboxamide)phenyl]-spiro-[cyclohexane-1-4′-(3′,4′-dihydro)quinazolin]-2′(1′H)-one, [0725]
  • 8′-chloro-6′-[4-(2-N-dimethylamino-ethylcarboxamide)phenyl]-spiro-[cyclohexane-1-4′-(3′,4′-dihydro)quinazolin]-2′(1′H)-one, [0726]
  • 8′-chloro-6′-[3-(3-N-dimethylamino-propylcarboxamide)phenyl]-spiro-[cyclohexane-1-4′-(3′,4′-dihydro)quinazolin]-2′(1′H)-one, [0727]
  • 8′-chloro -6′-[3-(4-methyl-piperazine-1-carbonyl)-phenyl]spiro-[cyclohexane-1-4′-(3′,4′-dihydro)quinazolin]-2′(1′H)-one, [0728]
  • 8′-chloro-6′-[3-(2-N-dimethylamino-ethylcarboxamide)phenyl]spiro-[cyclohexane-1-4′-(3′,4′-dihydro)quinazolin]-2′(1′H)-one, [0729]
  • 8′-Chlorospiro[cyclohexane-1-4′-(3′,4′-dihydro)quinazolin]-2′(1′H)-thione [0730]
  • 8′-Chloro-2′-cyanoiminospiro[cyclohexane-1-4′-(3′,4′-dihydro)quinazoline [0731]
  • 8′-chloro-6′-[4-(4-pyrimidin-2-yl-piperazine-1-carbonyl)phenyl]spiro[-cyclohexane-1-4′-(3′,4′-dihydro)quinazolin]-2′(1′H)-one, [0732]
  • 8′-chloro-6′-[4-(4-(2-morpholin-4-yl-ethyl)-piperazine-1-carbonyl)-phenyl]spiro[-cyclohexane-1-4′-(3′,4′-dihydro)quinazolin]-2′(1′H)-one, [0733]
  • 8′-chloro-6′-[4-(4-(2-morpholin-4-yl-2-oxo-ethyl)-piperazine-1-carbonyl)-phenyl]spiro[-cyclohexane-1-4′-(3′,4′-dihydro)quinazolin]-2′( 1′H)-one, [0734]
  • 8′-chloro-6′-[4-(4-(2-hydroxy-ethoxy)-ethyl)-piperazine-1-carbonyl)-phenyl]spiro[-cyclohexane-1-4′-(3′,4′-dihydro)quinazolin]-2′(1′H)-one, [0735]
  • 8′-Chloro-5′-methoxyspiro[cyclohexane-1-4′-(3′,4′-dihydro)quinazolin]-2′(1′H)-one, [0736]
  • 5′,8′-difluorospiro[cyclohexane-1-4′-(3′,4′-dihydro)quinazolin]-2′(1′H)-one, [0737]
  • 8′-Chloro-5′-methylspiro[cyclohexane-1-4′-(3′,4′-dihydro)quinazolin]-2′(1′H)-one, [0738]
  • 8′-Chloro-6′-(morpholin-4-yl)methylspiro[cyclohexane-1-4′-(3′,4′-dihydro)quinazolin]-2′(1′H)-one, [0739]
  • 8′-Chloro-5′-hydroxyspiro[cyclohexane-1-4′-(3′,4′-dihydro)quinazolin]-2′(1′H)-one, [0740]
  • 8′-Chloro-6′-cyano-5′-methoxy-spiro[cyclohexane-1-4′-(3′,4′-dihydro)quinazolin]-2′(1′H)-one, [0741]
  • 8′-Chloro-5′-[2-(4-morpholino)ethoxy]spiro[cyclohexane-1-4′-(3′,4′-dihydro)quinazolin]-2′(1′H)-one, [0742]
  • 8′-Chloro-5′-[2-dimethylaminoethoxy]spiro[cyclohexane-1-4′-(3′,4′-dihydro)quinazolin]-2′(1′H)-one, [0743]
  • 8′-Chloro-5′-[2-(methylamino)ethoxy]-spiro[cyclohexane-1-4′-(3′,4′-dihydro)quinazolin]-2′(1′H)-one, [0744]
  • 5′-carboxymethoxy-8′-chloro-spiro[cyclohexane-1-4′-(3′,4′-dihydro)quinazolin]-2′(1′H)-one, [0745]
  • 5′-carboxypropoxy-8′-chloro-spiro[cyclohexane-1-4′-(3′,4′-dihydro)quinazolin]-2′(1′H)-one, [0746]
  • 8′-chloro-5′-(3-sulphopropoxy)-spiro[cyclohexane-1-4′-(3′,4′-dihydro)quinazolin]-2′(1′H)-one, [0747]
  • 8′-Chloro-5′-(2-hydroxy-ethoxy)-spiro[cyclohexane-1-4′-(3′,4′-dihydro)quinazolin]-2′(1′H)-one, [0748]
  • 8′-Chloro-5′-(5-ethoxycarbonyl-furan-2-ylmethoxy)-spiro[cyclohexane-1-4′-(3′,4′-dihydro)quinazolin]-2′(1′H)-one, [0749]
  • 8′-Chloro-5′-(5-carboxy-furan-2-ylmethoxy)-spiro[cyclohexane-1-4′-(3′,4′-dihydro)quinazolin]-2′(1′H)-one, [0750]
  • 8′-Chloro-5′-cyanomethoxyspiro[cyclohexane-1-4′-(3′,4′-dihydro)quinazolin]-2′(1′H)-one, [0751]
  • 8′-Chloro-5′-(1H-tetrazol-5-ylmethoxy)-spiro[cyclohexane-1-4′-(3′,4′-dihydro)quinazolin]-2′(1′H)-one, [0752]
  • 8′-Chloro-5′-(5-hydroxy-[1,2,4]oxadiazol-3-ylmethoxy)-spiro[cyclohexane-1-4′-(3′,4′-dihydro) quinazolin]-2′(1′H)-one, [0753]
  • 6′-(4-carboxyphenyl)-8′-chloro-5′-methoxyspiro[cyclohexane-1-4′-(3′,4′-dihydro)quinazolin]-2′(1′H)-one, [0754]
  • 6′-(3-carboxyphenyl)-8′-chloro-5′-methoxyspiro[cyclohexane-1-4′-(3′,4′-dihydro)quinazolin]-2′(1′H)-one, [0755]
  • 8′-chloro-6′-[2-methyl-4-(4-methyl-piperazine-1-carbonyl)phenyl]spiro[cyclohexane-1-4′-(3′,4′-dihydro)quinazolin]-2′(1′H)-one, [0756]
  • 8′-chloro-6′-[4-(piperazine-1-carbonyl)phenyl]spiro[cyclohexane-1-4′-(3′,4′-dihydro)quinazolin]-2′(1′H)-one, [0757]
  • 8′-chloro-6′-[4-carbamoyl-phenyl]spiro[cyclohexane-1-4′-(3′,4′-dihydro)quinazolin]-2′(1′H)-one, [0758]
  • 8′-chloro-6′-[4-((1-methyl-piperidin-4-yl)-piperazine-1-carbonyl)phenyl]spiro[cyclohexane-1-4′-(3′,4′-dihydro)quinazolin]-2′(1′H)-one, [0759]
  • 8′-chloro-5′-methoxy-6′-[4-(4-methyl-piperazine-1-carbonyl)phenyl]spiro[cyclohexane-1-4′-(3′,4′-dihydro)quinazolin]-2′(1′H)-one, [0760]
  • 8′-Chloro-6′-cyanomethylspiro[cyclohexane-1-4′-(3′,4′-dihydro)quinazolin]-2′(1′H)-one, [0761]
  • 8′-Chloro-5′-(3-dimethylamino-2-hydroxy-propoxy)-spiro[cyclohexane-1-4′-(3′,4′-dihydro)quinazolin]-2′(1′H)-one, [0762]
  • 8′-Chloro-5′-(3-methylamino-2-hydroxy-propoxy)-spiro[cyclohexane-1-4′-(3′,4′-dihydro)quinazolin]-2′(1′H)-one, [0763]
  • 8′-Chloro-5′-[2-(carboxymethyl-amino)-ethoxy]-spiro[cyclohexane-1-4′-(3′,4′-dihydro)quinazolin]-2′(1′H)-one hydrochloride, [0764]
  • 8′-Chloro-5′-(2-methanesulfonylamino-2-oxo-ethoxy)-spiro[cyclohexane-1-4′-(3′,4′-dihydro)quinazolin]-2′(1′H)-one, [0765]
  • 8′-Chloro-5′-(2-[(5-methyl-isoxazol-3-ylmethyl)-amino]ethoxy)-spiro[cyclohexane-1-4′-(3′,4′-dihydro)quinazolin]-2′(1′H)-one. [0766]
  • Among the compounds mentioned above, the following compounds are more preferred: [0767]
  • 8′-bromospiro[cyclohexane-1-4′-(3′,4′-dihydro)quinazolin]-2′(1′H)-one, [0768]
  • 5′,8′-dichlorospiro[cyclohexane-1-4′-(3′,4′-dihydro)quinazolin]-2′(1′H)-one, [0769]
  • 8′-Bromospiro[cycloheptane-1-4′-(3′,4′-dihydro)quinazolin]-2′(1′H)-one, [0770]
  • 8′-chloro-6′-methoxyspiro[cyclohexane-1-4′-(3′,4′-dihydro)quinazolin]-2′(1′H)-one, [0771]
  • 8′-chloro-6′-phenylspiro[cyclohexane-1-4′-(3′,4′-dihydro)quinazolin]-2′(1′H)-one, [0772]
  • 8′-chloro-6′-(3-pyridyl)spiro[cyclohexane-1-4′-(3′,4′-dihydro)quinazolin]-2′(1′H)-one, [0773]
  • 8′-chloro-6′-(4-pyridyl)spiro[cyclohexane-1-4′-(3′,4′-dihydro)quinazolin]-2′(1′H)-one, [0774]
  • 6′-(4-carboxyphenyl)-8′-chlorospiro[cyclohexane-1-4′-(3′,4′-dihydro)-quinazolin]-2′(1′H)-one, [0775]
  • 6′-(3-carboxyphenyl)-8′-chlorospiro[cyclohexane-1-4′-(3′,4′-dihydro)-quinazolin]-2′(1′H)-one, [0776]
  • 8′-chloro-6′-(1H-indol-5yl)spiro[cyclohexane-1-4′-(3′,4′-dihydro)-quinazolin]-2′(1′H)-one, [0777]
  • 8′-chloro-6′-(2-pyridyl)spiro[cyclohexane-1-4′-(3′,4′-dihydro)quinazolin]-2′(1′H)-one, [0778]
  • 8′-chloro-6′-(3-dimethylamino-prop-1-ynyl)spiro[cyclohexane-1-4′-(3′,4′-dihydro)-quinazolin]-2′(1′H)-one, [0779]
  • 8′-chloro-6′-(3-methylamino-prop-1-ynyl)spiro[cyclohexane-1-4′-(3′,4′-dihydro)quinazolin]-2′(1′H)-one, [0780]
  • 8′-chloro-6′-[4-(4-methyl-piperazine-1-carbonyl)phenyl]spiro[cyclohexane-1-4′-(3′,4′-dihydro)quinazolin]-2′(1′H)-one, [0781]
  • 8′-chloro-6′-[4-(3-N-dimethylamino-propylcarboxamide)phenyl]-spiro-[cyclohexane-1-4′-(3′,4′-dihydro)quinazolin]-2′(1′H)-one, [0782]
  • 8′-chloro-6′-[4-(2-N-dimethylamino-ethylcarboxamide)phenyl]-spiro-[cyclohexane-1-4′-(3′,4′-dihydro)quinazolin]-2′(1′H)-one, [0783]
  • 8′-chloro-6′-[3-(3-N-dimethylamino-propylcarboxamide)phenyl]-spiro-[cyclohexane-1-4′-(3′,4′-dihydro)quinazolin]-2′( 1′H)-one, [0784]
  • 8′-chloro -6′-[3-(4-methyl-piperazine-1-carbonyl)-phenyl]spiro-[cyclohexane-1-4′-(3′,4′-dihydro)quinazolin]-2′(1′H)-one, [0785]
  • 8′-chloro-6′-[3-(2-N-dimethylamino-ethylcarboxamide)phenyl]spiro-[cyclohexane-1-4′-(3′,4′-dihydro)quinazolin]-2′(1′H)-one, [0786]
  • 8′-chloro-6′-[4-(4-pyrimidin-2-yl-piperazine-1-carbonyl)phenyl]spiro[-cyclohexane-1-4′-(3′,4′-dihydro)quinazolin]-2′(1′H)-one, [0787]
  • 8′-chloro-6′-[4-(4-(2-morpholin-4-yl-ethyl)-piperazine-1-carbonyl)-phenyl]spiro[-cyclohexane-1-4′-(3′,4′-dihydro)quinazolin]-2′(1′H)-one, [0788]
  • 8′-chloro-6′-[4-(4-(2-morpholin-4-yl-2-oxo-ethyl)-piperazine-1-carbonyl)-phenyl]spiro[-cyclohexane-1-4′-(3′,4′-dihydro)quinazolin]-2′(1′H)-one, [0789]
  • 8′-chloro-6′-[4-(4-(2-hydroxy-ethoxy)-ethyl)-piperazine-1-carbonyl)-phenyl]spiro[-cyclohexane-1-4′-(3′,4′-dihydro)quinazolin]-2′(1′H)-one, [0790]
  • 8′-Chloro-5′-methoxyspiro[cyclohexane-1-4′-(3′,4′-dihydro)quinazolin]-2′(1′H)-one, [0791]
  • 8′-Chloro-5′-methylspiro[cyclohexane-1-4′-(3′,4′-dihydro)quinazolin]-2′(1′H)-one, [0792]
  • 8′-Chloro-5′-hydroxyspiro[cyclohexane-1-4′-(3′,4′-dihydro)quinazolin]-2′(1′H)-one, [0793]
  • 8′-Chloro-6′-cyano-5 ′-methoxy-spiro[cyclohexane-1-4′-(3′,4′-dihydro)quinazolin]-2′(1′H)-one, [0794]
  • 8′-Chloro-5′-[2-(4-morpholino)ethoxy]spiro[cyclohexane-1-4′-(3′,4′-dihydro)quinazolin]-2′(1′H)-one, [0795]
  • 5′-carboxymethoxy-8′-chloro-spiro[cyclohexane-1-4′-(3′,4′-dihydro)quinazolin]-2′(1′H)-one, [0796]
  • 5′-carboxypropoxy-8′-chloro-spiro[cyclohexane-1-4′-(3′,4′-dihydro)quinazolin]-2′(1′H)-one, [0797]
  • 8′-chloro-5′-(3-sulphopropoxy)-spiro[cyclohexane-1-4′-(3′,4′-dihydro)quinazolin]-2′(1′H)-one, [0798]
  • 8′-Chloro-5′-(2-hydroxy-ethoxy)-spiro[cyclohexane-1-4′-(3′,4′-dihydro)quinazolin]-2′(1′H)-one, [0799]
  • 8′-Chloro-5′-(5-ethoxycarbonyl-furan-2-ylmethoxy)-spiro[cyclohexane-1-4′-(3′,4′-dihydro)quinazolin]-2′(1′H)-one, [0800]
  • 8′-Chloro-5′-(5-carboxy-furan-2-ylmethoxy)-spiro[cyclohexane-1-4′-(3′,4′-dihydro)quinazolin]-2′(1′H)-one, [0801]
  • 8′-Chloro-5′-cyanomethoxyspiro[cyclohexane-1-4′-(3′,4′-dihydro)quinazolin]-2′(1′H)-one, [0802]
  • 8′-Chloro-5′-(1H-tetrazol-5-ylmethoxy)-spiro[cyclohexane-1-4′-(3′,4′-dihydro)quinazolin]-2′(1′H)-one, [0803]
  • 8′-Chloro-5′-(5-hydroxy-[1,2,4]oxadiazol-3-ylmethoxy)-spiro[cyclohexane-1-4′-(3′,4′-dihydro) quinazolin]-2′(1′H)-one, [0804]
  • 6′-(4-carboxyphenyl)-8′-chloro-5′-methoxyspiro[cyclohexane-1-4′-(3′,4′-dihydro)quinazolin]-2′(1′H)-one, [0805]
  • 6′-(3-carboxyphenyl)-8′-chloro-5′-methoxyspiro[cyclohexane-1-4′-(3′,4′-dihydro)quinazolin]-2′(1′H)-one, [0806]
  • 8′-chloro-6′-[2-methyl-4-(4-methyl-piperazine-1-carbonyl)phenyl]spiro[cyclohexane-1-4′-(3′,4′-dihydro)quinazolin]-2′(1′H)-one, [0807]
  • 8′-chloro-6′-[4-(piperazine-1-carbonyl)phenyl]spiro[cyclohexane-1-4′-(3′,4′-dihydro)quinazolin]-2′(1′H)-one, [0808]
  • 8′-chloro-6′-[4-carbamoyl-phenyl]spiro[cyclohexane-1-4′-(3′,4′-dihydro)quinazolin]-2′(1′H)-one, [0809]
  • 8′-chloro-6′-[4-((1-methyl-piperidin-4-yl)-piperazine-1-carbonyl)phenyl]spiro[cyclohexane-1-4′-(3′,4′-dihydro)quinazolin]-2′(1′H)-one, and, [0810]
  • 8′-Chloro-5′-[2-(carboxymethyl-amino)ethoxy]-spiro[cyclohexane-1-4′-(3′,4′-dihydro)quinazolin]-2′(1′H)-one hydrochloride, [0811]
  • 8′-Chloro-5′-(2-methanesulfonylamino-2-oxo-ethoxy)-spiro[cyclohexane-1-4′-(3′,4′-dihydro)quinazolin]-2′(1′H)-one, [0812]
  • 8′-Chloro-5′-(2-[(5-methyl-isoaxazol-3-ylmethyl)-amino]ethoxy)-spiro[cyclohexane-1′-4′-(3′,4′-dihydro)quinazolin]-2′(1′H)-one. [0813]
  • General Process for the Preparation of Compounds of the Invention
  • One method for preparing a compound of the formula (I) defined above in which Y is N—R[0814] 12, X is N—R9 and Z is O comprises reacting a substituted urea of formula
    Figure US20020198198A1-20021226-C00018
  • in which X[0815] 1, X2, X3, X4, R9 and R12 are as defined in the summary of the invention, with a cyclic ketone of formula
    Figure US20020198198A1-20021226-C00019
  • in which A is as defined in the summary of the invention, to obtain said compound of formula (I). [0816]
  • An alternative method for preparing a compound of formula (I) in which X is N—R[0817] 9, Y is O, S or NH, and X1, X2, X3, X4, A and R9 are as defined in the summary of the invention and, comprises,
  • (1) reacting a compound (2a) [0818]
    Figure US20020198198A1-20021226-C00020
  •  in which X[0819] 1, X2, X3, X4 are as defined in the summary of the invention and Y is O, S or NH, with a group P-LG in which P is a protecting group and LG is a leaving group to obtain compound (2b)
    Figure US20020198198A1-20021226-C00021
  • (2) reacting compound (2b) with R—Li in which R is lower alkyl and then with a ketone of formula [0820]
    Figure US20020198198A1-20021226-C00022
  •  in which A is as defined in the summary of the invention to obtain compound (2c) [0821]
    Figure US20020198198A1-20021226-C00023
  • (3) removing the protecting group P either under reductive conditions, acidic condition or basic condition to obtain compound ([0822] 2d)
    Figure US20020198198A1-20021226-C00024
  • (4) reacting compound (2d) with a group O═C═N—R[0823] 9 in which R9 is as defined in the summary of the invention to obtain compound (2e)
    Figure US20020198198A1-20021226-C00025
  • (5) reacting compound (2e) with an acid to obtain said compound of formula (I), [0824]
  • (6) isolating said compound of formula (I). [0825]
  • An alternative process for the preparation of a compound of formula (I) in which X is O, S or NR[0826] 9, Y is O, S or NR12, Z is O, S or NR13, X1, X2, X3, X4, A, R9, R12 and R13 are as defined in the summary of the invention and Y is O, S or NH, comprises,
  • (1) reacting compound (2d) [0827]
    Figure US20020198198A1-20021226-C00026
  •  in which X[0828] 1, X2, X3, X4 and A are as defined in claim 1,
  • with a group LG-C(═X)Z′ or X═C═Z′ in which LG is a leaving group, X is O, S or NR[0829] 9, Z′ is OR, SR or NR13 in which R is lower alkyl or benzyl and R9 and R13 are as defined in the summary of the invention, to obtain compound (2′e)
    Figure US20020198198A1-20021226-C00027
  • (2) reacting compound (2′e) with a source of halonium to obtain compound (2′f) [0830]
    Figure US20020198198A1-20021226-C00028
  • (3) reduction of compound (2′f) to obtain said compound of formula (I) [0831]
  • (4) optionally, when Z′ is OR or SR, hydrolysis or hydrogenolysis of compound (2′f) is carried out to obtain compound said compound of formula (I) in which Z is O or S, and, [0832]
  • (5) isolating said compound of formula (I). [0833]
  • The compounds utilized in the invention include pharmaceutically acceptable derivatives of compounds of formula (I), (II) or (III) such as solvates, hydrates, pharmaceutically acceptable salts and polymorphs (different crystalline lattice descriptors). [0834]
  • Pharmaceutically acceptable salts of a compound of formula (I), (II) or (III) include salts having a basic part and salts having an acidic part. [0835]
  • The expression pharmaceutically acceptable salt of a compound of formula (I), (II) or (III) having a basic part should be understood to refer to the addition salts of the compounds of formula (I), (II) or (III) which may be formed from non-toxic inorganic or organic acids such as, for example, hydrobromic, hydrochloric, sulfuric, phosphoric, nitric, acetic, succinic, tartaric, citric, maleic, hydroxymaleic, benzoic, fumaric and toluenesulfonic acid salts, and the like. The various quaternary ammonium salts of the derivatives (I), (II) or (III) are also included in this category of compounds of the invention. In addition, the expression pharmaceutically acceptable salt of a compound of formula (I), (II) or (III) having an acidic part is understood to refer to the usual salts of the compounds of formula (I), (II) or (III) which may be formed from non-toxic inorganic or organic bases such as, for example, the hydroxides of alkali metals and alkaline-earth metals (sodium, potassium, magnesium and calcium), amines (dibenzylethylenediamine, trimethylamine, piperidine, pyrrolidine, benzylamine and the like) or alternatively quaternary ammonium hydroxides such as tetramethylammonium hydroxide. (See also “Pharmaceutical salts” by Berge S. M. et al. (1997) [0836] J. Pharm. Sci. 66: 1-19, which is incorporated herein by reference.).
  • Use of a prodrug of a compound of the invention such as it would occur to one skilled in the art (see Bundgaard, et al., [0837] Acta Pharm. Suec., 1987; 24: 233-246), is also contemplated.
  • Pharmaceutical Compositions
  • The products of the invention are administered in the form of compositions, which are appropriate for the nature, and severity of the complaint to be treated. The daily dose in humans is usually between 1 mg and 1 g of product, which may be taken in one or more individual doses. The compositions are prepared in forms which are compatible with the intended route of administration, such as, for example, tablets, coated tablets, capsules, mouthwashes, aerosols, powders for inhalation, suppositories, enemas, foams (such as rectal foams) gels or suspensions. These compositions are prepared by methods which are familiar to those skilled in the art and comprise from 0.5 to 60% by weight of active principle (compound of the invention) and 40 to 99.5% by weight of a pharmaceutical vehicle or carrier which is appropriate and compatible with the active principle and the physical form of the intended composition. [0838]
  • Solid form preparations include powders, tablets, dispersible granules, capsules, cachets, and suppositories. A solid carrier can be one or more substances which may also act as diluents, flavouring agents, solubilizers, lubricants, suspending agents, binders, or tablet disintegrating agents; it can also be an encapsulating material. In powders, the carrier is a finely divided solid, which is in a mixture with the finely divided active component. In tablets, the active component is mixed with the carrier having the necessary binding properties in suitable proportions and compacted in the shape and size desired. The powders, tablets, cachets or encapsulated forms for capsules preferably contain 5% to about 70% of the active component. Suitable carriers are magnesium carbonate, magnesium stearate, talc, lactose, sugar, pectin, dextrin, starch, tragacanth, methyl cellulose, sodium carboxymethyl cellulose, a low-melting wax, cocoa butter, and the like. [0839]
  • Tablets, powders, cachets, and capsules can be used as solid dosage forms suitable for oral administration. The drug may be delivered as a spray (either in a pressurized container fitted with an appropriate valve or in a non-pressurized container fitted with a metering valve). [0840]
  • Liquid form preparations include solutions, suspensions, and emulsions. [0841]
  • Sterile water or water-propylene glycol solutions of the active compounds may be mentioned as an example of liquid preparations suitable for parenteral administration. Liquid preparations can also be formulated in solution in aqueous polyethylene glycol solution. [0842]
  • Aqueous solutions for oral administration can be prepared by dissolving the active component in water and adding suitable colorants, flavouring agents, stabilizers, and thickening agents as desired. Aqueous suspensions for oral use can be made by dispersing the finely divided active component in water together with a viscous material such as natural synthetic gums, resins, methyl cellulose, sodium carboxymethyl cellulose, and other suspending agents known to the pharmaceutical formulation art. [0843]
  • For preparing suppository preparations, a low-melting wax such as a mixture of fatty acid glycerides and cocoa butter is first melted and the active ingredient is dispersed therein by, for example, stirring. The molten homogeneous mixture is then poured into convenient sized molds and allowed to cool and solidify. Enemas are obtained according to known procedures to prepare solutions adapted for rectal administration. Foams are prepared according to known methods (these foams can notably be similar to those used to administer a drug such as 5-ASA for treating rectocolite). [0844]
  • Preferably the pharmaceutical preparation is in unit dosage form. In such form, the preparation is divided into unit doses containing appropriate quantities of drug. The unit dosage form can be a packaged preparation, the package containing discrete quantities of the preparation, for example, packaged tablets, capsules, and powders in vials or ampoules. The unit dosage form can also be a capsule, cachet, or tablet itself, or it can be the appropriate number of any of these packaged forms. [0845]
  • Methods of Treatment
  • The compounds of the invention are PDE inhibitors, and particularly PDE7 inhibitors. These compounds have low IC[0846] 50 values, typically at most 5 μM, preferably below 1 μM, and even below 100 nM.
  • It has been shown according to the invention that compounds of the invention are selective PDE7 inhibitors. “selective PDE7 inhibitors” refers to a compound which have an IC[0847] 50 for PDE7 at least 5 times lower than the IC50 for a PDE distinct from PDE7, and preferably at least 10 times, 15 times, 20 times, 30 times, 40 times, 50 times or 100 times lower than the IC50 value for a PDE distinct from PDE7.
  • A PDE distinct from PDE7 refers preferably to a PDE chosen from PDE1, PDE3, PDE4 or PDE5. [0848]
  • In particular, it has been shown according to the invention that the compounds of the invention, and more particularly the family of compounds given as examples in the present description, have an IC[0849] 50 value for the enzyme PDE7 which is often 100 times lower than the value of their IC50 for a PDE distinct from PDE7, in particular PDE1, PDE3, PDE4 or PDE5.
  • Compounds of the invention can be used in the treatment of various diseases, as they can modulate inflammatory and immunological processes due to the increase of intracellular cAMP levels. [0850]
  • The diseases that can be treated are T-cell-related diseases, AE-cell-related diseases and immune disorders, such as autoimmune diseases, osteoarthritis, rheumatoid arthritis, multiple sclerosis, osteoporosis, asthma, COPD, cancer, AIDS, inflammation, allergy and various inflammatory disorders such as, for example, inflammatory bowel disease (IBD). [0851]
  • The invention finally relates to a method for the treatment of the above-mentioned diseases comprising administering to a mammal, particularly a human, in need thereof an effective amount of compound of the invention. [0852]
  • Processes for Synthetising the Compounds of General Formula (I), (II) and (III)
  • The compounds according to the present invention can be obtained by carrying out several synthetic processes. Some of these synthetic processes (protocols A-L) are described below. [0853]
  • The solvent, reaction time, temperature, catalyst if any, can be varied in all steps described below for all routes, as the skilled man will appreciate. [0854]
  • Protocol A
  • [0855]
    Figure US20020198198A1-20021226-C00029
  • In scheme 1, X[0856] 1, X2, X3, X4, A, R9 and R12 are as defined in the summary of the invention.
  • The starting materials are either commercially available or can be prepared according to routes known to the skilled person. If the starting urea in step 3 is not commercially available, it can be prepared by treating the corresponding isocyanate with a primary amine in a solvent such as tetrahydrofuran (step 1) or treating the corresponding aniline with a substituted isocyanate in an organic solvent such as dichloromethane or acetonitrile (step 2). [0857]
  • In step 3, the urea is converted into the desired quinazolinone by reacting it with a cyclic ketone in polyphosphoric acid at 80-130° C. [0858]
  • Protocol B
  • [0859]
    Figure US20020198198A1-20021226-C00030
  • In scheme 2, X[0860] 1, X2, X3, X4, A and R9 are as defined in the summary of the invention, Y may be O, S or NH and LG is a leaving group and R is lower alkyl.
  • The starting compounds are either commercially available or can be prepared according to routes known to the skilled person. [0861]
  • In step 1, compound (2a) is reacted with dialkyl-carbamoyl chloride to form the desired N,N dialkyl-carbamate or thiocarbamate according to routes known to the skilled person. See Poirier, M.; Simard, M.; Wuest, J. D.; [0862] Organometallics, 1996, 15 (4), 1296-1300.
  • Other protecting groups may be used as oxygen-based directed metalation groups such as OMe, OMOM, OP(OR[0863] 2), OPO(NMe)2. See Snieckus, Chem. Rev., 1990, 90, 879-933.
  • The aniline derivative is protected as a t-butyl carbamate or as a pivaloyl amide according to routes known to the skilled person. See [0864] Tet Lett., 1994, 35(48), 9003-9006.
  • In step 2, compound ([0865] 2b) is converted to a lithium salt (when Y is O or S) or to a dilithium salt thereof by reaction with an excess of lithium compound-forming agent such as t-butyllithium in a mixed solvent of anhydrous ether (for example, diethyl ether and tetrahydrofuran) and alkane (for example pentane), and reacted with an appropriate ketone. The reaction is carried out at low temperature (between −78° C. and 0° C. to give the expected tertiary alcool. The organolithium intermediate can also be formed by halogen-metal exchange. The organolithium can also be transmetallated into another organometallic reagent such as a cerate (with anhydrous cerium trichloride for example) prior to treatment with the ketone. In step 3, the protecting group is removed according to routes known to the skilled person either under reductive conditions (when Y═O—P or S—P), under acidic condition or under basic condition to give compound (2d).
  • In step 4, compound ([0866] 2d) is reacted with an appropriate substituted isocyanate to obtain compound (2e).
  • In step 5, treating compound ([0867] 2e) with an acid (mineral acid or lewis acid) triggers cyclisation to give compound (2f).
  • Protocol B′
  • [0868]
    Figure US20020198198A1-20021226-C00031
  • In scheme 2′, X[0869] 1, X2, X3, X4 and A are as defined in the summary of the invention, Y may be O, S or NR2, X may be O, S, NR9 and LG is a leaving group, Z′ may be OR, SR, NR16R17 or NR13, Hal is halogen, Z2 may be O or S and where R12, R13, R16, R17 and R9 are as defined in the summary of the invention and R is alkyl or benzyl.
  • In step 1, intermediate [0870] 2d obtained according to protocol B is reacted either with a carbonyl derivative such as a carbonate, a chloroformate, an isocyanate; a thiocarbonyl derivative such as an isothiocyanate, a thionochloroformate, or others such as cyanamide, 3,5-dimethyl-1H-pyrazole-1-carboximidamide nitrate, S-methylisothiourea or equivalent. Alternatively, as shown in step 1′, intermediate 2′e can be prepared in two steps by treating 2d with either cyanogens bromide or a carbonyl (or thiocarbonyl) derivative activated by two leaving groups such as phosgene (or thiophosgene), 1,1′-carbonyldiimidazole (or 1,1′-thiocarbonyldiimidazole), nitrophenylchloroformate or carbon disulfide, followed by addition of a nucleophile such as an amine, an alcohol or a thiol to introduce Z′. The appropriate reaction conditions for each route can be easily determined by the skilled person. When desired, certain intermediates 2e obtained can be derivatized into other intermediates 2e according to routes known to the skilled person. For instance, an intermediate thiourea 2e wherein Y═NH, X═S and Z′═NH2 can be treated with an alkyl halide R—X according to reaction conditions known to the skilled person to give an intermediate 2e wherein Y═NH, X═NH and Z′═SR.
  • In step 2, intermediate [0871] 2e is treated with a source of halonium such as iodine, N-iodosuccinimide, bromine or N-bromosuccinimide to yield intermediate 2′f. Similarly to 2′e, intermediate 2f can be derivatized into different intermediates 2′f according to routes known to the skilled person. The halide 2f can be reduced to 2g as shown in step 3 under reaction conditions known to the skilled person, such as treatment with trialkyl tin hydride and a radical initiator like azobisisobutyronitrile (AIBN) in an inert organic solvent. Alternatively, as shown in step 2′, intermediate 2e could be directly transformed into 2g under acidic treatment according to conditions that can be determined by the skilled person. If necessary, intermediate 2′g can also be derivatized into different 2′g according to routes known to the skilled person. When Z′ is OR or SR, intermediate 2q′ can be converted to 2′h as shown in step 4. This can be done according to conditions known to the skilled person by hydrolysis under aqueous acidic media or by hydrogenolysis when R is benzyl.
  • Protocol C
  • [0872]
    Figure US20020198198A1-20021226-C00032
  • In scheme 3, X[0873] 1, X2, X3, X4 and A are as defined in the summary of the invention, R9 is alkyl, aryl, alkylsulfonyl or arylsulfonyl, R is lower alkyl and Y may be O, S or NH.
  • An alternative method of preparing compound of the present invention is shown below and proceeds through the reaction of the organolithium intermediate with an imine. [0874]
  • In step 1, compound ([0875] 3a) is converted to a lithium salt (when Y is O or S) or to a dilithium salt (when Y is NH) thereof by reaction with an excess of lithium 15 compound-forming agent such as t-butyllithium in a mixed solvent of anhydrous ether (for example, diethyl ether and tetrahydrofuran) and alkane (for example pentane). The resulting organolithium is reacted with an appropriate imine at low temperature to give the expected tertiary amine (3b). The organolithium can also be transmetallated into another organometallic reagent such as a cerate (with anhydrous cerium trichloride for example) prior to treatment with the ketone.
  • In step 2, the protecting group is removed according to routes known to the skilled person either under reductive conditions (when Y═O—P or S—P), under acidic condition or under basic condition to give compound ([0876] 3c). When R9 is alkyl or arylsulfonyl, this group can be deprotected into the NH derivative by reductive methods or hydrolysis according to methods known to the skilled person. In step 3, compound (3c) is reacted with a compound selected from a carbonic acid halide such as phosgene a carbonic acid diester, 1,1′-carbonyldiimidazole and so on to obtain compound (3d).
  • In step 4, compound (3c) is reacted with an orthoester, in the presence of an acid to obtain compound (3e) or its tautomeric forms. [0877]
  • Protocol D
  • [0878]
    Figure US20020198198A1-20021226-C00033
  • In scheme 4, X[0879] 1, X2, X3, X4, A, R9 and R12 are as defined in the summary of the invention, Z is O or S.
  • The starting materials are either commercially available or can be prepared according to routes known to the skilled person. In step 1, the starting anthranilic acid is treated with phosgene or an equivalent source of carbonyl such as triphosgene or carbonyl diimidazole. Various solvents and reaction conditions can be used and will be easily determined by the skilled person. The resulting isatoic anhydride is treated with the Grignard reagent obtained from a dihalide and magnesium in a solvent such as tetrahydrofuran or ether (step 2). In step 3, the aniline is converted to an urea by treatment with a substituted isocyanate. Various solvents and reaction conditions can be used and will be easily determined by the skilled person. For example, the reaction can be performed at room temperature or reflux in an inert solvent such as dichloromethane, acetonitrile or tetrahydrofuran in the presence or not of a base such as triethylamine or pyridine. In step 4, the resulting hydroxy-urea is subjected to an acid with or without an organic solvent. For example, the reaction can be carried out at 70-90° C. in sulfuric acid. A solvent such as toluene or acetic acid may be added. [0880]
  • In step 3′, compound 4c is converted to compound 4f by treatment with a carbonyl (or thiocarbonyl) derivative activated by two leaving groups such as phosgene (or thiophosgene), 1,1′-carbonyldiimidazole (or 1,1′-thiocarbonyldiimidazole). [0881]
  • Protocol E
  • [0882]
    Figure US20020198198A1-20021226-C00034
  • In scheme 5, X[0883] 1, X3, X4, X, Y and A are as defined in the summary of the invention. The starting tricyclic compound is reacted with an electrophile E+ such as halonium or acylium in presence or not of an activating agent in an organic solvent. Various solvents and reaction conditions for this aromatic electrophilic substitution can be used depending on the electrophile and will be easily determined by the skilled person. For instance, the starting material can be treated with a source of halonium such as N-iodo or N-bromosuccinimide in dimethylformamide at 60-70° C. to give the corresponding halide. In another example, the starting material can be reacted with an acyl halide and aluminium trichloride, as Lewis acid, in a solvent such as dichloroethane at 80° C.
  • Protocol F
  • [0884]
    Figure US20020198198A1-20021226-C00035
  • In scheme 6, X[0885] 1, X3, X, Y and A are as defined in the summary of the invention and X2 is not CH.
  • The starting tricyclic compound is reacted with an electrophile E[0886] + in presence or not of an activating agent in an organic solvent. This aromatic electrophilic substitution is similar to Protocol E except that in this case, since X2 is different from CH, the substitution is oriented in position 8. Similarly to Protocol E, various solvents and reaction conditions for this aromatic electrophilic substituion can be used depending on the electrophile and will be easily determined by the skilled person.
  • Protocol G
  • [0887]
    Figure US20020198198A1-20021226-C00036
  • In scheme 7, X[0888] 1, X2, X3 and X4, X, Y, Z and A are as defined in the summary of the invention, R is alkenyl, alkynyl, aryl or heteroaryl and R′ is H or alkyl.
  • The starting aryl or heteroaryl iodide or bromide is subjected to a palladium-catalyzed cross-coupling reaction with an organometallic species, such as a boronate ester, a boronic acid, an organozinc (Hal═halogen) or a trialkylstannane in the presence of base when needed. The organometallic species can be replaced with a terminal alkene or alkyne in the coupling reaction. When an alkyne is used, a source of copper(l), such as copper iodide, can be added. Various palladium catalysts, solvents and reaction conditions can be used for these coupling reactions and will be easily determined by the skilled person. For example, the starting aryl or heteroaryl iodide or bromide can be reacted with a boronic acid in dimethylformamide at 80° C. in the presence of tetrakis(triphenylphosphine)palladium as catalyst and an aqueous solution of potassium carbonate as a base. [0889]
  • Protocol H
  • [0890]
    Figure US20020198198A1-20021226-C00037
  • In scheme 8, X[0891] 1, X2, X3, X4, X, Y, Z, R2, R3, R4 and A are as defined in the summary of the invention and R is selected from aryl, alkenyl, alkynyl or heteroaryl.
  • In step 1, the starting aryl or heteroaryl iodide or bromide is treated with bis(pinacolato)diboron under palladium catalysis to give the corresponding boronate ester. Various paladium catalysts, solvents and reaction conditions can be used and will be easily determined by the skilled person. For example, the starting heteroaryl iodide or bromide can be reacted with bis(pinacolato)diboron in dimethylformamide at 80° C. in the presence of tetrakis(triphenylphosphine) palladium as catalyst. The resulting boronate ester is then coupled to an aryl, alkenyl, alkynyl or heteroaryl iodide, bromide or triflate catalyzed by a palladium species (step 2). Again, various paladium catalysts, solvents and reaction conditions can be used for this coupling reactions and will be easily determined by the skilled person. For instance, the boronate ester is reacted with an aryl, alkenyl, alkynyl or heteroaryl iodide in dimethylformamide at 80° C. in the presence of sodium acetate as base and tetrakis(triphenylphosphine)palladium as catalyst to give the coupled product. [0892]
  • In step 3, the boronate ester is hydrolyzed to the corresponding boronic acid. This can be done by treating it with acid, e.g. an aqueous solution of hydrochloric acid, in an organic solvent, e.g. methanol. The resulting boronic acid is coupled, [0893]
  • (step 4) under air with a phenol or heteroaryl alcohol, or, [0894]
  • (step 5) with a primary or secondary amine, heteroarylamine, aniline, amide, sulfonamide, urea, carbamate or imide, [0895]
  • in the presence of a base such as triethylamine or pyridine and a source of copper(II) such as copper(II) acetate in a solvent like dichloromethane. Molecular sieves, 4 Å or 3 Å, can be added to the reaction mixture. [0896]
  • Protocol I
  • [0897]
    Figure US20020198198A1-20021226-C00038
  • In scheme 9, X[0898] 1, X2, X3 and X4, Y, R16, R17 and A are as defined in the summary of the invention.
  • In step 1, urea, carbamate or thio carbamate is initially converted into a halo-imine via a chlorinating agent such as POCl[0899] 3 which is then further reacted (step 2) with a suitable amine to form the final compound. The reaction can be carried out without solvent or in a solvent, for example an alcohol such as ethanol, at a temperature between 40 and 80° C. or under pressure for volatile amine, for example.
  • In step 3, the halo-imine is transformed into thio-derivative with thiourea. The process of scheme 9 above can also be applied to compounds of formula (I) in which Y is NH and X is N—R[0900] 9.
  • Protocol J
  • [0901]
    Figure US20020198198A1-20021226-C00039
  • In scheme 10, X[0902] 1, X2, X3, X4, R9, R12 and A are as defined in the summary of the invention and LG is a leaving group such as trifuoromethane sulfonate, mesylate or halogen.
  • In step 1, the quinazolinone is reacted with R[0903] 12-LG to obtain the N-substituted quinazoline
  • In step 2, the N-substituted quinazolinone is reacted with R[0904] 9-LG.
  • Various solvents, operating conditions and bases can be used and will be easily determined by the skilled person. For example, and without any limitation, one can use for the reaction sodium hydride or cesium carbonate as base in dimethylformamide as solvent. [0905]
  • Step 2 of the above process can also be applied to compounds of formula (I) in which Y is O or S. [0906]
  • Step 1 of the above process can also be applied to compounds of formula (I) in which X is O or S. [0907]
  • Protocol K
  • [0908]
    Figure US20020198198A1-20021226-C00040
  • In scheme 11, X[0909] 1, X2, X3, X4, R9 and A are as defined in the summary of the invention and LG is a leaving group such as trifuoromethane sulfonate, mesylate or halogen.
  • In step 1, the quinazolinone is reacted with paramethoxy-benzyl chloride (PMB). Other protecting group can be used. Various solvents, operating conditions, bases, can be used and will be easily determined by the skilled person. For example, and without any limitation, one can use for the reaction cesium carbonate as base in dimethylformamide as solvent. [0910]
  • In step 2, the protected quinazolinone is reacted with R[0911] 9-LG. Various solvents, operating conditions, bases, can be used and will be easily determined by the skilled person. For example, and without any limitation, one can use for the reaction sodium hydride as base in dimethylformamide as solvent.
  • In step 3, treatment of the N1-PMB protected quinazolinone with TFA removed the protecting group. Other protecting groups and deprotecting conditions can be used. [0912]
  • Protocol L
  • [0913]
    Figure US20020198198A1-20021226-C00041
  • In scheme 12, X[0914] 2, X3, X4, and A and Y are as defined in the summary of the invention, R is alkyl or C(═O)-alkyl and LG is a leaving group.
  • In step 1, the starting methoxy derivative is demethylated with boron tribromide in a solvent such as dichloromethane. The resulting phenol intermediate is treated in step 2 with an electrophile such as an alkyl halide, an acyl halide or the like in the presence of a base such as potassium carbonate, cesium carbonate or sodium hydride in a solvent like dimethylformamide.[0915]
  • Synthesis Examples
  • Examples 1 to 100 illustrate, without limiting it, the synthesis of particularly active compounds of formula (I) according to the invention. [0916]
  • In the following experimental protocols, the proton NMR data was acquired with a 400 MHz NMR apparatus unless specifically notified. [0917]
  • Example 1 Spiro[cyclohexane-1-4′-(3′,4′-dihydro)quinazolin]-2′(1′H)-one X1═CH, X2═CH, X3═CH, X4═CH, A≡cyclohexyl, X═NH, Z═O, Y═NH
  • The title compound was prepared according to protocol A. Phenyl urea (13.6 g, 0.1 mol) was added portionwise to a solution of polyphosphoric acid (100 g) stirred at 100° C. After complete dissolution of the urea, cyclohexanone (10.3 mL, 0.1 mol) was added dropwise to the hot mixture. The mixture was stirred at 100-120° C. until completion and poured into cold water. The precipitate was filtered, washed with cold water, taken up in hot ethanol and neutralized with NH[0918] 4OH solution. Water was added to make a 50% ethanol/water solution and the precipitate was filtered, washed with water and dried. The crude material was purified by crystallization in ethanol. The title compound was obtained as a white powder. Melting point (mp)=224-226° C.
  • [0919] 1H NMR [(CD3)2SO] δ9.11 (br s, 1H, NH), 7.24 (d, J=7.6 Hz, 1H), 7.09 (t, J=7.9 Hz, 1H), 6.88 (t, J=7.6 Hz, 1H), 6.78 (d, J=7.9 Hz, 1H), 6.74 (br s, 1H, NH), 1.79-1.63 (m, 7H), 1.50 (m, 2H), ), 1.20 (m, 1H).
  • Example 2 6′-Methoxyspiro[cyclohexane-1-4′-(3′,4′-dihydro)quinazolin]-2′(1′H)-one X1═CH, X2═C—O—CH3, X3═CH, X4═CH, A═cyclohexyl, X═NH, Z═O, Y═NH
  • The title compound was prepared according to protocol A, using 4-methoxyphenyl urea (30 g, 0.18 mol) and cyclohexanone (18.6 mL, 0.18 mol) in polyphosphoric acid (200 mL). The precipitate was filtered, washed with cold water, taken up in hot ethanol and neutralized with NH[0920] 4OH solution. Water was added to make a 50% ethanol/water solution and the precipitate was filtered, washed with water and dried. The crude material was purified by crystallization in ethanol. The title compound was obtained as a white powder (8.2 g, 18% yield). mp=233-235° C.
  • [0921] 1H NMR [(CD3)2SO] δ8.94 (br s, 1H, NH), 6.80 (br s, 1H), 6.72 (m, 2H), 6.61 (m, 1H), 3.69 (s, 3H), 1.76-1.47 (m, 9H), 1.23 (m, 1H).
  • Example 3 Spiro[cycloheptane-1-4′-(3′,4′-dihydro)quinazolin]-2′(1′H)-one X1═CH, X2═CH, X3═CH, X4═CH, A═cycloheptyl, X═NH, Z═O, Y═NH
  • The title compound was prepared according to protocol A, using phenyl urea (27.2 g, 0.2 mol) and cycloheptanone (23.5 mL, 0.2 mol) in polyphosphoric acid (200 mL). The precipitate was filtered, washed with cold water, taken up in hot ethanol and neutralized with NH[0922] 4OH solution. Water was added to make a 50% ethanol/water solution and the precipitate was filtered, washed with water and dried. The crude material was purified by crystallization in ethanol. The title compound was obtained as a white powder (14.7 g, 32% yield) mp=198-200° C.
  • [0923] 1H NMR [(CD3)2SO] δ9.11 (br s, 1H, NH), 7.21 (d, J=7.6 Hz, 1H), 7.09 (d, J=7.6 Hz, 1H), 6.88 (m, 2H), 6.78 (d, J=7.9 Hz, 1H), 1.94-1.72 (m, 6H), 1.54 (m, 6H).
  • Example 4 7′-Methoxyspiro[cyclohexane-1-4′-(3′,4′-dihydro)quinazolin]-2′(1′H)-one X1═CH, X2═CH, X3═C—O—CH3, X4═CH, A═cyclohexyl, X═NH, Z═O, Y═NH
  • The title compound was prepared according to protocol A, using 3-methoxyphenyl urea (33.2 g, 0.2 mol) and cyclohexanone (20.7 mL, 0.2 mol) in polyphosphoric acid (200 mL). The precipitate was filtered, washed with cold water, taken up in hot ethanol and neutralized with NH[0924] 4OH solution. Water was added to make a 50% ethanol/water solution and the precipitate was filtered, washed with water and dried. The crude material was purified by crystallization in ethanol. The title compound was obtained as a white powder (9.8 g, 20% yield) mp=228-230° C.
  • [0925] 1H NMR [(CD3)2SO] δ9.03 (br s, 1H, NH), 7.13 (d, J=8.5 Hz, 1H), 6.74 (br s, 1H, NH), 6.45 (dd, J=8.5, 2.3 Hz, 1H), 6.36 (d, J=2.3 Hz, 1H), 3.68 (s, 3H), 1.78-1.59 (m, 7H), 1.47 (m, 2H), 1.20 (m, 1H).
  • Example 5 6′-Phenylspiro[cycloheptane-1-4′-(3′,4′-dihydro)quinazolin]-2′(1′H)-one X1═CH, X2═C-phenyl, X3═CH, X4═CH, A═cycloheptyl, X═NH, Z═O, Y═NH
  • The title compound was prepared according to protocol A, using 4-phenyl-phenyl urea (42.4 g, 0.2 mol) and cycloheptanone (23.5 mL, 0.2 mol) in polyphosphoric acid (400 g). The precipitate was filtered, washed with cold water, taken up in hot ethanol and neutralized with NH[0926] 4OH solution. Water was added to make a 50% ethanol/water solution and the precipitate was filtered, washed with. water and dried. The crude material was purified by crystallization in ethanol. The title compound was obtained as a white powder (23.3 g, 38% yield). mp=180-182° C.
  • [0927] 1H NMR [(CD3)2SO] δ9.28 (br s, 1H, NH), 7.59 (m, 2H), 7.43 (m, 4H), 7.30 (m, 1H), 7.0 (br s, 1H, NH), 6.88 (m, 1H), 2.01 (m, 2H), 1.89 (m, 2H), 1.77 (m, 2H), 1.58 (m, 6H).
  • Example 6 8′-Methoxyspiro[cyclohexane-1-4′-(3′,4′-dihydro)quinazolin]-2′(1′H)-one X1═CH, X2═CH, X3═CH, X4═C—O—CH3, A═cyclohexyl, X═NH, Z═O, Y═NH
  • The title compound was prepared according to protocol A, using 2-methoxyphenyl urea (49.8 g, 0.3 mol) and cyclohexanone (31 mL, 0.3 mol) in polyphosphoric acid (600 g). The precipitate was filtered, washed with cold water, taken up in hot ethanol and neutralized with NH[0928] 4OH solution. Water was added to make a 50% ethanol/water solution and the precipitate was filtered, washed with water and dried. The crude material was purified by crystallization in isopropanol. The title compound was obtained as a white powder (48.1 g, 65% yield). mp=209-211° C.
  • [0929] 1H NMR [(CD3)2SO] δ7.79 (br s, 1H, NH), 6.87 (m, 4H), 3.79 (s, 3H), 1.79-1.60 (m, 7H), 1.48 (m, 2H), 1.22 (m, 1H).
  • Example 7
  • 8′-Chlorospiro[cyclohexane-1-4′-(3′,4′-dihydro)quinazolin]-2′(1′H)-one [0930]
  • X1═CH, X2═CH, X3═CH, X4═C—Cl, A═cyclohexyl, X═NH, Z═O, Y═NH.
  • The title compound was prepared according to protocol A, using 2-chlorophenyl urea (51.15 g, 0.3 mol) and cyclohexanone (29.4 g, 0.3 mol) in polyphosphoric acid (600 g). The precipitate was filtered, washed with cold water and recrystallized from ethyl acetate. The title compound was obtained as an orange solid (21% yield). mp=209-211° C. [0931]
  • [0932] 1H NMR [(CD3)2SO] δ8.42 (br s, 1H, NH), 7.29 (d, J=7.9 Hz, 2H), 7.16 (br s, 1H, NH), 6.95 (t, J=7.9 Hz, 1H), 1.81-1.61 (m, 7H), 1.52-1.39 (m, 2H), 1.25-1.22 (m, 1H).
  • Example 8 and Example 9 7′-Chlorospiro[cyclohexane-1-4′-(3′,4′-dihydro)quinazolin]-2′(1′H)-one (Example 8) X1═CH, X2═CH, X3═C—Cl, X4═CH, A═cyclohexyl, X═NH, Z═O, Y═NH 5′-chlorospiro[cyclohexane-1-4′-(3′,4′-dihydro)quinazolin]-2′(1′H)-one (Example 9) X1═C—Cl, X2═CH, X3═CH, X4═CH, A═cyclohexyl, X═NH, Z═O, Y═NH
  • The title compounds were prepared according to protocol A, using 3-chlorophenyl urea (0.51 g, 3 mmol) and cyclohexanone (0.5 mL, 4.8 mmol, 1.6 equiv.) in polyphosphoric acid (11 g). The aqueous layer was extracted with CH[0933] 2Cl2/MeOH (2/1). The combined organic extracts were dried over MgSO4, filtered and concentrated under reduced pressure. The residue was purified by flash chromatography on silica gel (CH2Cl2/CH3CN: 90/10 to 60/40) followed by recrystallization in toluene to give 7′-chlorospiro[cyclohexane-1-4′-(3′,4′-dihydro)quinazolin]-2′(1′H)-one as a white solid (110 mg, 15% yield). mp=254° C.
  • [0934] 1H NMR [(CD3)2SO] δ9.28 (br s, 1H, NH), 7.27 (d, J=8.0 Hz, 1H), 6.91-6.89 (m, 2H), 6.82 (s, 1H, NH), 1.83-1.61 (m, 7H), 1.49 (m, 2H), 1.24 (m, 1H). and 5′-chlorospiro[cyclohexane-1-4′-(3′,4′-dihydro)quinazolin]-2′(1′H)-one as a white solid (101 mg, 14% yield). mp=229° C.
  • [0935] 1H NMR [(CD3)2SO] δ9.34 (br s, 1H, NH), 7.11 (t, J=8.0 Hz, 1H), 6.91 (d, J=8.0 Hz, 1H), 6.84 (br s, 1H, NH), 6.77 (d, J=8.0 Hz, 1H), 2.60 (td, J=13.0, 4.0 Hz, 2H), 1.82 (m, 2H), 1.64-1.49 (m, 5H), 1.22 (m, 1H).
  • Example 10 8′-Methylspiro[cyclohexane-1-4′-(3′,4′-dihydro)quinazolin]-2′(1′H)-one X1═CH, X2═CH, X3═CH, X4═C—CH3, A═cyclohexyl, X═NH, Z═O, Y═NH
  • The title compound was prepared according to protocol A, using o-tolyl urea (551 mg, 3.66 mmol) and cyclohexanone (430 μL, 4.15 mmol, 1.1 equiv.) in polyphosphoric acid (5 g). The aqueous layer was extracted with CH[0936] 2Cl2/MeOH (2/1). The combined organic extracts were dried over MgSO4, filtered and concentrated under reduced pressure. The residue was purified by flash chromatography on silica gel (CH2Cl2/MeOH: 99/1 to 90/10) followed by recrystallization in toluene to give 290 mg (34% yield) of the title compound as a white solid. mp=204° C.
  • [0937] 1H NMR [(CD3)2SO] δ8.2 (br s, 1H, NH), 7.10 (d, J=7.7 Hz, 1H), 6.97 (d, J=7.2 Hz, 1H), 7.10 (m, 2H), 1.82-1.61 (m, 7H), 1.50 (m, 2H), 1.23 (m, 1H).
  • Example 11 6′-Chlorospiro[cyclohexane-1-4′-(3′,4′-dihydro)quinazolin]-2′(1′H)-one X1═CH, X2═C—Cl, X3═CH, X4═CH, A═cyclohexyl, X═NH, Z═O, Y═NH
  • The title compound was prepared according to protocol A, using 4-chlorophenyl urea (0.85 g, 5 mmol) and cyclohexanone (0.55 mL, 5.5 mmol, 1.1 equiv.) in polyphosphoric acid (29 g). The aqueous layer was extracted with CH[0938] 2Cl2/MeOH (2/1). The combined organic extracts were dried over MgSO4, filtered and concentrated under reduced pressure. The residue was purified by flash chromatography on silica gel (CH2Cl2/MeOH: 99/1 to 90/10) followed by recrystallization in toluene to give 79 mg (6% yield) of the title compound as a white solid. mp=241° C.
  • [0939] 1H NMR [(CD3)2SO] δ9.28 (br s, 1H, NH), 7.29 (d, J=2.0 Hz, 1H), 7.16 (dd, J=8.5, 2.5 Hz, 1H), 6.87 (br s, 1H, NH), 6.81 (d, J=8.5 Hz, 1H), 1.76-1.60 (m, 7H), 1.49 (m, 2H), 1.25 (m, 1H).
  • Example 12 8′-Bromospiro[cyclohexane-1-4′-(3′,4′-dihydro)quinazolin]-2′(1′H)-one X1═CH, X2═CH, X3═CH, X4═C—Br, A═cyclohexyl, X═NH, Z═O, Y═NH
  • The title compound was prepared according to protocol A, using 2-bromophenyl urea (1.075 g, 5 mmol) and cyclohexanone (0.6 mL, 5.8 mmol, 1.2 equiv.) in polyphosphoric acid (39 g). The aqueous layer was extracted with CH[0940] 2Cl2/MeOH (2/1). The combined organic extracts were dried over MgSO4, filtered and concentrated under reduced pressure. The residue was purified by flash chromatography on silica gel (CH2Cl2/MeOH: 99/1 to 90/10) followed by recrystallization in toluene to give 415 mg (28% yield) of the title compound as a white solid. mp=213° C.
  • [0941] 1H NMR [(CD3)2SO] δ7.86 (br s, 1H, NH), 7.45 (d, J=8.0 Hz, 1H), 7.32 (d, J=8.0 Hz, 1H), 7.17 (br s, 1H, NH), 6.90 (t, J=8.0 Hz, 1H), 1.81-1.49 (m, 9H) 1.23 (m, 1H).
  • Example 13 8′-Fluorospiro[cyclohexane-1-4′-(3′,4′-dihydro)quinazolin]-2′(1′H)-one X1═CH, X2═CH, X3═CH, X4═C—F, A═cyclohexyl, X═NH, Z═O, Y═NH
  • The title compound was prepared according to protocol A, using 2-fluorophenyl urea (0.77 g, 5 mmol) and cyclohexanone (0.55 mL, 5.5 mmol, 1.1 equiv.) in polyphosphoric acid (20 g). The aqueous layer was extracted with CH[0942] 2Cl2/MeOH (2/1). The combined organic extracts were dried over MgSO4, filtered and concentrated under reduced pressure. The residue was purified by flash chromatography on silica gel (CH2Cl2/MeOH: 99/1 to 95/5) followed by recrystallization in toluene to give 272 mg (23% yield) of the title compound as a white solid. mp=221° C.
  • [0943] 1H NMR [(CD3)2SO] δ9.12 (br s, 1H, NH), 7.11 (d, J=7.8 Hz, 1H), 7.05 (m, 1H), 6.94(br s, 1H, NH), 6.90 (m, 1H), 1.81-1.61 (m, 7H), 1.50 (m, 2H), 1.25 (m, 1H),
  • Example 14 6′-Methylspiro[cyclohexane-1-4′-(3′,4′-dihydro)quinazolin]-2′(1′H)-one X1═CH, X2═C—CH3, X3═CH, X4═CH, A═cyclohexyl, X═NH, Z═O, Y═NH
  • The title compound was prepared according to protocol A, using 4-methylphenyl urea (1.5 g, 10 mmol) and cyclohexanone (1.1 mL, 11 mmol, 1.1 equiv.) in polyphosphoric acid (38 g). The aqueous layer was extracted with CH[0944] 2Cl2/MeOH (2/1). The combined organic extracts were dried over MgSO4, filtered and concentrated under reduced pressure. The residue was purified by flash chromatography on silica gel (CH2Cl2/MeOH: 99/1 to 90/10) followed by recrystallization in toluene to give 405 mg (18% yield) of the title compound as a white solid. mp=229° C.
  • [0945] 1H NMR [(CD3)2SO] δ9.01 (br s, 1H, NH), 7.05 (s, 1H), 6.91 (d, J=8.0 Hz, 1H), 6.68-6.66 (m, 2H), 2.22 (s, 3H), 1.76-1.61 (m, 7H), 1.50 (m, 2H), 1.23 (m, 1H).
  • Example 15 5′,8′-Dichlorospiro[cyclohexane-1-4′-(3′,4′-dihydro)quinazolin]-2′(1′H)-one X1═C—Cl, X2═CH, X3═CH, X4═C—Cl, A═cyclohexyl, X═NH, Z═O, Y═NH
  • The title compound was prepared according to protocol A, using 2,5-dichlorophenyl urea (0.615 g, 3 mmol) and cyclohexanone (0.50 mL, 5 mmol, 1.6 equiv.) in polyphosphoric acid (15 g). The aqueous layer was extracted with CH[0946] 2Cl2/MeOH (2/1). The combined organic extracts were dried over MgSO4, filtered and concentrated under reduced pressure. The residue was purified by flash chromatography on silica gel (CH2Cl2/MeOH: 99/1 to 92/8) followed by recrystallization in toluene to give 56 mg (7% yield) of the title compound as a white solid. mp=243° C.
  • [0947] 1H NMR [(CD3)2SO] δ8.35 (br s, 1H, NH), 7.35 (d, J=8.5 Hz, 1H), 7.21 (br s, 1H, NH), 7.01 (d, J=9.0 Hz, 1H), 2.50 (ddd, J=13.5,13.5, 4.5 Hz, 2H), 1.83 (m, 2H), 1.68-1.51 (m, 5H), 1.24 (m, 1H).
  • Example 16 and Example 17 6′,7′-Dichlorospiro[cyclohexane-1-4′-(3′,4′-dihydro)quinazolin]-2′(1′H)-one (Example 16) X1═CH, X2═C—Cl, X3═C—Cl, X4═CH, A═cyclohexyl, X═NH, Z═O, Y═NH 5′,6′-dichlorospiro[cyclohexane-1-4′-(3′,4′-dihydro)quinazolin]-2′(1′H)-one (Example 17) X1═C—Cl, X2═C—Cl, X3═CH, X4═CH, A═cyclohexyl, X═NH, Z═O, Y═NH
  • The title compounds were prepared according to protocol A, using 3,4-dichlorophenyl urea (0.61 g, 3 mmol) and cyclohexanone (0.50 mL, 5 mmol, 1.6 equiv.) in polyphosphoric acid (16 g). The aqueous layer was extracted with CH[0948] 2Cl2/MeOH (2/1). The combined organic extracts were dried over MgSO4, filtered and concentrated under reduced pressure. The residue was purified by flash chromatography on silica gel (CH2Cl2/CH3CN: 90/10 to 60/40) followed by recrystallization in toluene to give 6′,7′-dichlorospiro[cyclohexane-1-4′-(3′,4′-dihydro)quinazolin]-2′(1′H)-one as a white solid (55 mg, 6% yield). mp=269° C.
  • [0949] 1H NMR [(CD3)2SO] δ9.40 (br s, 1H, NH), 7.51 (s, 1H), 7.03 (br s, 1H, NH), 6.98 (s, 1H), 1.75-1.59 (m, 7H), 1.48 (m, 2H), 1.24 (m, 1H). and 5′,6′-dichlorospiro[cyclohexane-1-4′-(3′,4′-dihydro)quinazolin]-2′(1′H)-one as a white solid (26 mg, 3% yield). mp=240° C. 1H NMR [(CD3)2SO] δ9.47 (br s, 1H, NH), 7.43 (d, J=8.5 Hz, 1H), 6.91 (br s, 1H, NH), 6.81 (d, J=9.0 Hz, 1H), 2.64 (ddd, J=13.4,13.4, 4.4 Hz, 2H), 1.83 (m, 2H), 1.65-1.53 (m, 5H), 1.26 (m, 1H).
  • Example 18 6′-Phenylspiro[cyclohexane-1-4′-(3′,4′-dihydro)quinazolin]-2′(1′H)-one X1═CH, X2═C-phenyl, X3═CH, X4═CH, A═cyclohexyl, X═NH, Z═O, Y═NH
  • The title compound was prepared according to protocol A, using 4-phenyl-phenyl urea (0.67 g, 3.15 mmol) and cyclohexanone (0.50 mL, 5 mmol, 1.6 equiv.) in polyphosphoric acid (16 g). The aqueous layer was extracted with CH[0950] 2Cl2/MeOH (2/1). The combined organic extracts were dried over MgSO4, filtered and concentrated under reduced pressure. The residue was purified by flash chromatography on silica gel (CH2Cl2/MeOH: 99/1 to 90/10) followed by recrystallization in toluene to give 410 mg (13% yield) of the title compound as a white solid. mp=213° C.
  • [0951] 1H NMR [(CD3)2SO] δ9.25 (br s, 1H, NH), 7.62 (d, J=7.4 Hz, 2H), 7.52 (d, J=1.6 Hz, 1H), 7.42 (m, 3H), 7.30 (t, J=7.3 Hz, 1H), 6.88 (d, J=8.2 Hz, 1H), 6.83 (br s, 1H, NH), 1.84-1.79 (m, 6H), 1.63 (m, 1H), 1.53 (m, 2H), 1.30 (m, 1H).
  • Example 19 8′-Iodospiro[cyclohexane-1-4′-(3′,4′-dihydro)quinazolin]-2′(1′H)-one X1═CH, X2═CH, X3═CH, X4═C—I, A═cyclohexyl, X═NH, Z═O, Y═NH
  • The title compound was prepared according to protocol A, using 2-iodophenyl urea (2 g, 7.6 mmol) and cyclohexanone (1 mL, 9.6 mmol, 1.25 equiv.) in polyphosphoric acid (25 g). The aqueous layer was extracted with CH[0952] 2Cl2/MeOH (2/1). The combined organic extracts were dried over MgSO4, filtered and concentrated under reduced pressure. The residue was purified by flash chromatography on silica gel (CH2Cl2/MeOH: 99/1 to 90/10) followed by recrystallization in toluene to give 80 mg (3% yield) of the title compound as a white solid. mp=256° C.
  • [0953] 1H NMR [(CD3)2SO] δ9.26 (br s, 1H, NH), 7.52 (m, 1H), 7.44 (dd, J=8.3, 1.6 Hz, 1H), 6.87 (br s, 1H, NH), 6.62 (d, J=8.3 Hz, 1H), 1.78-1.62 (m, 7H), 1.54 (m, 2H), 1.26 (m, 1H).
  • Example 20 8′-Bromospiro[cyclobutane-1-4′-(3′,4′-dihydro)quinazolin]-2′(1′H)-one X1═CH, X2═CH, X3═CH, X4═C—Br, A═cyclobutyl, X═NH, Z═O, Y═NH
  • The title compound was prepared according to protocol A, using 2-bromophenyl urea (0.6 g, 2.8 mmol) and cyclobutanone (0.25 mL, 3.35 mmol, 1.2 equiv.) in polyphosphoric acid (22 g). The aqueous layer was extracted with CH[0954] 2Cl2/MeOH (2/1). The organic extracts were dried over MgSO4, filtered and concentrated. The crude material was purified by flash chromatography on silica gel (CH2Cl2/MeOH:99/1 to 90/10) and the resulting powder was washed with diisopropyl ether. The title compound was obtained as a white powder (0.03 g, 4% yield). mp=203-205° C.
  • [0955] 1H NMR [(CD3)2SO] δ7.93 (br s, 1H, NH), 7.80 (br s, 1H, NH), 7.50 (d, J=7.7 Hz, 1H), 7.47 (d, J=7.7 Hz, 1H), 6.95 (t, J=7.7 Hz, 1H), 2.46-2.39 (m, 4H), 1.86 (m, 2H).
  • Example 21 8′-Bromospiro[cycloheptane-1-4′-(3′,4′-dihydro)quinazolin]-2′(1′H)-one X1═CH, X2═CH, X3═CH, X4═C—Br, A═cycloheptyl, X═NH, Z═O, Y═NH
  • The title compound was prepared according to protocol A, using 2-bromophenyl urea (0.6 g, 2.8 mmol) and cycloheptanone (0.5 mL, 4.2 mmol, 1.5 equiv.) in polyphosphoric acid (22 g). The aqueous layer was extracted with CH[0956] 2Cl2/MeOH (2/1). The organic extracts are dried over MgSO4, filtered and concentrated. The crude material was purified by flash chromatography on silica gel (CH2Cl2/MeOH:99/1 to 90/10) and the resulting powder was washed with diisopropyl ether. The title compound was obtained as a white powder (0.12 g, 14% yield).mp=215-217° C.
  • [0957] 1H NMR [(CD3)2SO] δ7.87 (br s, 1H, NH), 7.44 (d, J=7.8 Hz, 1H), 7.31 (br s, 1H, NH), 7.28 (d, J=7.8 Hz, 1H), 6.90 (t, J=7.8 Hz, 1H), 1.96-1.84 (m, 4H), 1.76-1.71 (m, 2H), 1.56 (m, 6H).
  • Example 22 8′-Bromo-4-methylspiro[cyclohexane-1-4′-(3′,4′-dihydro)quinazolin]-2′(1′H)-one X1═CH, X2═CH, X3═CH, X4═C—Br, A=4-methyl-cyclohexyl, X═NH, Z═O, Y═NH
  • The title compound was prepared according to protocol A, using 2-bromophenyl urea (0.6 g, 2.8 mmol) and 4-methylcyclohexanone (0.41 mL, 3.35 mmol, 1.2 equiv.) in polyphosphoric acid (22 g). The aqueous layer was extracted with CH[0958] 2Cl2/MeOH (2/1). The organic extracts were dried over MgSO4, filtered and concentrated. The crude material was purified by flash chromatography on silica gel (CH2Cl2/MeOH:99/1 to 90/10) and the resulting powder was washed with diisopropyl ether. The title compound was obtained as a white powder (0.11 g, 11% yield). mp=187-189° C.
  • [0959] 1H NMR [(CD3)2SO] δ7.85 (br s, 1H, NH), 7.44 (d, J=7.8 Hz, 1H), 7.31 (d, J=7.8 Hz, 1H), 7.14 (br s, 1H, NH), 6.89 (t, J=7.8 Hz, 1H), 1.75 (m, 4H), 1.56-1.43 (m, 5H), ), 1.85 (d, J=6.2 Hz, 3H).
  • Example 23 8′-Bromospiro[bicyclo[3,2,1]octane-2-4′-(3′,4′-dihydro)quinazolin]-2′(1′H)-one X1═CH, X2═CH, X3═CH, X4═C—Br, A=bicyclo[3,2,1]octane, X═NH, Z═O, Y═NH
  • The title compound was prepared according to protocol A, using 2-bromophenyl urea (0.6 g, 2.8 mmol) and bicyclo[3.2.1]octan-2-one (0.55 g, 4.47 mmol, 1.6 equiv.) in polyphosphoric acid (22 g). The aqueous layer was extracted with CH[0960] 2Cl2/MeOH (2/1). The organic extracts were dried over MgSO4, filtered and concentrated. The crude material was purified by flash chromatography on silica gel (CH2Cl2/MeOH:99/1 to 90/10) and the resulting powder was washed with diisopropyl ether. The title compound was obtained as a white powder (0.003 g, 1% yield). mp=276-278° C.
  • [0961] 1H NMR [(CD3)2SO] δ7.92 (br s, 1H, NH), 7.48 (d, J=7.7 Hz, 1H), 7.42 (br s, 1H, NH), 7.39 (d, J=7.7 Hz, 1H), 6.92 (t, J=7.7 Hz, 1H), 2.33 (td, J=13.8, 5.7 Hz , 1H), 2.15-2.10 (m, 3H), 1.98 (d, J=11.5 Hz, 1H), 1.58-1.52 (m, 2H), 1.37-1.28 (m, 4H), 1.18 (m, 1H).
  • Example 24 6′,8′-Dichlorospiro[cyclohexane-1-4′-(3′,4′-dihydro)quinazolin]-2′(1′H)-one X1═CH, X2═C—Cl, X3═CH, X4═C—Cl, A═cyclohexyl, X═NH, Z═O, Y═NH
  • A solution of Example 7 (100.2 mg, 0.4 mmol) in dimethylformamide (2 mL) was treated with N-chlorosuccinimide (80 mg, 0.6 mmol, 1.5 equiv.) at 60° C. overnight. The reaction mixture was concentrated then purified by flash chromatography on silica gel (CH[0962] 2Cl2/MeOH: 100/0 to 90/10) and reverse phase HPLC (C18 column, gradient of acetonitrile in water: 50/50 to 95:5) to give the title compound as a white solid (48% yield). mp=245° C.
  • [0963] 1H NMR [(CDCl3] δ7.26 (m, 1H), 7.19 (br s, 1H, NH), 7.10 (m, 1H), 5.80 (br s, 1H, NH), 1.97 (m, 2H), 1.82-1.57 (m, 7H), 1.29 (m, 1H).
  • Example 25 8′-Chloro-6′-iodospiro[cyclohexane-1-4′-(3′,4′-dihydro)quinazolin]-2′(1′H)-one X1═CH, X2═C—Cl, X3═CH, X4═C—Cl, A═cyclohexyl, X═NH, Z═O, Y═NH
  • To a solution of Example 7 (5 g, 20 mmol) in trifluoroacetic acid (25 mL) were subsequently added N-iodosuccinimide (6 g, 22 mmol, 1.1 equiv.) and sulfuric acid (4 mL). The resulting solution was heated to 55° C. overnight, concentrated under reduced pressure, taken into dichloromethane and washed twice with water. The reaction mixture was concentrated and purified by flash chromatography on silica gel (CH[0964] 2Cl2/MeOH: 97/3) to give 4.5 g (73% yield) of the title compound as a yellowish solid. mp=261° C.
  • [0965] 1H NMR [(CD3)2SO] δ8.64 (br s, 1H, NH), 7.64 (d, J=2.0 Hz, 1H), 7.56 (d, J=1.0 Hz, 1H), 7.22 (br s, 1H, NH), 1.76-1.59 (m, 7H), 1.49 (m, 2H), 1.25 (m, 1H).
  • Example 26 8′-Chloro-6′-phenylspiro[cyclohexane-1-4′-(3′,4′-dihydro)quinazolin]-2′(1′H)-one X1═CH, X2═C-phenyl, X3═CH, X4═C—Cl, A═cyclohexyl, X═NH, Z═O, Y═NH
  • A solution of Example 18 (232 mg, 0.79 mmol) in dimethylformamide (4 mL) was treated with N-chlorosuccinimide (80 mg, 0.6 mmol, 1.5 equiv.) at 60° C. overnight. The reaction mixture was concentrated then purified by flash chromatography on silica gel (CH[0966] 2Cl2/MeOH: 99/1 to 90/10) to give the title compound as a white solid (41% yield). mp=226° C.
  • [0967] 1H NMR [(CD3)2SO] δ8.50 (br s, 1H, NH), 7.68 (d, J=7.3 Hz, 2H), 7.60 (s, 1H), 7.56 (s, 1H), 7.44 (t, J=7.1 Hz, 2H), 7.34 (m, 1H), 7.15 (br s, 1H, NH), 1.88-1.22 (m, 10H).
  • Example 27 8′-Chloro-6′-methoxyspiro[cyclohexane-1-4′-(3′,4′-dihydro)quinazolin]-2′(1′H)-one X1═CH, X2═C—O—CH3, X3═CH, X4═C—Cl, A═cyclohexyl, X═NH, Z═O, Y═NH
  • A solution of Example 2 (500 mg, 2.03 mmol) in dimethylformamide (10 mL) was treated with N-chlorosuccinimide (300 mg, 2.24 mmol, 1.1 equiv.) at 60° C. overnight. The reaction mixture was concentrated and purified by flash chromatography on silica gel (CH[0968] 2Cl2/MeOH: 99/1 to 90/10) followed by recrystallization in toluene to give 76 mg (13% yield) of the title compound as a white solid. mp=226° C.
  • [0969] 1H NMR [(CD3)2SO] δ8.20 (br s, 1H, NH), 6.96 (br s, 1H, NH), 6.92 (m, 1H), 6.87 (m, 1H), 3.73 (s, 3H), 1.72-1.61 (m, 7H), 1.62 (m, 2H), 1.26 (m, 1H).
  • Example 28 8′-Chloro-6′-phenylspiro[cycloheptane-1-4′-(3′,4′-dihydro)quinazolin]-2′(1′H)-one X1═CH, X2═C-phenyl, X3═CH, X4═C—Cl, A═cycloheptyl, X═NH, Z═O, Y═NH
  • A solution of Example 5 (150 mg, 0.49 mmol) in dimethylformamide (2 mL) was treated with N-chlorosuccinimide (75 mg, 0.56 mmol, 1.1 equiv.) at 60° C. overnight. The reaction mixture was concentrated then purified by flash chromatography on silica gel (CH[0970] 2Cl2/MeOH: 99/1 to 90/10) to give 158 mg (95% yield) of the title compound as a yellowish solid. mp=201° C.
  • [0971] 1H NMR [(CDCl3] δ7.51-7.41 (m, 6H), 7.36 (m, 2H), 5.90 (br s, 1H, NH), 2.75-2.01 (m, 4H), 1.77-1.43 (m, 8H).
  • Example 29 8′-Chloro-6′-methylspiro[cyclohexane-1-4′-(3′,4′-dihydro)quinazolin]-2′(1 ′H)-one X1═CH, X2═C—CH3, X3═CH, X4═C—Cl, A═cyclohexyl, X═NH, Z═O, Y═NH
  • A solution of Example 14 (350 mg, 1.51 mmol) in dimethylformamide (7 mL) was treated with N-chlorosuccinimide (305 mg, 2.3 mmol, 1.5 equiv.) at 60° C. overnight. The reaction mixture was concentrated and purified by flash chromatography on silica gel (CH[0972] 2Cl2/MeOH: 99/1 to 90/10). The resulting solid was triturated with methanol to give the title compound as a white solid (28% yield). mp=266° C.
  • [0973] 1H NMR [(CD3)2SO] δ8.23 (br s, 1H, NH), 7.11 (m, 2H), 7.03 (br s, 1H, NH), 2.23 (s, 3H), 1.77-1.61 (m, 7H), 1.51 (m, 2H), 1.25 (m, 1H).
  • Example 30 8′-Chloro-6′-(3-pyridyl)spiro[cyclohexane-1-4′-(3′,4′-dihydro)quinazolin]-2′(1′H)-one X1═CH, X2═C-(3-pyridyl), X3═CH, X4═C—Cl, A═cyclohexyl, X═NH, Z═O, Y═NH
  • To a suspension of Example 25 (0.5 g, 1.4 mmol) in dimethylformamide (5 mL) were subsequently added 3-pyridylboronic acid (0.22 g, 1.7 mmol, 1.2 equiv.) and a 2M aqueous solution of potassium carbonate (1.5 mL). The mixture was degassed by bubbling nitrogen for 30 minutes and tetrakistriphenylphosphine palladium (60 mg, 0.05 mmol, 0.04 equiv.) was added. After heating to 90° C. overnight, the mixture was concentrated under reduced pressure, triturated with water and filtered. The resulting solid was triturated with ethyl acetate, filtered and purified by flash chromatography on silica gel (CH[0974] 2Cl2/EtOAc: 80/20 to 50/50) to give 140 mg (30% yield) of the title compound as white solid. mp=246° C.
  • [0975] 1H NMR [(CD3)2SO] δ8.93 (br s, 1H, NH), 8.55 (m, 2H), 8.10 (m, 1H), 7.71 (d, J=1.5 Hz, 1H), 7.65 (d, J=1.5 Hz, 1H), 7.45 (dd, J=8.0, 5.0 Hz, 1H), 7.19 (br s, 1H, NH), 1.91-1.77 (m, 6H), 1.63 (m, 1H), 1.54 (m, 2H), 1.32 (m, 1H).
  • Example 31 8′-Chloro-6′-(4-pyridyl)spiro[cyclohexane-1-4′-(3′,4′-dihydro)quinazolin]-2′(1′H)-one X1═CH, X2═C-(4-pyridyl), X3═CH, X4═C—Cl, A═cyclohexyl, X═NH, Z═O, Y═NH
  • To a suspension of Example 25 (0.5 g, 1.4 mmol) in dimethylformamide (5 mL) were subsequently added 4-pyridylboronic acid (0.22 g, 1.7 mmol, 1.2 equiv.) and a 2M aqueous solution of potassium carbonate (1.5 mL). The mixture was degassed by bubbling nitrogen for 30 minutes and tetrakistriphenylphosphine palladium (60 mg, 0.05 mmol, 0.04 equiv.) was added. After heating to 90° C. overnight, the mixture was concentrated under reduced pressure, washed with water and ethyl acetate then purified by flash chromatography on silica gel (CH[0976] 2Cl2/EtOAc: 80/20 to CH2Cl2/MeOH: 97/3) to give 40 mg (10% yield) of the title compound as white solid. mp=320-321° C.
  • [0977] 1H NMR [(CD3)2SO] δ8.64 (br s, 1H, NH), 8.59 (d, J=6.0 Hz, 2H), 7.80-7.72 (m, 4H), 7.22 (br s, 1H, NH), 1.99-1.77 (m, 6H), 1.65 (m, 1H), 1.54 (m, 2H), 1.31 (m, 1H).
  • Example 32 6′-(4-Carboxyphenyl)-8′-chlorospiro[cyclohexane-1-4′-(3′,4′-dihydro)quinazolin]-2′(1′H)-one X1═CH, X2═C-(4-carboxyphenyl), X3═CH, X4═C—Cl, A═cyclohexyl, X═NH, Z═O, Y═NH
  • To a suspension of Example 25 (1 g, 2.8 mmol) in dimethylformamide (10 mL) were subsequently added 4-carboxyphenylboronic acid (0.55 g, 3.35 mmol, 1.2 equiv.) and a 2M aqueous solution of potassium carbonate (3 mL). The mixture was degassed by bubbling nitrogen for 30 minutes and tetrakistriphenylphosphine palladium (120 mg, 0.1 mmol, 0.04 equiv.) was added. After heating to 90° C. for 4 hours, the mixture was concentrated under reduced pressure, taken into ethyl acetate and washed with water. The aqueous layer was acidified to pH 2 and extracted with ethyl acetate. The organic layer was concentrated under reduced pressure to a third of its volume and filtered. The resulting solid was purified by flash chromatography on silica gel (CH[0978] 2Cl2/MeOH: 97/3 to 95/5) to give 250 mg (40% yield) of the title compound as white solid. mp=309° C.
  • [0979] 1H NMR [(CD3)2SO] δ12.95 (br s, 1H, OH), 8.58 (br s, 1H, NH), 7.98 (d, J=8.5 Hz, 2H), 7.83 (d, J=8.5 Hz, 2H), 7.70 (d, J=1.5 Hz, 1H), 7.65 (s, 1H), 7.20 (br s, 1H, NH), 1.93-1.78 (m, 6H), 1.64 (m, 1H), 1.54 (m, 2H), 1.32 (m, 1H).
  • Example 33 6′-(3-Carboxyphenyl)-8′-chlorospiro[cyclohexane-1-4′-(3′,4′-dihydro)quinazolin]-2′(1′H)-one X1═CH, X2═C-(3-carboxyphenyl), X3═CH, X4═C—Cl, A═cyclohexyl, X═NH, Z═O, Y═NH
  • To a suspension of Example 25 (1 g, 2.8 mmol) in dimethylformamide (10 mL) were subsequently added 3-carboxyphenylboronic acid (0.55 g, 3.35 mmol, 1.2 equiv.) and a 2M aqueous solution of potassium carbonate (3 mL). The mixture was degassed by bubbling nitrogen for 30 minutes and tetrakistriphenylphosphine palladium (120 mg, 0.1 mmol, 0.04 equiv.) was added. After heating to reflux overnight, the mixture was concentrated under reduced pressure, taken into dichloromethane and washed with water. The aqueous layer was acidified to pH 1 and filtered to give 330 mg (58% yield) of the title compound as white solid. mp=300° C. [0980]
  • [0981] 1H NMR [(CD3)2SO] δ13.10 (br s, 1H, OH), 8.54 (br s, 1H, NH), 8.14 (s, 1H), 7.92 (t, J=7.5 Hz, 2H), 7.64 (d, J=1.5 Hz, 1H), 7.59-7.55 (m, 2H), 7.17 (br s, 1H, NH), 1.89-1.78 (m, 6H), 1.64 (m, 1H), 1.55 (m, 2H), 1.32 (m, 1H).
  • Example 34 8′-Chloro-6′-(1H-indol-5-yl)spiro[cyclohexane-1-4′-(3′,4′-dihydro)quinazolin]-2′(1′H)-one X1═CH, X2═C-indol-5-yl, X3═CH, X4═C—Cl, A═cyclohexyl, X═NH, Z═O, Y═NH
  • To a suspension of Example 25 (0.5 g, 1.4 mmol) in dimethylformamide (5 mL) were subsequently added 5-indolylboronic acid (0.26 g, 1.6 mmol, 1.2 equiv.) and a 2M aqueous solution of potassium carbonate (1.5 mL). The mixture was degassed by bubbling nitrogen for 30 minutes and tetrakistriphenylphosphine palladium (60 mg, 0.05 mmol, 0.04 equiv.) was added. After heating to 80° C. overnight, the mixture was concentrated under reduced pressure, taken into ethyl acetate and washed three times with water. The residue was then purified by flash chromatography on silica gel (CH[0982] 2Cl2/EtOAc: 80/20) to give 210 mg (44% yield) of the title compound as white solid. mp=257° C.
  • [0983] 1H NMR [(CD3)2SO] δ11.12 (br s, 1H, NH), 8.40 (br s, 1H, NH), 7.83 (s, 1H), 7.56 (m, 2H), 7.44 (d, J=8.0 Hz, 1H), 7.39-7.36 (m, 2H), 7.11 (s, 1H), 6.47 (br s, 1H, NH), 1.89-1.78 (m, 6H), 1.64 (m, 1H), 1.55 (m, 2H), 1.32 (m, 1H).
  • Example 35 8′-Chloro-6′-(2-pyridyl)spiro[cyclohexane-1-4′-(3′,4′-dihydro)quinazolin]-2′(1′H)-one X1═CH, X2═C-(2-pyridyl), X3═CH, X4═C—Cl, A═cyclohexyl, X═NH, Z═O, Y═NH
  • To a solution of Example 25 (0.5 g, 1.3 mmol) in tetrahydrofuran (5 mL) was added a 0.5 M solution of 2-pyridyl zinc bromide in tetrahydrofuran (60 μL, 30 mmol, 23 equiv.). The mixture was degassed bubbling nitrogen for 30 minutes and tetrakis(triphenylphosphine)palladium (60 mg, 0.05 mmol, 0.04 equiv.) was added. After refluxing for 4 h, additional tetrakis(triphenylphosphine)palladium (100 mg) and toluene (5 mL) were added. After heating to 90° C. overnight, the mixture was diluted with dichloromethane and washed three times with water. The organic layer was concentrated under reduced pressure and purified by flash chromatography on silica gel (CH[0984] 2Cl2/EtOAc: 90/10) to give 50 mg (2% yield) of the title compound as a solid. mp=251° C.
  • [0985] 1H NMR [(CD3)2SO] δ8.64 (br s, 1H, NH), 7.45 (dd, J=5.0, 1.0 Hz, 1H), 8.04-8.01 (m, 3H), 7.85 (td, J=7.5, 2.0 Hz, 1H), 7.32 (m, 1H), 7.21 (br s, 1H, NH), 1.89-1.83 (m, 6H), 1.66 (m, 1H), 1.56 (m, 2H), 1.32 (m, 1H).
  • Example 36 8′-Chloro-6′-(3-dimethylamino-prop-1-ynyl)spiro[cyclohexane-1-4′-(3′,4′-dihydro)quinazolin]-2′(1′H)-one X1═CH, X2═C-(3-dimethylaminoprop-1-ynyl), X3═CH, X4═C—Cl, A═cyclohexyl, X═NH,Z═O, Y═NH
  • To a suspension of Example 25 (0.5 g, 1.4 mmol) in pyrrolidine (10 mL) were subsequently added 1-dimethylamino-2-propyne (0.170 mL, 1.6 mmol, 1.2 equiv.), toluene (10 mL) and tetrakis(triphenylphosphine) palladium (80 mg, 0.07 mmol, 0.05 equiv.). After heating to 45° C. overnight, the mixture was filtered, diluted with ethyl acetate and washed twice with a 1 M aqueous solution of hydrochloric acid. The aqueous layer was basified to pH 9 and extracted twice with ethyl acetate. The combined extracts were dried over sodium sulfate, concentrated under reduced pressure and to give 60 mg (13% yield) of the title compound as yellowish solid. mp=208° C. [0986]
  • [0987] 1H NMR [(CD3)2SO] δ8.63 (br s, 1H, NH), 7.37 (d, J=1.5 Hz, 1H), 7.34 (s, 1H), 7.19 (br s, 1H, NH), 3.43 (s, 2H), 2.24 (s, 6H), 1.81-1.72 (m, 6H), 1.62 (m, 1H), 1.50 (m, 2H), 1.27 (m, 1H).
  • Example 37 8′-Chloro-6′-(3-methylamino-prop-1-ynyl)spiro[cyclohexane-1-4′-(3′,4′-dihydro)quinazolin]-2′(1′H)-one X1═CH, X2═C-(3-methylaminoprop-1-ynyl), X3═CH, X4═C—Cl, A═cyclohexyl, X═NH, Z═O, Y═NH
  • To a solution of Example 25 (0.2 g, 0.5 mmol) ) in dimethylformamide (3 mL) were subsequently added N-methylpropargylamine (0.1 mL, 1 mmol, 2 equiv.) and triethylamine (1 mL, 7 mmol, 14 equiv.). The mixture was degassed bubbling nitrogen for 30 minutes then tetrakis(triphenylphosphine)palladium (20 mg, 0.025 mmol, 0.05 equiv.) and copper(l) iodide (20 mg, 0.1 mmol, 0.02 equiv.) were added. After heating to 80° C. overnight, the mixture was diluted with dichloromethane and washed three times with water. The organic layer was dried over sodium sulfate, filtered, concentrated under reduced pressure and purified by flash chromatography on silica gel (CH[0988] 2Cl2/MeOH: 98/2 to CH2Cl2/MeOH/NH4OH: 96/3/1) to give 40 mg (25% yield) of the title compound as a solid. mp=188° C.
  • [0989] 1H NMR [(CD3)2SO] δ8.62 (br s, 1H, NH), 7.33 (s, 1H), 7.32 (s, 1H), 7.19 (br s, 1H, NH), 3.50 (br s, 2H), 2.35 (br s, 3H), 1.76-1.73 (m, 6H), 1.61 (m, 1H), 1.50 (m, 2H), 1.26 (m, 1H).
  • Example 38 8′-Chloro-6′-[4-(4-methyl-piperazine-1-carbonyl)phenyl]spiro[cyclohexane-1-4′-(3′,4′-dihydro)quinazolin]-2′(1′H)-one X1═CH, X2═C-(4-(4-methyl-piperazine-1-carbonyl)phenyl), X3═CH, X4═C—Cl, A═cyclohexyl, X═NH, Z═O, Y═NH
  • To a suspension of Example 32 (100 mg, 0.27 mmol) in toluene (3 mL) was added thionyl chloride (0.03 mL, 0.4 mmol, 1.5 equiv.). The resulting mixture was heated to reflux for 2 hours, then twice concentrated under reduced pressure and taken into toluene. To the resulting solid in toluene (2 mL) was added triethylamine (0.1 mL, 0.54 mmol, 2 equiv.) and 1-methylpiperazine (0.04 mL, 0.32 mmol, 1.2 equiv.). After stirring overnight, the mixture was diluted with dichloromethane and washed twice with water. The organic layer was concentrated under reduced pressure and purified by flash chromatography on silica gel (CH[0990] 2Cl2/MeOH: 97/3) to give 20 mg (16% yield) of the title compound as white solid. mp=277° C.
  • 1H NMR [(CD3)[0991] 2SO] δ8.55 (br s, 1H, NH), 7.80 (d, J=8.0 Hz, 2H), 7.67 (s, 1H), 7.61 (s, 1H), 7.50 (d, J=8.0 Hz, 2H), 7.18 (br s, 1H, NH), 3.60 (br m, 4H), 3.08 (br m, 4H), 2.67 (br s, 3H), 1.91-1.72 (m, 6H), 1.65 (m, 1H), 1.54 (m, 2H), 1.31 (m, 1H).
  • Example 39 8′-Chloro-6′-[4-(3-N-dimethylamino-propylcarboxamide)phenyl]-spiro[cyclohexane-1-4′-(3′,4′-dihydro)quinazolin]-2′(1′H)-one X1═CH, X2═C-[4-(3-N-dimethylamino-propylcarboxamide)phenyl], X3═CH, X4═C—Cl, A═cyclohexyl, X═NH, Z═O, Y═NH
  • To a suspension of Example 32 (122 mg, 0.33 mmol) in toluene (3 mL) was added thionyl chloride (0.04 mL, 0.5 mmol, 1.5 equiv.). The resulting mixture was heated to reflux overnight, then concentrated under reduced pressure. To the resulting solid in toluene (2 mL) was added triethylamine (0.1 mL, 0.54 mmol, 1.6 equiv.) and 3-dimethylaminopropylamine (0.037 mL, 0.26 mmol, 0.8 equiv.). After stirring for 4 h, the mixture was diluted with dichloromethane and washed twice with water and a 1N aqueous solution of hydrochloric acid. The aqueous layer was basified to pH 9 and extracted twice with dichloromethane. The combined organic extracts were concentrated under reduced pressure to give 40 mg (34% yield) of the title compound as white solid. mp=232° C. [0992]
  • [0993] 1H NMR [(CD3)2SO] δ8.59-8.55 (m, 2H), 7.90 (d, J=8.5 Hz, 2H), 7.79 (d, J=8.5 Hz, 2H), 7.68 (d, J=1.5 Hz, 1H), 7.63 (s, 1H), 7.18 (br s, 1H, NH), 3.29 (m, 2H) 2.26 (t, J=7.0 Hz, 2H), 2.14 (s, 6H), 1.92-1.77 (m, 6H), 1.67 (m, 3H), 1.54 (m, 2H), 1.32 (m, 1H).
  • Example 40 8′-Chloro-6′-[4-(2-N-dimethylamino-ethylcarboxamide)phenyl]spiro-[cyclohexane-1-4′-(3′,4′-dihydro)quinazolin]-2′(1′H)-one X1═CH, X2═C-[4-(2-N-dimethylamino-ethylcarboxamide)phenyl], X3═CH, X4═C—Cl, A═cyclohexyl, X═NH, Z═O, Y═NH
  • To a suspension of Example 32 (150 mg, 0.4 mmol) in toluene (3 mL) was added thionyl chloride (0.03 mL, 0.41 mmol, 1.0 equiv.). The resulting mixture was heated to reflux for 3 h, then concentrated under reduced pressure. To the resulting solid in toluene (3 mL) was added triethylamine (0.14 mL, 0.8 mmol, 2 equiv.) and 2-dimethylaminoethylamine (0.04 mL, 0.32 mmol, 0.8 equiv.). After stirring overnight, the mixture was concentrated, diluted with dichloromethane and washed twice with water and a 1N aqueous solution of hydrochloric acid. The aqueous layer was basified to pH 9 and extracted twice with dichloromethane. The combined organic extracts were concentrated under reduced pressure to give 100 mg (56% yield) of the title compound as white solid. mp=234° C. [0994]
  • [0995] 1H NMR [(CD3)2SO] δ8.54 (br s, 1H, NH), 8.44 (t, J=5.5 Hz, 1H), 7.91 (d, J=8.5 Hz, 2H), 7.79 (d, J=8.5 Hz, 2H), 7.69 (d, J=1.5 Hz, 1H), 7.63 (d, J=1.5 Hz, 1H), 7.18 (br s, 1H, NH), 3.37 (q, J=6.5 Hz, 2H), 2.45 (t, J=6.5 Hz, 2H), 2.22 (s, 6H), 1.90-1.74 (m, 6H), 1.65 (m, 1H), 1.54 (m, 2H), 1.32 (m, 1H).
  • Example 41 8′-Chloro-6′-[3-(3-N-dimethylamino-propylcarboxamide)phenyl]spiro[-cyclohexane-1-4′-(3′,4′-dihydro)quinazolin]-2′(1′H)-one X1═CH, X2═C-[3-(3-N-dimethylamino-propylcarboxamide)phenyl], X3═CH, X4═C—Cl, A═cyclohexyl, X═NH, Z═O, Y═NH
  • To a suspension of Example 33 (100 mg, 0.27 mmol) in toluene (10 mL) was added thionyl chloride (0.1 mL, 1.3 mmol, 5 equiv.). The resulting mixture was heated to reflux for 2 h, then concentrated under reduced pressure. To the resulting solid in toluene (10 mL) was added triethylamine (0.1 mL, 0.54 mmol, 2 equiv.) and 3-dimethylaminopropylamine (0.03 mL, 0.21 mmol, 0.8 equiv.). After stirring for 3 h, the mixture was concentrated, diluted with dichloromethane and washed twice with water and a 1N aqueous solution of hydrochloric acid. The aqueous layer was washed with ethyl acetate, basified to pH 9 and extracted twice with dichloromethane. The combined organic extracts were concentrated under reduced pressure to give 30 mg (30% yield) of the title compound as white solid. mp=208° C. [0996]
  • [0997] 1H NMR [(CD3)2SO] δ8.60 (m, 1H), 8.54 (br s, 1H, NH), 8.03 (br s, 1H, NH), 7.83 (d, J=7.5 Hz, 1H), 7.78 (d, J=8.0 Hz, 1H), 7.69 (d, J=1.5 Hz, 1H), 7.60 (s, 1H), 7.52 (t, J=7.5 Hz, 1H), 7.17 (br s, 1H, NH), 3.29 (m, 2H), 2.27 (t, J=7.0 Hz, 2H), 2.14 (s, 6H), 1.85-1.78 (m, 6H), 1.67 (m, 3H), 1.55 (m, 2H), 1.30 (m, 1H).
  • Example 42 8′-Chloro-6′-[3-(4-methyl-piperazine-1-carbonyl)-phenyl]spiro[cyclohexane-1-4′-(3′, 4′-dihydro)quinazolin]-2′(1′H)-one X1═CH, X2═C-[3-(4-methyl-piperazine-1-carbonyl)-phenyl], X3═CH, X4═C—Cl, A═cyclohexyl, X═NH, Z═O, Y═NH
  • To a suspension of Example 33 (100 mg, 0.27 mmol) in toluene (5 mL) was added thionyl chloride (0.03 mL, 0.4 mmol, 1.5 equiv.). The resulting mixture was heated to reflux for 3 hours, then twice concentrated under reduced pressure and taken into toluene. To the resulting solid in toluene (5 mL) was added triethylamine (0.1 mL, 0.54 mmol, 2 equiv.) and 1-methylpiperazine (0.024 mL, 0.21 mmol, 0.8 equiv.). After stirring overnight, the mixture was diluted with dichloromethane and washed twice with water. The organic layer was concentrated under reduced pressure, taken into ethyl acetate and washed with a 1N aqueous solution of hydrochloric acid. The aqueous layer was washed with ethyl acetate, basified to pH 9 and extracted twice with dichloromethane. The combined organic extracts were concentrated under reduced pressure to give 60 mg (61 % yield) of the title compound as white solid. mp=207° C. [0998]
  • [0999] 1H NMR [(CD3)2SO] δ8.52 (br s, 1H, NH), 7.76 (d, J=8.0 Hz, 1 H), 7.67 (s, 1H), 7.65 (d, J=1.5 Hz, 1H), 7.58 (d, J=1.5 Hz, 1H), 7.50 (t, J=7.5 Hz, 1H), 7.32 (d, J=7.5 Hz, 1 H), 7.16 (br s, 1H, NH), 3.64 (br m, 4H), 2.32 (br m, 4H), 2.20 (s, 3H), 1.89-1.77 (m, 6H), 1.64 (m, 1 H), 1.53 (m, 2H), 1.32 (m, 1 H).
  • Example 43 8′-Chloro-6′-[3-(2-N-dimethylamino-ethylcarboxamide)phenyl]spiro-[cyclohexane-1-4′-(3′, 4′-dihydro)quinazolin]-2′(1′H)-one X1═CH, X2═C-[3-(2-N-dimethylamino-ethylcarboxamide)phenyl], X3═CH, X4═C—Cl, A═cyclohexyl, X═NH, Z═O, Y═NH
  • To a suspension of Example 33 (100 mg, 0.27 mmol) in toluene (10 mL) was added thionyl chloride (0.1 mL, 1.3 mmol, 5 equiv.). The resulting mixture was heated to reflux for 2 h, then concentrated under reduced pressure. To the resulting solid in toluene (10 mL) was added triethylamine (0.1 mL, 0.54 mmol, 2 equiv.) and 2-dimethylaminoethyl amine (0.024 mL, 0.21 mmol, 0.8 equiv.). After stirring for 3 h, the mixture was concentrated, diluted with dichloromethane and washed twice with water and a 1N aqueous solution of hydrochloric acid. The aqueous layer was washed with ethyl acetate, basified to pH 9 and extracted twice with dichloromethane. The combined organic extracts were concentrated under reduced pressure to give 40 mg (40% yield) of the title compound as white solid. mp=225° C. [1000]
  • [1001] 1H NMR [(CD3)2SO] δ8.55 (br s, 1H, NH), 8.51 (t, J=5.5 Hz, 1H), 8.05 (b, s, 1H, NH), 7.84 (d, J=7.5 Hz, 1H), 7.79 (d, J=8.0 Hz, 1H), 7.70 (d, J=2.0 Hz, 1H), 7.59 (d, J=2.0 Hz, 1H), 7.52 (t, J=7.5 Hz, 1H), 7.18 (br s, 1H, NH), 3.39 (q, J=6.5 Hz, 2H), 2.42 (t, J=6.5 Hz, 2H), 2.19 (s, 6H), 1.89-1.78 (m, 6H), 1.65 (m, 1H), 1.54 (m, 2H), 1.31 (m, 1H).
  • Example 44 8′-Chlorospiro[cyclohexane-1-4′-(3′, 4′-dihydro)quinazolin]-2′(1′H)-thione X1═CH, X2═CH, X3═CH, X4═C—Cl, A═cyclohexyl, X═NH, Z═S, Y═NH a) Preparation of 2′,8′-dichlorospiro[cyclohexane-1-4′-(3′, 4′-dihydro)quinazoline] (Intermediate 1)
  • A solution of Example 7 (51 mg, 2 mmol) in phosphorus oxychloride (10 mL) containing Na[1002] 2CO3 (32 mg, 3 mmol) was heated at 95° C. for 5 hours. After cooling to room temperature, the phosphorus oxychloride was removed under reduced pressure. The crude product was used without purification in the next step.
  • [1003] 1H NMR [(CD3)2SO] δ8.31 (br s, 1H, NH), 7.28 (d, J=7.8 Hz, 1H), 7.23 (d, J=7.8 Hz, 1H), 7.04 (t, J=7.8 Hz, 1H), 1.89-1.61 (m, 7H), 1.51-1.48 (m, 2H), 1.28-1.24 (m, 1H).
  • b) Preparation of Example 44
  • A solution of 2′,8′-dichlorospiro[cyclohexane-1-4′-(3′, 4′-dihydro)quinazoline] (2 mmol) and thiourea (88 mg, 10.4 mmol) was heated to reflux overnight, cooled to room temperature and concentrated. The material was dissolved in EtOAc and washed sequentially with saturated aqueous NaHCO[1004] 3 and saturated aqueous NaCl. The organic extracts were dried over Na2SO4, filtered and concentrated. The crude material was purified by flash chromatography on silica gel (cyclohexane/EtOAc:95/5) to afford the title compound as a white solid (288 mg, 54%). mp=209-211° C.
  • [1005] 1H NMR [(CD3)2SO] δ9.15 (br s, 1H, NH), 8.69 (br s, 1H, NH), 7.39 (d, J=7.9 Hz, 1H), 7.35 (d, J=7.9 Hz, 1H), 7.09 (t, J=7.9 Hz, 1H), 1.85-1.51 (m, 9H), 1.26 (m, 1H).
  • Example 45 8′-Chloro-2′-cyanoiminospiro[cyclohexane-1-4′-(3′, 4′-dihydro)quinazoline] X1═CH, X2═CH, X3═CH, X4═C—Cl, A═cyclohexyl, X═NH, Z1═NH—CN, Y═N
  • 2′,8′-Dichlorospiro[cyclohexane-1-4′-(3′, 4′-dihydro)quinazoline] (2 mmol) and cyanamide (3 g) were heated to 60° C. overnight. The mixture was cooled to room temperature and water was added. The aqueous solution was extracted with CH[1006] 2Cl2. The organic extracts were washed with saturated aqueous NaCl, dried over Na2SO4, filtered and concentrated. The crude material was purified by flash chromatography on silica gel (cyclohexane/EtOAc: 90/10) to afford the title compound as a white solid (260 mg, 23%). mp=193-195° C.
  • [1007] 1H NMR [(CD3)2SO] δ9.45 (br s, 1H, NH), 8.05 (br s, 1H, NH), 7.42 (d, J=7.8 Hz, 1H), 7.37 (d, J=7.8 Hz, 1H), 7.13 (t, J=7.8 Hz, 1H), 1.81-1.57 (m, 9H), 1.28 (m, 1H).
  • Example 46 8′-Chloro-2′-methoxyiminospiro[cyclohexane-1-4′-(3′,4′-dihydro)-quinazoline] X1═CH, X2═CH, X3═CH, X4═C—Cl, A═cyclohexyl, X═NH, Z1═N—O—CH3, Y═NH
  • A solution of 2′,8′-Dichlorospiro[cyclohexane-1-4′-(3′,4′-dihydro)quinazoline] (2 mmol) in EtOH (10 mL) was added to a solution of methoxylamine hydrochloride (1 mg, 11.9 mmol) and triethylamine (1.67 mL, 11.9 mmol) in EtOH (3 mL) and heated to reflux overnight, cooled to room temperature and concentrated. The material was dissolved in EtOAc and washed sequentially with saturated aqueous NaHCO[1008] 3 and saturated aqueous NaCl. The organic extracts were dried over MgSO4, filtered and concentrated. The crude material was purified by flash chromatography on silica gel (cyclohexane/EtOAc:80/20 to cyclohexane/EtOAc/MeOH: 80/20/1) to afford the title compound as a white solid (120 mg, 22%). mp=113-115° C.
  • [1009] 1H NMR [(CD3)2SO] δ8.17 (br s, 0.4H, NH), 7.64 (br s, 0.6H, NH), 7.33 (d, J=8.0 Hz, 0.6H), 7.27 (d, J=8.0 Hz, 0.6H), 7.25 (d, J=7.5 Hz, 0.4H), 7.22 (d, J=7.5 Hz, 0.4H), 6.94 (t, J=8.0 Hz, 0.6H), 6.87 (t, J=7.5 Hz, 0.4H), 6.17 (br s, 0.6H, NH), 5.77 (br s, 0.4H, NH), 1.70 (m, 7H), 1.48 (m, 2H), 1.28 (m, 1H).
  • Example 47 8′-Chloro-2′-dimethylaminospiro[cyclohexane-1-4′-(3′,4′-dihydro)-quinazoline] X1═CH, X2═CH, X3═CH, X4═C—Cl, A═cyclohexyl, X═NH, Z1═N(CH3)2, Y═N
  • A solution of 2′,8′-dichlorospiro[cyclohexane-1-4′-(3′,4′-dihydro)quinazoline] (2 mmol) and dimethylamine (2M in ethanol) (3 mL, 6 mmol) was heated to 140° C. in a sealed tube overnight, cooled to room temperature and concentrated. The material was dissolved in CH[1010] 2Cl2 and washed sequentially with saturated aqueous NaHCO3 and saturated aqueous NaCl. The organic extracts were dried over MgSO4, filtered and concentrated. The crude material was purified by flash chromatography on silica gel (cyclohexane/EtOAc/NH3 (28% in water):70/30/1) to afford the title compound as a white solid (95 mg, 17%). mp=173-175° C.
  • [1011] 1H NMR [(CD3)2SO] δ7.14 (d, J=7.8 Hz, 1H), 7.04 (d, J=7.8 Hz, 1H), 6.73 (t, J=7.8 Hz, 1H), 5.84 (br s, 1H, NH), 3.0 (s, 6H), 1.73-1.53-(m, 9H), 1.29-1.17 (m, 1H).
  • Example 48 8′-Chloro-1′-methylspiro[cyclohexane-1-4′-(3′,4′-dihydro)quinazolin]-2′(1′H)-one X1═CH, X2═CH, X3═CH, X4═C—Cl, A═cyclohexyl, X═NH, Z═O, Y═N—CH3
  • To a stirred solution Example 7 (150 mg, 0.59 mmol) in dimethylformamide (10 mL) was added sodium hydride (50% in grease, 35.4 mg, 0.73 mmol) under N[1012] 2. The mixture was stirred until hydrogen evolution ceased and methyl iodide (40 μl, 0.65 mmol) was added. The mixture was stirred overnight at room temperature. After removal of the solvent, the material was dissolved in CH2Cl2, washed with saturated aqueous NaCl solution, dried over Na2SO4, filtered and concentrated. The crude material was purified by flash chromatography on silica gel (cyclohexane/EtOAc 90/10) to afford the title compound as a white solid (55 mg, 43%). mp=163-1650° C.
  • [1013] 1H NMR [(CD3)2SO] δ7.34 (d, J=7.8 Hz, 1H), 7.31 (d, J=7.8 Hz, 1H), 7.08 (t, J=7.8 Hz, 1H), 6.94 (br s, 1H, NH), 3.37 (s, 3H), 1.80-1.62 (m, 7H), 1.53 (m, 2H), 1.19(m, 1H).
  • Example 49 8′-Chloro-1′-(ethoxycarbonylmethyl)spiro[cyclohexane-1-4′-(3′,4′-dihydro)-quinazolin]-2′(1′H)-one X1═CH, X2═CH, X3═CH, X4═C—Cl, A═cyclohexyl, X═NH, Z═O, Y═N—(ethoxycarbonylmethyl)
  • To a stirred Example 7 (500 mg, 2 mmol) in dimethylformamide (10 mL) was added sodium hydride (50% in grease, 96 mg, 2 mmol) under N[1014] 2. The mixture was stirred until hydrogen evolution ceased and ethyl bromoacetate (0.77 mL, 7 mmol) was added. The mixture was stirred overnight at 80° C. After removal of the solvent under reduced pressure, the material was dissolved in CH2Cl2, washed with saturated aqueous NaCl solution, dried over Na2SO4, filtered and concentrated. The crude material was purified by flash chromatography on silica gel (cyclohexane/EtOAc/toluene: 70/30/100) to afford the title compound as a white solid (50 mg, 7%). mp=140-142° C.
  • [1015] 1H NMR [(CD3)2SO] δ7.35 (d, J=8.0 Hz, 1H), 7.32 (d, J=8.0 Hz, 1H), 7.23 (br s, 1H, NH), 7.07 (t, J=8.0 Hz, 1H), 4.71 (s, 2H), 4.09 (q, J=7.5 Hz, 2H), 1.95-1.92 (m, 2H), 1.78-1.62 (m, 5H), 1.54-1.51 (m, 2H), 1.23 (m, 1H), 1.15 (t, J=7.5 Hz, 3H).
  • Example 50 8′-Chloro-3′-methylspiro[cyclohexane-1-4′-(3′,4′-dihydro)quinazolin]-2′(1′H)-one X1═CH, X2═CH, X3═CH, X4═C—Cl, A═cyclohexyl, X═N—CH3, Z═0, Y═NH Preparation of 8′-Chloro-1′-(4-methoxybenzyl)spiro[cyclohexane-1-4′-(3′,4′-dihydro)guinazolin]-2′(1′H)-one (Intermediate 2)
  • A solution of Example 7 (5 g, 19.9 mmol), cesium carbonate (7.8 g, 23.9 mmol) and 4-methoxybenzylchloride (2.9 mL, 21.93 mmol) in dimethylformamide (250 mL) was stirred at room temperature for 3 days. The mixture was concentrated. The residue was dissolved in CH[1016] 2Cl2, washed with saturated aqueous NaCl solution, dried over Na2SO4, filtered and concentrated. AcOEt was added and the precipitate was filtered off to afford the title compound as a white solid (6.33 g, 86%).
  • [1017] 1H NMR [(CD3)2SO] δ7.33 (d, J=7.8 Hz, 1H), 7.26 (d, J=7.8 Hz, 1H), 7.06 (m, 3H), 6.77 (d, J=8.7 Hz, 2H), 5.25 (s, 2H), 3.66 (s, 3H), 1.67-1.47 (m, 5H), 1.40-1.27(m, 4H), 1.13(m, 1H).
  • Preparation of 8′-Chloro-3′-methyl-1′-(4-methoxybenzyl)spiro[cyclohexane-1-4′-(3′,4′-dihydro)quinazolin]-2′(1′H)-one (Intermediate 3)
  • To a stirred solution of 8′-chloro-1′-(4-methoxybenzyl)spiro[cyclohexane-1-4′-(3′,4′-dihydro)quinazolin]-2′(1′H)-one (260 mg, 0.7 mmol) in dimethylformamide (15 mL) was added sodium hydride (50% in grease, 48 mg, 1 mmol) under N[1018] 2. The mixture was stirred until hydrogen evolution ceased and methyl iodide (60 μl, 0.96 mmol) was added. The mixture was stirred overnight at room temperature. After removal of the solvent, the material was dissolved in CH2Cl2, washed with saturated aqueous NaCl, dried over Na2SO4, filtered and concentrated. The crude material was purified by flash chromatography on silica gel (cyclohexane/EtOAc/28% aqueous NH3:90/10/1) to afford the title compound as a white solid (190 mg, 70%).
  • [1019] 1H NMR [(CD3)2SO] δ7.45 (d, J=7.9 Hz , 1H), 7.40 (d, J=7.9 Hz, 1H), 7.12 (t,J=7.9 Hz, 1H), 7.07 (d, J=8.2 Hz, 2H), 6.79 (d, J=8.2 Hz, 2H), 5.25 (s, 2H), 3.67 (s, 3H), 2.85 (s, 3H), 1.66-1.35 (m, 1OH).
  • Preparation of Example 50
  • To a solution of 8′-Chloro-3′-methyl-1′-(4-methoxybenzyl)spiro[cyclohexane-1-4′-(3′,4′-dihydro)quinazolin]-2′(1′H)-one (180 mg, 047 mmol) in CH[1020] 2Cl2 (4 mL) cooled at −10° C. was added dropwise trifluoroacetic acid (4 mL). The mixture was stirred at −1° C. for 1 hour and at room temperature for 20 min. The mixture was poured into a saturated aqueous NaHCO3 solution and extracted with CH2Cl2. The organic extracts were washed with saturated aqueous NaCl solution, dried over MgSO4, filtered and concentrated. The crude material was purified by flash chromatography on silica gel (cyclohexane/EtOAc/NH3 (28% in water):90/10/1 to 70/30/1) to afford the title compound as a white solid (21 mg, 17%). mp=135-137°
  • [1021] 1H NMR [(CD3)2SO] δ8.80 (br s, 1H, NH), 7.46 (d, J=7.7 Hz, 1H), 7.29 (d, J=7.7 Hz, 1H), 7.00 (t, J=7.7 Hz, 1H), 2.96 (s, 3H), 1.96 (m, 4H), 1.66 (m, 2H), 1.56-1.39 (m, 4H).
  • Example 51 8′-Chloro-6′-[4-(4-pyrimidin-2-yl-piperazine-1-carbonyl)phenyl]spiro[-cyclohexane-1-4′-(3′,4′-dihydro)quinazolin]-2′(1′H)-one X1═CH, X2═C-[4-(4-pyrimidin-2-yl-piperazine-1-carbonyl)phenyl], X3═CH, X4═C—Cl, A═cyclohexyl, X═NH, Z═O, Y═NH
  • To a suspension of Example 32 (185 mg, 0.5 mmol) in toluene (10 mL) was added thionyl chloride (0.19 mL, 1.9 mmol, 5 equiv.). The resulting mixture was heated to reflux for 2 h, then concentrated under reduced pressure. To the resulting solid in toluene (4 mL) was added triethylamine (0.15 mL, 1 mmol, 2 equiv.) and 2-(1-piperazinyl)pyrimidine (100 mg, 0.6 mmol, 1.2 equiv.). After heating to 80° C. for 1 h, the mixture was diluted with dichloromethane and washed with water. The organic layer was concentrated under reduced pressure and the resulting solid was purified by flash chromatography on silica gel (CH[1022] 2Cl2/MeOH: 97/3) to give 210 mg (81% yield) of the title compound as white solid. mp=271° C.
  • [1023] 1H NMR [(CD3)2SO] δ8.30 (br s, 1H, NH), 8.15 (d, J=4.5 Hz, 2H), 7.55 (d, J=8.0 Hz, 2H), 7.44 (s, 1H), 7.39 (s, 1H), 7.27 (d, J=8.5 Hz, 2H), 6.94 (br s, 1H, NH), 6.43 (t, J=4.5 Hz, 1H), 3.57-3.27 (m, 8H), 1.69-1.54 (m, 6H), 1.41 (m, 1H), 1.30 (m, 2H), 1.07 (m, 1H).
  • Example 52 8′-Chloro-6′-[4-(4-(2-morpholin-4-yl-ethyl)-piperazine-1-carbonyl)-phenyl]spiro[-cyclohexane-1-4′-(3′,4′-dihydro)quinazolin]-2′(1′H)-one X1═CH, X2═C-[4-(4-(2-morpholin-4-yl-ethyl)-piperazine-1-carbonyl)-phenyl], X3═CH, X4═C—Cl, A═cyclohexyl, X═NH, Z═O, Y═NH
  • To a suspension of Example 32 (150 mg, 0.4 mmol) in toluene (2 mL) was added thionyl chloride (0.06 mL, 0.8 mmol, 2 equiv.). The resulting mixture was heated to reflux for 2 h, then concentrated under reduced pressure. To the resulting solid in toluene (2 mL) was added triethylamine (0.11 mL, 0.8 mmol, 2 equiv.) and 1-[2-(morpholin-4-yl)-ethyl]-piperazine (64 mg, 0.3 mmol, 0.8 equiv.). After stirring for 2 h, the mixture was diluted with dichloromethane, washed with water and washed with a 1M aqueous solution of sodium hydroxyde. The organic layer was dried over sodium sulfate, concentrated under reduced pressure and the resulting solid was triturated with ethyl acetate/methanol to give 106 mg (50% yield) of the title compound as white solid. mp=264° C. [1024]
  • [1025] 1H NMR [(CD3)2SO] δ8.53 (br s, 1H, NH), 7.75 (m, 2H), 7.65 (s, 1H), 7.60 (s, 1H), 7.43 (m, 2H), 7.17 (br s, 1H, NH), 3.53 (m, 8H), 2.50-2.36 (m, 12H), 1.84-1.78 (m, 6H), 1.63 (m, 1H), 1.56 (m, 2H), 1.29 (m, 1H).
  • Example 53 8′-Chloro-6′-[4-(4-(2-morpholin-4-yl-2-oxo-ethyl)-piperazine-1-carbonyl)-phenyl]spiro[-cyclohexane-1-4′-(3′,4′-dihydro)quinazolin]-2′(1′H)-one X1═CH, X2═C-[4-(4-(2-morpholin-4-yl-2-oxo-ethyl)-piperazine-1-carbonyl)-phenyl], X3═CH, X4═C—Cl, A═cyclohexyl, X═NH, Z═O, Y═NH
  • To a suspension of Example 32 (150 mg, 0.4 mmol) in toluene (2 mL) was added thionyl chloride (0.06 mL, 0.8 mmol, 2 equiv.). The resulting mixture was heated to reflux for 3 h, then concentrated under reduced pressure. To the resulting solid in toluene (2 mL) was added triethylamine (0.11 mL, 0.8 mmol, 2 equiv.) and 4-[2-(piperazin-1-yl)-acetyl]-morpholine (130 mg, 0.6 mmol, 1.5 equiv.). After stirring overnight, the mixture was diluted with dichloromethane, washed with water and washed with a saturated aqueous solution of sodium bicarbonate. The organic layer was dried over sodium sulfate, concentrated under reduced pressure and the resulting solid was triturated with ethyl acetate/methanol to give 0.1 g (45% yield) of the title compound as white solid. mp=239° C. [1026]
  • [1027] 1H NMR [(CD3)2SO] δ8.53 (br s, 1H, NH), 7.74 (d, J=8.0 Hz, 2H), 7.66 (s, 1H), 7.60 (s, 1H), 7.44 (d, J=8.0 Hz, 2H), 7.17 (br s, 1H, NH), 3.58-3.22 (m, 14H), 2.50 (m, 4H), 1.88-1.79 (m, 6H), 1.64 (m, 1H), 1.55 (m, 2H), 1.30 (m, 1H).
  • Example 54 8′-Chloro-6′-[4-(4-(2-hydroxy-ethoxy)-ethyl)-piperazine-1-carbonyl)-phenyl]spiro[-cyclohexane-1-4′-(3′,4′-dihydro)quinazolin]-2′(1′H)-one X1═CH, X2═C-[4-(4-(2-hydroxy-ethoxy)-ethyl)-piperazine-1-carbonyl)-phenyl], X3═CH, X4═C—Cl, A═cyclohexyl, X═NH, Z═O, Y═NH
  • To a suspension of Example 32 (150 mg, 0.4 mmol) in toluene (2 mL) was added thionyl chloride (0.06 mL, 0.8 mmol, 2 equiv.). The resulting mixture was heated to reflux for 3 h, then concentrated under reduced pressure. To the resulting solid in toluene (2 mL) was added triethylamine (0.11 mL, 0.8 mmol, 2 equiv.) and 1-hydroxyethylethoxypiperazine (77 mg, 0.4 mmol, 1.1 equiv.). After stirring for 2 h, the mixture was diluted with dichloromethane and washed with water and washed with a 1M aqueous solution of sodium hydroxyde. The organic layer was dried over sodium sulfate, concentrated under reduced pressure to give 0.06 g (29% yield) of the title compound as white solid. mp=100° C. [1028]
  • [1029] 1H NMR [(CD3)2SO] δ8.53 (br s, 1H, NH), 7.75 (d, J=8.0 Hz, 2H), 7.65 (s, 1H), 7.60 (s, 1H), 7.43 (d, J=8.0 Hz, 2H), 7.17 (br s, 1H, NH), 4.58 (br s, 1H), 3.59-3.39 (m, 1OH), 2.45 (m, 6H), 1.88-1.77 (m, 6H), 1.64 (m, 1H), 1.54 (m, 2H), (m, 1H).
  • Example 55 9′-Chlorospiro[cyclohexane-1-5′-(5′, 10′-dihydro)]-imidazo[2,1-b]quinazoline formula (I), X1═CH, X2═CH, X3═CH, X4═C—Cl, A═cyclohexyl, X-Z═NCH═CHNH, Y═NH Preparation of 8′-Chloro-2′-(2,2-dimethoxy-ethylamino)spiro[cyclohexane-1-4′-(3′,4′-dihydro)quinazoline](Intermediate 4)
  • A solution of Example 7 (1.34 mmol, 0.5 g) in phosphorus oxychloride (7 mL) containing Na[1030] 2CO3 (21 mg, 2 mmol) is heated to 95° C. for 4 hours. After cooling to room temperature, the phosphorus oxychloride was removed under reduced pressure. The residue was taken into EtOH (10 mL), amino acetaldehyde dimethyl acetal (1 mL, 8.04 mmol) was added and the resulting mixture is refluxed overnight. CH2Cl2 and a saturated aqueous solution of NaHCO3 were added. The layers were separated, the aqueous one being extracted three times with CH2Cl2. The combined organic layers were washed with brine, dried over Na2SO4 and concentrated. The crude material was purified by flash chromatography on silica gel (cyclohexane/EtOAc/MeOH: 80/20/5) to give 0.43 g (96%) of intermediate 4.
  • [1031] 1H NMR [(CD3)2SO] δ7.12 (d, J=7.5 Hz, 1H), 7.04 (d, J=7.5 Hz, 1H), 6.70 (t, J=7.5 Hz, 1H), 6.46 (br s, 1H), 6.08 (br s, 1H), 4.48 (t, J=5.3 Hz, 1H), 3.41 (t, J=5.3 Hz, 2H), 3.32 (m, 6H), 1.72-1.56 (m, 9H), 1.22 (m, 1H).
  • Preparation of Example 55
  • A solution of intermediate 4 (0.436 g, 1.29 mmol) in a mixture of isopropyl alcohol (10 mL) and 3M aqueous HCl (4 mL) was refluxed overnight. The reaction mixture was allowed to cool to room temperature, was concentrated under reduced pressure and taken into CH[1032] 2Cl2 and an aqueous saturated solution of NaHCO3. The layers were separated, the aqueous one being extracted three times with CH2Cl2. The combined organic layers were washed with brine, dried over Na2SO4 and concentrated. The crude material was recrystallised in EtOAc to afford the title compound as a white solid (0.07 g, 23%) (purity ═95.4%) mp=197-199° C.
  • [1033] 1H NMR [(CD3)2SO] δ9.58 (br s, 1H), 7.52 (m, 1H), 7.34 (d, J=7.7 Hz, 1H), 7.23 (d, J=1.5 Hz, 1H), 6.92 (t, J=7.7 Hz, 1H), 6.71 (d, J=1.5 Hz, 1H), 2.03 (m, 4H), 1.37-1.45 (m, 6H).
  • Example 56 9′-Chlorospiro[cyclohexane-1-5′-(5′, 10′-dihydro)]-[1,2,4]triazolo[3,4-b]quinazoline formula (I), X1═CH, X2═CH, X3═CH, X4═C—Cl, A═cyclohexyl, X-Z: NCH═NN, Y═NH Preparation of 8′-Chlorospiro[cyclohexane-1-4′-(3′,4′-dihydro)-quinazolin-2′-yl]-hydrazine
  • A solution of Example 7 (1.8 mmol, 0.45 g) in phosphorus oxychloride (9 mL) containing Na[1034] 2CO3 (0.28 g, 2.7 mmol) is heated at 95° C. for 4 hours. After cooling to room temperature, the phosphorus oxychloride was removed under reduced pressure. The residue was taken into EtOH (10 mL), hydrazine (35% wt. solution in water, 2 mL) was added and the resulting mixture was refluxed overnight. CH2Cl2 and a saturated aqueous solution of NaHCO3 were added. The layers were separated, the aqueous one being extracted three times with CH2Cl2. The combined organic layers were washed with brine, dried over Na2SO4 and concentrated. The crude material (0.43 g, 91%) was used without further purification in the next step. 1H NMR [(CD3)2SO] δ7.12 (d, 1H), 7.08 (m, 1H), 6.75 (t, 1H), 1.83-1.60 (m, 7H), 1.47 (m, 2H), 1.25 (m, 1H).
  • Preparation of Example 56
  • A solution of 8′-Chlorospiro[cyclohexane-1-4′-(3′,4′-dihydro)-quinazolin-2′-yl]-hydrazine (0.58 g, 2.19 mmol), triethyl orthoformate (1.82 mL, 10.95 mmol) and H[1035] 2SO4 (0.05 mL) in butanol (20 mL) was refluxed for 24 h. The reaction mixture was allowed to cool to room temperature, was concentrated under reduced pressure and taken into a mixture of CH2Cl2 and an aqueous saturated solution of NaHCO3. The layers were separated, the aqueous one being extracted three times with CH2Cl2. The combined organic layers were washed with brine, dried over Na2SO4 and concentrated. The crude material was recrystallized in EtOAc to afford the title compound as a white solid (0.13 g, 21%). (purity=96.6%) mp=237-239° C.
  • [1036] 1H NMR [(CD3)2SO] δ9.99 (br s, 1H), 8.72 (s, 1H), 7.55 (dd, J=7.9, 1.0 Hz, 1H), 7.37 (dd, J=7.9, 1.0 Hz, 1H), 6.97 (t, J=7.9 Hz, 1H), 2.07 (m, 4H), 1.72 (m, 5H), 1.53 (m, 1H).
  • Example 57 9′-Chlorospiro[cyclohexane-1-5′-(4′,5′-dihydro)]-[1,2,4]triazolo[4,3a]quinazoline formula (I), X1═CH, X2═CH, X3═CH, X4═C—Cl, A═cyclohexyl, X═NH, Y-Z: NCH═NN
  • To a solution of 8′-Chlorospiro[cyclohexane-1-4′-(3′,4′-dihydro)-quinazolin-2′-yl]-hydrazine (0.35 g, 1.32 mmol) and triethyl orthoformate (1.2 mL, 7.22 mmol) in CHCl[1037] 3 (16 mL) was added H2SO4 (0.04 mL). The mixture was stirred at room temperature for 3 h, was concentrated under reduced pressure and taken into a mixture of CH2Cl2 and an aqueous saturated solution of NaHCO3. The layers were separated, the aqueous one being extracted three times with CH2Cl2. The combined organic layers were washed with brine, dried over Na2SO4 and concentrated. The residue was taken into butanol (10 mL) and refluxed overnight. After completion, the solvent was evaporated under reduced pressure to give a mixture of 9′-Chlorospiro[cyclohexane-1-5′-(4′, 5′-dihydro)]-[1,2,4]triazolo[4,3-a]quinazoline and 9′-Chlorospiro[cyclohexane-1-5′-(5′,10′-dihydro)]-[1,2,4]triazolo[3,4-b]quinazoline as a 88/12 ratio. Crystallization in CH2Cl2 afford the title compound as a white powder (0.045 g, 43%). (purity ═97.2%) mp=285-287° C.
  • [1038] 1H NMR [(CD3)2SO] δ9.14 (s, 1H), 7.55 (m, 2H), 7.46 (s, 1H), 7.35 (t, J=8.0 Hz, 1H), 1.85-1.64 (m, 7H), 1.50 (m, 2H), 1.23 (m, 1H).
  • Example 58 Spiro[cyclohexane-1-9′-(8′,9′-dihydro)-pyrazolo[4′,3′-f]quinazolin]-7′(6H)-one Formula (I): X1-X2═C—CH:NNH—C, X3═CH, X4═CH, A═cyclohexyl, X═NH, Z═O, Y═NH
  • The title compound was prepared according to protocol A using (N-(1 H-indazol-5-yl)urea (1 g, 5.67 mmol), polyphosphoric acid (20 g) and cyclohexanone (0.9 mL, 1.5 equiv.). The crude product was purified by flash chromatography on silica gel (CH[1039] 2Cl2/MeOH: 99/01 to 97/3) followed by recrystallization in toluene to give the title compound as a white solid (14 mg, 1% yield) (purity 98.8%).
  • [1040] 1H NMR [(CD3)2SO] δ12.97 (br s, 1H, NH), 8.98 (br s, 1H, NH), 8.16 (s, 1H), 7.39 (d, J=8.5 Hz, 1H), 6.88 (d, J=9.0 Hz, 1H), 6.70 (br s, 1H, NH), 2.33-2.20 (m, 2H), 1.89-1.78 (m, 4H), 1.68-1.41 (m, 4H).
  • Example 59 8′-Chloro-5′-methoxyspiro[cyclohexane-1-4′-(3′,4′-dihydro)quinazolin]-2′(1′H)-one Formula (I): X1═C—OCH3, X2═CH, X3═CH, X4═C—Cl, A═cyclohexyl, X═NH, Z═O, Y═NH Preparation of (2-Chloro-5-methoxy-phenyl)-urea (Intermediate 5)
  • A solution of 2-chloro-5-methoxyaniline (5 g, 25.76 mmol) and potassium cyanate (5.22 g, 64.41 mmol) in a mixture of acetic acid (125 mL) and water (12.5 mL) was stirred at room temperature overnight. The solvent was evaporated, and the residue taken into a mixture of CH[1041] 2Cl2 and an aqueous saturated solution of NaHCO3. The layers were separated, the aqueous one being extracted three times with CH2Cl2. The combined organic layers were washed with brine, dried over Na2SO4 and concentrated. The crude material was purified by flash chromatography on silica gel (cyclohexane/EtOAc/MeOH: 80/20/2) to give 2.06 g (40%) of intermediate 5.
  • [1042] 1H NMR [(CD3)2SO] δ7.97 (br s, 1H, NH), 7.85 (d, J=3.0 Hz, 1H), 7.27 (d, J=9.0 Hz, 1H), 6.54 (dd, J=9.0, 3.0 Hz, 1H), 6.4-(br s, 2H), 3.71 (s, 3H).
  • Preparation of Example 59
  • Example 59 was prepared according to protocol A using intermediate 5 (1 g, 4.98 mmol), polyphosphoric acid (15 g) and cyclohexanone (0.88 mL, 7.47 mmol). After completion, ice was added, the precipitate was filtered and washed with cold water. The residue was recrystallized in ethanol to afford the title compound as a white powder (0.6 g, 78% yield) (purity 99.54%) mp=228.5-230.5° C. [1043]
  • [1044] 1H NMR [(CD3)2SO] δ7.93 (br s, 1H, NH), 7.27 (d, J=8.9 Hz, 1H), 7.00 (br s, 1H, NH), 6.65 (d, J=8.9 Hz, 1H), 3.79 (s, 3H), 2.45-2.38 (m, 2H), 1.84-1.74 (m, 2H), 1.63-1.56 (m, 3H), 1.46 (m, 2H), 1.23-1.13 (m, 1H).
  • Example 60 5′,8′-Difluorospiro[cyclohexane-1-4′-(3′,4′-dihydro)quinazolin]-2′(1′H)-one Formula (I): X1═C—F, X2═CH, X3═CH, )(4═C—F, A═cyclohexyl, X═NH, Z═O, Y═NH Preparation of 2,5-difluorophenyl urea (Intermediate 6)
  • To a solution of 2,5-difluorophenyl isocyanate (1 g, 6.45 mmol) in tetrahydrofuran (50 mL) at 0° C. was added a 28% aqueous solution of ammonia (30 mL). The mixture was stirred for 1 h allowing the temperature to warm up to room temperature, then concentrated under reduced pressure, taken into water and filtered. The solid was washed twice with water and with ether, then dried at 65° C. under reduced pressure to give 740 mg (67%) of intermediate 6. [1045]
  • [1046] 1H NMR [(CD3)2SO] δ8.53 (br s, 1H, NH), 8.02 (m, 1H), 7.21 (m, 1H), 6.72 (m, 1H), 6.29 (br s, 2H, NH2).
  • Preparation of Example 60
  • The title compound was prepared according to protocol A using intermediate 6 (740 mg, 4.3 mmol), polyphosphoric acid (20 g) and cyclohexanone (0.70 mL, 6.75 mmol). The crude product was purified by flash chromatography on silica gel (CH[1047] 2Cl2/MeOH: 100/0 to 95/5) followed by recrystallization in toluene to give the title compound as a white solid (28 mg, 3% yield) (purity 99%) mp=194-195° C.
  • [1048] 1H NMR [(CD3)2SO] δ9.26 (br s, 1H, NH), 7.13 (m, 1H), 7.05 (br s, 1H, NH), 6.71 (m, 1H), 2.01 (m, 2H), 1.86-1.75 (m, 4H), 1.64 (m, 1H), 1.49 (m, 2H), 1.18 (m, 1H).
  • Example 61 8′-Chloro-5′-methylspiro[cyclohexane-1-4′-(3′,4′-dihydro)quinazolin]-2′(1′H)-one Formula (I): X1═C—CH3, X2═CH, X3═CH, X4═C—Cl, A═cyclohexyl, X═NH, Z═O, Y═NH Preparation of (2-chloro-5-methyl-phenyl)urea (Intermediate 7)
  • A solution of 2-chloro-5-methylaniline (10 g, 70.6 mmol) and potassium cyanate (14.3 g, 176 mmol) in a mixture of acetic acid (340 mL) and water (34 mL) was stirred at room temperature during 4 hours. The solvent was evaporated and the residue taken into a mixture of CH[1049] 2Cl2 and an aqueous saturated solution of NaHCO3. The precipitate was filtered, washed with dichloromethane and dried under vacuum to give 12.6 g (97%) of intermediate 7.
  • [1050] 1H NMR [(CD3)2SO] δ8.05 (s, 1H, NH), 7.96 (s, 1H), 7.23 (d, 1H), 6.75 (d, 1H), 6.37 (br s, 2H), 2.24 (s, 3H).
  • Preparation of Example 61
  • The title compound was prepared according to protocol A using intermediate 7 (12.6 g, 68.2 mmol), polyphosphoric acid (150 g) and cyclohexanone (8.5 mL, 81.9 mmol). After completion, the mixture was poured into ice and water and stirred 45 minutes. The precipitate was filtered and washed with cold water, with diethyl ether and dried under vacuum to give 3.1 g of the title product. The residue (100mg) was recrystallized in ethanol to afford the title compound as a white powder (0.06 g, 17% yield) (purity with HPLC: 99.9%). [1051]
  • [1052] 1H NMR [(CD3)2SO] δ8.02 (br s, 1H, NH), 7.20 (d, J=8.04 Hz, 1H), 6.89 (br s, 1H, NH), 6.57 (d, J=8.03 Hz, 1H), 2.47 (s, 3H), 2.02-2.18 (m, 2H), 1.70-1.90 (m, 4H), 1.62-1.70(m, 1H), 1.1.48-1.60 (m, 2H), 1.20-1.35 (m, 1H).
  • Example 62 8′-Chloro-6′-(morpholin-4-yl)methylspiro[cyclohexane-1-4′-(3′,4′-dihydro)quinazolin]-2′(1′H)-one Formula (I): X1═CH, X2═C—CH2-morpholinyl, X3═CH, X4═C—Cl, A═cyclohexyl, X═NH, Z═O, Y═NH
  • The title compound was prepared according to protocol E. To a stirred solution of Example 7 (1 g, 4 mmol) in glacial acetic acid (15 mL) was sequentially added trioxane (0.55 g, 6 mmol, 1.5 equiv.) and a 48% aqueous solution of hydrobromic acid (5 mL). The mixture was heated to 95° C. overnight, poured on ice. The precipitate was filtered, washed twice with water then with ether to give 1.39 g of 8′-Chloro-6′-bromomethylspiro[cyclohexane-1-4′-(3′,4′-dihydro)quinazolin]-2′(1H)-one as a white solid. The crude bromomethyl derivative (150 mg, 0.43 mmol) was treated with morpholine (0.100 mL, 1.1 mmol, 2.6 equiv.) in DMF (3 mL) overnight. The mixture was concentrated under reduced pressure, taken into ethyl acetate, extracted with 1N aqueous HCl. The aqueous layer was washed twice with ethyl acetate, basified to pH 9 and extracted three times with ethyl acetate. The combined organic layers were washed three times with water and brine and concentrated under reduced pressure. The crude material was purified by recrystallization in toluene to give the title compound (102 mg, 68%) (purity 97%) as a white solid. mp=223° C. [1053]
  • [1054] 1H NMR [(CD3)2SO] δ8.33 (br s, 1H, NH), 7.21 (s, 1H), 7.18 (s, 1H), 7.08 (br s, 1H, NH), 3.56 (m, 4H), 3.39 (s, 2H), 2.32 (m, 4H), 1.84-1.49 (m, 9H), 1.25 (m, 1H).
  • Example 63 8′-Chloro-5′-hydroxyspiro[cyclohexane-1-4′-(3′,4′-dihydro)quinazolin]-2′(1′H)-one Formula (I): X1═C—OH, X2═CH, X3═CH, X4═C—Cl, A═cyclohexyl, X═NH, Z═O, Y═NH
  • The title compound was prepared according to protocol L. To a stirred solution Example 59 (0.83 g, 2.95 mmol) in CH[1055] 2Cl2 (100 mL) boron tribromide (1N in CH2Cl2, 21.8 mL, 21.8 mmol) was added at 0° C. The mixture was stirred at room temperature for 48 h, poured into a saturated aqueous solution of NaHCO3 and extracted with CH2Cl2. The combined organic layers were washed with brine, dried over Na2SO4, filtered and concentrated. The crude material was purified by precipitation in Et2O to afford the title compound as a white solid (0.25 g, 32%). (purity 97.6%) mp=252-254° C.
  • [1056] 1H NMR [(CD3)2SO] δ9.90 (br s, 1H), 7.75 (br s, 1H), 7.08 (d, J=8.7 Hz, 1H), 6.97 (br s, 1H, NH), 6.43 (d, J=8.7 Hz, 1H), 2.58-2.54 (m, 2H), 1.83-1.72 (m, 2H), 1.62-1.53 (m, 3H), 1.46 (m, 2H), 1.24-1.07 (m, 1H).
  • Example 64 8′-Chloro-5′-hydroxy-6′-iodo-spiro[cyclohexane-1-4′-(3′,4′-dihydro)quinazolin]-2′(1′H)-one X1═C—OH, X2═C—I, X3═CH, X4═C—Cl, A═cyclohexyl, X═NH, Z═O, Y═NH
  • To a stirred suspension of Example 63 (10 g, 37.5 mmol) in trifluoroacetic acid (150 mL) at 0 to 5° C. was added N-iodosuccinimide (9.47 g, 41.2 mmol) in portions over 10 minutes. The reaction mixture was stirred at 0 to 5° C. for 2 hours. The mixture was poured onto a mixture of water (700 mL) and ice (300 mL). The resulting brown solid was filtered and washed with water (250 mL) followed by heptane (4×40 mL). The solid was pulled dry on the filter bed for 2 hours and then slurried in a mixture of dichloromethane (30 mL) and methanol (5 mL). The dark pink precipitate was filtered and washed with dichloromethane (3×20 mL) to afford the titled compound (12.2 g, 31.0 mmol, 83%). [1057]
  • [1058] 1H NMR [(CD3)2SO] δ9.10 (s, 1H), 8.25 (s, 1H), 7.81 (s, 1H), 7.18 (s, 1H), 2.70 (m, 2H), 1.95 (m, 2H), 1.75 (m, 3H), 1.60 (m, 2H), 1.28 (m, 1H).
  • Example 65 8′-Chloro-6′-iodo-5′-methoxy-spiro[cyclohexane-1-4′-(3′,4′-dihydro)quinazolin]-2′(1′H)-one Formula (I): X1═C—OCH3, X2═C—I, X3═CH, X4═C—Cl, A═cyclohexyl, X═NH, Z═O, Y═NH
  • To a stirred suspension of Example 64 (16.27 g, 41.4 mmol) in DMF (325 mL) was added DBU (7.5 mL, 50.1 mmol) followed by methyl iodide (6.8 mL, 109 mmol) at 20 to 25° C. The reaction mixture was stirred for 3 hours. The mixture was poured into water (1625 mL) and the resulting solid was filtered and washed with water (500 mL) followed by heptane (2×150 mL). The solid was stirred in ethyl acetate containing 10% methanol (100 mL) for 10 minutes. The precipitate was filtered and washed with EtOAc (25 mL), TBME (10 mL) and dried in vacuo at 50° C. to afford the titled compound as a fawn solid (14.4 g, 35.5 mmol, 86%). [1059]
  • [1060] 1H NMR [CDCl3] δ7.67 (s, 1H), 7.18 (s, 1H), 5.68 (s, 1H), 3.83 (s, 3H), 2.23 (td, J=13.6, 4.5, 2H), 1.90 (m, 2H), 1.70 (m, 3H), 1.51 (m, 2H), 1.25 (m, 1H).
  • Example 66 8′-Chloro-6′-cyano-5′-methoxy-spiro[cyclohexane-1-4′-(3′,4′-dihydro)quinazolin]-2′(1′H)-one Formula (I): X1═C—OCH3, X2═C—CN, X3═CH, X4═C—Cl, A═cyclohexyl, X═NH, Z═O, Y═NH
  • To a stirred solution of Example 65 (3 g, 7.38 mmol) in NMP (60 mL) at 18 to 20° C. was added copper (I) cyanide (555 mg, 6.2 mmol). The mixture was heated to 150° C. for 4 days, quenched into ice/water (300 mL) and the crude product filtered off. The crude product was dissolved in EtOAc (500 mL) and washed with 33% NH[1061] 3(aq) solution (2×200 mL). The organic layer was further washed with brine (2×100 mL) and water (2×100 mL) and dried over MgSO4, filtered and concentrated in vacuo at 40° C. to give the crude product (1.2 g, 3.92 mmol). The crude product (650 mg, 2.12 mmol) was purified by preparative HPLC to yield the title compound as a pale yellow solid (97 mg, 3.27 mmol, 4%) (purity 96%).
  • [1062] 1H NMR (360 MHz, α6-DMSO) δ1.29-1.43 (m, 1H), 1.50-1.70 (m, 2H), 1.73-1.95 (m, 5H), 2.25 (ddd, J=4.5,13.5 & 13.5 Hz, 2H), 4.17 (s, 3H), 5.62-5.68 (br s, 1 H 7.25-7.29 (br s, 1H), 7.54 (s, 1H).
  • Example 67 8′-Chloro-5′-[2-(4-morpholino)ethoxy]spiro[cyclohexane-1-4′-(3′,4′-dihydro)quinazolin]-2′(1′H)-one Formula (I): X1═C—OCH2CH2-(4-morpholinyl), X2═CH, X3═CH, X4═C—Cl, A═cyclohexyl, X═NH, Z═O, Y═NH
  • The title compound was prepared according to protocol L. To a stirred solution of Example 63 (1 g, 3.93 mmol) in DMF (30 mL) under nitrogen at 18 to 20° C. was added 60% sodium hydride dispersion (0.16 g, 3.93 mmol). The mixture was stirred for 15 minutes before 4-(2-chloroethyl)morpholine (0.59 g, 3.93 mmol) was added. The mixture was then heated to 100° C. for 1.5 hours. After cooling to room temperature the reaction mixture was added to water (300 mL). The resulting solid was filtered and washed with water (50 mL). The crude solid was dried in vacuo at 45° C. and subsequent purification by column chromatography (silica 60 g, eluting with 5% methanol in dichloromethane) afforded the title compound (0.48 g, 1.23 mmol, 32%) as a cream solid after drying in vacuo at 50° C. (purity 96.9%) [1063]
  • [1064] 1H NMR (360 MHz, CDCl3) δ7.20 (d, J=8.8 Hz, 1H), 7.04 (s, 1H), 6.50 (d, J=8.8 Hz, 1H), 5.65 (s, 1H), 4.10 (t, J=5.5 Hz, 2H), 3.73 (t, J=4.5 Hz, 4H), 2.84 (t, J=5.5 Hz, 2H), 2.68 (td, J=13.5, 4.5 Hz, 2H), 2.56 (t, J=4.5 Hz, 4H), 1.74 (m, 5H), 1.56 (m, 2H), 1.32 (m, 1H).
  • Example 68 8′-Chloro-5′-[2-dimethylaminoethoxy]spiro[cyclohexane-1-4′-(3′,4′-dihydro)quinazolin]-2′(1′H)-one Formula (I): X1═C—OCH2CH2N(CH3)2, X2═CH, X3═CH, X4═C—C, A=cyclohexyl, X═NH, Z═O, Y═NH
  • To a stirred solution of Example 63 (6 g, 22.5 mmol) in DMF (20 mL) at 18 to 20° C. was added a solution of potassium carbonate (2M, 9.42 mL, 18.84 mmol) followed by 2-dimethyl-aminoethyl chloride hydrochloride (2M, 37.7 mL, 75.4 mmol). The mixture was heated to 100° C. for 18 hours and allowed to cool to 18 to 20° C. The reaction mixture was added to water (1.5L) and extracted with EtOAc (2×1L). The combined organic layer was back washed with water (1L) and separated. The combined organic fractions were dried over with MgSO[1065] 4, filtered and concentrated in vacuo at 40° C to give the crude material (4.7 g, 13.9 mmol). The crude product was purified by TBME wash (60 mL) and charcoal (5 g) treatment in DCM (200 mL) and column chromatography (silica; gradient elution, 100% EtOAc to 50% in DCM to EtOAc:DCM:MeOH; 2:10:1) to yield the title compound as a pale yellow solid (2.34 g, 6.93 mmol, 31%) (purity 99%) 1H NMR (360 MHz, d6-DMSO) δ1.21-1.33 (m, 1H), 1.40-1.55 (m, 2H), 1.60-1.72 (m, 5H), 2.29 (s, 6H), 2.57 (ddd, J=4.5, 13.5, 13.5 Hz, 2H), 2.72 (t, J=6.1 Hz, 2H), 4.02 (t, J=6.1 Hz, 2H), 5.48-5.54 (br s, 1H), 6.45 (d, J=9.0 Hz, 1H), 6.92-6.97 (br s, 1H, 7.14 (d, J=9.0 Hz, 1H;
  • Example 69 8′-Chloro-5′-(2-aminoethoxy)-spiro[cyclohexane-1-4′-(3′,4′-dihydro)quinazolin]-2′(1′H)-one Formula (I): X1═C—OCH2CH2NH2, X2═CH, X3═CH, X4═C—Cl, A═cyclohexyl, X═NH, Z═O, Y═NH Preparation of 8′-Chloro-5′-(2-methanesulphonylethoxy)-spiro[cvclohexane-1-4′-(3′,4′-dihydro)quinazolin]-2′ (1′H)-one (intermediate 8)
  • To a stirred solution of Example 78 (5 g, 1.61 mmol) and triethylamine (1.95 g, 1.93 mmol) in dichloromethane (200 mL) at 0 to 5° C. was added a solution of methanesulphonyl chloride (2.21 g, 1.93 mmol) in dichloromethane (10 mL). The reaction mixture was stirred at 20 to 25° C. for 5 hours. The mixture was washed with water (2×100 mL) and the organic phase was dried over magnesium sulphate. Filtration and concentration in vacuo at 40° C. afforded intermediate 8 as an off-white solid (5.4 g, 1.39 mmol, 86%). [1066]
  • [1067] 1H NMR [CDCl3] δ7.13 (d, J=9.1 Hz, 1′H, 6.99 (s, 1H, 6.38 (d, J=9.1 Hz, 1H), 5.60 (s, 1H), 4.53 (m, 2H), 4.20 (m, 2H), 3.00 (s, 3H), 2.47 (td, J=13.6, 4.5 Hz, 2H), 1.59-1.78 (m, 5H), 1.48 (m, 2H), 1.28 (m, 1H).
  • Preparation of Example 69
  • Intermediate 8 (1.0 g, 2.57 mmol) was stirred with a solution of ammonia in ethanol (40 mL) at 70° C. in a sealed pressure vessel for 21 hours. The ethanol was removed by evaporation in vacuo at 40° C. to leave a fawn coloured solid residue (0.81 g). 2N-Hydrochloric acid (40 mL) was added (no dissolution occurred), the acidic aqueous suspension was treated with 2N-sodium hydroxide to pH 12. The aqueous mixture was extracted twice with ethyl acetate containing 10% methanol (45 mL and 80 mL). The combined ethyl acetate was washed once with water (50 mL), dried over magnesium sulphate, filtered and concentrated in vacuo at 40° C. to low volume (10 mL). An off-white solid was filtered off and washed with ethyl acetate (5 mL). The crude amine was purified by column chromatography (silica 20 g, eluting with 20% methanol in dichloromethane) to yield the title compound as an off-white solid after drying in vacuo at 50° C. (0.30 g, 0.97 mmol, 38%) (purity 98.7%). [1068]
  • [1069] 1H NMR [(CD3)2SO] δ7.80 (br s, 1H), 7.10 (d, J=8.8 Hz, 1H), 6.90 (s, 1H), 6.48 (d, J=8.8 Hz, 1H), 3.78 (t, J=5.6, 2H), 2.78 (t, J=5.6, 2H), 2.40 (m, 2H), 1.65 (m, 2H), 1.25 to 1.51 (m, 7H), 1.01 (m, 1H;
  • Example 70 8′-Chloro-5′-[2-(methylamino)ethoxy]-spiro[cyclohexane-1-4′-(3′,4′-dihydro)quinazolin]-2′ (1′H)-one Formula (I): X1=C—OCH2CH2NHCH3, X2=CH, X3=CH, X4=C—Cl, A═cyclohexyl, X=NH, Z=O, Y=NH
  • Intermediate 8 (0.4 g, 1.03 mmol) was stirred with a solution of methylamine in ethanol (27 mL) at 700° C. for 7 hours. The ethanol was removed by evaporation in vacuo at 40° C. and the residue was partitioned between water (25 mL) and ethyl acetate (50 mL), adding 2M-sodium hydroxide (2 mL) to ensure the pH was ≧12. The ethyl acetate was washed once with water (15 mL), dried over magnesium sulphate and concentrated in vacuo at 40° C. to give a pink solid residue. The crude amine was purified by column chromatography (silica 20 g, eluting with 4% triethylamine and 16% methanol in ethyl acetate) to yield the title compound (0.23 g, 0.71 mmol, 69%) as an off-white solid after drying in vacuo at 50° C. (purity 99%) [1070]
  • [1071] 1H NMR (d6 DMSO) δ1.21 (m, 1H), 1.54 (m, 2H), 1.68 (m, 3H), 1.85 (m, 2H), 2.41 (s, 3H), 2.58 (m, 2H), 2.95 (t, J=5.7 Hz, 2H), 4.08 (t, J=5.7 Hz, 2H), 6.70 (d, J=8.9 Hz, 1H), 7.12 (s, 1H), 7.31 (d, J=8.9 Hz, 1H), 8.02 (s, 1H).
  • Example 71 8′-Chloro-5′-[2-(2-aminoethoxy)ethoxy]spiro[cyclohexane-1-4′-(3′,4′-dihydro)quinazolin]-2′(1′H)-one Formula (I): X1═C—OCH2CH2OCH2CH2NH2, X2═CH, X3═CH, X4═C—Cl, A═cyclohexyl, X=NH, Z=O, Y=NH
  • To a stirred solution of Example 63 (1.07 g, 4.0 mmol) in DMF (20 mL) at room temperature was added potassium carbonate (1.22 g, 8.8 mmol) and 2-[2-(2-chloroethoxy)ethyl]-1H-isoindole-1,3(2H)-dione (1.22 g, 4.8 mmol). The mixture was heated at 100° C. for 8 hours. More potassium carbonate (1.22 g) and 2-[2-(2-chloroethoxy)ethyl]-1H-isoindole-1,3(2H)-dione (1.22 g) were added and the stirred mixture was heated at 100° C. for a further 9 hours. After cooling to 18 to 20° C. the reaction mixture was added to water (200 mL). The resulting solid was filtered and washed with water (50 mL). The solid was purified by column chromatography (silica 50 g, eluting with 5% methanol in dichloromethane) to yield the phthalimide intermediate (1.0 g, 2.06 mmol, 52%) as a pink glassy solid. To a stirred suspension of the phthalimide intermediate (0.9 g, 1.86 mmol) in ethanol (23 mL) was added hydrazine hydrate (0.28 mL, 5.64 mmol). The mixture was heated at 60° C. for 4 hours. 2M-Hydrochloric acid (36 mL) was added and the reaction was heated at reflux for 1.25 hours. Cooling to 18 to 20° C. afforded a solid that was isolated by filtration and washed with water (10 mL). The pH of the filtrate was adjusted to 14 by the addition of 2M-sodium hydroxide (2 mL), the crude amine precipitated and was filtered and washed with water (10 mL) and TBME (10 mL). The amine was purified by column chromatography (silica 20 g, eluting with 4% triethylamine and 16% methanol in ethyl acetate) to yield the title compound (0.43 g, 1.21 mmol, 65%) as a white solid after drying in vacuo at 50° C. (purity 98%) [1072]
  • [1073] 1H NMR (360 MHz, d6 DMSO) δ1.40 (m, 1H), 1.65 (m, 2H), 1.75 (m, 3H), 2.00 (m, 2H), 2.77 (m, 2H), 2.87 (t, J=5.9 Hz, 2H), 3.65 (t, J=5.9 Hz, 2H), 3.95 (m, 2H), 4.29 (m, 2H), 6.81 (d, J=9.0 Hz, 1H, 7.22 (s, 1H), 7.44 (d, J=9.0 Hz, 1H), 8.13 (s,1H.
  • Example 72 8′-Chloro-5′-[3-dimethylaminopropoxy]spiro[cyclohexane-1-4′-(3′,4′-dihydro)quinazolin]-2′(1′H)-one Formula (I): X1═C=OCH2CH2CH2N(CH3)2, X2═CH, X3═CH, X4═C—Cl, A═cyclohexyl, X═NH, Z═O, Y═NH
  • To a stirred solution of Example 63 (1.5g, 5.63mmol) in DMF (20 mL) at 18 to 20° C. was added a solution of potassium carbonate (2M, 9.42 mL, 18.84 mmol) followed by 3-dimethyl-aminopropyl chloride hydrochloride (1.02 g, 6.45 mmol). The mixture was heated to 100° C. for 18 h. It was then added to water (400 mL) and extracted with EtOAc (2×400 mL). The combined organic layer was back washed with water (300 mL) and separated. Dried with MgSO[1074] 4, concentrated in vacuo at 40° C. to give crude material (1.27 g, 3.61 mmol). The crude product was purified by charcoal (1 g) treatment in DCM (120 mL) and column chromatography (silica; gradient elution, 100% EtOAc to 50% in DCM to EtOAc:DCM:MeOH; 2:10:1) to yield the desired product as an off white solid (305 mg, 0.87 mmol, 15%) (purity 99%)
  • [1075] 1H NMR (360 MHz, d6-DMSO) δ1.40-1.53 (m, 1H), 1.65-1.78 (m, 2H), 1.85-2.0 (m, 5H), 2.2 (m, J=7.3, 6.3 Hz, 2H), 2.45 (s, 6H), 2.67 (t, J=7.3 Hz, 2H), 2.7 (ddd, J=4.6, 13.6 & 13.6 Hz, 2H), 4.22 (t, J=6.3 Hz, 2H), 5.71-5.75 (br s, 1H), 6.68 (d, J=9.1 Hz, 1H, 7.16-7.20 (br s, 1H, 7.35 (d, J=9.1 Hz, 1H.
  • Example 73 8′-Chloro-5′-ethoxycarbonylmethoxyspiro[cyclohexane-1-4′-(3′,4′-dihydro)quinazolin]-2′(1′H)-one Formula (I): X1═C—OCH2CO2CH2CH3, X2═CH, X3═CH, X4═C-Cl, A═cyclohexyl, X═NH, Z═O, Y═NH
  • The title compound was prepared according to protocol L. To a stirred solution of Example 63 (0.5 g, 1.96 mmol) in DMF (10 mL) at 18 to 20° C. was added potassium carbonate (0.6 g, 4.31 mmol) and ethyl bromoacetate (0.36 g, 2.16 mmol). The mixture was heated at 100° C. for 1.5 hours, cooled to room temperature and then added to water (100 mL). The resulting solid was filtered and washed with water (50 mL) and heptane (20 mL). Drying in vacuo at 50° C. afforded the title compound (0.6 g, 1.7 mmol, 87%) as an off-white solid. [1076]
  • [1077] 1H NMR (360 MHz, CDCl3) δ7.2 (d, J=9.1 Hz, 1H), 7.03 (s, 1H), 6.37 (d, J=9.1 Hz, 1H, 5.60 (s, 1H, 4.64 (s, 2H), 4.30 (q, J=7.3 Hz, 2H), 2.70 (td, J=13.2, 4.1 Hz, 2H), 1.80 (m, 4H), 1.55 (m, 3H), 1.45 (m, 1H, 1.35 (t, J=7.3 Hz, 3H).
  • Example 74 5′-Carboxymethoxy-8′-chloro-spiro[cyclohexane-1-4′-(3′,4′-dihydro)quinazolin]-2′(1′H)-one Formula (I): X1═C—OCH2CO2H, X2═CH, X3═CH, X4═C—Cl, A═cyclohexyl, X═NH, Z═O, Y═NH
  • A solution of potassium hydroxide (0.32 g, 5.65 mmol) in water (1.1 mL) was added to a stirred suspension of the crude Example 73 (0.4 g, 1.13 mmol) in THF (30 mL) at room temperature. The mixture was stirred for 24 hours before the THF was removed by evaporation in vacuo at 400° C. Water (20 mL) was added to the residue and the mixture was washed once with ethyl acetate (10 mL). The aqueous solution was acidified to pH 1 with concentrated hydrochloric acid to afford an off-white solid. The solid was filtered and washed with water (10 mL) and heptane (5 mL). The solid was purified by column chromatography (silica 10 g, eluting with 10% acetic acid in ethyl acetate) to yield the title (0.15 g, 0.46 mmol, 41%) as an off-white solid after drying in vacuo at 50° C. (purity 98.9%) mp=284-286° C. [1078]
  • [1079] 1H NMR [(CD3)2SO]δ13.05 (br s, 1H), 7.95 (br s, 1H), 7.24 (d, J=9.0 Hz, 1H), 6.99 (br s, 1H, NH), 6.54 (d, J=9.0 Hz, 1H, 4.69 (s, 2H), 2.61 (m, 2H), 1.77 (m, 2H), 1.55 (m, 3H), 1.45 (m, 2H), 1.30 (m, 1H.
  • Example 75 5′-Carboxypropoxy-8′-chloro-spiro[cyclohexane-1-4′-(3′,4′-dihydro)quinazolin]-2′(1′H)-one Formula (I): X1, ═C—OCH2CH2CH2CO2H, X2═CH, X3═CH, X4═C—Cl, A═cyclohexyl, X═NH, Z═O, Y═NH
  • To a stirred solution of Example 63 (1.07 g, 4 mmol) in DMF (20 mL) at 18 to 20° C. was added potassium carbonate (1.22 g, 8.8 mmol) and ethyl 4-bromobutyrate (0.82 g, 4.2 mmol). The mixture was heated at 100° C. for 2 hours, cooled to room temperature and added to water (200 mL). The mixture was extracted with ethyl acetate (2×200 mL). The combined extracts were washed with water (100 mL), dried over magnesium sulfate and evaporated in vacuo at 50° C. to afford a solid residue. Trituration of the residue with heptane (10 mL) afforded the intermediate ethyl ester (1.27 g, 3.33 mmol, 84%) as a pink solid after drying in vacuo at 50° C. [1080]
  • [1081] H NMR (360 MHz, CDCl3) δ1.11 (t+m, 4H), 1.38 (m, 2H), 1.58 (m, 5H), 2.01 (m, 2H), 2.38 (m, 4H), 3.87 (t, J=5.7 Hz, 2H), 4.01 (q, J=6.3 Hz, 2H), 5.46 (s, 1H, 6.32 (d, J=8.1 Hz, 1H, 6.87 (s, 1H, 7.02 (d, J=8.1 Hz, 1H.
  • 6N-Hydrochloric acid (10 mL) was added to a stirred suspension of the ethyl ester (0.9 g, 2.36 mmol) in dioxane (6 mL) at 18 to 20° C. The mixture was stirred under reflux for 2.5 hours. After cooling to 18 to 20° C. the solid was filtered and washed with water (50 mL) and TBME (5 mL). The solid was triturated with TBME (30 mL) to afford the title compound (0.64 g, 1.79 mmol, 76%) as an off-white solid after drying in vacuo at 50° C. (purity 98%). [1082]
  • [1083] 1H NMR (360 MHz, d6 DMSO) δ1.03 (m, 1H), 1.34 (m, 2H), 1.47 (m, 3H), 1.68 (m, 2H), 1.80 (m, 2H), 2.30 (m, 4H), 3.87 (t, J=6.3 Hz, 2H), 6.40 (d, J=9.0 Hz, 1H), 6.90 (s, 1H), 7.11 (d, J=9.0 Hz, 1H), 7.80 (s, 1H), 12.05 (br s, 1H).
  • Example 76 8′-Chloro-5′-(3-sulphopropoxy)-spiro[cyclohexane-1-4′-(3′,4′-dihydro)quinazolin]-2′(1′H)-one Formula (I): X1═C—OCH2CH2CH2SO3H, X2═CH, X3═CH, X4═C—Cl, A═cyclohexyl, X═NH, Z═O, Y═NH
  • The title compound was prepared according to protocol L. To a stirred solution of Example 63 (1 g, 3.93 mmol) in DMF (20 mL) at 18 to 20° C. was added potassium carbonate (1.19 g, 8.65 mmol) followed by sodium 3-bromopropanesulphonate (0.97 g, 4.32 mmol). The mixture was heated at 100° C. for 6 hours, cooled to room temperature and then added to water (300 mL). The resulting solution was acidified to pH 1 with concentrated hydrochloric acid. The aqueous mixture was washed with ethyl acetate (200 mL) and evaporated in vacuo to dryness at 70° C. The residue was treated with TBME (200 mL) and a small amount of white solid was filtered and discarded. Decanting away the TBME from the filtrate isolated a pale yellow insoluble oil. Remaining DMF was removed from the oil by further evaporation in vacuo at 70° C. The resulting gum was triturated with acetonitrile (10 mL) to yield the title compound (0.11 g, 0.28 mmol, 7%) as a white solid after drying in vacuo at 50° C. (purity=99.7%) [1084]
  • [1085] 1H NMR (360 MHz, (CD3)2SO) δ8.27 (br s, 1H, 7.95 (s, 1H, 7.25 (d, J=8.6 Hz, 1H), 7.04 (s, 1H), 6.63 (d, J=8.6 Hz, 1H), 4.09 (t, J=6.5 Hz, 2H), 2.64 (t, J=7.5 Hz, 2H), 2.58 (m, 2H), 2.08 (m, 2H), 1.80 (br m, 2H), 1.60 (br m, 3H), 1.38 (br d, J=12.6 Hz, 2H), 1.22 (m, 1H).
  • Example 77 8′-Chloro-5′-[2-(tetrahydro-pyran-2-yloxy)-ethoxy]-spiro[cyclohexane-1-4′-(3′,4′-dihydro)quinazolin]-2′(1′H)-one Formula (I): X1═C—OCH2CH2O-(tetrahydro-pyran-2-yl), X2═CH, X3═CH, X4═C—Cl, A═cyclohexyl, X═NH, Z═O, Y═NH
  • The title compound was prepared according to protocol L. To a stirred solution of Example 63 (0.5 g, 1.96 mmol) in DMF (10 mL) at 18 to 20° C. was added potassium carbonate (0.6 g, 4.31 mmol) followed by 2-(2-bromoethoxy)tetrahydro-2H-pyran (0.45 g, 2.16 mmol). The mixture was heated at 100° C. for 3.2 hours, cooled to room temperature and then added to water (100 mL). The resulting solid was filtered and washed with water (50 mL) followed by heptane (20 mL). Drying in vacuo at 50° C. afforded the title compound (0.69 g, 1.75 mmol, 90%) as an off-white solid. [1086]
  • [1087] 1H NMR (360 MHz, (CD3)2SO ) δ7.94 (s, 1H, 7.21 (d, J=8.9 Hz, 1H, 6.99 (s, 1H, 6.59 (d, J=8.9 Hz, 1H, 4.68 (m, 1H), 4.08 (m, 2H), 3.92 (m, 1H, 3.70 (m, 2H), 3.41 (m, 1H), 2.56 (td, J=13.6, 4.1 Hz, 2H), 1.33-1.84 (m, 13H), 1.19 (m, 1H),
  • Example 78 8′-Chloro-5′-(2-hydroxy-ethoxy)-spiro[cyclohexane-1-4′-(3′,4′-dihydro)quinazolin]-2′(1′H)-one Formula (I): X1═C—OCH2CH2OH, X2+CH, X3═CH, X4═C—Cl, A+cyclohexyl, X=NH, Z═O, Y═NH
  • Example 77 (0.69 g, 1.75 mmol) was stirred in a mixture of THF (20 mL) and water (4 mL). Concentrated hydrochloric acid (0.4 mL) was added and the mixture was stirred at room temperature for 24 h then heated under reflux for 2 hours. The THF was removed by evaporation in vacuo at 40° C. and the residue was partitioned between water (25 mL) and ethyl acetate (40 mL). The aqueous phase was separated and extracted with ethyl acetate (20 mL). The combined extracts were washed with water (20 mL), dried over MgSO[1088] 4 and concentration in vacuo at 40° C. afforded the title compound (0.32 g, 1.03 mmol, 59%) as a cream solid after drying in vacuo at 50° C. (purity=95.7%) mp=176-178° C.
  • [1089] 1H NMR [(CD3)2SO]δ7.89 (br s, 1H), 7.23 (d, J=9.0 Hz, 1H), 6.98 (br s, 1H, NH), 6.63 (d, J=9.0 Hz, 1H, 4.81 (t, J=5 Hz, 2H), 4.00 (t, J=5 Hz, 2H), 3.76 (q, J=5 Hz, 2H), 2.58 (m, 2H), 1.77 (m, 2H), 1.53 (m, 3H), 1.45 (m, 2H), 1.30 (m, 1H.
  • Example 79 8′-Chloro-5′-(5-ethoxycarbonyl-furan-2-ylmethoxy)-spiro[cyclohexane-1-4′-(3′,4′-dihydro)quinazolin]-2′(1′H)-one Formula (I): X1═C—OCH2-(5-ethoxycarbonyl-furan-2-yl), X2═CH, X3═CH, X4═C—Cl, A═cyclohexyl, X═NH, Z═O, Y═NH
  • The title compound was prepared according to protocol L. To a stirred solution of Example 63 (0.5 g, 1.87 mmol) and sodium iodide (0.14 g, 1.87 mmol) in DMF (10 mL) at 18 to 20° C. was added potassium carbonate (0.258 g, 0.95 mmol) and 5-Chloromethyl-furan-2-carboxylic acid ethyl ester (0.29 mL, 1.87 mmol). The mixture was stirred at room temperature for 2 h. After completion, the solvent was removed under reduced pressure and a mixture of water and EtOAc was added. The layer were separated, the aqueous one being extrated three times with EtOAc. The combined organic layers were washed with brine, dried over Na[1090] 2SO4, filtered and concentrated. The solid was purified by column chromatography (silica 10 g, eluting with CH2Cl2/MeOH: 99/1 to 98/2) to yield the title compound (0.75 g, 96%) as a white solid after drying in vacuo at 50° C.
  • [1091] 1H NMR [(CD3)2SO]δ7.98 (br s, 1 H, NH), 7.30-7.28 (m, 2H), 7.01 (br s, 1H, NH), 6.80-6.76 (m, 2H), 5.2 (s, 2H), 4.28 (q, J=7.0 Hz, 2H), 2.43-2.4 (m, 2H), 1.75-1.72 (m, 2H), 1.56-1.53 (m, 3H), 1.40 (m, 2H), 1.28 (t, J=7.0 Hz, 3H), 0.97 (m, 1H),
  • Example 80
  • 8′-Chloro-5′-(5-carboxy-furan-2-ylmethoxy)-spiro[cyclohexane-1-4′-(3′, 4′-dihydro)quinazolin]-2′(1′H)-one [1092]
  • Formula (I): X1=C—OCH2-(5-carboxy-furan-2-yl), X2=CH, X3=CH, X4=C—Cl, A═cyclohexyl, X=NH, Z=O, Y=NH
  • A solution of lithium hydroxide monohydrate (0.85 g, 20 mmol) in water (1.35 mL), EtOH (11 mL) and MeOH (67 mL) was added to a stirred suspension of the crude Example 79 (0.6 g, 1.43 mmol) in CH[1093] 2Cl2 (17 mL) at room temperature. The mixture was stirred for 48 h before the solvents were removed by evaporation in vacuo at 40° C. Water was added to the residue and the mixture was acidified with concentrated aqueous HCl and extracted with CH2Cl2. The combined organic layers were dried over Na2SO4, filtered and concentrated. The solid was purified by column chromatography (silica 5 g, eluting with CH2Cl2/MeOH: 70/30) to yield the title compound (0.05 g, 9%) as a white solid after drying in vacuo at 50° C. (purity 98%)
  • [1094] 1H NMR [(CD3)2SO]δ13.10 (s, 1H, 7.96 (br s, 1 H, NH), 7.29 (d, J=9.1 Hz, 1H), 7.12 (br s, 1H, NH), 6.99 (s, 1H), 6.79 (d, J=9.1 Hz, 1H), 6.70 (br s , 1H), 5.15 (s, 2H), 2.43-2.40 (m, 2H), 1.70 (m, 2H), 1.55-1.52 (m, 3H), 1.40 (m, 2H), 0.98-1.00 (m, 1H.
  • Example 81 8′-Chloro-5′-cyanomethoxyspiro[cyclohexane-1-4′-(3′,4′-dihydro)quinazolin]-2′(1′H)-one Formula (I): X1═C—OCH2CN, X2═CH, X3═CH, X4═C—Cl, A═cyclohexyl, X═NH, Z═O, Y═NH
  • The title compound was prepared according to protocol L. To a stirred solution of Example 63 (2 g, 7.85 mmol) in DMF (30 mL) at 18 to 20° C. was added potassium carbonate (2.39 g, 17.3 mmol) followed by bromoacetonitrile (1.04 g, 8.64 mmol). The mixture was heated at 100° C. for 2 hours, cooled to 18 to 20° C. and added to water (300 mL). The resulting solid was filtered and washed with water (60 mL). Drying in vacuo at 50° C. afforded crude title compound (2.35 g). The crude product was purified by column chromatography (silica 70 g eluting with 10% methanol in dichloromethane) to yield title compound (1.72 g, 5.6 mmol, 72%) as a fawn solid after drying in vacuo at 50° C. (purity =97%) mp=193-195° C. [1095]
  • [1096] 1H NMR [(CD3)2SO]δ8.12 (br s, 1H), 7.36 (d, J=9.0 Hz, 1H), 7.07 (br s, 1H, NH), 6.75 (d, J=9.0 Hz, 1H, 5.24 (s, 2H), 2.34 (m, 2H), 1.80 (m, 2H), 1.63 (m, 3H), 1.47 (m, 2H), 1.20 (m, 1H).
  • Example 82 8′-Chloro-5′-(1H-tetrazol-5-ylmethoxy)-spiro[cyclohexane-1-4′-(3′,4′-dihydro)quinazolin]-2′(1′H)-one Formula (I): X1═C—OCH2-(1H-tetrazol-5-yl), X2═CH, X3═CH, X4═C—Cl, A═cyclohexyl, X═NH, Z═O, Y═NH
  • Example 81 (0.05 g, 0.16 mmol), trimethyltin azide (0.05 mL, 0.179 mmol) and toluene (2 mL) were mixed and refluxed under nitrogen for 15 h. 10M NaOH (0.02 mL, 0.2 mmol) was added and the mixture was stirred at room temperature overnight. The upper layer was removed, hexane was added to the residue, the resulting mixture was stirred for 30 min, hexane was removed. This operation was repeated three times, and EtOAc was added, the precipitate was filtered and washed with EtOAc. The residue was taken into CH[1097] 2Cl2 and 1 M HCl (1 mL, 1 mmol) and concentrated under reduced pressure. The precipitate was washed successively with water and MeOH to give the title compound (0.04 g, 71%) as a white powder (purity=98.1%) mp=287-289° C.
  • [1098] 1H NMR [(CD3)2SO]δ8.02 (br s, 1H), 7.34 (d, J=8.9 Hz, 1H), 7.01 (br s, 1H), 6.82 (d, J=8.9 Hz, 1H, 5.47 (s, 2H), 2.35 (m, 2H), 1.73 (m, 2H), 1.50 (m, 3H), 1.36 (m, 2H), 0.88 (m, 1H.
  • Example 83 8′-Chloro-5′-(5-hydroxy-[1,2,4]oxadiazol-3-ylmethoxy)-spiro[cyclohexane-1-4′-(3′,4′-dihydro) quinazolin]-2′(1′H)-one Formula (I): X1═COCH2-(5-hydroxy-[1,2,4]oxadiazol-3-yl), X2═CH, X3═CH, X4═C—Cl, A═cyclohexyl, X═NH, Z═O, Y═NH Preparation of 8′-chloro-5′-(N-hydroxycarbamimidoylmethoxy)-spiro[cyclohexane-1-4′-(3′,4′-dihydro)quinazolin]-2′(1′H)-one (Intermediate 9)
  • To a mixture of Example 81 (0.6 g, 1.96 mmol) and hydroxylamine hydrochloride (0.186 g, 2.94 mmol) in ethanol (7 mL) was added sodium hydroxyde (0.114 g, 2.85 mmol) dissolved in the minimum of water. The reaction mixture was heated to reflux for 24 h with stirring. After cooling, the solvent was concentrated under reduced pressure. The residue was taken into CH[1099] 2Cl2, the precipitate was filtered, washed with CH2Cl2 and dried under vacuum at 45° C. to afford intermediate 9 in a quantitative yield.
  • [1100] 1H NMR [(CD3)2SO]δ9.34 (br s, 1H, OH), 7.94 (br s, 1H, NH), 7.73 (d, J=9.0 Hz, 1H, 6.98 (br s, 1H, NH), 6.70 (d, J=9.0 Hz, 1H, 5.61 (s, 2H), 4.40 (br s, 2H, NH2), 2.58-2.54 (m, 2H), 1.83-1.72 (m, 2H), 1.62-1.53 (m, 3H), 1.46 (m, 2H), 1.24-1.07 (m, 1H.
  • Preparation of Example 83
  • To a mixture of intermediate 9 (0.3 g, 0.885 mmol) and ethyl chloroformate (0.13 mL, 1.3 mmol) in anhydrous CHCl[1101] 3 (4 mL) was added triethylamine (0.22 mL, 1.6 mmol). The reaction mixture was stirred at room temperature for 5 h. After completion, the precipitate was filtered to afford the (ethoxycarbonyl)oxy]amino intermediate (0.275 mg, 76%), which was used directly in the next step without further purification.
  • [1102] 1H NMR [(CD3)2SO]δ7.98 (br s, 1H, NH), 7.30 (d, J=9.0 Hz, 1H), 6.98 (br s, 1H, NH), 6.78 (br s, 2H, NH2), 6.70 (d, J=9.0 Hz, 1H, 4.48 (s, 2H), 4.20 (q, J=7.7 Hz, 2H), 2.58-2.54 (m, 2H), 1.83-1.72 (m, 2H), 1.62-1.53 (m, 3H), 1.46 (m, 2H), 1.28-1.20 (m, 1H, 1.23(t, J=7.7 Hz, 3H).
  • A mixture [(ethoxycarbonyl)oxy]amino intermediate (0.275 g, 0.67 mmol) and 1,8-diazabicyclo[5,4,0] undec-7-ene (0.4 mL, 2.67 mmol) in CH[1103] 3CN (4 mL) was refluxed for 24 h with stirring. The reaction mixture was concentrated under reduced pressure and taken into a mixture of CH2Cl2 and aqueous 1M HCl. The layers were separated and the aqueous one being extracted three times with CH2Cl2. The combined organic layers were dried over Na2SO4, filtered and concentrated to yield the title compound (0.17 g, 70%) as a white solid after drying in vacuo at 50° C.
  • [1104] 1 H NMR [(CD3)2SO]δ12.86 (br s, 1H, 8.04 (br s, 1H, 7.32 (d, J=9.0 Hz, 1H), 7.03 (br s, 1H, 6.72 (d, J=9.0 Hz, 1H, 5.07 (s, 2H), 2.42-2.36 (m, 2H), 1.78-1.74 (m, 2H), 1.59-1.56 (m, 3H), 1.44 (m, 2H), 1.11 (m, 1H.
  • Example 84 8′-Chloro-6′-iodo-5′-[2-dimethylamino-ethoxy]spiro[cyclohexane-1-4′-(3′, 4′-dihydro)quinazolin]-2′(1′H)-one Formula (I): X1═C—OCH2CH2N(CH3)2, X2═C—l, X3═CH , X4=C—Cl, A═cyclohexyl, X═NH, Z═O, Y═NH
  • The title compound was prepared according to protocol L. To a stirred solution of Example 68 (1.5 g, 4.44 mmol) in trifluoroacetic acid (15 mL) were subsequently added N-iodosuccinimide (1.1 g, 4.89 mmol, 1.1 equiv.) and sulfuric acid (4 mL). The resulting solution was stirred for 4 h, and then ethyl acetate and water were added. The organic layer was separated. The aqueous layer was twice washed with ethyl, basified to pH 9 with 30% aqueous sodium hydroxide then extracted three times with ethyl acetate. The combined organic extracts were washed with water, brine and concentrated under reduced pressure to give 1.95 g (95%) of the title compound as a white solid. (purity 99%) [1105]
  • [1106] 1H NMR (CDCl3) δ7.71 (s, 1H), 7.06 (br s, 1H), 5.43 (br s, 1H), 4.06 (t, J=6.0 Hz, 2H), 2.82 (t, J=6.0 Hz, 2H), 2.36 (s, 6H), 2.34 (m, 2H), 1.93 (m, 2H), 1.80-1.71 (m, 3H), 1.59-1.50 (m, 2H), 1.33 (m, 1H.
  • Example 85 6′-(4-Carboxyphenyl)-8′-chloro-5′-methoxyspiro[cyclohexane-1-4′-(3′,4′-dihydro)quinazolin]-2′(1′H)-one Formula (I): X1═C—OCH3, X2═C-(4-carboxyphenyl), X3═CH , X4═C—Cl, A═cyclohexyl, X═NH, Z═O, Y═NH
  • The title compound was prepared according to protocol G. To a stirred solution of Example 65 (7 g, 17.2 mmol) in DMF (84 mL) at 18 to 20° C. was added a solution of 4-carboxyphenyl-boronic acid (343 mg, 20.64 mmol) and potassium carbonate (2M, 34 mL, 68 mmol) under N2. After degassing the mixture by bubbling with N2 for 2 h, tetrakis (triphenylphosphine) palladium (1.33 g, 1.147 mmol) was added. The solution was heated to 100° C. for 18 h. It was then added to water (1L) and EtOAc (1L). The desired product was precipitated and collected by filtration to give the crude product (3.5 g, 51%). The aqueous filtrate was separated and acidified to pH 1 with concentrated HCl (20 mL). The white solid was collected by filtration (2.7 g, 39%). The crude products were combined and purified by column chromatography (silica 80 g; gradient elution, 20% DCM in EtOAc to 50% DCM in MeOH) to give the title compound (1.77 g, 4.41 mmol, 18%) as an off-white solid. (purity =99.4%) mp=309-311° C. [1107]
  • [1108] 1H NMR [(CD3)2SO]δ8 8.27 (s, 1H, 7.98 (d, J=8.0 Hz, 2H), 7.50 (d, J=8.0 Hz, 2H), 7.29 (s, 1H), 6.98 (s, 1H), 3.18 (s, 3H), 2.25 (m, 2H), 1.80 (m, 4H), 1.61 (m, 1H), 1.48 (m, 2H), 1.19 (m, 1H).
  • Example 86 6′-(3-Carboxyphenyl)-8′-chloro-5′-methoxyspiro[cyclohexane-1 4′-(3′,4′-dihydro)quinazolin]-2′(1′H)-one Formula (I): X1═C—OCH3, X2═C-(3-carboxyphenyl), X3═CH , X4═C—Cl, A═cyclohexyl, X═NH, Z═O, Y═NH
  • The title compound was prepared according to protocol G. To a stirred solution of Example 65 (1.75 g, 4.30 mmol) in DMF (30 mL) at 18 to 20° C. was added a solution of 3-carboxyphenyl-boronic acid (0.86 g, 5.18 mmol) and potassium carbonate (2M, 8.5 mL, 17 mmol) under N2. The mixture was degassed by bubbling N2 for 2 h and tetrakis(triphenylphosphine)palladium (331 mg, 0.286 mmol) was added. The solution was heated to 100° C. for 24 h and allowed to cool to 18 to 20° C. The reaction mixture was added to water (200 mL) and EtOAc (300 mL). The desired product was precipitated and collected by filtration, dried in vacuo at 40° C. to yield the title compound (567 mg, 1.42 mmol, 33%) as a light brown solid. (purity=96%) [1109]
  • [1110] 1H NMR ((CD3)2SO) δ13.06 (br s, 1H), 8.30 (br s, 1H, 8.04 (s, 1H), 7.94 (d, J=8.1 Hz, 1H), 7.74 (d, J=8.0 Hz, 1H), 7.58 (t, J=8.0 Hz, 1H), 7.34 (s, 1H), 7.01 (br s, 1H, 3.21 (s, 3H), 2.30 (m, 2H), 1.87-1.78 (m, 4H), 1.67-1.64 (m, 1H), 1.53-1.50 (m, 2H), 1.24 (m, 1H.
  • Example 87 8′-Chloro-6′-[2-(4-methyl-piperazine-1-carbonyl)phenyl]spiro[cyclohexane-1-4′-(3′,4′-dihydro)quinazolin]-2′(1′H)-one Formula (I): X1═CH, X2═C-(2-(4-methyl-piperazine-1-carbonyl)phenyl), X3═CH, X4═C—Cl, A═cyclohexyl, X═NH, Z═O, Y═NH Preparation of (2-bromo-phenyl)-(4-methyl-piperazin-1-yl)-methanone (intermediate 10)
  • To a solution of 2-bromobenzoyl chloride (2 g, 9 mmol) in toluene (30 mL) was added N-methylpiperazine (2 mL, 18 mmol, 2 equiv.). The resulting mixture was stirred overnight. The precipitate was filtered and the filtrate was concentrated under reduced pressure. The residue was taken into dichloromethane, washed with water. The organic layer was concentrated under reduced pressure to give 2 g (77% yield) of intermediate 10. [1111]
  • [1112] 1H NMR [CDCl3]δ7.60 (m, 1H), 7.35 (m, 1H), 7.20 (m, 2H), 3.90-3.80 (m, 2H), 3.40-3.20 (m, 2H), 2.60-2.40 (m, 3H), 2.30 (s, 3H), 2.30-2.25 (m, 1H).
  • Preparation of Example 87
  • To a suspension of Example 25 (200 mg, 0.5 mmol) in dimethylformamide (6 mL) were subsequently added sodium acetate (130 mg, 1.6 mmol, 3 equiv.) and bis(pinacolato)diboron (152 mg, 0.6 mmol). The mixture was degassed by bubbling nitrogen and tetrakis(triphenylphosphine)palladium (30 mg, 0.026 mmol, 0.05 equiv.) was added. The resulting mixture was heated to 45° C. overnight and to 90° C. for 2 h, concentrated under reduced pressure. The residue was taken into dichloromethane, washed once with water. The organic layer was dried over sodium sulfate, concentrated under reduced pressure and purified by flash chromatography on silica gel (heptane/ethyl acetate : 80/20), the resulting solid was hydrolized by hydrochloric acid (1 N) in methanol and concentrated under reduced pressure to give 400 mg (66% yield) of the boronic acid. To a suspension of the crude boronic acid (40 mg, 0.14 mmol) in dimethylformamide (2 mL) were subsequently added intermediate 10 (46 mg, 0.16 mmol, 1.2equiv.) and a 2M aqueous solution of potassium carbonate (0.2 mL, 0.4 mmol, 3equiv.). The mixture was degassed by bubbling nitrogen and tetrakis(triphenylphosphine)palladium (8 mg, 0.007 mmol, 0.05 equiv.) was added. After heating to 90° C. for 3 hours, the mixture was concentrated under reduced pressure, taken into ethyl acetate and washed with water. The organic layer was washed three times with HCl (1N). The aqueous layer was basified to pH 9 and extracted three times with dichlomethane. The organic layer was concentrated under reduced pressure, the resulting solid was crystallized in toluene/methanol to give 10 mg (16% yield) of the title compound as a white solid. mp=250° C. [1113]
  • [1114] 1H NMR [(CD3)2SO]δ8.58 (br s, 1H, NH), 7.50-7.49 (m, 2H), 7.43 (m, 1H), 7.33-7.28 (m, 3H), 7.18(brs, 1H, NH), 3.70 (m, 1H), 3.20 (m, 1H), 2.95 (m, 1H), 2.78 (m, 1H), 2.38 (m, 1H), 2.10 (m, 1H), 1.98 (s, 3H), 1.86-1.75 (m, 6H), 1.62-1.48 (m, 4H), 1.24-1.16 (m, 2H),
  • Example 88 8′-Chloro-6′-[2-methyl-4-(4-methyl-piperazine-1-carbonyl)phenyl]spiro[cyclohexane-1-4′-(3′,4′-dihydro)quinazolin]-2′(1′H)-one Formula (I): X1═CH, X2═C-(2-methyl-4-(4-methyl-piperazine-1-carbonyl)phenyl), X3═CH, X4═C—Cl, A═cyclohexyl, X═NH, Z═O, Y═NH Preparation of (4-Bromo-3-methyl-phenyl)-(4-methyl-piperazin-1-yl)-methanone (intermediate 11)
  • To a solution of 4-bromo-3-methylbenzoyl chloride (0.5 g, 2 mmol) in toluene (6 mL) was added N-methylpiperazine (0.5 mL, 4 mmol, 2 equiv.). The resulting mixture was stirred overnight, The precipitate was filtered and the filtrate was concentrated under reduced pressure. The residue was taken into ethyl acetate and washed with water. The organic layer was dried over sodium sulfate, concentrated under reduced pressure to give 0.2 g (34% yield) of intermediate [1115]
  • Preparation of Example 88
  • To a suspension of Example 25 (1 g, 2.5 mmol) in dimethylformamide (25 mL) were subsequently added sodium acetate (650 mg, 8 mmol, 3 equiv.) and bis(pinacolato)diboron (760 mg, 3 mmol, 1.2 equiv.). The mixture was degassed by bubbling nitrogen and tetrakis(triphenylphosphine) palladium (150 mg, 0.13 mmol, 0.05 equiv.) was added . The resulting mixture was heated to 45° C. overnight, then additional bis(pinacolato)diboron (635 mg, 2.5 mmol, 1 equiv.) and tetrakis(triphenylphosphine) palladium (100 mg, 0.087 mmol, 0.035 equiv.) was added. The mixture was heated to 90° C. overnight and concentrated under reduced pressure. The residue was taken into ethyl acetate, washed once with water. The organic layer was concentrated under reduced pressure and the resulting solid was washed with ethyl acetate to give 0.7 g (78% yield) of boronate. To a suspension of the boronate (200 mg, 0.5 mmol) in dimethylformamide (3 mL) were subsequently added intermediate 11 (200 mg, 0.7 mmol, 1.4 equiv.) and sodium acetate (123 mg, 1.5 mmol, 3 equiv.). The mixture was degassed by bulbbling nitrogen and tetrakis(triphenylphosphine)palladium (29 mg, 0.025 mmol, 0.05 equiv.) was added. After heating to 90° C. overnight, the mixture was concentrated under reduced pressure, taken into dichloromethane and washed with water. The organic layer was concentrated under reduced pressure and purified by flash chromatography on silica gel (dichloromethane/methanol : 97/3 to 95/5) and the resulting solid was crystallized in toluene/methanol to give 10 mg (6% yield) of the title compound as a white solid. mp=184 ° C. [1116]
  • [1117] 1H NMR [(CD3)2SO]δ8.50 (br s, 1H, NH), 7.30-7.23 (m, 5H), 7.15 (br s, 1H, NH), 3.60-3.37 (m, 4H), 2.33-2.27 (m, 7H), 2.20 (s, 3H), 1.78 (m, 6H), 1.62 (m, 1H), 1.5 (m, 2H), 1.24 (m, 1H).
  • Example 89 8′-Chloro-6′-[4-(piperazine-1-carbonyl)phenyl]spiro[cyclohexane-1-4′-(3′,4′-dihydro)quinazolin]-2′(1′H)-one Formula (I): X1═CH, X2═C-(4-(piperazine-1-carbonyl)phenyl), X3═CH, X4═C—Cl, A═cyclohexyl, X═NH, Z═O, Y═NH
  • To a suspension of Example 32 (400 mg, 1.08 mmol) in toluene (4 mL) was added thionyl chloride (0.2 mL, 2.16 mmol, 2 equiv.). The resulting mixture was heated to reflux for 3 h, then concentrated under reduced pressure taken into THF (8 mL). To a 0.135 M solution of the acyl chloride in THF (4 mL, 0.54 mmol) was added triethylamine (0.1 mL, 0.15 mmol, 3 equiv.) and piperazine (70 mg, 0.81 mmol, 1.5 equiv.). After stirring for 2 days, the mixture was concentrated, taken into dichloromethane, washed with water and extracted with a 1N aqueous solution of HCl. The aqueous layer was washed twice with dichloromethane, basified to pH 9 and extracted three times with dichloromethane. The combined organic extracts were concentrated under reduced pressure and purified by flash chromatography on silica gel (CH[1118] 2Cl2/MeOH: 99/1 to 95/5) to give 181 mg (75% yield) of the title compound as a white solid.
  • [1119] 1H NMR [(CD3)2SO]δ8.54 (br s, 1H, NH), 7.78 (d, J=8.5 Hz, 2H), 7.66 (s, 1H), 7.63 (s, 1H), 7.48 (d, J=8.0 Hz, 2H), 7.17 (br s, 1H, NH), 3.57 (br m, 4H), 2.96 (br m, 4H), 1.88-1.77 (m, 6H), 1.64 (m, 1H, 1.54 (m, 2H), 1.28 (m, 1H.
  • Example 90 8′-Chloro-6′-[4-carbamoyl-phenyl]spiro[cyclohexane-1-4′-(3′,4′-dihydro)quinazolin]-2′(1′H)-one Formula (I): X1═CH, X2═C-(4-carbamoyl-phenyl), X3═CH, X4═C—Cl, A═cyclohexyl, X═NH, Z═O, Y═NH
  • To a suspension of Example 32 (1 g, 2,7 mmol) in toluene (10 mL) was added thionyl chloride (0.4 mL, 5.4 mmol, 2equiv.). The resulting mixture was heated to reflux overnight. The precipitate was isolated by filtration, washed with toluene and dried under reduced pressure to give 0.9 g (90% yield) of the acyl chloride. To a suspension of the acyl chloride (100 mg, 0.25 mmol) in toluene (2 mL) was added a 0.5M solution of ammonia in dioxane (1 mL, 0.5 mmol, 2 equiv.). The mixture was stirred overnight and concentrated under reduced pressure. The residue was taken into dichloromethane and washed with water. The organic layer was concentrated under reduced pressure and the resulting solid was purified by flash chromatography on silica gel (dichloromethane/methanol : 97/3) to give 10 mg (66% yield) of the title compound as a white solid. mp=327° C. [1120]
  • [1121] 1H NMR [(CD3)2SO]δ8.55 (br s, 1H, NH), 8.02 (br s, 1H, NH), 7.95-7.93 (d, J=8.5 Hz, 2H), 7.80-7.77 (d, J=8.5 Hz, 2H), 7.69 (s, 1H), 7.63 (s, 1H), 7.36 (br s, 1H, NH), 7.17 (brs, 1H, NH), 1.92-1.77 (m, 6H), 1.66-1.63 (m, 1H), 1.55-1.53 (m, 2H), 1.32-1.23 (m, 1H,
  • Example 91 8′-Chloro-6′-[4-((1-methyl-piperidin-4-yl)-piperazine-1-carbonyl)phenyl]spiro[cyclohexane-1-4′-(3′,4′-dihydro)quinazolin]-2′(1′H)-one Formula (I): X1═CH, X2═C-(4-((1-methyl-piperidin-4-yl)-piperazine-1-carbonyl)phenyl), X3═CH, X4═C—Cl, A═cyclohexyl, X═NH, Z═O, Y═NH
  • To a suspension of Example 32 (150 mg, 0.4 mmol) in toluene (2 mL) was added thionyl chloride (0.06 mL, 0.8 mmol, 2 equiv.). The resulting mixture was heated to reflux for 3 hours, and then concentrated under reduced pressure. The resulting solid was added to a solution of 1-(N-methyl-piperidin-4-yl) piperazine (100 mg, 0.6 mmol, 1.5 equiv.) and triethylamine (0.1 mL, 0.8 mmol, 2 equiv.) in toluene (2 mL). After stirring overnight, the mixture was diluted with dichloromethane and washed with a satured solution of sodium bicarbonate. The organic layer was concentrated under reduced pressure. The resulting solid was washed with ethyl acetate/methanol and crystallized in ethyl acetate/methanol to give 70 mg (33% yield) of the title compound as a white solid. mp =181° C. [1122]
  • [1123] 1H NMR [(CD3)2SO]δ68.53 (br s, 1H, NH), 7.75 (d, J=8 Hz, 2H), 7.65 (s, 1H), 7.60 (s, 1H), 7.43 (d, J=8 Hz, 2H), 7.17 (br s, 1H, NH), 3.59-3.31 (br m, 7H), 2.78-2.75 (m, 2H), 2.16-2.12 (m, 4H), 1.88-1.29 (m, 17H).
  • Example 92 8′-Chloro-5′-methoxy-6′-[4-(4-methyl-piperazine-1-carbonyl)phenyl]spiro[cyclohexane-1-4′-(3′,4′-dihydro)quinazolin]-2′(1′H)-one Formula (I): X1═C—OCH3, X2═C-(4-(4-methyl-piperazine-1-carbonyl)phenyl), X3═CH, X4═C—Cl, A═cyclohexyl, X═NH, Z═O, Y═NH
  • To a stirred solution of Example 85 (1 g, 2.55 mmol) in DCM (15 mL) at 18 to 20° C. was added a solution of thionyl chloride (0.6 g, 5 mmol) and DMF (0.8 mL). The mixture was stirred at 18 to 20° C. for 2 h. The resulting mixture was concentrated in vacuo at 55° C. Toluene (10 mL) was added to the intermediate and concentrated in vacuo at 55° C. (This procedure was repeated to ensure all the unreacted thionyl chloride was removed.). The crude intermediate was dissolved in toluene (1 mL) and N-methyl piperazine (0.5 g, 5 mmol) was added. The reaction was stirred for 15 h at 18 to 20° C. and concentrated in vacuo at 55° C. The crude product was purified by column chromatography (silica 35 g; 60% EtOAc in MeOH) to yield title compound as a pale brown solid (170 mg, 0.35 mmol, 14%) (purity 95%). [1124]
  • [1125] 1H NMR [(CD3)2SO]δ1.25 (m, 1H), 1.54 (m, 2H), 1.68 (m, 1H), 1.83 (m, 4H), 2.22 (s, 3H), 2.32 (m, 6H), 3.25 (s, 3H), 3.36-3.40 (br s, 2H), 3.56-3.70 (br s, 2H), 7.05-7.09 (br s, 1H, 7.36 (s, 1H, 7.47 (d, J=8.3 Hz, 2H), 7.58 (d, J=8.3 Hz, 2H), 8.36-8.40 (br s, 1H.
  • Example 93 8-Chloro-5-methoxyspiro[4H-benzo[d][1,3]oxazin-2-ylamine-4-4′-(tetrahydro-pyran-4′-yl)] formula (III), X1═C—OCH3, X2═CH, X3═CH, X4═C—Cl, A=tetrahydro-pyran-4-yl, X=O, Z1=NH2, Y=N Preparation of N-(2-chloro-5-methoxy-phenyl)-2,2-dimethyl-propionamide (intermediate 12)
  • To a solution of 2-chloro-5-methoxyaniline hydrochloride (8 g, 41.1 mmol) and triethylamine (12.6 mL, 90.42 mmol) in CH[1126] 2Cl2 (200 mL) under nitrogen pivaloyl chloride (5.57 mL, 45.22 mmol) was added dropwise at 0° C. The reaction mixture was stirred at room temperature overnight. The mixture was poured into a saturated aqueous NaHCO3 solution and extracted with CH2Cl2. The organic extracts were washed with saturated aqueous NaCl solution, dried over Na2SO4, filtered and concentrated. The crude material was purified by flash chromatography on silica gel (cyclohexane/EtOAc: 98/2) to afford intermediate 12 as a pink oil (7.54 g, 76%).
  • [1127] 1H NMR [CDCl3]δ8.15 (d, J=3.0 Hz, 1H), 8.0 (br s, 1H), 7.17 (d, J=9.0 Hz, 1H), 6.57 (dd, J=9.0, 3.0 Hz, 1H), 3.79 (s, 3H), 1.33 (s, 9H).
  • Preparation of N-[6-chloro-2-(4-hydroxy-tetrahydro-pyran-4-yl)-3-methoxy-phenyl]-2,2-dimethyl-propionamide (Intermediate 13)
  • To a stirred solution of intermediate 12 (1 g, 4.13 mmol) in THF (25 mL) under nitrogen at −20° C. was added dropwise n-butyllithium (2.5M in hexane, 4.13 mL, 10.34 mmol). The reaction mixture was stirred at −10° C. for 4 h and n-butyllithium (2.5M in hexane, 4.13 mL, 10.34 mmol) was added dropwise at −10° C. The mixture was further stirred for 7 h and tetrahydropyran-4-one was added dropwise at 0° C. The mixture was stirred overnight at room temperature, poured into water and extracted with EtOAc. The organic extracts were washed with saturated aqueous NaCl solution, dried over Na[1128] 2SO4, filtered and concentrated. The crude material was purified by precipitation in EtOAc to afford intermediate 13 as a white powder (0.25 g, 18%).
  • [1129] 1H NMR [CDCl3]δ8.08 (br s, 1H, NH), 7.32 (d, J=8.5 Hz, 1H), 6.82 (d, J=8.5 Hz, 1H), 3.95 (t, J=11.5 Hz, 2H), 3.84 (s, 3H), 3.79 (m, 2H), 3.35 (m, 1H, OH), 2.86 (m, 1H, 2.33 (m, 1H, 1.84 (m, 2H), 1.33 (s, 9H).
  • Preparation of 6-chloro-2-(3,6-dihydro-2H-Pyran-4-yl)-3-methoxy-phenylamine (Intermediate 14)
  • A solution of intermediate 13 (0.365 g, 1.06 mmol) and potassium hydroxide (0.24 g, 4.27 mmol) in glycol (0.5 mL) was stirred at 100° C. overnight. The reaction mixture was poured into water and extracted three times with CH[1130] 2Cl2. The combined organic layers were washed with brine, dried over Na2SO4 and concentrated. The crude product was purified by flash column chromatography (eluent: cyclohexane/EtOAc: 90/10) to give title compound (0.187 g, 73%) as a white solid.
  • [1131] 1H NMR [CDCl3]δ7.09 (d, J=9.0 Hz, 1H, 6.24 (d, J=9.0 Hz, 1H, 5.71 (m, 1H), 4.29 (m, 2H), 4.20 (m, 2H), 3.92 (m, 2H), 3.73 (s, 3H), 2.29 (m, 2H).
  • Preparation of [6-chloro-2-(3.6-dihydro-2H-pyran-4-yl)-3-methoxy -phenyl]-urea (intermediate 15)
  • A solution of intermediate 14 (0.187 g, 0.78 mmol) and potassium cyanate (0.15 g, 1.95 mmol) in a mixture of acetic acid (5 mL) and water (0.5 mL) was stirred at room temperature overnight. The solvent was evaporated, and the residue taken into a mixture of CH[1132] 2Cl2 and an aqueous saturated solution of NaHCO3. The layers were separated, the aqueous one being extracted three times with CH2Cl2. The combined organic layers were washed with brine, dried over Na2SO4 and concentrated to give 0.15 g (68%) of crude intermediate 15.
  • [1133] 1H NMR [(CD3)2SO]δ7.51 (br s, 1H, 7.32 (d, J=8.5 Hz, 1H, 6.89 (d, J=8.5 Hz, 1H, 5.75 (br s, 2H), 5.49 (m, 1H, 4.12 (m, 2H), 3.74 (m, 5H), 2.16 (m, 2H).
  • Preparation of 8-chloro-5-methoxyspiro[4H-benzo[d][1,31oxazin-2-ylamine-4-4′-(3′-iodo-tetrahydro-pyran-4′-yl)](Intermediate 16)
  • A solution of iodine (0.23 g, 0.9 mmol) and sodium iodide (0.2 g, 1.35 mmol) in an aqueous solution of NaHCO[1134] 3 (10%) (3 mL) was added dropwise to a stirred solution of crude intermediate 15 (0.128 g, 0.45 mmol) in CH2Cl2 (5 mL) at room temperature. After a further 3 h, the reaction mixture was treated with a small amount of Na2S2O3. The layers were separated and the aqueous one being extracted three times with CH2Cl2. The combined organic layers were dried over Na2SO4, filtered and concentrated. The crude material was precipitate in Et2O to yield intermediate 16 (0.1 g, 56%) as a white solid after drying in vacuo at 50° C.
  • [1135] 1H NMR [(CD3)2SO]δ7.26 (d, J=8.8 Hz, 1H), 7.17 (br s, 2H), 6.59 (d, J=8.8 Hz, 1H, 4.47 (m, 1H, 4.25 (dd, J=10.3, 2.0 Hz, 1H, 3.97 (m, 1H, 3.82-3.79 (m, 2H), 3.75 (s, 3H), 3.70-3.62 (m, 1H), 1.81 (d, J=14.6 Hz, 1H).
  • Preparation of Example 93
  • To a mixture of intermediate 16 (100 mg, 0.24 mmol) and AIBN (0.02 g, 0.12 mmol) in toluene (4 mL) under argon was added tributyltin hydride (0.08 mL, 0.29 mmol). The reaction mixture was heated to 80° C. for 10 h. After completion, the mixture was concentrated under reduced pressure, the residue was taken into CH[1136] 3CN and washed three times with hexane. The crude product was purified by flash column chromatography (eluent: CH2Cl2/MeOH: 95/5) to give the title compound (31 mg, 46%) as a white solid.
  • [1137] 1H NMR [CDCl3]δ7.22 (d, J=9.0 Hz, 1H), 6.48 (d, J=9.0 Hz, 1H), 5.29 (br s, 2H), 3.88-3.85 (m, 4H), 3.80 (s, 3H), 2.81-2.73 (m, 2H), 1.81 (d, J=14 Hz, 2H).
  • Example 94 8′-Trifluoromethylspiro[cyclohexane-1-4′-(3′,4′-dihydro)quinazolin]-2′(1′H)-one Formula (I): X1═CH, X2═CH ; X3═CH , X4═C—CF3, A═cyclohexyl, X═NH, Z═O, Y═NH
  • The title compound was prepared according to protocol A using 2-trifluoromethylphenylurea (500 mg, 2.45 mmol), polyphosphoric acid (3 g) and cyclohexanone (0.3 mL, 2.89 mmol). The crude product was purified by flash chromatography on silica gel (hexane/EtOAc: 100/0 to 50/50) followed by reverse-phase chromatography on a C18 column (water/acetonitrile : 90/10 to 0/100) to give the title compound (13 mg, 2% yield). [1138]
  • [1139] 1H NMR [CDCl3]δ7.46 (m, 2H), 7.07 (m, 1H, 7.01 (br s, 1H, NH), 5.60 (br s, 1H, NH), 2.00 (m, 2H), 1.83-1.57 (m, 7H), 1.30 (m, 1H.
  • Example 95 8′-Chloro-6′-cyanomethylspiro[cyclohexane-1-4′-(3′,4′-dihydro)quinazolin]-2′(1′H)-one Formula (I): X1═CH , X2═C—CH2CN, X3═CH , X4═C—Cl, A═cyclohexyl, X═NH, Z═O, Y═NH
  • The title compound was prepared according to protocol E. To a stirred solution of Example 7 (1 g, 4 mmol) in glacial acetic acid (15 mL) was sequentially added trioxane (0.55 g, 6 mmol, 1.5 equiv.) and a 48% aqueous solution of hydrobromic acid (5 mL). The mixture was heated to 95° C. overnight, poured on ice. The precipitate was filtered, washed twice with water then with ether to give 1.39 g of 8′-Chloro-6′-bromomethylspiro[cyclohexane-1-4′-(3′,4′-dihydro)quinazolin]-2′(1′H)-one as a white solid. The crude bromomethyl derivative (256 mg, 74 mmol) was treated with sodium cyanide (40 mg, 82 mmol, 1.1equiv.) in DMF (10 mL) and was heated to 60° C. for two hours. The mixture was concentrated under reduced pressure, taken into water, extracted twice with CH[1140] 2Cl2, dried over Na2SO4, filtered and concentrated under reduced pressure. The crude material was purified twice by flash chromatography on silica gel (CH2Cl2/MeOH: 99/1 followed by cyclohexane/EtOAc: 60/40+2% NH4OH), to give the title compound (60 mg , 28%) (purity 95%) as a white solid. mp=239° C.
  • [1141] 1H NMR [(CD3)2SO]δ8.50 (brs, 1H, NH), 7.30-7.29 (d, 2H), 7.15 (br s, 1H, NH). 3.94 (s, 2H), 1.81-1.68 (m, 7H), 1.54-1.50 (m, 2H), 1.25 (m, 1H).
  • Example 96 8′-Chloro-5′-(3-dimethylamino-2-hydroxy-propoxy)-spiro[cyclohexane-1-4′-(3′,4′-dihydro)quinazolin]-2′(1′H)-one X1═C—OCH2CH(OH)CH2N(CH3)2, X2═CH , X3═CH , X4═C—Cl, A═cyclohexyl, X═NH, Z═O, Y═NH Preparation of 8′-Chloro-5′-(oxiran-2-ylmethoxy)-spiro[cyclohexane-1-4′-(3′,4′-dihydro)quinazolin]-2′(1′H)-one (Intermediate 17)
  • To a stirred solution of Example 63 (5 g, 18.75 mmol) in DMF (80 mL) at 18 to 20° C. was added anhydrous potassium carbonate (6.5 g, 46.9 mmol) followed by epibromohydrin (2.83 g, 20.6 mmol) in one portion. The mixture was heated to 80° C. for 2 h and then 90° C. for 2 h. The crude mixture was quenched into water (800 ml) and extracted with EtOAc (2×1L). The organic layer was dried over anhydrous MgSO[1142] 4, filtered and concentrated in vacuo at 40° C. to give the crude product (3.4 g, 57% yield). The crude product was subjected to column chromatography (silica 100 g, eluting with 30% to 50% EtOAc in heptane) to afford intermediate 17 (2.7 g, 45% yield) as a white solid after drying in vacuo at 45° C. (purity 98.9%).
  • [1143] 1H NMR [CDCl3]δ6.96 (d, J=8.8 Hz, 1H, 6.76-6.79 (br s, 1H, 6.24 (d, J=8.8 Hz, 1H, 5.30-5.35 (br s, 1H, 4.09 (dd, J=2.8, 10.9 Hz, 1H, 3.67 (dd, J=6.3, 10.9 Hz, 1H), 3.16 (m, 1H), 2.73 (dd, J=4.3, 4.8 Hz, 1H), 2.53 (dd, J=2.5, 4.8 Hz, 1H), 2.28-2.38 (m, 2H), 1.45-1.61 (m, 5H), 1.23-1.36 (m, 2H), 1.04-1.15 (m, 1H).
  • Preparation of example 96
  • To a stirred solution of dimethylamine in EtOH (17 mL, 5.6M, 95.2 mmol) at 18 to 20° C. was added intermediate 17 (730 mg, 2.26 mmol) in one portion. The mixture was heated to 40° C. for 2.6 h. The solid was filtered, washed with EtOH (40 mL) and dried in vacuo at 40° C. to yield the desired product as a white solid (515 mg, 1.40 mmol, 62%)(purity 99%). [1144]
  • [1145] 1H NMR [(CD3)2SO]δ8 7.10 (d, J=9.0 Hz, 1H), 6.90-6.94 (br s, 1H), 6.42 (d, J=9.0 Hz, 1H, 5.44-5.50 (br s, 1H, 3.99 (m, 1H, 3.91 (m, 2H), 3.50-3.54 (br s, 1H), 2.52 (m, 3H), 2.33 (dd, J=12.1, 3.5 Hz, 1H), 2.27, (s, 6H), 1.59-1.76 (m, 5H), 1.38-1.52 (m, 2H), 1.18-1.30 (m, 1H.
  • Example 97 8′-Chloro-5′-(3-methylamino-2-hydroxy-propoxy)-spiro[cyclohexane-1-4′-(3′,4′-dihydro)quinazolin]-2′(1′H)-one X1═C—OCH2CH(OH)CH2NHCH3, X2═CH , X3═CH , X4═C—Cl, A=cyclohexyl, X═NH, Z═O, Y═NH
  • To a stirred solution of methylamine in EtOH (12 mL, 8M, 96 mmol) at 18 to 20° C. was added intermediate 17 (500 mg, 1.55 mmol) in one portion. The mixture was heated to 40° C. for 2 h. A further portion of methylamine in EtOH (10 mL, 8M, 80 mmol) was added and the reaction heated at 40° C. for another 20mins. The mixture was concentrated in vacuo at 40° C. and TBME (30 mL) was added. The white solid (390 mg, 1.1 mmol) formed was filtered to give the crude product (390 mg, 1.1 mmol). The material was dissolved in DCM (20 mL) and heated to 35° C. for ten minutes in the presence of charcoal (2 g). The suspension was filtered through a pad of celite, washed with DCM (20 mL) and concentrated in vacuo at 40° C. to yield the title compound as a white solid (200 mg, 36% yield) (purity 97.3%). [1146]
  • [1147] 1H NMR [(CD3)2SO]δ7.21 (d, J=9.0 Hz, 1H), 7.00-7.06 (br s, 1H), 6.54 (d, J=9.0 Hz, 1H, 5.55-5.59 (br s, 1H), 4.04 (m, 2H), 4.13 (m, 1H, 2.90 (dd, J=3.8, 12.0 Hz, 1H), 2.80 (dd, J=8.4, 12.0 Hz, 1H), 2.60 (m, 2H), 2.54 (s, 3H), 2.05-2.25 (br s, 2H), 1.70-1.88 (m, 5H), 1.48-1.63 (m, 2H), 1.25-1.38 (m, 1H.
  • Example 98 8′-Chloro-5′-[2-(ethoxycarbonylmethyl-amino)-ethoxy]-spiro[cyclohexane-1-4′-(3′,4′-dihydro)quinazolin]-2′(1′H)-one X1═C—OCH2CH2NHCH2COOCH2CH3, X2═CH , X3═CH , X4=C—Cl, A═cyclohexyl, X═NH, Z═O, Y═NH
  • To a stirred suspension of intermediate 8 (2.0 g, 5.14 mmol) in acetonitrile (28 mL) was added a solution of ethyl glycinate (3.72 g, 3.6 mmol) in acetonitrile (12 mL). The mixture was stirred under reflux for 24 hours. Concentration in vacuo at 40° C. afforded an orange oil (5 g) which was subjected to column chromatography (silica 110 g, eluting with 50% to 100% EtOAc in heptane followed by 90% EtOAc in DCM) to give the title compound (450 mg, 22% yield) as a white solid after drying in vacuo at 45° C. [1148]
  • [1149] 1H NMR [(CD3)2SO]δ7.94-7.98 (br s, 1H, 7.24 (d, J=9.0 Hz, 1H), 7.01-7.05 (br s, 1H), 6.62 (d, J=9.0 Hz, 1H), 4.08 (t, J=7.1 Hz, 2H), 4.01 (t, J=5.6 Hz, 2H), 3.41 (s, 2H), 2.95 (t, J=5.6 Hz, 2H), 2.45-2.55 (m, 2H), 2.12 (br s, 1H), 1.70-1.85 (m, 2H), 1.52-1.63 (m, 3H), 1.40-1.49 (m, 2H), 1.21-1.25 (m, 1H), 1.18 (t, J=7.1 Hz, 3H). Hz, 3H).
  • Example 99 8′-Chloro-5′-[2-(carboxymethyl-amino)-ethoxy]-spiro[cyclohexane-1-4′-(3′,4′-dihydro)quinazolin]-2′(1′H)-one hydrochloride X1═C—OCH2CH2NHCH2COOH, X2═CH , X3═CH, X4═C—Cf, A═cyclohexyl, X═NH, Z═O, Y═NH
  • To a stirred solution of Example 98 (600 mg, 1.52 mmol) in 1,4-dioxane (8 mL) was added a solution of HCl (6N, 10.5 mL) at 18 to 20° C. The reaction mixture was heated to 90° C. for 2 h. It was then quenched onto water (100 mL) and washed with DCM (200 mL). The aqueous layer was concentrated and dried in vacuo at 60° C. to give title compound (614 mg, 99.9% yield) as a white solid (purity 95.9%). [1150]
  • [1151] 1H NMR (400 MHz, CD3OD) δ7.07 (d, J=9.1 Hz, 1H), 6.56 (d, J=9.1 Hz, 1H), 4.17 (t, J=5.6 Hz, 2H), 3.86 (s, 2H), 3.39 (t, J=5.6 Hz, 2H), 2.24-2.34 (m, 2H), 1.40-1.60 (m, 7H), 1.15-1.26 (m, 1H.
  • Biological Results In vitro Inhibition of the Phosphodiesterase 7 and of Other Phosphodiesterases
  • The capacity of the compounds of the invention to inhibit cyclic nucleotide phosphodiesterases was evaluated by measuring their IC[1152] 50 (concentration necessary to inhibit the enzymatic activity by 50%).
  • PDE3A3, PDE4D3, PDE7A1 were cloned and expressed in insect cells Sf21 using the baculovirus expression system and we uses directly the cell culture supernatant as enzyme source. The source of PDE1 and of PDE5 were human cell lines (respectively TPH1 human monocytes and MCF7 human caucasian breast adenocarcinoma). [1153]
  • They were obtained partially purified on an anion exchange column (Mono Q) according to a method adapted from Lavan B. E.,Lakey T., Houslay M. D. Biochemical Pharmacology, 1989, 38 (22), 4123-4136. [1154]
  • Measurement of the enzymatic activity for the various types of PDE was then made according to a method adapted from W. J. Thompson et al. 1979, Advances in Cyclic Nucleotide Research, Vol.10 : 69-92, ed. G. Brooker et al. Raven Press, NY. [1155]
  • The substrate used was cGMP for PDE1 and PDE5 and cAMP for PDE 3, PDE 4 and PDE 7. The substrate concentration was 0.2 μM for PDE 1, PDE 3 and PDE 5, 0,25 μM for PDE 4 and 50nM for PDE 7. [1156]
  • The enzymatic reaction was stopped after 1 hour for PDE 1, PDE 3 and PDE 5 and 10 minutes for PDE 4 and PDE 7. [1157]
  • In order to determine their IC50, compounds of the invention were assayed at 8 to 11 concentrations ranging from 0.02 nM to 100 nM for PDE 4 and PDE 7 and at least at 6 concentrations ranging from 0,1 μM to 30 μM for PDE 1, 3 and 5. [1158]
  • The IC[1159] 50 (μM) were determined for some of the compounds of the invention, and the IC50 of most of the compounds of examples 1 to 99 were comprise between 0.008 μM and 18 μM.
  • The activity of some of the most active compounds are summarized in the following table: [1160]
    Example
    number IC50 PDE7 (μM)
    15 0,014
    26 0,016
    34 0,012
    38 0,018
    41 0,02
    51 0,008
    52 0,015
    53 0,013
    54 0,013
  • These results show that the compounds of the invention inhibit PDE7 at very low concentrations, with some IC[1161] 50 values lower than 100 nM. The results of the assays with other PDE (1, 3, 4 and 5) show IC50 values often superior to 1 μM or even 10 μM.
  • It demonstrates that compounds of the invention are strong and selective PDE7 inhibitors. [1162]

Claims (33)

1. Compounds having the following formula (I), (II) or (III),
Figure US20020198198A1-20021226-C00042
in which,
a) X1, X2, X3 and X4 are the same or different and are selected from:
N, provided that not more than two of the groups X1, X2, X3 and X4 simultaneously represent a nitrogen atom, or,
C-R1, in which R1 is selected from:
Q1, or
lower alkyl, lower alkenyl or lower alkynyl, these groups being unsubstituted or substituted with one or several groups Q2;
the group x5-R5 in which,
x5 is selected from:
a single bond,
lower alkylene, lower alkenylene or lower alkynylene, optionally interrupted with 1 or 2 heteroatoms chosen from O, S, S(═O), SO2 or N, ,the carbon atoms of these groups being unsubstituted or substituted with one or several groups, identical or different, selected from SR6, OR6, NR6R7, ═O, ═S or ═N-R6 in which R6 and R7 are the same or different and are selected from hydrogen or lower alkyl, and,
R5 is selected from aryl, heteroaryl, cycloalkyl optionally interrupted with C(═O) or with 1, 2, or 3 heteroatoms chosen from o; S, S(═O), SO2 or N, cycloalkenyl optionally interrupted with C(═O) or with 1, 2, or 3 heteroatoms chosen from O, S, S(═O), SO2 or N, or a bicyclic group, these groups being unsubstituted or substituted with one or several groups selected from Q3, heteroaryl or lower alkyl optionally substituted with Q3;
in which Q1, Q2, Q3 are the same or different and are selected from
hydrogen, halogen, CN, NO2, SO3H, P(═O)(OH)2
OR2, OC(═O)R2, C(═O)OR2, SR2, S(═O)R2, C(═O)—NH—SO2—CH3, NR3R4, Q-R2, Q-NR3R4, NR2-Q-NR3R4 or NR3-Q-R2 in which Q is selected from C(═NR), C(═O), C(═S) or SO2, R is selected from hydrogen, CN, SO2NH2 or lower alkyl and R2, R3 and R4 are the same or different and are selected from:
hydrogen,
lower alkyl optionally interrupted with C(═O), Q4-aryl, Q4-heteroaryl, Q4-cycloalkyl optionally interrupted with C(═O) or with 1 or 2 heteroatoms chosen from O, S, S(═O), SO2 or N, or Q4-cycloalkenyl optionally interrupted with C(═O) or with 1 or 2 heteroatoms chosen from O, S, S(═O), SO2 or N, in which
Q4 is selected from (CH2)n, lower alkyl interrupted with one heteroatom selected from O, S or N, lower alkenyl or lower alkynyl, these groups being optionally substituted with lower alkyl, OR′ or NR′R″ in which R′ and R″ are the same or different and are selected from hydrogen or lower lower alkyl;
n is an integer selected from 0, 1, 2, 3 or 4;
these groups being unsubstituted or substituted with one or several groups selected from lower alkyl, halogen, CN, CH3, SO3H, SO2CH3, C(═O)—NH—SO2—CH3, CF3, OR6, COOR6, C(═O)R6, NR6R7, NR6C(═O)R7, C(═O)NR6R7 or SO2NR6R7, in which R6 and R7 are the same or different and are selected from hydrogen or lower alkyl optionally substituted with one or two groups selected from OR, COOR or NRR8 in which R and R8 are hydrogen or lower alkyl, and,
R6 and R7, and/or, R3 and R4, together with the nitrogen atom to which they are linked, can form a 4- to 8-membered heterocyclic ring, which may contain one or two heteroatoms selected from O, S, S(═O), SO2, or N, and which may be substituted with,
(CH2)n-Q5, in which n is an integer selected from 0, 1, 2 and 3, and Q5 is a 4- to 8-membered heterocyclic ring which may contain one or two heteroatoms selected from O, S or N and which may be substituted with a lower alkyl, or,
a lower alkyl optionally substituted with OR′, NR′R″, C(═O)NR′R″ or COOR′ in which R′ and R″ are the same or different and are selected from,
H, or,
lower alkyl optionally substituted with OR or COOR in which R is hydrogen or lower alkyl and,
R′ and R″ together with the nitrogen atom to which they are linked, can form a 4- to 8-membered heterocyclic ring, which may contain one or two heteroatoms selected from O, S or N; or,
when X1 and X2 both represent C-R1, the 2 substituents R1 may form together with the carbon atoms to which they are attached, a 5-membered heterocyclic ring comprising a nitrogen atom and optionally a second heteroatom selected from O, S or N;
b) X is O or NR9, in which R9 is selected from,
hydrogen, CN, OH, NH2,
lower alkyl, lower alkenyl or lower alkynyl, these groups being unsubstituted or substituted with cycloalkyl optionally interrupted with 1 or 2 heteroatoms chosen from O, S, S(═O), SO2 or N, cycloalkenyl optionally interrupted with 1 or 2 heteroatoms chosen from O, S, S(═O), SO2 or N, aryl, heteroaryl, OR10, COOR10 or NR10R11 in which R10 and R11 are the same or different and are selected from hydrogen or lower alkyl;
c) Y is selected from O, S or N-R12, in which R12 is selected from:
hydrogen, CN, OH, NH2,
lower alkyl, lower alkenyl or lower alkynyl, these groups being unsubstituted or substituted with, cycloalkyl optionally interrupted with 1 or 2 heteroatoms chosen from O, S, S(═O), SO2 or N, cycloalkenyl optionally interrupted with 1 or 2 heteroatoms chosen from O, S, S(═O), SO2 or N, aryl, heteroaryl, OR10, COOR10 or NR10R11 in which R10 and R11 are the same or different and are selected from hydrogen or lower alkyl;
d) Z is chosen from CH—NO2, O, S or NR13 in which R13 is selected from:
hydrogen, CN, OH, NH2, aryl, heteroaryl, cycloalkyl optionally interrupted with one or several heteroatoms chosen from O, S, S(═O), SO2 or N, cycloalkenyl optionally interrupted with one or several heteroatoms chosen from O, S, S(═O), SO2 or N, C(═O)R14, C(═O)NR14R15, OR14, or,
lower alkyl, unsubstituted or substituted with one or several groups which are the same or different and which are selected OR14, COOR10 or NR14R15;
R14 and R15 being independently selected from hydrogen or lower alkyl, or, R14 and R15, together with the nitrogen atom to which they are linked, can form a 4- to 8-membered heterocyclic ring which may contain one or two heteroatoms chosen from O, S or N, and which may be substituted with a lower alkyl, or,
when Y is N—R12 and Z is N—R13, may form together a —CH═N— group or a —C═C— group,
when X is N—R9 and Z is N—R13, R9 and R13 may form together a —CH═N— group or a —C═C— group;
e) Z1 is chosen from H, CH3 or NR16R17 in which R16 and R17 are the same or different and are selected from:
hydrogen, CN, aryl, heteroaryl, cycloalkyl optionally interrupted with one or several heteroatoms chosen from O, S, S(═O), SO2 or N, cycloalkenyl optionally interrupted with one or several heteroatoms chosen from O, S, S(═O), SO2 or N, C(═O)R14, C(═O)NR14R15, OR4, or,
lower alkyl unsubstituted or substituted with one or several groups selected from OR4, COOR14 or NR4R15,
R14 and R15 being chosen from hydrogen or lower alkyl, and,
R14 and R15, and/or, R16 and R 17, together with the nitrogen atom to which they are linked, can form a 4- to 8-membered heterocyclic ring which may contain one or two heteroatoms chosen from O, S or N, and which may be substituted with a lower alkyl;
f) A is a cycle chosen from:
Figure US20020198198A1-20021226-C00043
 in which,
A1, A2, A4, A5 and A6 are the same or different and are selected from O, S, C, C(═O), SO, SO2 or N—R18 in which R18 is selected from:
hydrogen, aryl, heteroaryl, cycloalkyl optionally interrupted with one or several heteroatoms chosen from O, S, S(═O), SO2 or N, cycloalkenyl optionally interrupted with one or several heteroatoms chosen from O, S, S(═O), SO2 or N,
lower alkyl unsubstituted or substituted with aryl, heteroaryl, cycloalkyl optionally interrupted with one or several heteroatoms chosen from O, S, S(═O), SO2 or N, cycloalkenyl optionally interrupted with one or several heteroatoms chosen from O, S, S(═O), SO2 or N, CN, NR19R20, C(═O)NR19R20, OR19, C(═O)R19 or C(═O)OR19 in which R19 and R20 are identical or different and are selected from hydrogen or lower alkyl;
A3 is selected from O, S, C, C(═O), SO or SO2, or N—R18 when A1 and/or A2 are C(═O) or when Y is O or S, wherein R18 is as defined above;
represents the carbon atom which is shared between the cycle A and the backbone cycle containing X and/or Y;
each carbon atom of the cycle A is unsubstituted or substituted with 1 or 2 groups, identical or different, selected from lower alkyl optionally substituted with OR21, NR21R22, COOR21 or CONR21 R22, lower haloalkyl, CN, F, ═O, SO2NR19R20, OR19, SR19, C(═O)OR19, C(═O)NR19R20 or NR19R20 in which R19 and R20 are identical or different and are selected from hydrogen or lower alkyl optionally substituted with OR21, NR21R22, COOR21 or CONR21R22 in which R21 and R22 are identical or different and are selected from hydrogen or lower alkyl, and,
R19 and R20, and/or, R21 and R22, together with the nitrogen atom to which they are linked, can form a 4- to 8-membered heterocyclic ring;
2 atoms of the cycle A, which are not adjacent, may be linked by a 2, 3 or 4 carbon atom chain which may be interrupted with 1 heteroatom chosen from O, S or N;
provided that:
not more than two of the groups A1, A2, A3, A4, A5 and A6 simultaneously represent a heteroatom;
the cycle A does not contain more than 2 carbon atoms in an sp2 hybridization state;
when X is O,X2 is not C-R1 in which R1 is
a thienyl substituted with CN or with CN and CH3,
a phenyl substituted with CN, Cl, NO2 or CN and F,
Br
F;
or their tautomeric forms, their racemic forms or their isomers and their pharmaceutically acceptable derivatives.
2. A compound of formula (II) or (III) according to claim 1, in which,
a) X1, X2 and X3 are the same or different and are C-R1, in which R1 is selected from:
hydrogen, halogen, CN, SO3H, NO2, CF3, OR2, SR2, NR2R3, COR2, COOR2, CONR2R3, SO2CH3, SO2NR2R3 in which R2 and R3 are the same or different and are selected from hydrogen or lower alkyl optionally substituted with halogen, CN, SO3H, OR6, COOR6, NR6R7, SO2NR6R7 or C(═O)NR6R7 in which R6 and R7 are the same or different and are selected from hydrogen or lower alkyl, and,
R6 and R7, together with the nitrogen atom to which they are linked, can form a 4- to 8-membered heterocyclic ring;
lower alkyl, lower alkenyl or lower alkynyl, these groups being unsubstituted or substituted with 1, 2 or 3 groups selected from halogen, CN, OR2, COOR2, NR3R4, SO2NR3R4 or C(═O)NR3R4 in which R2, R3 and R4 are the same or different and are selected from hydrogen or lower alkyl, and,
R3 and R4, together with the nitrogen atom to which they are linked, can form a 4- to 8-membered heterocyclic ring;
the group X5—R5 in which,
X5 is selected from a lower alkylene or a single bond, and,
R5 is selected from phenyl, pyridyl or indolyl,
these groups being unsubstituted or substituted with one or several groups selected from Q3, heteroaryl or lower alkyl optionally substituted with Q3 in
which Q3 is selected from:
halogen, CN, SO3H, NO2, CF3, OR2, OC(═O)R2, C(═O)R2, C(═O)OR2, NH—C(═O)R2, NR3R4, SO2NR3R4 or C(═O)NR3R4 in which R2, R3 and R4 are the same or different and are selected from:
hydrogen, lower alkyl unsubstituted or substituted with one or several groups selected from halogen, OR6, COOR6 or NR6R7 in which R6 and R7 are the same or different and are selected from hydrogen or lower alkyl and,
R6 and R7, and/or, R3 and R4, together with the nitrogen atom to which they are linked, can form a 4- to 8-membered heterocyclic ring, which may contain one or two heteroatoms selected from O, S or N, and which may be substituted with
a 4- to 8-membered heterocyclic ring, which may contain one or two heteroatoms selected from O, S or N and which may be substituted with a lower alkyl, or,
a lower alkyl optionally substituted with OR′, NR′R″, C(═O)NR′R″ or COOR′ in which R′ and R″ are the same or different and are selected from
H, or,
lower alkyl optionally substituted with OR or COOR in which R is hydrogen or lower alkyl and,
R′ and R″ together with the nitrogen atom to which they are linked, can form a 4- to 8-membered heterocyclic ring, which may contain one or two heteroatoms selected from O, S or N;
b) X4 is C-R1 in which R1 is selected from hydrogen, halogen, CN, NO2, SO2CH3, SO3H, CH3, CF3, OR2, SR2, NR2R3, COOR2, CONR2R3 or SO2NR2R3 in which R2 and R3 are the same or different and are selected from hydrogen or lower alkyl;
c) X is NH;
d)Y is NH;
e) Z1 is chosen from NR16R17 in which R16 and R17 are the same or different and are selected from:
hydrogen, CN, C(═O)R14, (C═O)NR14R15, OR14
lower alkyl unsubstituted or substituted with one or several groups selected from OR14 or NR14R15,
R14 and R15 being chosen from hydrogen or lower alkyl, and,
R14 and R15, and/or, R16 and R17, together with the nitrogen atom to which they are linked, can form a 4- to 8-membered heterocyclic ring which may contain one or two heteroatoms selected from O, S or N, and which may be substituted with a lower alkyl;
f) A is a cycle chosen from:
Figure US20020198198A1-20021226-C00044
 in which,
A1, A2, A3, A4 and A5 are the same or different and are selected from:
a carbon atom, unsubstituted or substituted with 1 or 2 groups, identical or different selected from lower alkyl, OH or F, or,
an oxygen atom;
represents the carbon atom which is shared between the cycle A and the backbone cycle containing X and/or Y;
2 atoms of the cycle A, which are not adjacent, may be linked by a 2, 3 or 4 carbon atom chain;
provided that:
not more than one of the groups A1, A2, A3, A4 and A5 simultaneously represent an oxygen atom.
3. A compound of formula (I) in which X1, X2, X3, X4, X, Y, Z and A are as defined in claim 1.
4. A compound of formula (I) according to claim 3 in which
a) X1, X2 and X3 are the same or different and are C—R1, in which R1 is selected from:
hydrogen, halogen, CN, SO3H, NO2, CF3, OR2, SR2, NR2R3, COR2, COOR2, CONR2R3, SO2CH3, SO2NR2R3 in which R2 and R3 are the same or different and are selected from hydrogen or lower alkyl optionally substituted with halogen, CN, OR6, COOR6, NR6R7, SO2NR6R7 or C(═O)NR6R7 in which R6 and R7 are the same or different and are selected from hydrogen or lower alkyl, and,
R6 and R7, together with the nitrogen atom to which they are linked, can form a 4- to 8-membered heterocyclic ring;
lower alkyl, lower alkenyl or lower alkynyl, these groups being unsubstituted or substituted with 1, 2 or 3 groups selected from halogen, CN, SO3H, OR2, COOR2, NR3R4, SO2NR3R4 or C(═O)NR3R4 in which R2, R3 and R4 are the same or different and are selected from hydrogen or lower alkyl, and,
R3 and R4, together with the nitrogen atom to which they are linked, can form a 4- to 8-membered heterocyclic ring;
the group X5 13 R5 in which,
X5 is selected from a lower alkylene or a single bond, and,
R5 is selected from phenyl, pyridyl or indolyl,
these groups being unsubstituted or substituted with 1, 2 or 3 groups selected from Q3, heteroaryl or lower alkyl optionally substituted with Q3 in which Q3 is selected from:
halogen, CN, SO3H, NO2, CF3, OR2, OC(═O)R2, C(═O)R2, C(═O)OR2, NH-C(═O)R2, NR3R4, SO2NR3R4 or C(═O)NR3R4 in which R2, R3 and R4 are the same or different and are selected from:
hydrogen, lower alkyl unsubstituted or substituted with one or several groups selected from halogen, OR6, COOR6 or NR6R7 in which R6 and R7 are the same or different and are selected from hydrogen or lower alkyl and,
R6 and R7, and/or, R3 and R4, together with the nitrogen atom to which they are linked, can form a 4- to 8-membered heterocyclic ring, which may contain one or two heteroatoms selected from O, S or N, and which may be substituted with,
a 4- to 8-membered heterocyclic ring, which may contain one or two heteroatoms selected from O, S or N and which may be substituted with a lower alkyl, or,
a lower alkyl optionally substituted with OR′, NR′R″, C(═O)NR′R″ or COOR′ in which R′ and R″ are the same or different and are selected from,
H, or,
lower alkyl optionally substituted with OR or COOR in which R is hydrogen or lower alkyl and,
R′ and R″ together with the nitrogen atom to which they are linked, can form a 4- to 8-membered heterocyclic ring, which may contain one or two heteroatoms selected from O, S or N;
b) X4 is C-R1 in which R1 is selected from hydrogen, halogen, CN, NO2, SO2CH3, SO3H, CH3, CF3, OR2, SR2, NR2R3, COOR2, CONR2R3 or SO2NR2R3 in which R2 and R3 are the same or different and are selected from hydrogen or lower alkyl;
c) X is NH;
d) Y is NH;
e) Z is chosen from O, S or NR13 in which R13 is hydrogen or CN;
f) A is a cycle chosen from:
Figure US20020198198A1-20021226-C00045
 in which,
A1, A2, A3, A4 and A5 are the same or different and are selected from:
a carbon atom, unsubstituted or substituted with 1 or 2 groups, identical or different selected from lower alkyl, OH or F, or,
an oxygen atom;
represents the carbon atom which is shared between the cycle A and the backbone cycle containing X and/or Y;
2 atoms of the cycle A, which are not adjacent, may be linked by a 2, 3 or 4 carbon atom chain;
provided that:
not more than one of the groups A1, A2, A3, A4 and A5 simultaneously represent an oxygen atom.
5. A compound of formula (I), according to claim 1 in which, X1, X2, X3 and X4 are the same or different and are C—R1, in which R1 is selected from:
Q1, or
lower alkyl, lower alkenyl or lower alkynyl, these groups being unsubstituted or substituted with 1, 2 or 3 groups Q2;
the group X5 13 R5 in which,
X5 is selected from:
a single bond,
a lower alkylene, optionally interrupted with 1 heteroatoms chosen from O, S and N
R5 is selected from aryl, heteroaryl, cycloalkyl optionally interrupted with C(═O) or with 1, 2, or 3 heteroatoms chosen from O, S, S(═O), SO2 or N, cycloalkenyl optionally interrupted with C(═O) or with 1, 2, or 3 heteroatoms chosen from O, S, S(═O), SO2 or N, or a bicyclic group, these groups being unsubstituted or substituted with 1, 2 or 3 groups selected from Q3, heteroaryl or lower alkyl optionally substituted with Q3;
in which Q1, Q2, Q3 are the same or different and are selected from
hydrogen, halogen, CN, NO2, SO3H,
OR2, OC(═O)R2, C(═O)OR2, SR2, S(═O)R2, C(═O)—NH—SO2—CH3, NR3R4, Q-R2, Q-NR3R4, NR2-Q-NR3R4 or NR3-Q-R2 in which Q is selected from C(═NR), C(═O), C(═S) or SO2, R is selected from hydrogen or lower alkyl and R2, R3 and R4 are the same or different and are selected from:
hydrogen,
lower alkyl optionally interrupted with C(═O), Q4-aryl, Q4-heteroaryl, Q4-cycloalkyl optionally interrupted with C(═O) or with 1 or 2 heteroatoms chosen from O, S, S(═O), SO2 or N, or Q4-cycloalkenyl optionally interrupted with C(═O) or with 1 or 2 heteroatoms chosen from O, S, S(═O), SO2 or N, in which
Q4 is selected from (CH2)n, lower alkyl interrupted with one heteroatom selected from O, S or N, lower alkenyl or lower alkynyl, these groups being optionally substituted with lower alkyl, OR′ or NR′R″ in which R′ and R″ are the same or different and are selected from hydrogen or lower alkyl;
n is an integer selected from 0, 1, 2, 3 or 4;
these groups being unsubstituted or substituted with 1 or 2 groups selected from lower alkyl, halogen, CN, CH3, SO3H, SO2CH3, CF3, C(═O)NH—SO2CH3, OR6, COOR6, C(═O)R6, NR6R7, C(═O)NR6R7 or SO2NR6R7, in which R6 and R7 are the same or different and are selected from hydrogen or lower alkyl optionally substituted with one or two groups selected from OR, COOR or NRR8 in which R and R8 are hydrogen or lower alkyl, and,
R6 and R7, and/or, R3 and R4, together with the nitrogen atom to which they are linked, can form a 4- to 8-membered heterocyclic ring, which may contain one or two heteroatoms selected from O, S, S(═O), SO2 or N, and which may be substituted with,
(CH2)n-Q5, in which n is an integer selected from 0, 1, 2 and 3, and Q5 is a 4- to 8-membered heterocyclic ring which may contain one or two heteroatoms selected from O, S or N and which may be substituted with a lower alkyl, or,
a lower alkyl optionally substituted with OR′, NR′R″, C(═O)NR′R″ or COOR′ in which R′ and R″ are the same or different and are selected from,
H, or,
lower alkyl optionally substituted with OR or COOR in which R is hydrogen or lower alkyl and,
R′ and R″ together with the nitrogen atom to which they are linked, can form a 4- to 8-membered heterocyclic ring, which may contain one or two heteroatoms selected from O, S or N.
6. A compound of formula (I) according to claim 5, in which X1, X2, X3 and X4 are the same or different and are C—R1, in which R1 is selected from:
Q1, or
lower alkyl or lower alkynyl, these groups being unsubstituted or substituted with 1, 2 or 3 fluor atoms, OR3, COOR3 or NR3R4 in which R3 and R4 are the same or different and are selected from hydrogen or lower alkyl;
R3 and R4 together with the nitrogen atom to which they are linked, may also form a 6-membered heterocyclic ring, which may contain one or two heteroatoms selected from O or N;
the group X5—R5 in which X5 is a single bond and R5 is selected from aryl, heteroaryl, or a bicyclic group, these groups being unsubstituted or substituted with 1, 2 or 3 groups selected from Q3,
in which Q1 and Q3 are the same or different and are selected from
hydrogen, halogen, CN, lower alkyl,
OR2, C(═O)OR2, NR3R4, C(═O)NR3R4 or SO2NR3R4 in which R2, R3and R4 are the same or different and are selected from:
hydrogen,
lower alkyl, Q4-heteroaryl in which Q4 is selected from lower alkyl interrupted with one heteroatom selected from O, S or N and (CH2)n in which n is an integer selected from 0, 1, 2 or 3;
these groups being unsubstituted or substituted with 1 or 2 groups selected from lower alkyl, CN, SO3H, C(═O)—NH—SO2—CH3, OR6, COOR6 or NR6R7, in which R6 and R7 are the same or different and are selected from hydrogen or lower alkyl optionally substituted with one or two groups selected from OR, COOR or NRR8 in which R and R8 are hydrogen or lower alkyl, and,
R6 and R7, and/or, R3 and R4, together with the nitrogen atom to which they are linked, can form a 4- to 6-membered heterocyclic ring, which may contain one or two heteroatoms selected from 0 or N, and which may be substituted with,
a 6-membered heterocyclic ring, which may contain one or two heteroatoms selected from 0 or N and which may be substituted with a lower alkyl, or,
a lower alkyl optionally substituted with OR′, NR′R″, C(═O)NR′R″ or COOR′ in which R′ and R″ are the same or different and are selected from,
H , or,
lower alkyl optionally substituted with OR or COOR in which R is hydrogen or lower alkyl and,
R′ and R″ together with the nitrogen atom to which they are linked, can form a 6-membered heterocyclic ring, which may contain one or two heteroatoms selected from O or N.
7. A compound of formula (I) according to claim 5, in which, X1 is C—R1, in which R1 is selected from
hydrogen, halogen, OR2, COR2, COOR2,CONR2R3 in which R2 and R3 are the same or different and are selected from
hydrogen,
lower alkyl, Q4-aryl, Q4-heteroaryl, Q4-cycloalkyl optionally interrupted with C(═O) or with 1 or 2 heteroatoms chosen from O, S, or N, or Q4-cycloalkenyl optionally interrupted with C(═O) or with 1 or 2 heteroatoms chosen from O, S, or N, in which
Q4 is selected from (CH2)n, lower alkyl interrupted with one heteroatom selected from O, S or N, lower alkenyl or lower alkynyl;
n is an integer selected from 0, 1, 2 or 3;
these groups being unsubstituted or substituted with lower alkyl, CN, OR6, SO3H, C(═O)—NH—SO2—CH3, CONR6R7, COOR6, COR6 or NR6R7, in which and R6 and R7 are the same or different and are selected from hydrogen or lower alkyl, optionally substituted with NH2, COOH, OH;
R6 and R7 together with the nitrogen atom to which they are linked, can form a 4- to 8-membered heterocyclic ring, which may contain one or two heteroatoms selected from O, S or N and which may be substituted with,
(CH2)n-Q5, in which n is an integer selected from 0, 1, 2 and 3, and Q5 is a 4- to 8-membered heterocyclic ring which may contain one or two heteroatoms selected from O, S or N and which may be substituted with a lower alkyl, or,
COR′ or lower alkyl optionally substituted with OR′, NR′R″, C(═O)NR′R″ or COOR′ in which R′ and R″ are the same or different and are selected from hydrogen or lower alkyl;
lower alkyl optionally substituted with CN, SO3H, OR3, NR3R4, COOR3 or CONR3R4 in which R3 and R4 are the same or different and are selected from
hydrogen and,
lower alkyl optionally substituted with OH, COOH or NH2
the group X5—R5 in which X5 is a lower alkylene optionally interrupted with a heteroatom selected from O and N and R5 is selected from aryl, heteroaryl, cycloalkyl optionally interrupted with C(═O) or with 1, 2, or 3 heteroatoms chosen from O, S or N and cycloalkenyl optionally interrupted with C(═O) or with 1, 2, or 3 heteroatoms chosen from O, S or N,
these groups being unsubstituted or substituted OR3 or COOR3 in which R3 is selected from hydrogen and lower alkyl;
R3 and R4, together with the nitrogen atom to which they are linked, can form a 4- to 6-membered heterocyclic ring, which may contain one or two heteroatoms selected from O or N, and which may be substituted with,
(CH2)n-Q5, in which n is an integer selected from 0, 1, 2 and 3, and Q5 is a 4- to 8-membered heterocyclic ring which may contain one or two heteroatoms selected from O, S or N and which may be substituted with a lower alkyl, or,
C(═O)—R′ or a lower alkyl optionally substituted with OR′, NR′R″, C(═O)NR′R″ or COOR′ in which R′ and R″ are the same or different and are selected from hydrogen or lower alkyl.
8. A compound of formula (I) according to claim 5 in which, X1 is C—R1, in which R1 is selected from hydrogen, halogen or OR2 in which R2 is selected from
hydrogen,
lower alkyl, unsubstituted or substituted with CN, C(═O)—NH—SO2—CH3, OR6, SO3H, COOR6 or NR6R7;
Q4-oxadiazole, Q4-tetrazole, Q4-morpholine, Q4-furan, Q4-isoxazole, in which Q4 is selected from lower alkyl interrupted with one heteroatom selected from O, S or N and (CH2)n in which n is an integer selected from 1 and 2;
these groups being unsubstituted or substituted with CH3, OR6 or COOR6, in which R6 and R7 are the same or different and are selected from hydrogen or lower alkyl, optionally substituted with NH2 or COOH.
9. A compound of formula (I) according to any one of claims 5, 7 and 8 in which X2 is C—R1, in which R1 is X5—R5, in which
X5 is a single bond,
R5 is phenyl or pyridyl,
optionally substituted with a lower alkyl, and,
substituted with C(═O)NR3R4 in which R3 and R4 together with the nitrogen atom to which they are linked, form a 4- to 8-membered heterocyclic ring, which may contain one or two heteroatoms selected from O, S, S(═O), SO2 or N, and which may be substituted with,
a 4- to 8-membered heterocyclic ring, which may contain one or two heteroatoms selected from O, S or N and which may be substituted with a lower alkyl, or,
a lower alkyl optionally substituted with OR′, NR′R″, C(═O)NR′R″ or COOR′ in which R′ and R″ are the same or different and are selected from,
H, or,
lower alkyl optionally substituted with OR or COOR in which R is hydrogen or lower alkyl and,
R′ and R″ together with the nitrogen atom to which they are linked, can form a 4- to 8-membered heterocyclic ring, which may contain one or two heteroatoms selected from O, S or N.
10. A compound of formula (I) according to any one of claims 5 to 9 in which one of X1, X2, X3 and X4 is C—R1 in which R1 is hydrogen while the others are identical or different and are C—R1 in which R1 is other than hydrogen.
11. A compound of formula (I) according to claim 10, in which X3 is C—R1 in which R1 is hydrogen.
12. A compound of formula (I) according to any one of claims 5 to 10, in which X3 is C—R1, in which R1 is selected from
hydrogen or halogen, or,
X5—R5 in which R5 is a single bond and R5 is aryl or heteroaryl, optionally substituted with one, two or three groups which are the same or different and which are selected from halogen, CN, CF3, SO2Me, OR2, COOR2, NR2R3, SO2NR2R3 and CONR2R3 in which R2 and R3 are the same or different and are selected from hydrogen or lower alkyl.
13. A compound of formula (I) according to claim 12 in which X3 is C—R1, in which R1 is selected from hydrogen or halogen.
14. A compound of formula (I) according to any one of claims 5 to 13 in which X4 is C—R1 in which R1 is selected from
hydrogen, halogen, CF3, O-lower alkyl, COOR2 or,
lower alkyl optionally substituted with OR2, COOR2 or SO2NR2R3 in which R2 and R3 are the same or different and are selected from hydrogen or lower alkyl.
15. A compound of formula (I) according to any one of claims 5 to 14 in which X is NH.
16. A compound of formula (I) according to any one of claims 5 to 15 in which Y is NH.
17. A compound of formula (I) according to any one of claims 5 to 16 in which Z is O or N—CN.
18. A compound of formula (I) according to any one of claims 17 in which Z is O.
19. A compound of formula (I) according to any one of claims 5 to 18 in which A is selected from cyclohexyl or cycloheptyl, optionally interrupted with C(═O) or O, and unsubstituted or substituted with CH3, OH or OCH3.
20. A compound of formula (I) according to any one of claims 5 to 19 in which A is selected from unsubstituted cyclohexyl or cycloheptyl.
21. A compound of formula (I), (II) or (III) according to any one of claims 1 to 20 wherein when X2 is C—R1and R1 is X5 13 R5, then X5 is not a single bond
22. A compound selected from the group consisting of
Spiro[cyclohexane-1-4′-(3′,4′-dihydro)quinazolin]-2′(1′H)-one,
6′-Methoxyspiro[cyclohexane-1-4′-(3′,4′-dihydro )quinazolin]-2′(1′H)-one,
Spiro[cycloheptane-1-4′-(3′,4′-dihydro)quinazolin]-2′(1′H)-one,
7′-Methoxyspiro[cyclohexane-1-4′-(3′,4′-dihydro)quinazolin]-2′(1′H)-one,
6′-Phenylspiro[cycloheptane-1-4′-(3′,4′-dihydro)quinazolin]-2′(1′H)-one,
8′-Methoxyspiro[cyclohexane-1-4′-(3′,4′-dihydro)quinazolin]-2′(1′H)-one,
8′-Chlorospiro[cyclohexane-1-4′-(3′,4′-dihydro)quinazolin]-2′(1′H)-one,
7′-chlorospiro[cyclohexane-1-4′-(3′,4′-dihydro)quinazolin]-2′(1′H)-one,
5′-chlorospiro[cyclohexane-1-4′-(3′,4′-dihydro)quinazolin]-2′(1′H)-one,
8′-methylspiro[cyclohexane-1-4′-(3′,4′-dihydro)quinazolin]-2′(1′H)-one,
6′-chlorospiro[cyclohexane-1-4′-(3′,4′-dihydro)quinazolin]-2′(1′H)-one,
8′-bromospiro[cyclohexane-1-4′-(3′,4′-dihydro)quinazolin]-2′(1′H)-one,
8′-fluorospiro[cyclohexane-1-4′-(3′,4′-dihydro)quinazolin]-2′(1′H)-one,
6′-methylspiro[cyclohexane-1-4′-(3′,4′-dihydro)quinazolin]-2′(1′H)-one,
5′,8′-dichlorospiro[cyclohexane-1-4′-(3′,4′-dihydro)quinazolin]-2′(1′H)-one,
6′,7′-dichlorospiro[cyclohexane-1-4′-(3′,4′-dihydro)quinazolin]-2′(1′H)-one,
5′,6′-dichlorospiro[cyclohexane-1-4′-(3′,4′-dihydro)quinazolin]-2′(1′H)-one,
6′-phenylspiro[cyclohexane-1-4′-(3′,4′-dihydro)quinazolin]-2′(1′H)-one,
8′-iodospiro[cyclohexane-1-4′-(3′,4′-dihydro)quinazolin]-2′(1′H)-one,
8′-Bromospiro[cyclobutane-1-4′-(3′,4′-dihydro)quinazolin]-2′(1′H)-one,
8′-Bromospiro[cycloheptane-1-4′-(3′,4′-dihydro)quinazolin]-2′(1′H)-one,
8′-Bromo-4-methylspiro[cyclohexane-1-4′-(3′,4′-dihydro)quinazolin]-2′(1′H)-one,
8′-Bromospiro[bicyclo[3,2,1]octane-2-4′-(3′,4′-dihydro)quinazolin]-2′(1′H)-one,
6′,8′-dichlorospiro[cyclohexane-1-4′-(3′,4′-dihydro)quinazolin]-2′(1′H)-one
8′-chloro-6′-iodospiro[cyclohexane-1-4′-(3′,4′-dihydro)quinazolin]-2′(1′H)-one,
8′-chloro-6′-methoxyspiro[cyclohexane-1-4′-(3′,4′-dihydro)quinazolin]-2′(1′H)-one,
8′-chloro-6′-phenylspiro[cycloheptane-1-4′-(3′,4′-dihydro)quinazolin]-2′(1′H)-one,
8′-chloro-6′-phenylspiro[cyclohexane-1-4′-(3′,4′-dihydro)quinazolin]-2′(1′H)-one,
8′-chloro-6′-methylspiro[cyclohexane-1-4′-(3′,4′-dihydro)quinazolin]-2′(1′H)-one,
8′-chloro-6′-(3-pyridyl)spiro[cyclohexane-1-4′-(3′,4′-dihydro)quinazolin]-2′(1′H)-one,
8′-chloro-6′-(4-pyridyl)spiro[cyclohexane-1-4′-(3′,4′-dihydro)quinazolin]-2′(1′H)-one,
6′-(4-carboxyphenyl)-8′-chlorospiro[cyclohexane-1-4′-(3′,4′-dihydro)-quinazolin]-2′(1′H)-one,
6′-(3-carboxyphenyl)-8′-chlorospiro[cyclohexane-1-4′-(3′,4′-dihydro)-quinazolin]-2′(1′H)-one,
8′-chloro-6′-(1H-indol-5yl)spiro[cyclohexane-1-4′-(3′,4′-dihydro)-quinazolin]-2′(1′H)-one,
8′-chloro-6′-(2-pyridyl)spiro[cyclohexane-1-4′-(3′,4′-dihydro)quinazolin]-2′(1′H)-one,
8′-chloro-6′-(3-dimethylamino-prop-1-ynyl)spiro[cyclohexane-1-4′-(3′,4′-dihydro)-quinazolin]-2′(1′H)-one,
8′-chloro-6′-(3-methylamino-prop-1-ynyl)spiro[cyclohexane-1-4′-(3′,4′-dihydro)quinazolin]-2′(1′H)-one,
8′-chloro-6′-[4-(4-methyl-piperazine-1-carbonyl)phenyl]spiro[cyclohexane-1-4′-(3′,4′-dihydro)quinazolin]-2′(1′H)-one,
8′-chloro-6′-[4-(3-N-dimethylamino-propylcarboxamide)phenyl]-spiro-[cyclohexane-1-4′-(3′,4′-dihydro)quinazolin]-2′(1′H)-one,
8′-chloro-6′-[4-(2-N-dimethylamino-ethylcarboxamide)phenyl]-spiro-[cyclohexane-1-4′-(3′,4′-dihydro)quinazolin]-2′(1′H)-one,
8′-chloro-6′-[3-(3-N-dimethylamino-propylcarboxamide)phenyl]-spiro-[cyclohexane-1-4′-(3′,4′-dihydro)quinazolin]-2′(1′H)-one,
8′-chloro -6′-[3-(4-methyl-piperazine-1-carbonyl)-phenyl]spiro-[cyclohexane-1-4′-(3′,4′-dihydro)quinazolin]-2′(1′H)-one,
8′-chloro-6′-[3-(2-N-dimethylamino-ethylcarboxamide)phenyl]spiro-[cyclohexane-1-4′-(3′,4′-dihydro)quinazolin]-2′(1′H)-one,
8′-Chlorospiro[cyclohexane-1-4′-(3′,4′-dihydro)quinazolin]-2′(1′H)-thione
8′-Chloro-2′-cyanoiminospiro[cyclohexane-1-4′-(3′,4′-dihydro)quinazoline
8′-Chloro-2′-methoxyiminospiro[cyclohexane-1-4′-(3′,4′-dihydro)quinazoline,
8′-Chloro-2′-dimethylaminospiro[cyclohexane-1-4′-(3′,4′-dihydro)quinazoline],
8′-Chloro-1′-methylspiro[cyclohexane-1-4′-(3′,4′-dihydro)quinazolin]-2′(1′H)-one,
8′-Chloro-1′-(ethoxycarbonylmethyl)spiro[cyclohexane-1-4′-(3′,4′-dihydro)-quinazolin]-2′(1′H)-one,
8′-Chloro-3′-methylspiro[cyclohexane-1-4′-(3′,4′-dihydro)quinazolin]-2′(1′H)-one,
8′-chloro-6′-[4-(4-pyrimidin-2-yl-piperazine-1-carbonyl)phenyl]spiro[-cyclohexane-1-4′-(3′,4′-dihydro)quinazolin]-2′(1′H)-one,
8′-chloro-6′-[4-(4-(2-morpholin-4-yl-ethyl)-piperazine-1-carbonyl)-phenyl]spiro[-cyclohexane-1-4′-(3′,4′-dihydro)quinazolin]-2′(1′H)-one,
8′-chloro-6′-[4-(4-(2-morpholin-4-yl-2-oxo-ethyl)-piperazine-1-carbonyl)-phenyl]spiro[-cyclohexane-1-4′-(3′,4′-dihydro)quinazolin]-2′(1′H)-one,
8′-chloro-6′-[4-(4-(2-hydroxy-ethoxy)-ethyl)-piperazine-1-carbonyl)-phenyl]spiro[-cyclohexane-1-4′-(3′,4′-dihydro)quinazolin]-2′(1′H)-one,
9′-Chlorospiro[cyclohexane-1-5′-(5′,10′-dihydro)]-imidazo[2, 1-b]quinazoline
9′-Chlorospiro[cyclohexane-1-5′-(5′,10′-dihydro)]-[1,2,4]triazolo[3,4-b]quinazoline,
9′-Chlorospiro[cyclohexane-1-5′-(4′,5′-dihydro)]-[1 ,2,4]triazolo[4,3-a]quinazoline, Spiro[cyclohexane-1-9′-(8′,9′-dihydro)-pyrazolo[4′,3′-f]quinazolin]-7′(6′H)-one,
8′-Chloro-5′-methoxyspiro[cyclohexane-1-4′-(3′,4′-dihydro)quinazolin]-2′(1′H)-one,
5′,8′-difluorospiro[cyclohexane-1-4′-(3′,4′-dihydro)quinazolin]-2′(1′H)-one,
8′-Chloro-5′-methylspiro[cyclohexane-1-4′-(3′,4′-dihydro)quinazolin]-2′(1′H)-one,
8′-Chloro-6′-(morpholin-4-yl)methylspiro[cyclohexane-1-4′-(3′,4′-dihydro)quinazolin]-2′(1′H)-one,
8′-Chloro-5′-hydroxyspiro[cyclohexane-1-4′-(3′,4′-dihydro)quinazolin]-2′(1′H)-one,
8′-Chloro-5′-hydroxy-6′-iodo-spiro[cyclohexane-1-4′-(3′,4′-dihydro)quinazolin]-2′(1′H)-one,
8′-Chloro-6′-iodo-5′-methoxy-spiro[cyclohexane-1-4′-(3′,4′-dihydro)quinazolin]-2′(1′H)-one,
8′-Chloro-6′-cyano-5′-methoxy-spiro[cyclohexane-1-4′-(3′,4′-dihydro)quinazolin]-2′(1′H)-one,
8′-Chloro-5′-[2-(4-morpholino)ethoxy]spiro[cyclohexane-1-4′-(3′,4′-dihydro)quinazolin]-2′(1′H)-one,
8′-Chloro-5′-[2-dimethylaminoethoxy]spiro[cyclohexane-1-4′-(3′,4′-dihydro)quinazolin]-2′(1′H)-one,
8′-Chloro-5′-(2-aminoethoxy)-spiro[cyclohexane-1-4′-(3′,4′-dihydro)quinazolin]-2′(1′H)-one,
8′-Chloro-5′-[2-(methylamino)ethoxy]-spiro[cyclohexane-1-4′-(3′,4′-dihydro)quinazolin]-2′(1′H)-one,
8′-Chloro-5′-[2-(2-aminoethoxy)ethoxy]spiro[cyclohexane-1-4′-(3′,4′-dihydro)quinazolin]-2′(1′H)-one,
8′-Chloro-5′-[3-dimethylaminopropoxy]spiro[cyclohexane-1-4′-(3′,4′-dihydro)quinazolin]-2′(1′H)-one,
8′-Chloro-5′-ethoxycarbonylmethoxyspiro[cyclohexane-1-4′-(3′,4′-dihydro)quinazolin]-2′(1′H)-one,
5′-carboxymethoxy-8′-chloro-spiro[cyclohexane-1-4′-(3′,4′-dihydro)quinazolin]-2′(1′H)-one,
5′-carboxypropoxy-8′-chloro-spiro[cyclohexane-1-4′-(3′,4′-dihydro)quinazolin]-2′(1′H)-one,
8′-chloro-5′-(3-sulphopropoxy)-spiro[cyclohexane-1-4′-(3′,4′-dihydro)quinazolin]-2′(1′H)-one,
8′-Chloro-5′-[2-(tetrahydro-pyran-2-yloxy)-ethoxy]-spiro[cyclohexane-1-4′-(3′,4′-dihydro)quinazolin]-2′(1′H)-one,
8′-Chloro-5′-(2-hydroxy-ethoxy)-spiro[cyclohexane-1-4′-(3′,4′-dihydro)quinazolin]-2′(1′H)-one,
8′-Chloro-5′-(5-ethoxycarbonyl-furan-2-ylmethoxy)-spiro[cyclohexane-1-4′-(3′,4′-dihydro)quinazolin]-2′(1′H)-one,
8′-Chloro-5′-(5-carboxy-furan-2-ylmethoxy)-spiro[cyclohexane-1-4′-(3′, 4′-dihydro)quinazolin]-2′(1′H)-one,
8′-Chloro-5′-cyanomethoxyspiro[cyclohexane-1-4′-(3′,4′-dihydro)quinazolin]-2′(1′H)-one,
8′-Chloro-5′-(1H-tetrazol-5-ylmethoxy)-spiro[cyclohexane-1-4′-(3′, 4′-dihydro)quinazolin]-2′(1′H)-one,
8′-Chloro-5′-(5-hydroxy-[1 ,2,4]oxadiazol-3-ylmethoxy)-spiro[cyclohexane-1-4′-(3′,4′-dihydro) quinazolin]-2′(1′H)-one,
8′-Chloro-6′-iodo-5′-[2-dimethylamino-ethoxy]spiro[cyclohexane-1-4′-(3′,4′-dihydro)quinazolin]-2′(1′H)-one,
6′-(4-carboxyphenyl)-8′-chloro-5′-methoxyspiro[cyclohexane-1-4′-(3′,4′-dihydro)quinazolin]-2′(1′H)-one,
6′-(3-carboxyphenyl)-8′-chloro-5′-methoxyspiro[cyclohexane-1-4′-(3′,4′-dihydro)quinazolin]-2′(1′H)-one,
8′-chloro-6′-[2-(4-methyl-piperazine-1-carbonyl)phenyl]spiro[cyclohexane-1-4′-(3′,4′-dihydro)quinazolin]-2′(1′H)-one,
8′-chloro-6′-[2-methyl-4-(4-methyl-piperazine-1-carbonyl)phenyl]spiro[cyclohexane-1-4′-(3′,4′-dihydro)quinazolin]-2′(1′H)-one,
8′-chloro-6′-[4-(piperazine-1-carbonyl)phenyl]spiro[cyclohexane-1-4′-(3′,4′-dihydro)quinazolin]-2′(1′H)-one,
8′-chloro-6′-[4-carbamoyl-phenyl]spiro[cyclohexane-1-4′-(3′,4′-dihydro)quinazolin]-2′(1′H)-one,
8′-chloro-6′-[4-((1-methyl-piperidin-4-yl)-piperazine-1-carbonyl)phenyl]spiro[cyclohexane-1-4′-(3′,4′-dihydro)quinazolin]-2′(1′H)-one,
8′-chloro-5′-methoxy-6′-[4-(4-methyl-piperazine-1-carbonyl)phenyl]spiro[cyclohexane-1-4′-(3′,4′-dihydro)quinazolin]-2′(1′H)-one,
8—CHloro-5-methoxyspiro[4H-benzo[d][1 ,3]oxazin-2-ylamine-4-4′-(tetrahydro-pyran-4′-yl)],
8′-Trifluoromethylspiro[cyclohexane-1-4′-(3′,4′-dihydro)quinazolin]-2′(1′H)-one,
8′-Chloro-6′-cyanomethylspiro[cyclohexane-1-4′-(3′,4′-dihydro)quinazolin]-2′(1′H)-one,
8′-Chloro-5′-(3-dimethylamino-2-hydroxy-propoxy)-spiro[cyclohexane-1-4′-(3′,4′-dihydro)quinazolin]-2′(1′H)-one,
8′-Chloro-5′-(3-methylamino-2-hydroxy-propoxy)-spiro[cyclohexane-1-4′-(3′,4′-dihydro)quinazolin]-2′(1′H)-one,
8′-Chloro-5′-[2-(ethoxycarbonylmethyl-amino)-ethoxy]-spiro[cyclohexane-1-4′-(3′,4′-dihydro)quinazolin]-2′(1′H)-one,
8′-Chloro-5′-[2-(carboxymethyl-amino)-ethoxy]-spiro[cyclohexane-1-4′-(3′,4′-dihydro)quinazolin]-2′(1′H)-one hydrochloride,
8′-Chloro-5′-(2-methanesulfonylamino-2-oxo-ethoxy)-spiro[cyclohexane-1-4′-(3′,4′-dihydro)quinazolin]-2′(1′H)-one,
8′-Chloro-5′-(2-[(5-methyl-isoxazol-3-ylmethyl)-amino]ethoxy)-spiro[cyclohexane-1-4′-(3′,4′-dihydro)quinazolin]-2′(1′H)-one.
23. A compound selected from the group consisting of
8′-bromospiro[cyclohexane-1-4′-(3′,4′-dihydro)quinazolin]-2′(1′H)-one, 5′,8′-dichlorospiro[cyclohexane-1-4′-(3′,4′-dihydro)quinazolin]-2′(1′H)-one,
8′-Bromospiro[cycloheptane-1-4′-(3′,4′-dihydro)quinazolin]-2′(1′H)-one,
8′-methoxyspiro[cyclohexane-1-4′-(3′,4′-dihydro )quinazolin]-2′(1′H )-one,
8′-chloro-6′-phenylspiro[cyclohexane-1-4′-(3′,4′-dihydro)quinazolin]-2′(1′H)-one,
8′-chloro-6′-(3-pyridyl)spiro[cyclohexane-1-4′-(3′,4′-dihydro)quinazolin]-2′(1′H)-one,
8′-chloro-6′-(4-pyridyl)spiro[cyclohexane-1-4′-(3′,4′-dihydro)quinazolin]-2′(1 ′H)-one,
6′-(4-carboxyphenyl)-8′-chlorospiro[cyclohexane-1-4′-(3′,4′-dihydro)-quinazolin]-2′(1′H)-one,
6′-(3-carboxyphenyl)-8′-chlorospiro[cyclohexane-1-4′-(3′,4′-dihydro)-quinazolin]-2′(1′H)-one,
8′-chloro-6′-(1H-indol-5yl)spiro[cyclohexane-1-4′-(3′,4′-dihydro)-quinazolin ]-2′(1′H)-one,
8′-chloro-6′-(2-pyridyl)spiro[cyclohexane-1-4′-(3′,4′-dihydro)quinazolin]-2′(1′H)-one,
8′-chloro-6′-(3-dimethylamino-prop-1-ynyl)spiro[cyclohexane-1-4′-(3′,4′-dihydro)-quinazolin]-2′(1′H)-one,
8′-chloro-6′-(3-methylamino-prop-1-ynyl)spiro[cyclohexane-1-4′-(3′,4′-dihydro)quinazolin]-2′(1′H)-one,
8′-chloro-6′-[4-(4-methyl-piperazine-1-carbonyl)phenyl]spiro[cyclohexane-1-4′-(3′,4′-dihydro)quinazolin]-2′(1′H)-one,
8′-chloro-6′-[4-(3-N-dimethylamino-propylcarboxamide)phenyl]-spiro-[cyclohexane-1-4′-(3′,4′-dihydro)quinazolin]-2′(1′H)-one,
8′-chloro-6′-[4-(2-N-dimethylamino-ethylcarboxamide)phenyl]-spiro-[cyclohexane-1-4′-(3′,4′-dihydro)quinazolin]-(1′H)-one,
8′-chloro-6′-[3-(3-N-dimethylamino-propylcarboxamide)phenyl]-spiro-[cyclohexane-1-4′-(3′,4′-dihydro)quinazolin]-2′(1′H)-one,
8′-chloro -6′-[3-(4-methyl-piperazine-1-carbonyl)-phenyl]spiro-[cyclohexane-1-4′-(3′,4′-dihydro)quinazolin]-2′(1′H)-one,
8′-chloro-6′-[3-(2-N-dimethylamino-ethylcarboxamide)phenyl]spiro-[cyclohexane-1-4′-(3′,4′-dihydro)quinazolin]-2′(1′H)-one,
8′-chloro-6′-[4-(4-pyrimidin-2-yl-piperazine-1-carbonyl)phenyl]spiro[-cyclohexane-1-4′-(3′,4′-dihydro)quinazolin]-2′(1′H)-one,
8′-chloro-6′-[4-(4-(2-morpholin-4-yl-ethyl)-piperazine-1-carbonyl)-phenyl]spiro[-cyclohexane-1-4′-(3′,4′-dihydro)quinazolin]-2′(1′H)-one,
8′-chloro-6′-[4-(4-(2-morpholin-4-yl-2-oxo-ethyl)-piperazine-1-carbonyl)-phenyl]spiro[-cyclohexane-1-4′-(3′,4′-dihydro)quinazolin]-2′(1′H)-one,
8′-chloro-6′-[4-(4-(2-hydroxy-ethoxy)-ethyl)-piperazine-1-carbonyl)-phenyl]spiro[-cyclohexane-1-4′-(3′,4′-dihydro)quinazolin]-2′(1′H)-one,
8′-Chloro-5′-methoxyspiro[cyclohexane-1-4′-(3′,4′-dihydro)quinazolin]-2′(1′H)-one,
8′-Chloro-5′-methylspiro[cyclohexane-1-4′-(3′,4′-dihydro)quinazolin]-2′(1′H)-one,
8′-Chloro-5′-hydroxyspiro[cyclohexane-1-4′-(3′,4′-dihydro)quinazolin]-2′(1′H)-one,
8′-Chloro-6′-cyano-5′-methoxy-spiro[cyclohexane-1-4′-(3′,4′-dihydro)quinazolin]-2′(1′H)-one,
8′-Chloro-5′-[2-(4-morpholino)ethoxy]spiro[cyclohexane-1-4′-(3′,4′-dihydro)quinazolin]-2′(1′H)-one,
5′-carboxymethoxy-8′-chloro-spiro[cyclohexane-1-4′-(3′,4′-dihydro)quinazolin]-2′(1′H)-one,
5′-carboxypropoxy-8′-chloro-spiro[cyclohexane-1-4′-(3′,4′-dihydro)quinazolin]-2′(1′H)-one,
8′-chloro-5′-(3-sulphopropoxy)-spiro[cyclohexane-1-4′-(3′,4′-dihydro)quinazolin]-2′(1′H)-one,
8′-Chloro-5′-(2-hydroxy-ethoxy)-spiro[cyclohexane-1-4′-(3′,4′-dihydro)quinazolin]-2′(1′H)-one,
8′-Chloro-5′-(5-ethoxycarbonyl-furan-2-ylmethoxy)-spiro[cyclohexane-1-4′-(3′,4′-dihydro)quinazolin]-2′(1′H)-one,
8′-Chloro-5′-(5-carboxy-furan-2-ylmethoxy)-spiro[cyclohexane-1-4′-(3′,4′-dihydro)quinazolin]-2′(1′H)-one,
8′-Chloro-5′-cyanomethoxyspiro[cyclohexane-1-4′-(3′,4′-dihydro)quinazolin]-2′(1′H)-one,
8′-Chloro-5′-(1H-tetrazol-5-ylmethoxy)-spiro[cyclohexane-1-4′-(3′,4′-dihydro)quinazolin]-2′(1′H)-one,
8′-Chloro-5′-(5-hydroxy-[1,2,4]oxadiazol-3-ylmethoxy)-spiro[cyclohexane-1-4′-(3′,4′-dihydro) quinazolin]-2′(1′H)-one,
6′-(4-carboxyphenyl)-8′-chloro-5′-methoxyspiro[cyclohexane-1-4′-(3′,4′-dihydro)quinazolin]-2′(1′H)-one,
6′-(3-carboxyphenyl)-8′-chloro-5′-methoxyspiro[cyclohexane-1-4′-(3′,4′-dihydro)quinazolin]-2′(1 ′H)-one,
8′-chloro-6′-[2-methyl-4-(4-methyl-piperazine-1-carbonyl)phenyl]spiro[cyclohexane-1-4′-(3′,4′-dihydro)quinazolin]-2′(1′H)-one,
8′-chloro-6′-[4-(piperazine-1-carbonyl)phenyl]spiro[cyclohexane-1-4′-(3′,4′-dihydro)quinazolin]-2′(1′H)-one,
8′-chloro-6′-[4-carbamoyl-phenyl]spiro[cyclohexane-1-4′-(3′,4′-dihydro)quinazolin]-2′(1′H)-one,
8′-chloro-6′-[4-((1-methyl-piperidin-4-yl)-piperazine-1-carbonyl)phenyl]spiro[cyclohexane-1-4′-(3′,4′-dihydro)quinazolin]-2′(1′H)-one, and,
8′-Chloro-5′-[2-(carboxymethyl-amino)-ethoxy]-spiro[cyclohexane-1-4′-(3′,4′-dihydro)quinazolin]-2′(1′H)-one hydrochloride,
8′-Chloro-5′-(2-methanesulfonylamino-2-oxo-ethoxy)-spiro[cyclohexane-1-4′-(3′,4′-dihydro)quinazolin]-2′(1′H)-one,
8′-Chloro-5′-(2-[(5-methyl-isoxazol-3-ylmethyl)-amino]ethoxy)-spiro[cyclohexane-1-4′-(3′,4′-dihydro)quinazolin]-2′(1′H)-one.
24. A compound according to any one of claim 1 to 23 for use as a medicament
25. A pharmaceutical composition comprising a compound according to any one of claims 1 to 23 in combination with an appropriate carrier.
26. Use of a compound of formula (I), (II) or (III),
Figure US20020198198A1-20021226-C00046
in which,
a) X1, X2, X3 and X4 are the same or different and are selected from:
N, provided that not more than two of the groups X1, X2, X3 and X4 simultaneously represent a nitrogen atom, or,
C—R1, in which R1 is selected from:
Q1, or
lower alkyl, lower alkenyl or lower alkynyl, these groups being unsubstituted or substituted with one or several groups Q2;
the group X5—R5 in which,
X5 is selected from:
a single bond,
lower alkylene, lower alkenylene or lower alkynylene, optionally interrupted with 1 or 2 heteroatoms chosen from O, S, S(═O), SO2 or N, the carbon atoms of these groups being unsubstituted or substituted with one or several groups, identical or different, selected from SR6, OR6, NR6R7, ═O, ═S or ═N—R6 in which R6 and R7 are the same or different and are selected from hydrogen or lower alkyl, and,
R5 is selected from aryl, heteroaryl, cycloalkyl optionally interrupted with C(═O) or with 1, 2, or 3 heteroatoms chosen from O, S, S(═O), SO2 or N, cycloalkenyl optionally interrupted with C(═O) or with 1, 2, or 3 heteroatoms chosen from O, S, S(═O), SO2 or N, or a bicyclic group, these groups being unsubstituted or substituted with one or several groups selected from Q3, heteroaryl or lower alkyl optionally substituted with Q3;
in which Q1, Q2, Q3 are the same or different and are selected from
hydrogen, halogen, CN, NO2, SO3H, P(═O)(OH)2
OR2, OC(═O)R2, C(═O)OR2, SR2, S(═O)R2, C(═O)—NH—SO2—CH3, NR3R4, Q-R2, Q-NR3R4, NR2-Q-NR3R4 or NR3-Q-R2 in which Q is selected from C(═NR), C(═O), C(═S) or SO2, R is selected from hydrogen, CN, SO2NH2 or lower alkyl and R2, R3 and R4 are the same or different and are selected from:
hydrogen,
lower alkyl optionally interrupted with C(═O), Q4-aryl, Q4-heteroaryl, Q4-cycloalkyl optionally interrupted with C(═O) or with 1 or 2 heteroatoms chosen from O, S, S(═O), SO2 or N, or Q4-cycloalkenyl optionally interrupted with C(═O) or with 1 or 2 heteroatoms chosen from O, S, S(═O), SO2 or N, in which
Q4 is selected from (CH2)n, lower alkyl interrupted with one heteroatom selected from O, S or N, lower alkenyl or lower alkynyl, these groups being optionally substituted with lower alkyl, OR′ or NR′R″ in which R′ and R″ are the same or different and are selected from hydrogen or lower alkyl;
n is an integer selected from 0, 1, 2, 3 or 4;
these groups being unsubstituted or substituted with one or several groups selected from halogen, lower alkyl, CN, CH3, SO3H, SO2CH3, C(═O)—NH—SO2—CH3, CF3, OR6, COOR6, C(═O)R6, NR6R7, NR6C(═O)R7, C(═O)NR6R7 or SO2NR6R7, in which R6 and R7 are the same or different and are selected from hydrogen or lower alkyl optionally substituted with one or two groups selected from OR, COOR or NRR8 in which R and R8 are hydrogen or lower alkyl, and,
R6 and R7, and/or, R3 and R4, together with the nitrogen atom to which they are linked, can form a 4- to 8-membered heterocyclic ring, which may contain one or two heteroatoms selected from O, S, S(═O), SO2 or N, and which may be substituted with,
(CH2)n-Q5, in which n is an integer selected from 0, 1, 2 and 3, and Q5 is a 4- to 8-membered heterocyclic ring which may contain one or two heteroatoms selected from O, S or N and which may be substituted with a lower alkyl, or,
a lower alkyl optionally substituted with OR′, NR′R″, C(═O)NR′R″ or COOR′ in which R′ and R″ are the same or different and are selected from,
H, or,
lower alkyl optionally substituted with OR or COOR in which R is hydrogen or lower alkyl and,
R′ and R″ together with the nitrogen atom to which they are linked, can form a 4- to 8-membered heterocyclic ring, which may contain one or two heteroatoms selected from O, S or N; or,
when X1 and X2 both represent C—R1, the 2 substituents R1 may form together with the carbon atoms to which they are attached, a 5-membered heterocyclic ring comprising a nitrogen atom and optionally a second heteroatom selected from O, S or N;
b) X is O, S or NR9, in which R9 is selected from,
hydrogen, CN, OH, NH2,
lower alkyl, lower alkenyl or lower alkynyl, these groups being unsubstituted or substituted with cycloalkyl optionally interrupted with 1 or 2 heteroatoms chosen from O, S, S(═O), SO2 or N, cycloalkenyl optionally interrupted with 1 or 2 heteroatoms chosen from O, S, S(═O), SO2 or N, aryl, heteroaryl, OR10, COOR10 or NR10R11 in which R10 and R11 are the same or different and are selected from hydrogen or lower alkyl;
c) Y is selected from O, S or N—R12, in which R12 is selected from:
hydrogen, CN, OH, NH2,
lower alkyl, lower alkenyl or lower alkynyl, these groups being unsubstituted or substituted with, cycloalkyl optionally interrupted with 1 or 2 heteroatoms chosen from O, S, S(═O), SO2 or N, cycloalkenyl optionally interrupted with 1 or 2 heteroatoms chosen from O, S, S(═O), SO2 or N, aryl, heteroaryl, OR10, COOR10 or NR10R11 in which R10 and R11 are the same or different and are selected from hydrogen or lower alkyl;
d) Z is chosen from CH—NO2, O, S or NR13 in which R13 is selected from:
hydrogen, CN, OH, NH2, aryl, heteroaryl, cycloalkyl optionally interrupted with one or several heteroatoms chosen from O, S, S(═O), SO2 or N, cycloalkenyl optionally interrupted with one or several heteroatoms chosen from O, S, S(═O), SO2 or N, C(═O)R14, C(═O)NR14R 15, OR14, or,
lower alkyl, unsubstituted or substituted with one or several groups which are the same or different and which are selected OR14, COOR14 or NR14R15;
R14 and R15 being independently selected from hydrogen or lower alkyl, or, R14 and R15, together with the nitrogen atom to which they are linked, can form a 4- to 8-membered heterocyclic ring which may contain one or two heteroatoms chosen from O, S or N, and which may be substituted with a lower alkyl, or,
when Y is N—R12 and Z is N—R13, R12 and R13 may form together a —CH═N— group or a —C═C═group,
when X is N—R9 and Z is N—R13, R9 and R13 may form together a —CH═N— group or a —C═C— group;
e) Z1 is chosen from H, CH3 or NR16R17 in which R16 and R17 are the same or different and are selected from:
hydrogen, CN, aryl, heteroaryl, cycloalkyl optionally interrupted with one or several heteroatoms chosen from O, S, S(═O), SO2 or N, cycloalkenyl optionally interrupted with one or several heteroatoms chosen from O, S, S(═O), SO2 or N, C(═O)R14, C(═O)NR14R15, OR4, or,
lower alkyl unsubstituted or substituted with one or several groups selected from OR14, COOR14 or NR14R15,
R14 and R15 being chosen from hydrogen or lower alkyl, and,
R14 and R15, and/or, R16 and R17, together with the nitrogen atom to which they are linked, can form a 4- to 8-membered heterocyclic ring which may contain one or two heteroatoms chosen from O, S or N, and which may be substituted with a lower alkyl;
f) A is a cycle chosen from:
Figure US20020198198A1-20021226-C00047
 in which,
A1, A2, A3, A4, A5 and A6 are the same or different and are selected from O, S, C, C(═O), SO, SO2 or N—R18 in which R18 is selected from:
hydrogen, aryl, heteroaryl, cycloalkyl optionally interrupted with one or several heteroatoms chosen from O, S, S(═O), SO2 or N, cycloalkenyl optionally interrupted with one or several heteroatoms chosen from O, S, S(═O), SO2 or N,
lower alkyl unsubstituted or substituted with aryl, heteroaryl, cycloalkyl optionally interrupted with one or several heteroatoms chosen from O, S, S(═O), SO2 or N, cycloalkenyl optionally interrupted with one or several heteroatoms chosen from O, S, S(═O), SO2 or N, CN, NR19R20, C(═O)NR19R20, OR19, C(═O)R19 or C(═O)OR19 in which R19 and R20 are identical or different and are selected from hydrogen or lower alkyl;
*represents the carbon atom which is shared between the cycle A and the backbone cycle containing X and/or Y;
each carbon atom of the cycle A is unsubstituted or substituted with 1 or 2 groups, identical or different, selected from lower alkyl optionally substituted with OR21, NR21R22, COOR21 or CONR21R22, lower haloalkyl, CN, F, ═O, SO2NR19R20, OR19, SR19, C(═O)OR19, C(═O)NR19R20 or NR19R20 in which R19 and R20 are identical or different and are selected from hydrogen or lower alkyl optionally substituted with OR21, NR21R22, COOR21 or CONR21R22 in which R21 and R22 are identical or different and are selected from hydrogen or lower alkyl, and,
R19 and R20, and/or, R21 and R22, together with the nitrogen atom to which they are linked, can form a 4- to 8-membered heterocyclic ring;
2 atoms of the cycle A, which are not adjacent, may be linked by a 2, 3 or 4 carbon atom chain which may be interrupted with 1 heteroatom chosen from O, S or N;
provided that not more than two of the groups A1, A2, A3, A4, A5 and A6 simultaneously represent a heteroatom;
of their tautomeric forms, their racemic forms or their isomers and of their pharmaceutically acceptable derivatives,
for the preparation of a medicament for the prevention or the treatment of disorders for which therapy by a PDE7 inhibitor is relevant.
27. Use according to claim 26 in which said compound is a compound of formula (I) in which X1, X2, X3, X4, X, Y, Z and A are as defined in claim 25.
28. Use of a compound according to any one of claims 1 to 23 for the preparation of a medicament for the prevention or the treatment of disorders for which therapy by a PDE7 inhibitor is relevant.
29. Use according to any one of claims 26 to 28 in which said disorder is selected from T-cell-related diseases, autoimmune diseases, osteoarthritis, multiple sclerosis, osteoporosis, chronic obstructive pulmonary disease, asthma, cancer, acquired immune deficiency syndrome, allergy or inflammatory bowel disease.
30. A method for the prevention or the treatment of a disorder for which a therapy by a PDE7 inhibitor is relevant, comprising administering to a mammal in need thereof, an effective amount of a compound according to any one of claims 1 to 23.
31. A method according to claim 30 in which said disorder is selected from T-cell-related diseases, autoimmune diseases, osteoarthritis, multiple sclerosis, osteoporosis, chronic obstructive pulmonary disease, asthma, cancer, acquired immune deficiency syndrome, allergy or inflammatory bowel disease.
32. A method for preparing a compound of formula (I) according to claim 1 in which Y is N—R12, X is N—R9 and Z is O comprising reacting a substituted urea of formula
Figure US20020198198A1-20021226-C00048
in which X1, X2, X3, X4, R9 and R12 are as defined claim 1, with a cyclic ketone of formula
Figure US20020198198A1-20021226-C00049
 in which A is as defined in claim 1, to obtain said compound of formula (I) and isolating said compound of formula (I).
33. A method for preparing a compound of formula (I) according to claim 1 in which X1, X2, X3, X4, A and R9 are as defined in claim 1 and Y is O, S or NH, said method comprising,
(1) reacting a compound (2a)
Figure US20020198198A1-20021226-C00050
 in which X1, X2, X3, X4 are as defined in claim 1 and Y is O, S or NH, with a group P-LG in which P is a protecting group and LG is a leaving group to obtain compound (2b)
Figure US20020198198A1-20021226-C00051
(2) reacting compound (2b) with R-Li in which R is lower alkyl and then with a ketone of formula
Figure US20020198198A1-20021226-C00052
 in which A is as defined in claim 1 to obtain compound (2c)
Figure US20020198198A1-20021226-C00053
(3) removing the protecting group P either under reductive conditions, acidic condition or basic condition to obtain compound (2d)
Figure US20020198198A1-20021226-C00054
(4) reacting compound (2d) with a group O═C═N—R9 in which R9 is as defined in claim 1 to obtain compound (2e)
Figure US20020198198A1-20021226-C00055
(5) reacting compound (2e) with an acid to obtain said compound of formula (I),
(6) isolating said compound of formula (I).
US10/101,996 2001-03-21 2002-03-19 Spirotricyclic derivatives and their use as phosphodiesterase-7 inhibitors Abandoned US20020198198A1 (en)

Priority Applications (2)

Application Number Priority Date Filing Date Title
PCT/EP2001/003355 WO2002076953A1 (en) 2001-03-21 2001-03-21 New spirotricyclic derivatives and their use as phosphodiesterase-7 inhibitors
EPPCT/EP01/03355 2001-03-21

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US10/852,404 US7214676B2 (en) 2001-03-21 2004-05-24 Spirotricyclic derivatives and their use as phosphodiesterase-7 inhibitors
US11/551,687 US20070049558A1 (en) 2001-03-21 2006-10-20 New Spirotricyclic Derivatives and Their Use as Phosphodiesterase-7 Inhibitors

Related Child Applications (1)

Application Number Title Priority Date Filing Date
US10/852,404 Continuation US7214676B2 (en) 2001-03-21 2004-05-24 Spirotricyclic derivatives and their use as phosphodiesterase-7 inhibitors

Publications (1)

Publication Number Publication Date
US20020198198A1 true US20020198198A1 (en) 2002-12-26

Family

ID=8164349

Family Applications (3)

Application Number Title Priority Date Filing Date
US10/101,996 Abandoned US20020198198A1 (en) 2001-03-21 2002-03-19 Spirotricyclic derivatives and their use as phosphodiesterase-7 inhibitors
US10/852,404 Expired - Fee Related US7214676B2 (en) 2001-03-21 2004-05-24 Spirotricyclic derivatives and their use as phosphodiesterase-7 inhibitors
US11/551,687 Abandoned US20070049558A1 (en) 2001-03-21 2006-10-20 New Spirotricyclic Derivatives and Their Use as Phosphodiesterase-7 Inhibitors

Family Applications After (2)

Application Number Title Priority Date Filing Date
US10/852,404 Expired - Fee Related US7214676B2 (en) 2001-03-21 2004-05-24 Spirotricyclic derivatives and their use as phosphodiesterase-7 inhibitors
US11/551,687 Abandoned US20070049558A1 (en) 2001-03-21 2006-10-20 New Spirotricyclic Derivatives and Their Use as Phosphodiesterase-7 Inhibitors

Country Status (45)

Country Link
US (3) US20020198198A1 (en)
EP (2) EP1801106A3 (en)
JP (1) JP4086663B2 (en)
KR (1) KR100617435B1 (en)
CN (1) CN100447136C (en)
AP (1) AP1699A (en)
AR (1) AR033617A1 (en)
AT (1) AT367381T (en)
AU (1) AU2002304800B2 (en)
BG (1) BG108181A (en)
BR (1) BR0208192A (en)
CA (1) CA2441313C (en)
CU (1) CU23218A3 (en)
CZ (1) CZ20032451A3 (en)
DE (1) DE60221233T2 (en)
DK (1) DK1373224T3 (en)
EA (1) EA006815B1 (en)
EC (1) ECSP034750A (en)
EE (1) EE200300459A (en)
ES (1) ES2288552T3 (en)
GE (1) GEP20053631B (en)
GT (1) GT200200053A (en)
HK (1) HK1061854A1 (en)
HR (1) HRP20030740A2 (en)
HU (1) HU0303637A3 (en)
IL (2) IL157659D0 (en)
IS (1) IS2529B (en)
MA (1) MA27001A1 (en)
MX (1) MXPA03008485A (en)
MY (1) MY142045A (en)
NO (1) NO326086B1 (en)
NZ (1) NZ527847A (en)
OA (1) OA12454A (en)
PA (1) PA8541601A1 (en)
PE (1) PE10102002A1 (en)
PL (1) PL367058A1 (en)
PT (1) PT1373224E (en)
RS (1) RS50429B (en)
SI (1) SI1373224T1 (en)
SK (1) SK11562003A3 (en)
SV (1) SV2003000925A (en)
TN (1) TNSN03076A1 (en)
TW (1) TWI267509B (en)
WO (2) WO2002076953A1 (en)
ZA (1) ZA200306601B (en)

Cited By (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20040106631A1 (en) * 2002-09-17 2004-06-03 Patrick Bernardelli Spirocondensed quinazolinones and their use as phosphodiesterase inhibitors
US20080064671A1 (en) * 2006-09-08 2008-03-13 Braincells, Inc. Combinations containing a 4-acylaminopyridine derivative
WO2008119057A2 (en) 2007-03-27 2008-10-02 Omeros Corporation The use of pde7 inhibitors for the treatment of movement disorders
US7678808B2 (en) 2006-05-09 2010-03-16 Braincells, Inc. 5 HT receptor mediated neurogenesis
US20100113486A1 (en) * 2007-03-27 2010-05-06 Omeros Corporation Use of pde7 inhibitors for the treatment of movement disorders
WO2010099217A1 (en) 2009-02-25 2010-09-02 Braincells, Inc. Modulation of neurogenesis using d-cycloserine combinations
EP2258359A2 (en) 2005-08-26 2010-12-08 Braincells, Inc. Neurogenesis by muscarinic receptor modulation with sabcomelin
EP2275095A2 (en) 2005-08-26 2011-01-19 Braincells, Inc. Neurogenesis by muscarinic receptor modulation
EP2314289A1 (en) 2005-10-31 2011-04-27 Braincells, Inc. Gaba receptor mediated modulation of neurogenesis
WO2011063115A1 (en) 2009-11-19 2011-05-26 Braincells Inc. Combination of nootropic agent with one or more neurogenic or neurogenic sensitizing agents for stimulating or increasing neurogenesis
US7985756B2 (en) 2005-10-21 2011-07-26 Braincells Inc. Modulation of neurogenesis by PDE inhibition
WO2011091033A1 (en) 2010-01-20 2011-07-28 Braincells, Inc. Modulation of neurogenesis by ppar agents
EP2377531A2 (en) 2006-05-09 2011-10-19 Braincells, Inc. Neurogenesis by modulating angiotensin
WO2012064667A2 (en) 2010-11-08 2012-05-18 Omeros Corporation Treatment of addiction and impulse-control disorders using pde7 inhibitors
WO2013106547A1 (en) 2012-01-10 2013-07-18 President And Fellows Of Harvard College Beta-cell replication promoting compounds and methods of their use
US9220715B2 (en) 2010-11-08 2015-12-29 Omeros Corporation Treatment of addiction and impulse-control disorders using PDE7 inhibitors

Families Citing this family (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB0230195D0 (en) * 2002-12-24 2003-02-05 Biofocus Plc Compound Libraries
CA2523426C (en) 2003-04-24 2013-02-26 Incyte Corporation Aza spiro alkane derivatives as inhibitors of metalloproteases
JP2006219374A (en) 2003-06-13 2006-08-24 Daiichi Asubio Pharma Co Ltd Imidazotriazinone derivative having pde 7 inhibition
JP2006219373A (en) 2003-06-13 2006-08-24 Daiichi Asubio Pharma Co Ltd Pyridinylpyrazolopyrimidinone derivative having pde 7 inhibition
JP2007501822A (en) * 2003-08-12 2007-02-01 エフ.ホフマン−ラ ロシュ アーゲーF. Hoffmann−La Roche Aktiengesellschaft Corticotropin releasing factor (crf) spiro-substituted tetrahydroquinazoline as antagonists
CA2569530C (en) 2004-07-01 2013-07-30 Daiichi Asubio Pharma Co., Ltd. Thienopyrazole derivative having pde 7 inhibitory activity
WO2006092692A1 (en) * 2005-03-01 2006-09-08 Pfizer Limited Use of combinations of pde7 inhibitors and alpha-2-delty ligands for the treatment of neuropathic pain
GB0504209D0 (en) * 2005-03-01 2005-04-06 Pfizer Ltd New use of PDE7 inhibitors
US20090111837A1 (en) * 2005-03-01 2009-04-30 Peter Cox Use of pde7 inhibitors for the treatment of neuropathic pain
KR100680497B1 (en) * 2005-07-25 2007-02-08 엘지전자 주식회사 Method for connecting a terminal to access point in short-range communication system
BRPI0618643A2 (en) 2005-11-09 2011-09-06 Combinatorx Inc Composition comprising a pair of pharmaceuticals, the composition comprising a corticosteroid and immunosuppressive immunophilin-dependent non-steroid use kits and
EA200801145A1 (en) 2005-12-02 2008-10-30 Пфайзер Лимитед Spyrocyclic derivatives of hinazolin as pde7 inhibitors
EP2160381A2 (en) * 2007-05-24 2010-03-10 Pfizer Limited Spirocyclic quinazoline derivatives and their use as pde7 inhibitors
US8754114B2 (en) 2010-12-22 2014-06-17 Incyte Corporation Substituted imidazopyridazines and benzimidazoles as inhibitors of FGFR3
PE20190736A1 (en) 2012-06-13 2019-05-23 Incyte Holdings Corp Tricyclic substituted compounds as receptor inhibitors fibroblast growth factor (FGFR)
WO2014026125A1 (en) 2012-08-10 2014-02-13 Incyte Corporation Pyrazine derivatives as fgfr inhibitors
US9266892B2 (en) 2012-12-19 2016-02-23 Incyte Holdings Corporation Fused pyrazoles as FGFR inhibitors
CA2909207A1 (en) 2013-04-19 2014-10-23 Incyte Corporation Bicyclic heterocycles as fgfr inhibitors
US9890156B2 (en) 2015-02-20 2018-02-13 Incyte Corporation Bicyclic heterocycles as FGFR4 inhibitors
KR20170127467A (en) 2015-02-20 2017-11-21 인사이트 코포레이션 Bicyclic heterocyclic inhibitors as Fgfr
US9580423B2 (en) 2015-02-20 2017-02-28 Incyte Corporation Bicyclic heterocycles as FGFR4 inhibitors
CN107382976A (en) * 2017-07-04 2017-11-24 孙秀芹 Compound for treating pelvic inflammation, preparation method and application
WO2019014305A1 (en) * 2017-07-12 2019-01-17 Dart Neuroscience, Llc Substituted benzoxazole and benzofuran compounds as pde7 inhibitors

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS5815979A (en) 1981-07-11 1983-01-29 Kyowa Hakko Kogyo Co Ltd Novel piperidine derivative and its preparation
US4764512A (en) 1986-08-27 1988-08-16 Rorer Pharmaceutical Corporation Benzodiazinone-pyridone compounds, cardiotonic compositions including the same, and their uses
GR1000821B (en) 1988-11-22 1993-01-25 Tanabe Seiyaku Co Process for preparing quinazolinone derivatives
US5578593A (en) * 1992-12-11 1996-11-26 Merck & Co., Inc. Spiro piperidines and homologs promote release of growth hormone
RO115804B1 (en) 1992-12-11 2000-06-30 Merck & Co Inc Spiropyperidine derivatives, processes for preparation and pharmaceutical compositions thereof
US5602143A (en) * 1994-12-08 1997-02-11 Allergan Method for reducing intraocular pressure in the mammalian eye by administration of guanylate cyclase inhibitors
EE9800116A (en) * 1995-10-17 1998-10-15 Astra Pharmaceuticals Limited The pharmaceutically active compounds of the quinazoline
CN1205008A (en) 1997-08-29 1999-01-13 协和发酵工业株式会社 Imidazoquinazoline derivatives
WO2000066560A1 (en) * 1999-05-04 2000-11-09 American Home Products Corporation Quinazolinone and benzoxazine derivatives as progesterone receptor modulators
JP2002543155A (en) 1999-05-04 2002-12-17 リガンド・フアーマシユーチカルズ・インコーポレーテツド Contraceptive composition comprising an anti-progestin and progestin
US6498154B1 (en) 1999-05-04 2002-12-24 Wyeth Cyclic regimens using quinazolinone and benzoxazine derivatives
US6358948B1 (en) * 1999-05-04 2002-03-19 American Home Products Corporation Quinazolinone and benzoxazine derivatives as progesterone receptor modulators
US6436929B1 (en) 1999-05-04 2002-08-20 Wyeth Cyclothiocarbamate derivatives as progesterone receptor modulators
US6509334B1 (en) 1999-05-04 2003-01-21 American Home Products Corporation Cyclocarbamate derivatives as progesterone receptor modulators
AU2274101A (en) 1999-12-21 2001-07-03 Merck & Co., Inc. Inhibitors of prenyl-protein transferase

Cited By (27)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7429598B2 (en) * 2002-09-17 2008-09-30 Warner-Lambert Company Spirocondensed quinazolinones and their use as phosphodiesterase inhibitors
US20040106631A1 (en) * 2002-09-17 2004-06-03 Patrick Bernardelli Spirocondensed quinazolinones and their use as phosphodiesterase inhibitors
EP2258359A2 (en) 2005-08-26 2010-12-08 Braincells, Inc. Neurogenesis by muscarinic receptor modulation with sabcomelin
EP2258357A2 (en) 2005-08-26 2010-12-08 Braincells, Inc. Neurogenesis with acetylcholinesterase inhibitor
EP2275096A2 (en) 2005-08-26 2011-01-19 Braincells, Inc. Neurogenesis via modulation of the muscarinic receptors
EP2275095A2 (en) 2005-08-26 2011-01-19 Braincells, Inc. Neurogenesis by muscarinic receptor modulation
EP2258358A2 (en) 2005-08-26 2010-12-08 Braincells, Inc. Neurogenesis with acetylcholinesterase inhibitor
US7985756B2 (en) 2005-10-21 2011-07-26 Braincells Inc. Modulation of neurogenesis by PDE inhibition
EP2377530A2 (en) 2005-10-21 2011-10-19 Braincells, Inc. Modulation of neurogenesis by PDE inhibition
EP2314289A1 (en) 2005-10-31 2011-04-27 Braincells, Inc. Gaba receptor mediated modulation of neurogenesis
US7678808B2 (en) 2006-05-09 2010-03-16 Braincells, Inc. 5 HT receptor mediated neurogenesis
EP2377531A2 (en) 2006-05-09 2011-10-19 Braincells, Inc. Neurogenesis by modulating angiotensin
EP2382975A2 (en) 2006-05-09 2011-11-02 Braincells, Inc. Neurogenesis by modulating angiotensin
US20080064671A1 (en) * 2006-09-08 2008-03-13 Braincells, Inc. Combinations containing a 4-acylaminopyridine derivative
US7998971B2 (en) 2006-09-08 2011-08-16 Braincells Inc. Combinations containing a 4-acylaminopyridine derivative
US9119822B2 (en) 2007-03-27 2015-09-01 Omeros Corporation Use of PDE7 inhibitors for the treatment of movement disorders
US8637528B2 (en) 2007-03-27 2014-01-28 Omeros Corporation Use of PDE7 inhibitors for the treatment of movement disorders
US20100113486A1 (en) * 2007-03-27 2010-05-06 Omeros Corporation Use of pde7 inhibitors for the treatment of movement disorders
US20080260643A1 (en) * 2007-03-27 2008-10-23 Omeros Corporation Use of pde7 inhibitors for the treatment of movement disorders
WO2008119057A2 (en) 2007-03-27 2008-10-02 Omeros Corporation The use of pde7 inhibitors for the treatment of movement disorders
US20110091388A1 (en) * 2007-03-27 2011-04-21 Omeros Corporation Use of pde7 inhibitors for the treatment of movement disorders
WO2010099217A1 (en) 2009-02-25 2010-09-02 Braincells, Inc. Modulation of neurogenesis using d-cycloserine combinations
WO2011063115A1 (en) 2009-11-19 2011-05-26 Braincells Inc. Combination of nootropic agent with one or more neurogenic or neurogenic sensitizing agents for stimulating or increasing neurogenesis
WO2011091033A1 (en) 2010-01-20 2011-07-28 Braincells, Inc. Modulation of neurogenesis by ppar agents
WO2012064667A2 (en) 2010-11-08 2012-05-18 Omeros Corporation Treatment of addiction and impulse-control disorders using pde7 inhibitors
US9220715B2 (en) 2010-11-08 2015-12-29 Omeros Corporation Treatment of addiction and impulse-control disorders using PDE7 inhibitors
WO2013106547A1 (en) 2012-01-10 2013-07-18 President And Fellows Of Harvard College Beta-cell replication promoting compounds and methods of their use

Also Published As

Publication number Publication date
MA27001A1 (en) 2004-12-20
US20070049558A1 (en) 2007-03-01
TWI267509B (en) 2006-12-01
KR100617435B1 (en) 2006-08-31
MY142045A (en) 2010-08-30
AR033617A1 (en) 2003-12-26
JP2004529123A (en) 2004-09-24
SK11562003A3 (en) 2005-01-03
HU0303637A2 (en) 2004-03-01
TNSN03076A1 (en) 2005-12-23
US20040214843A1 (en) 2004-10-28
CZ20032451A3 (en) 2004-09-15
CU23218A3 (en) 2007-07-20
PE10102002A1 (en) 2003-02-01
NZ527847A (en) 2005-06-24
EE200300459A (en) 2004-02-16
JP4086663B2 (en) 2008-05-14
BG108181A (en) 2004-09-30
KR20030086315A (en) 2003-11-07
DK1373224T3 (en) 2007-10-15
NO20034187D0 (en) 2003-09-19
IS6934A (en) 2003-08-29
IL157659D0 (en) 2004-03-28
SV2003000925A (en) 2003-05-20
EP1373224B1 (en) 2007-07-18
GT200200053A (en) 2003-02-12
CA2441313C (en) 2009-03-31
EP1801106A2 (en) 2007-06-27
HU0303637A3 (en) 2004-07-28
AP1699A (en) 2006-12-26
AT367381T (en) 2007-08-15
YU74003A (en) 2006-05-25
EA006815B1 (en) 2006-04-28
AU2002304800B2 (en) 2007-08-30
EP1801106A3 (en) 2007-07-04
CN1498212A (en) 2004-05-19
MXPA03008485A (en) 2003-12-08
CA2441313A1 (en) 2002-09-26
HRP20030740A2 (en) 2005-06-30
PL367058A1 (en) 2005-02-21
EP1373224A1 (en) 2004-01-02
RS50429B (en) 2009-12-31
GEP20053631B (en) 2005-10-10
IS2529B (en) 2009-07-15
EA200300906A1 (en) 2004-02-26
DE60221233T2 (en) 2008-04-03
WO2002076953A1 (en) 2002-10-03
PT1373224E (en) 2007-09-25
SI1373224T1 (en) 2007-10-31
NO326086B1 (en) 2008-09-15
ECSP034750A (en) 2003-10-28
US7214676B2 (en) 2007-05-08
WO2002074754A1 (en) 2002-09-26
AP200302857A0 (en) 2003-09-30
PA8541601A1 (en) 2003-05-14
CN100447136C (en) 2008-12-31
HK1061854A1 (en) 2009-08-14
ZA200306601B (en) 2004-08-25
DE60221233D1 (en) 2007-08-30
IL157659A (en) 2008-08-07
ES2288552T3 (en) 2008-01-16
BR0208192A (en) 2004-03-02
OA12454A (en) 2004-09-30
NO20034187L (en) 2003-10-15

Similar Documents

Publication Publication Date Title
CA2463989C (en) Pyrimidine derivatives, pharmaceutical compositions containing these compounds, the use thereof and process for the preparation thereof
US5681954A (en) Piperazine derivatives
JP5702396B2 (en) Benzodiazepine-bromo-domain inhibitor
US6531477B1 (en) 6-substituted pyrazolo [3,4-d] pyrimidin-4-ones useful as cyclin dependent kinase inhibitors
EP0672031B1 (en) Catechol diethers as selective pde iv inhibitors
EP0591528B1 (en) PYRAZOLO[1,5-a]PYRIMIDINE DERIVATIVE AND ANTI-INFLAMMATORY CONTAINING THE SAME
JP4942486B2 (en) Pyrazole derivatives as inhibitors of receptor tyrosine kinases
EP0674641B1 (en) Pyrrolopyrimidines as crf antagonists
ES2238437T3 (en) muscarinic agonists.
JP4394442B2 (en) Useful as anti-inflammatory agents spiro - hydantoin compound
EP0738270B1 (en) Dihydro pyrazolopyrroles
ES2271967T3 (en) Piperazine and piperidine compounds.
AU726447B2 (en) 1-phenyl-benzimidazole compounds and their use as BAGA-A receptor modulators
AU680370B2 (en) Pyrazolo(1,5-a)pyrimidine derivative
ES2341540T3 (en) Derivatives of 1H-1,2,4-triazole-3-carboxamide as cannabinoid receptor ligands cb1.
AU675055B2 (en) Isatin derivatives, processes for the preparation thereof and pharmaceutical composition comprising the same
CA2132514C (en) Antiproliferative quinazolines
US8338437B2 (en) Amines as small molecule inhibitors
CN1049654C (en) Piperazine derivatives and medicine composition containing same and use thereof
CA2071529C (en) Diaromatic substituted anti-aids compounds
US20040171606A1 (en) Tetrahydrobenzazepine derivatives useful as modulators of dopamine d3 receptors (antipsychotic agents)
ES2206729T3 (en) bicyclic heteroaromatic compounds as inhibitors of protein tyrosine kinase.
DE69837346T2 (en) Anilide derivatives, their preparation and use
RU2095361C1 (en) Fused heterocyclic compounds, method of their synthesis and pharmaceutical composition based on thereof
ES2273047T3 (en) Phenylaminopyrimidines substituted heteroaryloxy as inhibitors of rho kinase.

Legal Events

Date Code Title Description
AS Assignment

Owner name: WARNER-LAMBERT COMPANY LLC, NEW JERSEY

Free format text: ASSIGNMENT OF ASSIGNORS INTEREST;ASSIGNORS:BERNARDELLI, PATRICK;DUCROT, PIERRE;LORTHIOIS, EDWIGE;AND OTHERS;REEL/FRAME:013844/0501

Effective date: 20030227

STCB Information on status: application discontinuation

Free format text: ABANDONED -- FAILURE TO RESPOND TO AN OFFICE ACTION